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Marek’s disease (MD) is a highly infectious economically important oncogenic viral 
disease of chickens. It is found throughout the world and is caused by an 
alphaherpesvirus, Marek’s disease virus (MDV). Though this disease can currently 
be successfully controlled by vaccination, the virus has continuously evolved to 
greater virulence over the last several decades. Hence, there is a need for alternative 
approaches to control MD. Selection and breeding of MD-resistant chickens presents 
an attractive option for prevention of this disease. MHC-congenic chicken inbred 
lines, 61 and 72, which are highly resistant and susceptible to MD, respectively, have 
been identified, but the cellular and genetic basis for these phenotypes is unknown. 
The overall aim of this study was to investigate the cellular basis of resistance to MD 
using an in vitro MDV infection model with the hypothesis that resistance is exerted 
by the innate immune cells. MDV is a highly cell-associated virus which makes in 
vitro studies difficult. In vivo, MDV infects APCs (antigen-presenting cells: 
macrophages and/or dendritic cells [DCs]), B cells and activated T cells. Though 
both B and T cells can be infected in vitro, co-culture infection models have not been 
described for APCs. Thus, the primary goal was to develop a model for infecting 
these cells with MDV in vitro and to characterise infected and uninfected cells. 
Developmental studies used APCs derived from outbred chickens. Chicken bone 
marrow cells were cultured with chCSF-1 (for macrophages) or chIL-4 and chCSF-2 
(for DCs) for 4 days and then infected by the addition of chicken embryo fibroblasts 
(CEFs) infected with recombinant MDV expressing GFP. CEF preparations naturally 




infectable with MDV. Infected CEFs were therefore separated from infected 
macrophages by FACS before adding to the bone marrow-derived APCs. Infected 
and uninfected APCs were sorted by FACS using GFP expression and APC-specific 
mAb staining (KUL01 and anti-CD45). Characteristic virus-infected and uninfected 
APCs were revealed via examination with live cell confocal microscopy. The 
presence of herpesvirus specific immediate early (ICP4), early (pp38), late (gB) 
transcripts and MDV specific transcript, L-Meq, in infected APCs was confirmed by 
RT-PCR providing evidence for MDV replication. Hence, a new in vitro MDV 
infection model of APCs has been established. Using the infected macrophages to 
infect CEFs showed that the infection was productive. 
This model was then extended to infect APCs of lines 61 and 72. Flow cytometric 
analysis revealed that a higher percentage of macrophages were infected in the 
susceptible line (72) than in the resistant line (61). To analyse this in detail, RNA-Seq 
was carried out to identify differentially expressed (DE) genes between the two lines 
pre- and post-MDV infection. From these DE genes, potential candidate genes 
involved in MD resistance and susceptibility were identified. Functional analysis of 
DE genes support the hypothesis that resistance to MD is determined at the 
macrophage level of the resistant line (61) and the JAK-STAT signalling pathway is 







Marek’s disease (MD) is an economically important cancerous disease of chickens 
caused by Marek’s disease virus (MDV). Despite successful control by vaccination, 
the virus has continuously evolved to greater virulence over the last several decades. 
Hence, there is a need for alternative approaches to control MD. Selection and 
breeding of MD-resistant chickens presents an attractive option for prevention of this 
disease. Two chicken inbred lines, 61 and 72, which share the same MHC (major 
histocompatibility complex) genes and are highly resistant and susceptible to MD, 
respectively, have been identified, but the cellular and genetic basis for MD-
resistance is still unknown. MDV infects APCs (antigen-presenting cells: 
macrophages and/or dendritic cells [DCs]), B cells and activated T cells in its life 
cycle in chickens. The overall aim of this study was to investigate the cellular basis 
of resistance to MD using an in vitro (in cell culture) MDV infection model with the 
hypothesis that resistance is exerted by the APCs. Though both B and T cells can be 
infected in vitro, co-culture infection models have not been described for APCs. 
Thus, the primary goal was to develop a model for infecting these cells with MDV in 
vitro and to characterise infected and uninfected cells. Developmental studies used 
APCs derived from outbred chickens. Chicken bone marrow-derived macrophages 
and DCs were cultured with chicken specific cytokines for 4 days and then infected 
by the addition of chicken embryo fibroblasts (CEFs) infected with a MDV 
expressing GFP (green fluorescent protein). CEF preparations naturally contain a 
mixture of CEFs and macrophages and both appear to be infectable with MDV. 




before adding to the bone marrow-derived APCs. Infected and uninfected APCs were 
sorted using GFP expression and APC-specific antibody staining. Characteristic 
virus-infected and uninfected APCs were revealed via examination with live cell 
confocal microscopy. The presence of herpesvirus and MDV specific transcripts in 
infected APCs was confirmed by RT-PCR providing evidence for MDV replication. 
Hence, a new in vitro MDV infection model of APCs has been established.  
This model was then extended to infect APCs of lines 61 and 72. Flow cytometric 
analysis revealed that a higher percentage of macrophages were infected in the 
susceptible line (72) than in the resistant line (61).To analyse this in detail, RNA-
Sequencing was carried out to identify differentially expressed (DE) genes between 
the two lines pre- and post-MDV infection. From these DE genes, potential candidate 
genes involved in MD resistance and susceptibility were identified. Functional 
analysis of DE genes support the hypothesis that resistance to MD is determined at 
the macrophage level of the resistant line (61) and the JAK-STAT signalling pathway 
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1.1 Marek’s disease - the early events 
The story began in 1907 when József Marek, a Hungarian scientist, first described 
Marek’s disease (MD), so named in his honour later in 1960 by Peter M. Biggs 
(Biggs, 1961). József Marek described the disease as fowl paralysis in chickens, 
causing polyneuritis or inflammation of the major nerves, specifically the sciatic 
nerve and certain areas of the spinal cord (Marek, 1907). Later, Pappenheimer et al. 
(1929a; 1929b) suggested the name ‘neurolymphomatosis gallinarum’ for this 
disease. Because, along with nerve tissues, tumorous lesions were observed in 
various visceral organs and there was also similarity in the cytological composition 
of the visceral lymphomas to those in nervous tissues. Coincidentally, a disease 
causing lymphatic leukosis, now known as lymphoid leukosis (LL), with very similar 
symptoms to MD, had also been described around the same time (Ellermann, 1921). 
Unfortunately, MD was often confused with LL and for several decades of research 
was carried out trying to classify MD and LL based only on pathological lesions as 
there was no aetiological basis until late 1960s, when the causal agent of MD was 
first identified as a herpesvirus by an electron microscopic examination of infected 
chicken kidney cell cultures (Churchill and Biggs, 1967). 
1.2 Herpesviruses - a brief biology 
Herpesviruses are important pathogens that cause diseases in mammals and birds. 
They are DNA viruses belonging to the family Herpesviridae. The name ‘Herpes’ is 
derived from the Greek word "herpein" (to creep), referring to the skin conditions 
such as eczema and cancer, that were evident in ancient times (Wildy, 1973). All 




characteristic for each virus. In the latent phase of infection, the viral genome 
remains in the host cell with the expression of only a few viral genes. 
Herperviruses have a unique four-layered structure: a core containing the large, 
double-stranded DNA genome is enclosed by an icosahedral capsid which is 
composed of capsomers. The capsid is surrounded by an amorphous protein coat 
called the tegument, which is again encased in a glycoprotein-bearing lipid bilayer 
envelope (Davison, 2010). Transcription, genome replication and capsid assembly 
occur in the host cell nucleus. Genes are replicated in a specific order: (1) immediate-
early genes, which encode regulatory proteins; (2) early genes, which encode 
enzymes for replicating viral DNA and (3) late genes, which encode structural 
proteins. 
The family Herpesviridae is divided into three subfamilies, such as 
Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae (Davison, 2010). 
The alphaherpesviruses usually have a short replicative cycle, induce cytopathology 
in monolayer cell culture and have a broad host range. The general replicative cycle 
of betaherpesviruses is long and has a restricted host range; and the 
gammaherpesviruses have a long replicative cycle with a very restricted host range. 
Marek’s disease virus (MDV), the causal agent of MD, belongs to the 
Alphaherpesvirinae family. 
1.3  MDV and its gene contents 
MDV belongs to the genus Mardivirus (Marek’s disease like viruses) in the 
Alphaherpesvirinae family. MDV was initially considered as a member of 
Gammaherpesvirinae because it grows slowly in cell culture and induces T cell 




infection of the Gammaherpesvirinae members, such as Epstein-Barr virus (EBV) 
(Osterrieder et al., 2006). However, molecular characterisation and genome 
sequencing revealed that MDV and HVT (Herpes virus of Turkey) have similarity to 
alphaherpesviruses, such as Herpes Simplex Virus (HSV) or Varicella Zoster Virus 
(VZV) (Fukuchi et al., 1984; Buckmaster et al., 1988; Tulman et al., 2000). There are 
three serotypes of the Mardivirus genus which were initially classified using indirect 
immunofluorescence tests (Bulow and Biggs, 1975). The serotypes are MDV-1, 
which includes all the oncogenic strains and their attenuated forms; MDV-2 includes 
all the non-oncogenic strains isolated from chickens and serotype 3 includes all the 
non-oncogenic strains isolated in turkeys, herpesvirus of turkeys (HVT) (Davison, 
2002; Nair, 2005; Gimeno, 2008).  
A detailed classification of the genus Mardivirus in the context of MDV is given in 
Table 1.1. MDV-1 is now classified as Gallid herpesvirus 2 (GaHV-2), MDV-2 as 
Gallid herpesvirus 3 (GaHV-3) and HVT as a Meleagrid herpesvirus (Schumacher et 
al., 2000), though Osterrieder and Vautherot (2004) proposed changing the 
nomenclature of MDV serotype 1 to be referred to as MDV, because only MDV-1 is 
virulent and thus capable of causing tumours; a feature which is absent in MDV-2 
and HVT as they are avirulent. 
The general genome organizations of Herpesviridae are categorised into six classes, 
from A to F, of which, only class D and E are found in the Alphaherpesvirinae and 
all the members of the Mardivirus demonstrate class E genomes which represent two 
unique sequences (Figure 1.1), a long (unique-long, UL) and a short (unique-short, 
US), each of which is again linked by inverted internal (IRL and IRS) and terminal 




genus revealed that all the members have approximately similar gene contents but 
they differ in terms of GC (guanine and cytosine) content, with 44.1% in MDV-1 and 
53.6% in MDV-2, while in HVT it is 47.2% (Lee et al., 2000a; Tulman et al., 2000; 
Afonso et al., 2001; Kingham et al., 2001). There are several MDV-1 specific genes 
which are not expressed by MDV-2 or HVT, such as Meq (MDV EcoR1-Q) (Jones et 
al., 1992), pp38 (phosphoprotein 38) (Cui et al., 1990) and vIL-8 (viral interleukin-8) 
(Parcells et al., 2001) and two small open reading frames (ORF), BamHI-H family of 
transcripts (pp14 and RLORF9) (Hong and Coussens, 1994; Tahiri-Alaoui et al., 
2009). 
















































1.3.1 pp38 complex 
pp38 is a complex of two related phosphoproteins, pp24 and pp38 (Cho et al., 1998) 
and was initially described as a gene having a potential role in oncogenesis, as it was 
expressed on tumour cells and lymphoid cell lines (Cui et al., 1990). Xie et al. (1996) 
also mentioned that pp38 plays a role in the proliferation of lymphoblastoid cells. 
However, deletion of pp38 in a vv (very virulent) MDV strain resulted in severe 
impairment of in vivo early lytic replication with the retention of low levels of 
oncogenicity, indicating that pp38 is involved in early cytolytic infection and 
dispensable for induction of tumours (Reddy et al., 2002). 
1.3.2 Meq 
Meq is a 339-amino acid (aa)-long protein encoded within the genome of MDV-1 
strains. A variant of Meq is L-Meq which has an insertion of 59 aa of the proline-rich 
repeat and it is found in the MDV-1 vaccine strain (CVI988) (Lee et al., 2000b) and 
in the low virulent strains. Meq is a major determinant of MDV virulence as 
Figure 1.1. Structure of the MDV genome. Two unique regions (UL and US) are 
flanked by the repeats TRL and IRL and TRS and IRS, respectively. The enlarged IRL 
region with the major open reading frames is shown. Adapted and modified from 




indicated by its expression in both latent and transformation stages (Jones et al., 
1992; Lupiani et al., 2004; Spatz et al., 2007; Lee et al., 2008). Meq is characterised 
by an N-terminal bZIP (basic leucine zipper) domain and a proline-rich C-terminal 
transactivation domain (Jones et al., 1992). The bZIP domain of Meq protein 
structurally and functionally resembles oncoproteins of the bZIP family, such as c-
Jun and c-Fos (Qian et al., 1995). 
1.3.3 vIL-8 or vCXC 
MDV genome encodes a highly spliced CXC chemokine gene which was originally 
identified as an IL-8 homologue (Liu et al., 1999; Parcells et al., 2001). Davison and 
Kaiser (2004) proposed the name vCXC for vIL-8 because, like the B-lymphocyte 
chemoattractant CXC chemokines, vIL-8 gene consists of three exons and two 
introns and lacks the ELR (glutamic acid-leucine-arginine) motif. The vIL-8 has a 
significant role in MDV pathogenesis as deletion of vIL-8 in a vvMDV strain 
resulted in highly reduced disease and tumour incidence, when compared to the 
parental virus (Cui et al., 2005). 
1.3.4 BamHI-H family of transcripts 
The MDV BamHI-H region first came into focus as a pathogenic determinant when 
it was revealed that an expansion of the 132 bp tandem repeats takes place within the 
BamHI-D/BamHI-H region during attenuation, though it was reported later that this 
expansion was not the sole determinant for attenuation (Niikura et al., 2006a; Silva 
and Gimeno, 2007). The BamHI-H transcripts include the 1.8 kb transcript which is a 
member of a family of mRNAs expressed as immediate-early genes (Hong and 
Coussens, 1994; Hong et al., 1995). It has two open reading frames (ORF). The first 




encodes a 12 kDa protein, which is expressed through an internal ribosomal entry 
site (IRES) (Tahiri-Alaoui et al., 2009). Though the precise roles have not been 
explored yet, the 1.8 kb family of transcripts were shown to be involved in the 
induction and maintenance of MDV latency (Peng et al., 1994; Hong and Coussens, 
1994; Hong et al., 1995; Hayashi et al., 1999). 
1.4 MD - an evolving viral infection 
Based on the pathogenicity of the virus, MDV-1 can be grouped into four 
pathotypes: (i) mild (mMDV), (ii) virulent (vMDV), (iii) very virulent (vvMDV) and 
(iv) very virulent plus (vv+MDV) (Witter, 1997; Witter and Schat, 2003). These 
pathotypes have been identified on a regular basis over the years, hence indicating a 
continuous evolution of MDV towards greater virulence (Witter, 1997). The 
pathotype was thought to be a mild form of the virus (mMDV) until 1950s based on 
lesions caused by the disease, although there was no isolated virus from this time 
period. The lesions caused by mMDV strains are mainly restricted to nerve tissues 
and sometimes a low incidence of ovarian lymphomas (Witter, 1997). Then, from the 
late 1950s through the 1960s an acute form of MD emerged that caused major 
outbreaks and led to very high mortality (40%) in layers. These virulent strains of 
MDV (vMDV) caused high incidence of visceral and neural lymphomas (Witter, 
1997). The very virulent form of the virus (vvMDV) was discovered in the late 
1970s. This form was able to cause severe acute cytolytic diease and bursal and 
thymic atrophy resulting in early death of the bird (Witter et al., 1980). The increase 
in virulence continued into the late 1990s when very virulent plus strains (vv+MDV) 
were first discovered that can cause high incidence of lymphomas and can even be 




1.5 Pathology and clinical stages of MD 
Pathologically MD is characterized by viraemia (Lee et al., 1981), infection of 
feather-follicle epithelium (Moriguchi et al., 1982), central and peripheral 
neuropathy (Burgess et al., 2001; Gimeno et al., 2001), visceral lymphomatosis 
(Payne and Rennie, 1976), atherosclerosis (Fabricant et al., 1978) and ocular lesions 
(Ficken et al., 1991). MDV clinical signs vary greatly according to the stage of 
infection and the virulence of the virus. The disease has many clinical forms 
including classical MD, lymphomatosis, early mortality syndrome, skin form, ocular 
form and atherosclerosis.  
1.5.1 Classical form of MD 
The classical form of MD is also known as Fowl paralysis which is characterised by 
both peripheral neuropathy, usually associated with the gross enlargement of the 
peripheral nerves and lymphomatosis in visceral organs, predominantly in the 
ovaries. The disease appears as asymmetrical spastic leg paralysis and gradual death 
of birds (Biggs and Payne, 1967).  
1.5.2 Lymphomatosis 
In this form of MD, visceral lymphomas might occur in the gonads, lung, heart, 
mesentery, kidney, liver, spleen, bursa, thymus, adrenal gland, pancreas, 
proventriculus, iris, skeletal muscle and skin due to multifocal lymphoid proliferation 
along with the presence or absence of gross nerve lesions (Payne and Rennie, 1976; 
Witter and Schat, 2003; Payne, 2004). The affected birds usually have no particular 
clinical signs, but sometimes show varying signs from general depression to total 




appears as an enlargement of the affected organ with diffuse or nodular white or grey 
discoloration, whereas in the ovary it has a distinct cauliflower-shaped appearance.  
1.5.3 Early mortality syndrome 
This form was reported in the infection with vv and vv+MDV strains. Though the 
clinical signs of the early mortality syndrome vary according to the susceptibility of 
birds to MD, it is generally characterised by acute cytolytic infection that leads to 
high rates of early morality. The acute cytolytic infection of vvMDV strains is 
characterised by marked atrophy in the bursa and thymus and increased splenic 
necrosis compared to other low virulent MDV strains (Witter et al., 1980; Witter, 
1983). These strains can induce lymphoma in HVT vaccinated birds and in birds 
genetically resistant to less virulent strains (Witter et al., 1980). The vv+MDV strains 
can cause severe brain oedema and acute death and are oncogenic in birds vaccinated 
with bivalent vaccines (Witter, 1997; Gimeno et al., 1999). 
1.5.4 Skin form 
Feather-follicle epithelium (FFE) of skin is the only site in the chicken where MDV 
infection is fully productive. The FFE infection starts usually after 1-2 weeks of 
primary infection, and continues for many weeks. The cells in the corneous and 
transitional layer of the FFE are commonly affected and cloudy swelling and 
hydropic degeneration can be noticed in these cells, followed by local perivascular 
and perifollicular aggregation and proliferation of lymphoid cells (Moriguchi et al., 
1982). Skin biopsies of the perifollicular skin lesions revealed that two distinct 
patterns could be developed in this area: a tumour-associated pattern and a non-




1.5.5 Ocular form 
The ocular form of MD is observed in sporadic cases. The main clinical 
manifestation of this outbreak is blindness in the infected birds (Ficken et al., 1991), 
due to the infiltration of mononuclear cells mainly in the iris, ciliary body and 
conjunctiva. The gross pathology of the eye is characterised by acute uveitis and 
corneal oedema. 
1.5.6 Atherosclerosis 
Atherosclerosis is thickening in the artery walls as a result of deposition of 
cholesterol and other lipid droplets. Infection with MDV is sometimes associated 
with atherosclerosis in the aorta, coronary arteries and other large arteries, which 
appears as a marked narrowing in the lumen of the affected artery with small focal 
plaques 1-2 mm in diameter usually occurring one month after the infection (Minick 
et al., 1979). The association between atherosclerosis and MDV infection was 
investigated by Fabricant et al. (1978) and it was suggested that virus-induced 
necrosis of the medial layer is a crucial factor in the development of atherosclerosis. 
MDV antigens were readily detectable in the medial layer of affected arteries by 
immunofluorescence (Fabricant et al., 1978; Minick et al., 1979; Hajjar et al., 1986).  
1.6 Economic impact of MD in poultry industry 
MD has a tremendous economic impact on the global poultry industry, firstly, 
because of the continuing losses due to the disease and secondly, because of the costs 
of vaccination. The vaccination can prevent formation of tumours but not the 
generation of infectious viruses. Despite the widespread and successful use of 
vaccines since the 1970s, MDV strains have shown continuous evolution in virulence 




(Witter, 1997). The crude estimation of worldwide MD-induced loss is thought to be 
US$1-2 billion per annum (Morrow and Fehler, 2004) which validates the 
importance of developing further control strategies for MD. 
1.7 Major approaches to control MD 
MD is largely a lymphoproliferative disease which can be effectively controlled by 
vaccination. 
1.7.1 Control by vaccination 
MD is the first virus-induced tumour disease to be prevented by vaccination 
(reviewed in Baigent et al., 2006). Though, as mentioned above, despite successful 
vaccination, the virulence of MDV has increased in the course of time. Nair (2005) 
described a periodic step-wise evolution of MDV with the vaccines implemented 
over the last several decades (Figure 1.2).Various vaccines developed from different 
strains of MDV have been introduced since the 1970s. The first vaccine for MD was 
prepared from the oncogenic HPRS-16 strain of MDV-1, which was attenuated by 
serial passages through chicken kidney cell cultures (Churchill et al., 1969). This was 
very soon replaced by the widely used HVT vaccine, developed from the FC126 
strain (Okazaki et al., 1970) to control vMDV strains (Figure 1.2). Both ‘cell-free’ 
and ‘cell-associated’ types of HVT vaccines are available and they are still in use 
either alone, or in combination with other vaccines (Bublot and Sharma, 2004). 
Later, Schat and Calnek (1978) introduced another widely used vaccine, SB-1, which 
was developed from MDV-2, and had synergistic activity when administered with 
HVT (Calnek et al., 1983; Witter and Lee, 1984). Bivalent vaccines were used for 
controlling vvMDV strains (Figure 1.2). Meanwhile in the early 1970s, a vaccine 




vaccine (Rispens et al., 1972a; 1972b), which has been in widespread use and is now 












This vaccine has protective efficacy against vv+ field strains of MDV (Figure 1.2) 
because, being serotype 1, it has a close antigenic relationship with those field strains 
(Baigent et al., 2006). Although vaccination against MD is highly effective, it has 
apparently contributed to the evolution of field strains towards increased virulence. 
1.7.1.1 Future of MD vaccination 
Though MD vaccines are capable of reducing disease incidence, virus replication and 
tumour formation, they do not confer sterile immunity. Vaccination cannot halt 
superinfection with virulent strains and hence, cannot stop virus shedding, resulting 
in the spread of MDV from vaccinated birds to other uninfected birds. Besides this, 
the diffident nature of vaccinal immunity might lead to the evolution of viral 
pathogenicity and emergence of more virulent strains (Gimeno, 2008). The 
Figure 1.2. Periodic step-wise evolution of MDV in response to the introduction of 





increasing virulence of MDV could also be the cumulative effect of some other 
events which have happened globally over the last few decades, such as the 
intensification of poultry production, changes in host genetics, and vaccination 
pressure (Witter, 1997). 
Though the vaccines from the CVI988 strain are still successfully capable of 
controlling MD, it is a matter of great concern that this is one of the last effective 
vaccines currently used and if its efficacy declines in the foreseeable future, the 
result would be disastrous for the global poultry industry (Nair, 2005; Spatz et al., 
2007). To overcome this, one of the areas of research is now focused on modifying 
the MDV genome and hence, building a way for a new generation of molecularly 
defined vaccines, such as vaccines produced by BAC (Bacterial Artificial 
Chromosome) technology (Nair, 2005). 
1.7.1.1.1 BAC and BAC-derived MDV vaccines  
BACs are derivatives of the naturally occurring F (Fertility)-plasmid DNA found in 
E. coli (Kim et al., 1992; Shizuya et al., 1992). Large DNA fragments from various 
genomic sources can be cloned into E. coli using the BAC system, where the DNA is 
easy to manipulate and highly stable due to its low copy number (Shizuya et al., 
1992). Messerle et al. (1997) constructed the first herpesvirus BAC mutant for 
murine cytomegalovirus (MCV) and since then this technology has proved to be a 
vital tool for studying herpesvirus pathogenesis (Warden et al., 2011). 
Several BAC clones have so far been developed for different strains of MDV. 
Schumacher et al. (2000) first reported a MDV BAC clone of the attenuated MDV-1 




region of the virus by homologous recombination, emphasising the fact that the US2 
ORF was non-essential for MDV growth (Petherbridge et al., 2003). 
The BAC mutants grew and replicated as well as their parental strain (Schumacher et 
al., 2000). Subsequently, the vaccine strain CVI988 (Rispens), the virulent Md11 
strain and the very virulent RB1B strain were cloned as infectious BACs 
(Petherbridge et al., 2003; Niikura et al., 2006b). 
MDV BAC clones can be used to study the role of various genes in virus growth and 
replication. For example, UL46-UL49 genes have been studied which encode the 
major tegument proteins (Dorange et al., 2002), and also the viral membrane 
glycoprotein encoding genes, UL10 (gM) and UL49.5 (Tisher et al., 2002).  
Apart from the study of virus genes and their role in virus growth and pathogenesis, 
BACs can also be used to develop new vaccines. Using BAC technology, the large 
sized herpesvirus genome can be easily manipulated. For example, genes which are 
not essential for effective in vitro or in vivo viral replication can be deleted or 
replaced with any marker gene, a feature which made herpesvirus BACs suitable 
candidates for prospective vaccine vectors (Brun et al., 2008). 
Wasson (2011) constructed several mutants of CVI988 BAC strain by replacing 
UL41, US10 and UL50 genes with GFP (Green Fluorescent Protein) as a first step to 
create MDV vaccine vectors that could deliver influenza genes. A Meq-deleted 
MDV BAC vaccine has been developed which was non-oncogenic in vivo and 
provided greater protection than that of the CVI988 or Rispens strain (Silva et al., 
2010). A cosmid-derived Meq-deleted vaccine of a vvMDV strain (Md5) was also 
shown to confer a better or equal efficacy compared to the CVI988 vaccines but 




in chickens with no maternal antibodies (Lee et al., 2008), though it was later 
revealed that the lesions could be attenuated by serial passage of the vaccine strain in 
vitro (Lee et al., 2013). 
1.7.2 Alternative control method - selection and breeding of MD-
resistant chickens 
Another key control measure of MD could be the selection and breeding of MD-
resistant chickens for meat and high egg production (von Krosigk et al., 1972). The 
estimates of heritability of MD resistance were 61% (reviewed in Gavora and 
Spencer, 1979) suggesting good potential for genetic improvement by selection and 
breeding. Genetic resistance to MD and the accompanying immune responses to 
MDV infection are complex, as they are controlled by many genes within and 
outside of the MHC. Moreover, each gene has only a small effect that can also be 
influenced by environmental conditions and other genes (Liu et al., 2001). 
1.7.2.1 The chicken major histocompatibility complex (MHC) 
The chicken MHC is much more compact and simple than the mammalian MHC. It 
contains only 19 genes in a 92 kb region of the B locus of the chicken 
microchromosome 16, making the chicken MHC approximately 20-fold smaller than 
the human MHC (Kaufman et al., 1999). The B-F/B-L region of B locus has all of 
the features of the MHC (Figure 1.3) identified in mammals, as it contains classical 
class I and class II genes and determines serological alloantigens, rapid allograft 
rejection, strong mixed lymphocyte reactions and cellular cooperation in the immune 
response. Briles et al. (1983) suggested that a gene or genes from this region are 












1.7.2.1.1 Role of the MHC in resistance to MD 
Within the chicken MHC (B-F/B-L region), there are two classical class I genes 
(Figure 1.3), of which only one is highly expressed. Shaw et al. (2007) proposed that 
drifting and selection within stable MHC haplotypes led to predominant expression 
of a single class I molecule, which in turn led to strong associations of the chicken 
MHC with resistance to infectious pathogens and response to vaccines. Among MHC 
haplotypes, the B21 haplotype confers the highest order of resistance to MD 
compared to the B4, B12, B15 and B19 haplotypes (reviewed in Kaufman et al., 
1995). Overall, B21 haplotypes have the lowest and B19 have the highest levels of 
MHC class I expression on the cell surface (Kaufman and Venugopal, 1998). 
This MHC-dependent resistance or susceptibility of various haplotypes to MD has 
been studied extensively. The C-type lectin-like receptor genes, B-NK (also called 
BNK or Blec2 (Rogers and Kaufman, 2008)) and B-lec (also called Blec or Blec1 
(Rogers and Kaufman, 2008)) are located next to each other in opposite orientations 
in the chicken MHC (Figure 1.3). They have been considered as potential candidate 
genes for the MHC-mediated resistance to MD as previous reports (Lee et al., 2001b; 
Iizuka et al., 2003) showed that the C-type lectin-like receptors in mouse and rat 
Figure 1.3. The chicken MHC. Adapted and modified from Bumstead and Kaufman 




(Ly49H, NKR-P1 and Clr) are associated with resistance to another herpesvirus, 
cytomegalovirus (CMV). Sequence examination revealed that B-lec is well 
conserved between different haplotypes. In contrast, B-NK has high allelic 
polymorphism and moderate sequence diversity. B-NK is also polymorphic at the 
protein level, and modelling demonstrates significant variation between haplotypes 
in the predicted ligand binding face of B-NK (Rogers and Kaufman, 2008), which 
could be a factor in differing MHC-based resistance to MD in various haplotypes. An 
up-regulation of both MHC class II (Niikura et al., 2007) and vitamin D receptor 
(VDR), which modulates MHC class II cell surface expression and is thus associated 
with MD resistance (Praslickova et al., 2008), was observed following MDV 
infection, suggesting MHC class II as a candidate gene for MD resistance. 
1.7.2.2 Genes outside the MHC 
Resistance to MD is not just influenced by genes in the MHC. Non-MHC genes also 
play a pivotal role in MD resistance. At least 21 separate QTL (quantitative trait loci) 
are involved (Yonash et al., 1999; McElroy et al., 2005). This can be most clearly 
explained by the examples of two inbred chicken lines (61 and 72), which are 
homozygous for the B2 haplotype (Cole, 1968). Lines 61 and 72 are highly resistant 
and highly susceptible to clinical MD, respectively, which is reflected by great 
differences in viraemia levels when challenged with MDV (Lee et al., 1981; 
Bumstead et al., 1997). Bumstead (1998) suggested that a cluster of genes (the 
MDV1 locus) on chicken chromosome 1 are involved in MD resistance in these 
lines. This region has conserved synteny with the lectin-like natural killer (NK) cell 
antigen complex in mice and human (Yabe et al., 1993; Lanier and Phillips, 1996). It 




cytomegalovirus, also maps to this region (Scalzo et al., 1995; Brown et al., 2001; 
Lee et al., 2001a). The chicken protein-protein interactions during MDV infection 
also provided evidence that various non-MHC genes, such as GH (growth hormone), 
SCA2 (Stem cell antigen 2), are associated with MD resistance because the 
transcripts for these genes were differentially expressed between MD-resistant and -
susceptible birds following MDV infection (Liu et al., 2001; Liu et al., 2003). The 
allele frequencies of GH have also altered in response to selection for MD resistance 
(Kuhnlein et al., 1997), suggesting GH as an MD resistance gene. An allele-specific 
expression analysis (Meydan et al., 2011) revealed that the allelic ratios of CD79B 
alter in bursa and thymus in response to MDV infection at 4 and 15 dpi. CD79B 
plays a crucial role in the immune response and, is transcriptionally combined with 
GH, one of the previously identified MD resistance genes. 
Using microarray techniques, Smith et al. (2011) analysed genes differentially 
expressed in the spleen between lines 61 and 72 and identified sixteen genes as 
potential candidates for involvement in MD resistance. Furthermore, by conducting 
ingenuity pathway analysis (IPA) it was shown that one of these genes, immune-
responsive gene 1 (IRG1), was highly expressed in the susceptible line following 
MDV infection. The precise function of IRG1 remains to be determined but it is 
likely to be involved in apoptosis as it clusters with other genes in its expression 
patterns, which are known to be involved in apoptosis or its regulation. This study 
also revealed a unique pathogenicity mechanism of MDV infection in which genes, 
involved in anti-tumour regulation, were down-regulated as early as 4 days after 
infection. In a separate microarray-based study, Yu et al. (2011) identified a total of 




susceptibility which were up-regulated in spleen at 5, 10 and 21 dpi. Of these, genes 
involved in more than 5 bio-functions, such as CD8α, IL-8, USP18, and CTLA-4 
(cytotoxic T-lymphocyte associated antigen-4) were considered to be potentially 
important genes regarding MD resistance or susceptibility. Recently, Haunshi and 
Cheng (2014) reported a differential expression of several non-MHC genes, such as 
TLR3 along with cytokines, IL-6 and IL-8 between CEFs (chicken embryo 
fibroblasts) from resistant and susceptible lines, suggesting an important role for 
these genes in resistance to MD. 
1.7.2.3 Role of host microRNAs in genetic resistance to MD  
MicroRNAs (miRNA) are small (19-24 nucleotides) non-coding RNAs generated 
from longer precursor RNAs and involved in RNA silencing and post-transcriptional 
regulation of gene expression (Treiber et al., 2012). Host miRNAs may also play 
important roles to determine resistance or susceptibility to MD as Zhang et al. (2014) 
reported a significantly differed expression of 34 and 21 miRNA genes between 
resistant and susceptible lines in the control and MDV challenged groups, 
respectively.  
1.8 MDV life cycle 
The well-established ‘Cornell Model’ (reviewed in Calnek, 2001) describes natural 
infection with MDV in susceptible chickens in four phases: (1) early cytolytic (2) 
latent (3) late cytolytic, and (4) transformation. Later, Baigent and Davison (2004) 


















1.8.1 Mode of MDV infection 
MDV is a highly contagious virus and the natural infection occurs with cell-free 
virus through the respiratory tract. The FFE is the only site in infected birds where 
fully productive infection of MDV takes place and infectious, cell-free viruses are 
shed in the environment. Cell-free MDV can be found in two forms in the poultry 
dust. In one form, cell-free viruses are mixed with keratin, which are highly 
infectious but labile, whereas in another form, virus particles remained keratin-
wrapped which are less infectious but more stable in the environment and can remain 
infectious for several months (Carrozza et al., 1973). The MDV-infected poultry dust 
and dander are inhaled by birds and hence, natural infection occurs. 
Following initial infection, MDV is thought to be taken up by macrophages in the 
respiratory tract (Calnek, 2001). However, the actual site(s) and cellular 
Figure 1.4. The life cycle of MDV. Picture kindly provided by Prof. Venugopal 




mechanism(s) involved with uptake have not yet been clearly identified. Little is also 














The avian lung differs significantly from its mammalian counterpart in several ways 
(reviewed in Reese et al., 2006). Firstly, it differs morphologically as birds use air 
sacs to ventilate their lungs in the absence of a diaphragm and unlike mammals, the 
avian lung has unidirectional airflow. The avian lung also lacks alveoli but owns 
tertiary bronchi or parabronchi which are surrounded by a network of blood 
capillaries and are considered as the functional units of gas exchange. A microscopic 
section of the parabronchus is shown in Figure 1.5. A parabronchus is surrounded by 
the interparabronchial septa (5). Air from the lumen of the parabronchus enters into 
the atria (1) and by crossing the interatrial septum (2) into the infundibula (3). The 
Figure 1.5. Microscopic section of parabronchus of a chicken lung. (A) 
Longitudinal section (methylene blue staining) of the parabronchus wall. 1 – 
atrium; 2 – interatrial septum; 3 – infundibulum; 4 – air capillaries; 5 – 
interparabronchial septum. (B) Scanning electron micrograph of a parabronchus 
cut in longitudinal section. (C) Horizontal section of the atria demonstrating 
macrophages in the interatrial septa by immunohistochemistry (stained with mAb 




gaseous exchange then takes place in the blood capillaries (4) that surround the 
infundibulum. The second and most striking difference between the mammalian and 
avian lungs is immunological as avian lungs do not have draining lymph nodes and 
also lack alveolar macrophages due to the absence of alveoli. Hence, the avian lungs 
differ from mammals in terms of immune strategies. Though they have fewer surface 
(free) macrophages, a large population of sub-epithelial macrophages is present. The 
lining epithelial cells of atria and infundibula are phagocytic and also a significant 
number of intravascular macrophages are present in lungs (Maina, 2002). 
It is not exactly known whether lung macrophages directly pick up MDV or become 
infected after an initial round of replication in epithelial cells as seen in the 
respiratory tract infection with VZV (Varicella Zoster virus) (Zerboni et al., 2014). 
Abdul-Careem et al. (2009b) reported a significantly increased number of 
macrophages in lungs of infected chickens compared to uninfected control birds 
based on an aerosol-based infection model with cell-free MDV via the respiratory 
route, suggesting a potential role of macrophages at the primary stages of MDV 
infection. 
1.8.2 Early cytolytic phase  
Macrophages are not only excellent candidates for transporting MDV to primary 
lymphoid organs but they can also be cytolytically infected. Barrow et al. (2003) first 
presented evidence in support of this as viral antigens were identified in the splenic 
macrophages following MDV infection. However, to date no research has been 
carried out regarding MDV-DC (dendritic cell) interaction and it is certainly possible 
that DCs are also infected and transport the virus. From the lungs, MDV is 




caecal tonsil, the thymus and the early cytolytic phase of infection is then evident in 
these tissues with the expression of large amounts of pp38 (MDV early protein) and 
with the presence of MDV genome, between 1 and 7 days post-infection (dpi) (Schat 
et al., 1981). During MDV infection, B lymphocytes are cytolytically infected first 
(Schat, 1981), resting T cells are not, but in turn are cytolytically infected when 
activated, presumably through the cytolytic infection of the B cells (Calnek et al., 
1984b). The cytolytic infection is therefore characterised by lymphocytolysis, 
resulting in necrosis as well as infiltration of inflammatory cells (Baigent and 
Davison, 2004). 
B cells are the primary targets of acute cytolytic infection and in various lymphoid 
tissues, almost 90% of cytolytically infected cells are B lymphocytes, with only 3-
6% cells being CD4+, CD8+ and TCRαβ+ T lymphocytes (Baigent et al., 1998). In the 
spleen, the reason for B lymphocytes to be the main target of cytolytic infection is 
perhaps the anatomical structure, where B cells are directly surrounded by ellipsoid-
associated reticular cells (EARCs). The EARCs are phagocytic and MDV antigens 
can be detected in these cells (Jeurissen et al., 1989). Though infection of B cells 
leads to the activation of T cells, B cells are not absolutely required to activate T 
cells as it was observed in bursectomised chicks that T cells could possibly be 
directly infected by macrophages (Calnek et al., 1984b). 
A microarray analysis revealed an increased expression level (2 to11 fold) of more 
than 78 MDV genes during the cytolytic infection compared to the latent infection. 
Of these, pp38, UL49.5, vLIP, US3 and vIL-8 (vCXC) play critical roles in virus 
pathogenesis (Heidari et al., 2008b). As mentioned above, pp38 is an early protein 




et al., 2002; Lee et al., 2005). UL49.5 is a non-glycosylated transmembrane protein 
involved in down-regulation of MHC class I (Tischer et al., 2002), which is the 
hallmark of lytic infection (Osterrieder et al., 2006). The MDV genome encodes a 
secreted glycoprotein, vLIP, with homology to the pancreatic lipases, which forms a 
covalent bond with lipids and is essential for efficient lytic replication (Kamil et al., 
2005). The US3 orthologue of MDV is involved in virus spread and rearrangement 
of the actin cytoskeleton; and is also essential for growth of some virulent MDV 
strains (Schumacher et al., 2005). 
vIL-8 or vCXC has a significant role during lytic infection as a vIL-8-deleted MDV 
strain showed decreased level of lytic infection (Parcells et al., 2001), though 
deletion of vIL-8 could not prevent the virus either from entering latency or to 
maintain oncogenicity (Cui et al., 2004). However, infection of birds with a mutant 
MDV strain that lacked secreted vIL-8 but not Meq-vIL-8 splice variants resulted in 
significantly reduced disease and tumour incidence (Engel et al., 2012). vIL-8 also 
has a role in recruiting target cells for both lytic and latent infection as it acts as a 
chemoattractant for B and CD4+ CD25+ T cells in vitro (Engel et al., 2012). 
The influence of the host immune system may also direct the course of early MDV 
pathogenesis. Kaiser et al. (2003) reported the role of cytokines during the early 
stage of MDV infection (between 3 and 10 dpi) in resistant and susceptible lines. 
Differences between inbred lines were observed for IL-6 and IL-18, with splenocytes 
from susceptible chickens expressing high levels of both cytokines which might play 
a role in formation of lymphoma in these birds, while splenocytes from resistant 
birds did not express any of these cytokines suggesting their role in promoting 




of the mRNA expression levels of IL-1β, IL-4, IL-6, IL-10, IL-12p35, and IL-13, 
IFN-α, IFN-β, and IFN-γ, chicken myelomonocytic growth factor (cMGF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), and inducible nitric 
oxide synthase (iNOS) in the splenic tissues of chickens infected with a vv+ strain of 
MDV at 5 days post-inoculation (lytic infection).  
1.8.3 Latent phase  
Establishing latent infection inside host cells is an innate feature of Herpesviruses. 
MDV infection shifts from lytic to latent at around 6-7 dpi and a cell-associated 
viraemia (i.e. latent infection of peripheral blood lymphocytes) can be detected.  
In contrast to the cytolytically infected cells, the majority of latently infected 
lymphocytes are T cells with only a smaller proportion of B cells (Calnek et al., 
1984b; Morimura et al., 1998). The cell-mediated rather than the humoral immune 
responses are crucial in the latent phase because the establishment of latency can be 
delayed by thymectomy but not by bursectomy (Schat et al., 1981). 
In the latent phase of infection, the viral genome remains in the host cell with the 
expression of only a few viral genes. Also there is no production of infectious virus 
apart from reactivation of virus. Both host determined and viral factors are evident in 
the switch from cytolysis to latency. However, it is yet to be determined specifically 
whether host-innate immunity or sequential events during MDV pathogenesis switch 
the infection from cytolytic to latent phase (reviewed in Nair, 2013). 
A lack of expression of pro-inflammatory cytokines, such as IL-6 and IL-18 may 
contribute to the establishment and maintenance of latency in MD-resistant lines 
(Kaiser et al., 2003). Soluble mediators like nitric oxide (NO), produced by host 




(Xing and Schat, 2000), thus creating an environment hostile to the virus which in 
turn might lead to latency. MDV expresses a number of genes during latency, such as 
pp14, Meq and latency-associated transcripts (LATs) and also represses the genes 
from the pp38 family, which in turn play a role in the balance between latent and 
lytic infections (Parcells et al., 2003). MDV LATs include two small spliced, non-
polyadenylated RNAs which are called MDV small RNAs (MSRs) and a 10 kb 
polyadenylated RNA. The LATs are antisense to the MDV major immediate early 
regulatory protein, ICP4 (infected cell protein 4), and are thought to interfere with 
translation of ICP4, suggesting their role in suppression of lytic infection (Cantello et 
al., 1994; 1997). Among the genes expressed, Meq plays an important role in 
maintaining MDV latency by blocking the apoptosis of latently infected CD4+ T 
cells and also by transactivating gene expression (Parcells et al., 2003). Microarray 
analysis revealed that a 23 kDa nuclear protein, Meq, and RLORF5 were among the 
few viral genes that were expressed in both lytic and latent phases of infection 
(Heidari et al., 2008b). 
1.8.3.1 Role of MDV microRNAs in latency 
MDV miRNAs have a potential role in the induction and maintenance of latency. 
Burnside et al. (2006) first reported MDV-encoded miRNAs in CEFs infected with a 
very virulent strain (RB1B). A total of 14 pre-miRNA sequences, producing 26 
mature miRNAs, have so far been identified in the MDV-1 genome 
(www.mirbase.org, v.21). As in other herpesviruses, MDV miRNAs are located in 
genomic repeat regions. They are located in two major clusters; the first cluster maps 
to the oncogene Meq, and the second cluster maps ICP4-LAT region (reviewed in 




The functions of most MDV-1 miRNAs are yet to be explored. To date, the well 
characterized MDV-1 miRNA is miR-M4, an orthologue of host miR-155, located in 
the Meq cluster (reviewed in Hicks and Liu, 2013). MDV-1-miR-M4-3p acts to 
maintain latency by down-regulating the production of UL28 and UL32 which are 
involved in the cleavage or packaging of herpesvirus DNA (Muylkens et al., 2010). 
MDV microRNAs produced from LAT transcripts may also contribute to establish 
and/or maintain latency. For example, MDV-1-miR-M7-5p targets MDV immediate-
early (IE) genes ICP4 and ICP27 to down-regulate their expression and thus establish 
latency (Strassheim et al., 2012). 
1.8.3.2 Epigenetic regulations of latency 
Recent studies suggest that the epigenetic machineries, such as histone modifications 
and DNA methylation also play a role in maintaining MDV latency. MDV gene 
expression during latency is mostly restricted to the repeat regions of the viral 
genome (Sugaya et al., 1990). Meq and several noncoding RNAs, including two 
miRNA clusters, are expressed from the repeats of the MDV genome during latent 
infection of T cells. Brown et al. (2012) carried out chromatin immunoprecipitation 
(ChIP) analysis to identify distinct regions of histone modifications in the viral 
genome in MDV-transformed T cell lines and revealed the presence of active histone 
marks, such as H3K9 acetylation and H3K4 trimethylation around the promoters for 
Meq and the miRNAs, but there were no active histone marks in the lytic origin of 
replication (OriLyt), suggesting a role for Meq in the epigenetic regulation of the 
MDV genome repeats. Abundant DNA methylation was also observed across the 
repeats but that was significantly reduced or absent around the active promoters 




be associated with disease resistance or susceptibility as DNMT3a and 3b (DNA 
methyltransferase) were differentially expressed in chicken MD-resistant line (63) 
and MD-susceptible line (72) at 21 day post-MDV infection (Tian et al., 2013). 
1.8.4 Late cytolytic phase 
In the resistant chicken genotypes, latent infection persists at a low level in the spleen 
and blood lymphocytes without additional effects. However, in susceptible birds, or 
those infected with a vvMDV pathotype, a second wave of cytolytic infection begins 
2-3 weeks after primary infection. It is assumed that the virus is carried to the 
thymus, bursa and some epithelial tissues, including the FFE, kidney, adrenal gland 
and proventriculus by latently infected cells, where it becomes reactivated due to a 
secondary phase of immunosuppression. Reactivation from latency is most likely 
associated with a significant increase in expression of the lytic protein pp38. Parcells 
et al. (2003) reported that during reactivation to lytic infection, a number of splice 
variants of Meq predominate which lack several of the domains important to Meq 
trans-activation and trans-repression. At this point, a family of genes, including pp38 
are expressed from the OriLyt region during early stages of reactivation. Recently, 
Jarosinski and Du (2014) reported the expression of RLORF4 gene during 
reactivation, though its precise role is yet to be elucidated. Lymphocytic and 
epithelial necrosis, associated with marked inflammation, infiltration of mononuclear 
cells with severe atrophy, is observed in the above mentioned organs in the late 
cytolytic phase of infection (Baigent and Davison, 2004).  
1.8.5 Fully productive infection in the FFE 
MDV infects various cell and tissue types but only the skin and associated FFE cells 




1970). The virus can be detected in the skin from 10-12 dpi, where it is thought to be 
carried by latently infected peripheral blood lymphocytes, however Abdul-Careem et 
al. (2008) reported detecting MDV in the FFE as early as 4 dpi. Lymphoproliferative 
skin lesions are also associated with the FFE due to virus infection. Induction of host 
responses against MDV is manifested by the infiltration of inflammatory cells, 
consisting of lymphocytes and heterophils into the feather pulp region (Moriguchi et 
al., 1987; Abdul-Careem et al., 2008). Though it is a suitable site for production and 
release of infectious cell-free virus, no cellular component has been identified so far 
to be associated with the productive viral replication in the FFE. It is most likely the 
gradually keratinising cells in the FFE that show less lysosomal activity which 
perhaps protects the virus from degradation (Baigent and Davison, 2004). The MDV 
glycoprotein D (gD) (encoded by US6 gene) might also play a crucial role in the 
production of cell-free virus in vivo, as it is expressed only in the FFE (Niikura et al., 
1999). The role of gD expression in the FFE is still unclear because the US6 gene is 
not required for horizontal transmission of MDV (Anderson et al., 1998). The 
tegument protein VP13/14 (encoded by the UL47 gene) is also highly expressed in 
the FFE of infected chickens (Jarosinski et al., 2012), though its association with 
high viral productivity in the FFE has not been investigated. Infected chickens, 
regardless of their genotypes, shed cell-free virus all through their life spans. 
1.8.6 Transformation 
The eventual outcome of interaction of MDV with the host cell is the neoplastic 
transformation of latently infected lymphocytes to lymphoblastoid tumour cells 
which starts three weeks post-infection. Neoplastic lesions can be found in various 




tissues, resulting in blindness, paralysis and mortality (Calnek, 2001). The spleen is 
likely to be the main, but not only, site for initial proliferation of transformed cells, 
as neoplastic MD lesions can also be seen in splenectomised birds (Schat, 1981). 
MDV-infected neoplastic cells show higher expression of a host-encoded 
extracellular antigen, CD30, which can be identified in the spleen and blood of both 
resistant and susceptible chickens at the later phase of cytolytic infection (Baigent et 
al., 1998; Burgess and Davison, 2002). The vast majority (about 75%) of the cells 
involved in visceral lymphomas are T (CD4+) lymphocytes, whereas only around 
15% are B lymphocytes (Payne and Rennie, 1976). This could be because integration 
of viral DNA into the host cell genome requires cell proliferation; a condition easily 
fulfilled by the population of activated, latently infected T cells, but perhaps not by 
the depleting B cells (Baigent and Davison, 2004). Massive proliferation of 
CD4+TCRαβ+ T cells totally replaces normal tissues in susceptible birds and these 
cells form mature lymphomas by 50 dpi, but in resistant birds CD8α+ T cells prevail 
and the lesions usually disappear from 30 dpi, accompanied by apoptosis (Burgess et 
al., 2001). 
Immunological mediators, produced by MD tumour cells, may be able to down-
regulate immune responses resulting in development of tumour lesions. For example, 
MD tumour cells can express IL-10 and IL-10R, suggesting a strategy of MDV to 
evade host response, which suppresses anti-tumour immunity by increasing Treg 
responses, thereby inhibiting cytotoxic T lymphocyte differentiation and cytokine 
production (Buza and Burgess, 2007). Based on a proteomic approach, Kumar et al. 
(2009) demonstrated that MDV-induced tumours are enriched for expression of 




suppressive environment. Among the MDV genes, Meq plays potential roles in 
transformation of cells in vitro (Levy et al., 2005). Various biochemical and genetic 
studies have revealed that Meq is the principal oncogene of MDV (Parcells et al., 
2001). Along with Meq, telomerase RNAs (vTR) and miRNAs also have important 
roles in MDV oncogenesis.  
1.8.6.1 Role of Meq 
As mentioned before, the oncogene Meq is unique to MDV-1 and is one of the most 
widely studied MDV proteins (reviewed in Nair, 2013). The expression of Meq is 
observed in latency and transformation stages (Qian et al., 1995). Meq is a bZIP 
protein and to show oncogenic property, Meq needs to dimerize with itself and a 
number of other bZIP- and non-bZIP proteins (Brown et al., 2006, Reinke et al., 
2010). Meq plays an important role in oncogenesis as deletion or mutation of Meq 
can prevent tumourigenesis. A Meq-deleted mutant of a vvMDV strain of MDV 
(Md5) did not able to form lymphomas in vivo (Lupiani et al., 2004). The non-bZIP 
interaction of Meq with the CtBP (Carboxyl-terminal binding protein) through the 
PLDLS (proline-leucine-aspartic acid-leucine-serine) motif was shown to be crucial 
for the oncogenicity of the virus, as mutations in the CtBP-interaction domain 
completely eliminated lymphomatosis by MDV (Brown et al., 2006). However, Meq 
is not exclusively required for the induction of tumours by the virus, as Meq 
encoding MDV-1 vaccine strains (such as CVI988) cannot induce tumours, though 
CVI988-encoded Meq proteins are weak transactivators compared to their virulent 




1.8.6.2 Role of MDV telomerase RNA (vTR)  
The IRL-TRL region of the oncogenic MDV genome encodes a telomerase RNA 
(vTR) which has a potential role in tumourigenesis (Fragnet et al., 2003). The vTR is 
a noncoding RNA having structural and functional similarity to the telomerase RNA. 
The enzyme telomerase is involved in preserving the integrity of chromosomes 
during the cell cycle by maintaining the length of telomeres (Greider and Blackburn, 
1985; Yu et al., 1990). It is presumed that vTR might play a role in the generation of 
telomeric elongations at the ends of the viral genome which is crucial for integration 
of MDV genome to the host genome (Morissette and Flamand, 2010). Telomerase is 
a ribonucleoprotein complex consisting of two essential components: a protein 
component (TERT), which is essentially reverse transcriptase (Lingner et al., 1997), 
and an RNA component (TR) which acts as a template for TERT (Greider and 
Blackburn, 1989; Yu et al., 1990). However, MDV-induced lymphomagenesis does 
not require the interaction of vTR with the telomerase protein component (TERT) 
(Kaufer et al., 2010). Shkreli et al. (2007) demonstrated the involvement of c-Myc 
oncoprotein in the transcriptional regulation of vTR during MDV-induced 
lymphomagenesis. While an elevated expression of vTR was essential for the 
induction of tumours (Kaufer et al., 2010), a deletion of vTR substantially reduced 
the ability to induce T cell lymphomas by MDV (Trapp et al., 2006; Kaufer et al., 
2011).  
1.8.6.3 Role of microRNAs in MDV oncogenesis 
MiRNAs are a key component of MDV pathogenesis especially in the transformation 
stage. It was reported that MDV1-miR-M4 is the highest expressed miRNA in MD 




involved in regulating host genes that are involved in several cellular processes, such 
as modulation of lymphocyte proliferation and differentiation and regulation of 
lymphoid-specific transcription (spleen focus forming virus pro-viral integration 
oncogene spi1 [SPI1]), signifying its role in MDV oncogenesis (Hicks and Liu, 
2013). The in vivo role of miR-M4 in the induction of lymphoma has also been 
demonstrated, as viruses deleted in or having a 2-nucleotide mutation in the seed 
region of miR-M4 failed to induce lymphomas (Zhao et al., 2011). An elevated 
expression of the MDV-1 miRNAs, miR-M4, miR-M8, and miRM12 was observed 
in tumour tissues compared to non-tumour tissues in chickens infected with RB1B, 
suggesting a role for these miRNAs in MDV-induced transformation (Xu et al., 
2008). MDV encoded miRNAs are also directly involved in modulating antiviral 
cellular factors including apoptosis. For example, MDV-1-miR-M3 blocked cisplatin 
(a chemotherapy drug)-induced apoptosis by down-regulating the protein level 
expression of Smad2, a crucial  element of the TGF-β (transforming growth factor 
beta) signalling pathway, suggesting a pre-emptive role of this miRNA to create a 
cellular environment suitable for viral latency and oncogenesis (Xu et al., 2011). 
Recently, the role of MDV-1-miR-M4-5p in MDV tumourigenesis has been 
investigated. Luo et al. (2014) identified the latent TGF-β binding protein 1 (LTBP1) 
as a critical target of miR-M4-5p. Down-regulation of LTBP1 leads to the 
suppression of TGF-β which in turn activates the expression of c-myc, a well-known 
oncogene which is crucial for the virus-induced oncogenesis. 
1.9 Mode of spread of MDV 
MDV entry and exit during in vivo infection are mediated by cell-free viruses, but 




infectivity cannot be recovered from supernatant or even from cell lysates. Moreover, 
free enveloped infectious virus particles cannot be detected in the culture medium of 
infected cells, either directly by microscopy techniques or indirectly by infectivity 
assays, which again strongly supports the theory of high cell-associated nature of 
MDV in culture (reviewed in Denesvre, 2013). Nevertheless, MDV spreads from 
cell-to-cell though the exact mechanism(s) is not yet known.  
On the basis of morphology and location, all types of intracellular MDV particles, 
i.e., naked nuclear and cytoplasmic capsids, as well as the primarily and secondarily 
enveloped virions can be identified, but the number of enveloped virions is very low 
and cannot be found in all cells (Denesvre, 2013). Moreover, no extracellular virions 
can be detected, suggesting that MDV is deficient in three crucial steps of 
herpesvirus morphogenesis: the release from the nucleus, the secondary 
envelopment, and the exocytosis of cell-free viruses (Denesvre, 2013). Hence, a 






































Figure 1.6. Mechanisms of virus cell-to-cell spread. (a) Cell-to-cell plasma 
membrane fusion followed by movement of infectious viral material (viral core) into 
the uninfected target cell. Herpesviruses, paramyxoviruses and retroviruses can 
spread by cell-cell plasma membrane fusion. (b) Passage of virions across a tight 
junction. The virus exits basolaterally from an infected cell and is trapped between 
the infected and uninfected cell membranes at the tight junctions. Virions fuse with 
and penetrate the uninfected target cell within the tight junctions. Herpesviruses can 
move across tight junctions. (c) Movement of virions across a neural synapse. 
Virions either bud through the membrane into the synaptic space or are released 
from synaptic vesicles into the cleft. Virions then either fuse directly with the 
opposing synaptic cell or are endocytosed. Rhabdoviruses, herpesviruses and 
paramyxoviruses move across neural synapses. (d) Viral induction of actin- or 
tubulin-containing structures. Poxviruses project from infected to uninfected cells 
using actin tails (left). Herpesviruses can induce actin- and tubulin-containing 
structures that project virions toward adjacent cells (middle). Afsavirus-induced 
actin-containing filopodia project virions towards adjacent cells (right). (e) Viral 
subversion of actin-containing structures. Virus-infected cells stably anchor 
filopodia that project from uninfected cells, which allows virions to travel from an 
infected to an uninfected cell in an actin-myosin-dependent manner. Only 
retroviruses have so far been shown to use this method of spread. (f) Membrane 
nanotube subversion. Nanotubes can form between immune cells, including myeloid 
and lymphocytic cells. Nanotubes appear to be continuous with the plasma 
membrane, contain actin but not tubulin. HIV-1 virions that bud from an infected 
cell can move along nanotubes and infect distant target cells. (g) Virological 
synapses. Immune cells are not constitutively polarised, but contain machinery that 
allows them to polarise their secretory apparatus towards a second cell that is 
involved in an immunological synapse. This machinery can be subverted by 
retroviruses so that an infected cell can polarise viral budding towards the receptor-
expressing target cell in a structure called a virological synapse. Virions bud from 
the infected cell into a synaptic cleft, from which they fuse with the target-cell 





Several possible routes were described for the movement of infectious virus particles 
from cell-to-cell in case of human viruses (Figure 1.6) (Sattentau, 2008), a number of 
which could potentially be used by herpesviruses. Cell-to-cell communication is 
essential for the immune system because by establishing intercellular connectivity 
networks, the cell protrusions may enable immune cells to amplify protective 
responses without relying on the slower process of diffusion (Watkins and Salter, 
2005). However, pathogens may hijack these communication processes to undergo 
cell-to-cell spread. For example, HIV-1 (human immunodeficiency virus type-1) 
utilises a specialised area of immune contact known as virological synapse to spread 
from DCs or macrophages to CD4+ T cells (Fackler et al., 2007). Moreover, like 
other retroviruses, HIV-1 can use intercellular channels for efficient cell-to-cell 
transmission (Sherer et al., 2007). Murid herpesvirus-4 (MuHV-4) also induces 
large-scale cytoskeletal reorganisation in infected myeloid cells (Smith et al., 2007). 
In vitro transmission of MDV in chicken embryo cells requires polymerisation of 
actin cytoskeleton, but not microtubulin (Schumacher et al., 2005). Denesvre (2013) 
proposed two hypotheses to explain the cell-to-cell spread of MDV. The first 
hypothesis suggested the extracellular appearance of a few fully mature virions from 
infected cells which rapidly enter into adjacent cells most likely at specific cell-cell 
contacts, a feature which is also followed by the Human T-cell lymphotropic virus 
type I (HTLV-I) (Majorovits et al., 2008). The second hypothesis proposed that 
intercellular transmission of virions occurred through direct connections between two 
cells. However, the author preferred the first hypothesis because intercellular 
junctions for travelling MDV nucleocapsids of 100 nm or larger in diameter have 




requires gB, gH, and gL (fusion glycoproteins) for replication and cell-to-cell spread 
(Schumacher et al., 2000; Wu et al., 2001), which also suggests an extracellular state 
of the virus. 
1.10 Host immunity against MD 
The outcome of MD is determined not only by the virulence of the virus but also by 
the result of the complex interaction between the components of host immune 
systems. Effective immunity to MD requires involvement and a coordinated activity 
of both the innate and adaptive immunity. These include immune mediators, such as 
cytokines, soluble factors, antibodies, as well as cells, such as macrophages, natural 
killer (NK) cells, T helper (Th) cells, cytotoxic T lymphocytes (CTLs) (Baaten et al., 
2004). Host immunity to MDV is a complex phenomenon and, though various 
components of the innate and adaptive immune systems may differ, there is 
accumulating evidence that both these host responses are in a close and constant 
interaction in infected birds. Following entry through the respiratory tract, cell-free 
MDV is most likely picked up by the phagocytic cells, although the actual site(s) and 
cellular mechanism(s) involved is not yet fully understood. Various receptors, 
cytokines and cells from the innate and adaptive immune systems play crucial roles 
during MDV infection. 
1.10.1 Receptors 
Pathogens of distinct entity have conserved molecular patterns known as pathogen-
associated molecular patterns (PAMPs). PAMPs can be of either exogenous or 
endogenous origin, which includes lipoprotein, peptidoglycan, LPS and pathogen 
nucleic acids, such as dsRNA, ssRNA and CpG DNA. These PAMPs are recognised 




immune system, such as NK cells, macrophages and DCs. Of the various PRRs, 
TLRs (toll-like receptors) are the best characterised family, though the interactions of 
TLRs with MDV have not yet been fully investigated. An up-regulation of TLR3 and 
TLR7 was measured in the lungs of chickens infected with cell-free MDV, 
presumably expressed by the epithelial cells or macrophages in the lungs (Abdul-
Careem et al., 2009b). The mRNA expression level of TLR15 was increased in the 
spleen of MDV-infected chickens at 4, 14 and 21 dpi and the expression of TLR3 
and TLR15 was also up-regulated in MDV-infected bursa at 7 and 14 dpi, 
respectively (Jie et al., 2013). Recently, a higher expression of TLR3 was observed 
in CEFs from a resistant line compared to a susceptible line, indicating a role for this 
gene in exerting resistance to MD (Haunshi and Cheng, 2014). The chicken TLR3 
and TLR7 are intracellular receptors that interact with viral dsRNA and ssRNA, 
respectively (Philbin et al., 2005; Schwarz et al., 2007). TLR15 binds with a variety 
of ligands including viral CpG (Ciraci and Lamont, 2011). MDV is a dsDNA virus, 
therefore the correlation between elevated TLRs (3 and 7) and MDV infection needs 
to be elucidated. However, DNA viruses such as adenovirus, HSV (herpes simplex 
virus) and vaccinia virus can produce dsRNA during their replication cycles within a 
few hours of infection (Weber et al., 2006). An up-regulation of MDA-5 (melanoma 
differentiation-associated gene-5) was also measured in the splenocytes of MDV-
infected chickens at 4, 7 and 21 dpi, indicating that MDA-5 might be involved in 
detecting MDV in chicken (Feng et al., 2013). MDA-5 is another PRR from the RLR 
(retinoic-acid-inducible-gene-I- (RIG-I-) like receptors)-family which recognises 




1.10.2 Role of cytokines  
1.10.2.1 Interferons  
Like mammals, all the members of type I interferons (IFN) are present in chickens 
with the exception of IFN-τ (Kaiser, 2010). IFN-α is down-regulated in various 
Herpesvirus infections (Ambagala and Cohen, 2007; Wu et al., 2009). For example, 
the mRNA expression level of IFN-α was down-regulated in blood of MD-resistant 
chickens compared to the susceptible birds from 1 to 7 dpi with either MDV (RB1B 
strain) or HVT (Quere et al., 2005). The absence of IFN-α transcripts was also 
reported in the latently infected splenocytes of MDV infected birds (Xing and Schat, 
2000). However, Jarosinski et al. (2005) detected an increased expression of IFN-α 
along with other pro-inflammatory cytokines in the chicken brain, suggesting a 
crucial role of pro-inflammatory responses in the development of neurological 
lesions in birds infected with vv+MDV strains. Type I IFNs are also involved in the 
induction of interferon regulatory factors (IRFs), a family of transcription factors that 
take part in antiviral defence, cell growth, and immune regulation. Microarray 
analyses revealed an up-regulation of IRF-1 (Morgan et al., 2001) and IRF-3 (Karaca 
et al., 2004) in the CEFs infected with MDV and HVT, respectively. 
Buscaglia and Calnek (1988) suggested that IFN-γ (type II interferon) might play a 
role in maintaining MDV latency. However, IFN-γ expression was elevated in the 
splenocytes of chickens at the cytolytic phase of MDV infection (Xing and Schat, 
2000; Djeraba et al., 2002a). Quere et al. (2005) reported a down-regulation of IFN-γ 
mRNA level in the blood of susceptible but not in resistant lines of chickens at 1 and 
7 dpi. A significantly higher expression of IFN-γ transcripts was observed in the 




infection with a virulent MDV strain (JM-16) (Abdul-Careem et al., 2009a). Heidari 
et al. (2014) also reported an increased mRNA expression level of IFN-γ in the 
caecal tonsils of MD-susceptible chickens compared to that of resistant line during 
cytolytic phase of infection. However, Kaiser et al. (2003) did not observe any 
differential expression of IFN-γ in the splenocytes between resistant and susceptible 
lines at 3 and 10 dpi. An earlier onset of IFN-γ production along with delayed virus 
replication was evident in leukocytes of resistant chicken lungs compared to 
susceptible birds following intratracheal infection with MDV (Baaten et al., 2009). 
Recently, an up-regulation of the mRNA expression level of IFN-γ was observed in 
the lung mononuclear cells of chickens infected with RB1B strain of MDV at 
cytolytic and latent phases of infection (Parvizi et al., 2014).  
1.10.2.2 Interleukins 
A group of interleukins, including IL-6, IL-10 and IL-18, was up-regulated in MDV 
infection which was more likely associated with disease development rather than 
protection from the disease (Abdul-Careem et al., 2007). Kaiser et al. (2003) reported 
a significant up-regulation of IL-6 and IL-18 in the splenocytes of MD-susceptible 
chickens, whereas neither of the two transcripts was expressed in resistant lines. 
Jarosinski et al. (2005) observed an elevated expression of IL-1β, IL-6, and IL-8 in 
the chicken brain infected with a vv+MDV strain (RK-1). Chickens infected with a 
vvMDV strain (RB1B) also showed higher expression of IL-6 and IL-18 in their 
brain tissues (Abdul-Careem et al., 2006). The mRNA expression level of IL-10 was 
increased in the lung mononuclear cells of chickens infected with RB1B strain of 
MDV (Parvizi et al., 2014). An up-regulation of IL-6, IL-10, IL-13 and IL-18 




that of resistant line during cytolytic phase of infection (Heidari et al., 2014). The 
mRNA expression of IL-6 and IL-8 was increased in CEFs from resistant line than 
those of susceptible line following MDV infection, suggesting an important role for 
these cytokines in resistance to MD (Haunshi and Cheng, 2014). 
1.10.3 Role of NK cells 
NK cells have potent anti-viral activity in the context of herpesvirus infections 
(Paludan et al., 2011). Sarson et al. (2008a) reported elevated expression levels of 
cytolytic proteins, granzyme A and NK lysin in MDV-infected birds, suggesting a 
role of NK cells in the host response in the early stage of MDV infection. An 
increased cytotoxic activity of NK cells was also observed in MD-resistant and 
vaccinated chickens compared to MD-susceptible and unvaccinated chickens 
(Sharma and Okazaki, 1981; Heller and Schat, 1987; Garcia-Camacho et al., 2003). 
NK cells might also play a role during the transformation phase and can target MD-
tumour cells in vitro (Quere and Dambrine, 1988). Bumstead (1998) reported that 
NK cells are also strongly associated with MD-resistance as the MDV-1 locus on 
chicken chromosome 1 has synteny with the NK-cell receptor locus on mouse 
chromosome 6 and human chromosome 12. 
1.10.4 Role of macrophages  
Macrophages play a number of crucial roles in MDV infection (Baaten et al., 2004). 
They were primarily thought to be the carrier cells that phagocytose MDV and 
transport it to the lymphoid tissues. Barrow et al. (2003) first showed MDV 
replication in splenic macrophages in vivo, though in vitro studies could not mimic 
this (Haffer et al., 1979; Barrow et al., 2003). Macrophages can produce large 




inhibitory effects on in vitro and in vivo replication of MD virus in the cytolytic and 
latent phase of MDV infection (Xing and Schat, 2000; Djeraba et al., 2002a). 
Furthermore, genetically resistant chickens produce higher levels of NO than 
susceptible chickens after infection with vMDV (Jarosinski et al., 2002). This is 
perhaps due to an increased arginase production, which inhibits the iNOS pathway in 
susceptible chickens (Djeraba et al., 2002b). Higher levels of NO are produced in the 
infection with vv+MDV strains in vivo than infection with vMDV strains, which 
could initiate NO-induced immunosuppression by prompting apoptosis (Schat, 
2004). NO induced apoptosis is thought to be caused by mitochondrial dysfunction 
(Bustamante et al., 2000). Macrophages, either isolated from MD tumours or 
stimulated with LPS, are also able to kill MDV-transformed chicken cell-line 
(MDCC) cells (Sharma, 1983; Qureshi and Miller, 1991). 
1.10.5 Role of B lymphocytes and antibodies 
B lymphocytes play an important role in MDV infection as indicated by a delay in 
latency and tumourigenesis in bursectomised birds (Schat et al., 1981). In the acute 
cytolytic phase of MDV infection, splenic B cells are the primary targets and 
cytolytic infection of B cells induces activation of T cells (Schat, 1981), which in 
turn play an important role in the context of cell-mediated immunity against MDV. 
Shek et al. (1983) also observed that the primary targets of the cytolytic MDV 
infection were B cells, whereas the subsequent latent infection was found mostly in 
non-B lymphocytes. A rapid depletion of pulmonary B cells was observed in MD-
susceptible chickens which reduced viraemia and substantially affected pathogenesis 
compared to resistant birds following an intratracheal infection with MDV, 




during cytolytic phase of MDV pathogenesis (Baaten et al., 2009). A vIL-8 (vCXC) 
mediated recruitment of B and CD4+ CD25+ T cells was reported as potential targets 
for both lytic and latent infection, which further demonstrates an important role of B 
cells in MDV infection (Engel et al., 2012). The exact role of the antibody mediated 
immune response has not been clearly established in MDV infection as the virus is 
highly cell-associated. Antibodies are produced against MDV glycoproteins, such as 
gB, gE, and gI and there is evidence that antibodies play a role in immunity against 
the virus by neutralizing cell-free viruses, blocking entry of virus into cells, and 
antibody-dependent cell-mediated cytotoxicity (ADCC) (Kodama et al., 1979). 
However, maternally derived antibodies (MDA) can play a dual role during infection 
and vaccination stages. For example, naturally acquired MDA via the egg can delay 
the progression of clinical MD, provide protection against MD-morbidity and 
mortality as well as tumour formation (Burgoyne and Witter, 1973; Lee and Witter, 
1991). On the other hand, MDA can neutralise cell-free HVT vaccines and thus 
reduce host immune response to MDV (Calnek, 1972; Sharma and Graham, 1982). 
1.10.6 T cells and MDV infection 
Although resting T cells are refractory to MDV infection in the cytolytic phase, 
activated T lymphocytes are the predominant target for latent infection and 
transformation (Calnek, 2001). The close immunological and anatomical proximity 
between B and T cells facilitates the spread of MDV to T cells (Baigent and Davison, 
2004). Antiviral immunity against MDV is principally mediated by CD8αβ+ CTLs 
and CD4+ T helper cells, though it is difficult to demonstrate which subset of T 
lymphocytes plays the more crucial role, due to the highly cell-associated nature of 




important antiviral effect that controls the course and outcome of MD, as depletion 
of CD8+ T cells led to higher MDV titres in CD4+ T cells. Omar and Schat (1996) 
reported the cytotoxic activity of CD8+ T cells against cells expressing immediate-
early (ICP4), early (pp38) and late (gB) MDV antigens, whereas no activity of CD4+ 
and γδ T cells was observed for the elimination of these cells. Other studies have also 
confirmed the effect of CD8+ CTLs against various MDV glycoproteins (Omar et al., 
1998; Markowski-Grimsrud and Schat, 2002). CTL responses may also play a role in 
genetic resistance to MD. MDV-stimulated splenocytes demonstrated syngeneic cell-
mediated immune responses against MDV protein ICP4, only in the MD-resistant 
MHC haplotype (B21) but not in the susceptible one (B19), suggesting a protective 
role by inhibiting the secondary cytolytic infection and subsequent lymphoma 
formation in resistant genotype (Omar and Schat, 1996). Using a microarray 
approach, Sarson et al. (2006) showed an increased expression of granzyme A and 
CD8α genes at 7, 14 and 21 dpi, which is suggestive of an up-regulation of CTL 
activity in infected birds following infection with MDV. Another microarray study 
(Yu et al., 2011) also showed that the CD8α gene was significantly up-regulated at 
10 dpi in the splenocytes of MD-resistant chicken line (63), but down-regulated in the 
MD-susceptible chicken line (72). On the other hand, the fold change of CTLA-4 
gene was much lower in line 63 than in line 72 at 10 dpi, indicating a lower level of 
CTLA-4 could possibly be involved in anti-tumor immune response in resistant 
chickens (Yu et al., 2011). 
1.11 Aims and hypothesis 
Resistance to MD in the inbred lines 61 and 72, in terms of viral load, is established 




virus has infected APCs (macrophages and/or DCs), B cells and activated T cells. 
Hence, the resistance mechanisms could be exerted in any or all of these cell types. 
However, it is still unclear at what stage of infection and in/or by which immune 
cells those resistance mechanisms or genes are expressed. Therefore, the overall aim 
of this study is to explore the cellular basis of resistance to MD by developing a new 
in vitro MDV infection model.  
Though the in vivo infection of MDV in macrophages has been reported previously 
(Barrow et al., 2003), in vitro MDV infection of macrophages or DCs has not been 
established yet. In fact, several previous in vitro attempts with macrophages derived 
from blood and bone marrow were not successful (Haffer et al., 1979; von Bulow 
and Klasen, 1983; Barrow et al., 2003) and this led to the belief that MDV-
macrophage infection absolutely requires in vivo conditions (Barrow et al., 2003). 
Therefore, the foremost aim is to set up an in vitro MDV infection model of APCs 
which will eventually bring the opportunity to study the cellular basis of resistance in 
MD resistant (61) and susceptible (72) chickens. Macrophages and DCs will be 
cultured from the chicken bone marrow to establish the model. Macrophages will be 
cultured with CSF-1 (Garceau et al., 2010), whereas DCs will be cultured with 
recombinant chicken cytokines, IL-4 and GM-CSF (CSF-2) (Wu et al., 2010). 
In vitro infection of B and T lymphocytes with MDV-infected CEFs has been 
established (Calnek et al., 1984a; Kaspers, 2014). It remains to be established if the 
virus infection can be transmitted from APCs to these cells in vitro. B and T 
lymphocytes will be isolated from spleen rather than bursa or thymus as MDV is first 
carried to the spleen in vivo, presumably by lung phagocytes (macrophages and/or 




The in vitro model system will be established first in outbred chickens, using cell 
(CEF)-associated recombinant GFP-MDV. The model will be developed in several 
steps. In the first step, cell-associated MDV will be co-cultured with macrophages 
and DCs. Infected cells will be separated from uninfected ones using flow cytometry 
based on the presence of GFP-MDV. The aim of this step is to measure and 
characterise the potential in vitro MDV-APC infections. 
In the second step, infected APCs will be co-cultured with B and activated T cells 
with the aim to establish the transmission of MDV infection from APCs to 
lymphocytes. Infected and uninfected lymphocytes will then be characterised. 
In the third step, once the in vitro model is established with cells from outbred birds, 
the model will be repeated with the cells from the inbred resistant (61) and 
susceptible (72) chickens. Following infection, infected and uninfected cells will be 
sorted by fluorescence-activated cell sorter (FACS). The complete transcriptome of 
infected vs. uninfected sorted cells from each line will then be sequenced by RNA-
Seq, and compared to identify signatures of expression associated with infection and 
with resistance. The events of differential viraemia (Burgess and Davison, 2002) and 
gene expression profiles (Smith et al., 2011) occur at the very early stages of 
infection in these two lines, suggesting that the differences between lines 61 and 72 
are due to innate rather than an adaptive host immune responses (Bumstead and 
Kaufman, 2004). Therefore, in this study the hypothesis is that transcriptional 
signatures pre- and post-infection in vitro of APCs from the two inbred lines will 
indicate the gene(s) and possible mechanism(s) involved in resistance or 

















Chapter 2:  






2.1 Bacterial techniques 
2.1.1 Bacterial strains 
E. coli strains JM109 (Promega) and DH5α (Invitrogen), were routinely used for 
propagation of plasmids and BACs (Bacterial Artificial Chromosome). 
Chromosomal genotype of JM109: endA1 recA1 gyrA96 thi hsdR17 (rk-, mk+) 
relA1 supE44 D(lac-proAB) [F´traD36 proAB laqIqZΔM15]. 
Chromosomal genotype of DH5α: F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 
endA1 hsdR17 (rk-, mk+) phoA supE44 λ-thi-1 gyrA96 relA1. 
2.1.2 Preparation of bacterial glycerol stocks 
Bacterial strains containing plasmids of interest or BAC DNA were stored in 
glycerol at -80oC. A bacterial glycerol containing MDV BAC DNA was kindly 
provided by Dr. Bob Dalziel (The Roslin Institute). A single bacterial colony was 
used to inoculate 3 ml of LB medium containing the appropriate antibiotics (see 
section 2.1.3). Cultures were incubated overnight at 225 rpm in an orbital shaker at 
37ºC until the culture had an absorbance reading of OD600 0.6. 850 μl of culture were 
mixed with 150 μl sterile glycerol in a 1.8 ml screw-cap cryovial (Thermo 
FisherScientific, UK) and incubated on ice for 2 h before storage at -80oC. 
2.1.3 Bacterial culture 
E. coli strains were grown in Luria Broth (LB) medium or on LB plates with 1.5 % 
(w/v) agar (see Appendix 1). Autoclaved solid agar was broken up using a sterile 
pipette and melted, followed by cooling to 56oC in a pre-heated water-bath for at 
least 1 h to ensure the agar was not too hot to deactivate the antibiotics added 
subsequently. LB agar was supplemented with the appropriate antibiotic and poured 




μg/ml) (Sigma, UK) were used to propagate E. coli containing plasmids and BACs, 
respectively. Bacteria were plated onto LB agar by streaking with a sterile plastic 
loop and incubated inverted, overnight at 37oC. A single colony was isolated from 
glycerol stocks and inoculated into 5 ml of LB medium supplemented with the 
selective antibiotic. This starter culture was incubated at 37oC for 5-6 h in an orbital 
shaker at 225 rpm. 2.5 ml of the starter culture were used to inoculate 200 ml of LB 
medium, supplemented with the appropriate antibiotic, in a sterile 500 ml 
Erlenmeyer flask. The culture was incubated overnight at 225 rpm in an orbital 
shaker at 37oC. 
2.1.4 Plasmid DNA extraction 
An Endofree Plasmid Maxi Kit (Qiagen, UK) was used for large-scale isolation of 
plasmid DNA. Details of the buffer compositions are given in Appendix 1. The 
procedures were carried out according to the manufacturer’s instructions. Liquid 
bacterial cultures were incubated overnight at 37oC in an orbital shaker (section 
2.1.3). On the following day, bacteria were harvested by centrifugation at 6000 g for 
20 min at 4oC. The bacterial pellet was resuspended in 10 ml buffer P1, before being 
lysed by the addition of 10 ml lysis buffer P2 with vigorous inversion. The mixture 
was then incubated at room temperature (RT) for efficient lysis to take place. The 
lysis reaction was stopped by the addition of 10 ml chilled buffer P3, mixed 
thoroughly by vigorously inverting the sealed tube 4-6 times and centrifuged at 1500 
g for 10 min. Addition of buffer P3 enhanced the precipitation of genomic DNA, 
proteins and cell debris which were removed by passing the lysate through a 




by inverting the tube approximately 10 times, and incubated on ice for 30 min to 
remove the endotoxin. 
Meanwhile, a QIAGEN-tip 500 was equilibrated by applying 10 ml of buffer QBT. 
The filtered lysate was then applied to the column and allowed to drain through the 
QIAGEN-tip. The ER-treated plasmid solution passes through the column by gravity 
flow and plasmids bind to the column. The flow through was discarded and the 
column was washed twice with 30 ml wash buffer QC. Plasmid DNA was eluted 
using 15 ml of Buffer QN. To precipitate the plasmid DNA, 10.5 ml RT isopropanol 
were added to the elution solution, mixed by inversion and centrifuged immediately 
at 3220 g for 60 min at 4oC. The pelleted DNA was washed with 5 ml of endotoxin-
free RT 70% ethanol. The sample was centrifuged again at 3220 g for 10 min, the 
supernatant was removed and the pellet was redissolved in 200 μl TE buffer after air 
drying and stored at -20oC. 
2.1.5 BAC DNA extraction 
BAC DNA extraction was performed using a NucleoBond® BAC 100 Kit 
(Macherey-Nagel GmbH, Germany). Buffer compositions are documented in 
Appendix 1. Bacteria were harvested from LB culture by centrifugation at 6000 g for 
15 min at 4oC. Supernatants were discarded and the bacterial cell pellet was 
resuspended in buffer S1 containing RNase A. Resuspended cells were lysed by 
adding lysis buffer S2 and incubated at RT for 2-3 min. Pre-cooled neutralisation 
buffer S3 was added to the suspension, mixed immediately by inverting the tube 6-8 
times until a homogenous suspension containing an off-white flocculate was formed 
and incubated on ice for 5 min. In the meantime, a NucleoBond BAC 100 column 




through a NucleoBond Folded Filter placed in a funnel of appropriate size. BAC 
DNA binding to the column was carried out by allowing the column to empty by 
gravity flow. The column was then washed twice with buffer N3 and the flow-
through was discarded. DNA was eluted with pre-heated buffer N5 and subsequently 
precipitated by centrifuging at 3220 g for 60 min at 4oC after adding RT isopropanol. 
Pelleted DNA was washed with RT 70% ethanol and centrifuged at 3220 g for 30 
min at 20oC. The ethanol was removed carefully and the pellet was allowed to dry at 
RT for 15-20 min. DNA was reconstituted by dissolving the pellet in 150 μl sterile 
nuclease-free H2O. 
2.2 Cell culture work 
2.2.1 Common reagents for cell culture 
Cell culture media were purchased from Gibco Life Technologies (Paisley, UK) or 
Sigma-Aldrich (Poole, UK). Supplementary components for optimal cell growth, 
such as 100× penicillin-streptomycin (pen-strep) containing 5000 U of penicillin and 
5 mg of streptomycin per ml, 100× L-glutamine (200 mM), 100× non-essential 
amino acids (NEAA), 100 mM sodium pyruvate, foetal bovine serum (FBS, EU 
approved, South American origin), chicken serum (CS, New Zealand origin), 2.5% 
trypsin and 1× versene were all purchased from Gibco Life Technologies. Heat-
inactivated FBS, specifically for macrophage cultures, was purchased from PAA 
Laboratories. 0.4% Trypan-blue solution was obtained from Sigma-Aldrich. FBS 





2.2.2 Growth and maintenance of COS-7 cell line 
COS-7 cells (an African green monkey kidney cell line) were cultured in Dulbecco’s 
Modified Essential Medium (DMEM) (Gibco, UK), supplemented with 10% (v/v) 
FBS (Gibco), 1% (v/v) L-glutamine and 1% (v/v) NEAA. Cells were maintained in 
T75 tissue culture flasks (ThermoFisher Scientific, UK) and grown in a 37
oC 
incubator with 5% CO2. Cell monolayers were split every three to four days. 
Confluent cells were rinsed once with 10 ml PBS followed by addition of 5 ml 
trypsin (2.5%)/versene solution (1:9) per flask and then incubated at 37oC for 4-5 
min. The effect of trypsin was neutralised by adding 10 ml complete DMEM per 
flask and centrifuged for 5 min at 500 g to pellet cells in a bench-top centrifuge. 
Supernatant was discarded, the cell pellet resuspended in 10 ml DMEM and live cells 
counted using a haemocytometer (20 μl cell suspension and 20 μl trypan blue 
solution). Viable cell numbers were calculated using the following equation: 
                                  Number of viable cells 
         Cells/ml =         in middle 25 squares      × 104 × dilution factor 
                                   (haemocytometer) 
A density of 7.5×105 cells was used to seed each T75 flask for routine growth while, 
for transfection purposes, the concentration was 6×106 cells per flask in 12-15 ml 
media. 
2.2.3 Transfecting COS-7 cells for the expression of recombinant 
cytokines 
COS-7 cells were transfected with the mammalian expression vector pCI-neo 
(Promega, UK) containing the gene of interest (IL-4 or CSF-2) and pTARGET 
(Promega, UK) containing CSF-1, for high level, transient expression. Plasmid 




diethylaminoethyl (DEAE)-dextran/DNA method. On the day before transfection, 
6×106 cells were seeded per T75
 flask and incubated at 37oC with 5% CO2. Once cells 
were ready for transfection, a DNA/DEAE complex was prepared as follows: 15 ml 
of serum-free DMEM was added to a Universal and 150 μl chloroquine (10 M), 
112.5 μg plasmid DNA and 90 μl DEAE/dextran were added into the medium 
sequentially. The DNA/DEAE complex was added to the flask after washing the cell 
monolayer twice with PBS and incubated for 3-3.5 h at 37oC with 5% CO2. 
Following incubation, the complex was removed and the cells were washed once 
with PBS. 10% dimethyl sulfoxide (DMSO) in PBS was added to the flask and kept 
at RT for 2 min. This was then removed and replaced with 15 ml DMEM containing 
10% FBS and incubated for 16-24 h at 37oC with 5% CO2. Medium was changed to 
serum-free medium after incubation. Supernatants were harvested on day 3 post-
media change by removing supernatant to a Universal and centrifuging at 200 g for 5 
min to pellet cell debris. Supernatants, containing recombinant cytokine, were stored 
at 4oC. 
2.2.4 Chickens 
The outbred vaccinated chickens used in this study were Brown Leghorn J line birds, 
bred and reared in the poultry unit of The Roslin Institute. The unvaccinated inbred 
line 61 birds were bred in the Poultry Production Unit at the Institute for Animal 
Health, Compton, UK and reared in the poultry unit of The Moredun Research 
Institute, while unvaccinated inbred line 72 chickens were hatched and reared at The 




2.2.5 Generation of chicken bone marrow-derived dendritic cells 
(BMDC) 
Dendritic cells (DCs) were cultured following procedures described in Wu et al. 
(2010). Femurs and tibia from 3 to 6 week-old birds were removed using sterile 
instruments, after the birds were killed by cervical dislocation, and submerged in 
phosphate-buffered saline solution (PBS) on ice until use. Both ends of the bones 
were cut with scissors and each end was flushed with pre-warmed PBS with a 0.45 
mm diameter needle (21 G). Cells were washed once in PBS, pelleted by 
centrifugation and then resuspended in PBS. The cell suspension was then loaded 
onto Histopaque 1077 (Sigma-Aldrich) and centrifuged for 25-30 min at 1200 g with 
the brakes off. Cells from the interface were removed using Pasteur pastettes and 
washed twice in PBS. Cell numbers and viability were assessed with a 
haemocytometer and trypan blue staining (section 2.2.2). The cell concentration was 
then adjusted to 1×106 cells/ml with pre-warmed complete RPMI-1640 medium 
(Sigma-Aldrich) containing 10% heat-inactivated CS, 1% L-glutamine and 0.1% 
pen-strep. Recombinant chicken interleukin-4 (chIL-4) and granulocyte-macrophage 
colony stimulating factor (chCSF-2) were added to the culture medium. A 1:285 
dilution of each cytokine was found to be sufficient for optimal DC growth after 
testing a series of different dilutions. Cells were seeded in 6-well plates (3 ml/well) 
and incubated at 41oC with 5% CO2. On day 2 and 4 of culture, three-quarters of the 





2.2.6 Generation of chicken bone marrow-derived macrophages 
(BMDM) 
Leg bones (femurs and tibia) from 3 to 6 week-old birds were removed and 
processed to isolate cells as in the previously described method (Wu et al., 2010). For 
flow cytometric analysis, cells were cultured at a final concentration of 1×107 
cells/15 ml in Sterilin non-compartmentalised (single-square) tissue culture plates 
(Thermal Scientific, UK) with pre-warmed RPMI-1640 complete medium containing 
10% FBS (PAA), 1% L-glutamine and 0.1% pen-strep. Cells were also seeded at 
1×106 cells/well of Sterilin compartmentalised (25-square) plates (Thermal 
Scientific, UK) specifically for TaqMan qRT-PCR experiments. ExCOS-7 cell 
culture supernatant containing recombinant chCSF-1 (2.5%) was added to the culture 
medium. Cells were incubated at 41oC with 5% CO2. The medium was replaced with 
fresh, pre-warmed complete RPMI-1640 medium containing CSF-1 on day 2 and 5 
of culture. On day 7 of culture, cells were used for further studies. 
2.2.7 Stimulation of DCs and macrophages with lipopolysaccharide 
To induce maturation, cultured DCs were stimulated with lipopolysaccharide (LPS: 
200 ng/ml, Sigma-Aldrich) on day 6 of culture for 24 h, while macrophages were 
stimulated on day 7 of culture with LPS (100 ng/ml) for the time-point mentioned 
above by replacing old culture media with fresh medium containing no cytokines. 
2.2.8 Phagocytosis assay 
This assay was used to determine whether cultured macrophage-like cells are 
phagocytic, by their ability to engulf fluorescently labelled, heat- or chemically-
killed yeast particles (Saccharomyces cerevisiae), called zymosan particles 




media were replaced with fresh media containing zymosan bioparticles (at a ratio of 
50 particles per cell) after washing with pre-warmed PBS. The cells were then 
incubated at 41oC, 5% CO2 for 1 h to allow particle uptake by the cells. Ice-cold PBS 
was used to stop phagocytosis and then the cells were washed four times with cold 
PBS. Fresh media were added into wells before the cells were examined under a 
fluorescence microscope. 
2.2.9 Culturing BMDM and BMDC in T75 flasks 
Sterilin single-square plates were found to be unsuitable for culturing CEFs and co-
culturing of CEFs and DCs could not be achieved in 6-well plates as these plates 
could not accommodate required numbers of CEFs. Thus, both macrophages and 
DCs were cultured in T75 flasks for subsequent co-culturing with CEFs. Bone 
marrow cells were collected and processed as described previously (Wu et al., 2010) 
and cells were resuspended in appropriate cell culture medium and cytokines for 
macrophages (section 2.2.6) and DCs (section 2.2.5). Cells were seeded at a 
concentration of 1.3×107 cells/12 ml for macrophages and 1.6×107 cells/13 ml for 
DCs per flask as repeated trials, in both cases, revealed that it had been possible to 
harvest around 1×107 cells from this amount of seeded cells. Cultured cells were 
incubated at 41oC with 5% CO2 for 4 days and then harvested using 100 mM EDTA 
(section 2.4.3.2). Phenotypic expression of various molecules in these cells was 
examined by flow cytometry before infecting with MDV. 
2.2.10 Collection and culture of chicken embryo fibroblasts (CEFs)  
Fertile eggs from Brown Leghorn chickens were incubated at 37.5oC with 40-50% 
humidity for up to 9-11 days. Chicken embryos were collected aseptically by 




the limbs, wings and visceral organs were also removed. The embryo bodies were 
then chopped into pieces, 4 to 5 were pooled and placed into a 15 ml Falcon tube 
containing 1× trypsin-EDTA (Sigma-Aldrich). The tissues were then incubated for 
15 min at 37oC for proper digestion with vigorous shaking after every 5 min. The 
digestion process was stopped by adding M-199 medium (Gibco) containing 10% 
FBS (Gibco). Cells were pelleted by centrifugation at 500 g for 8 min and 
resuspended with pre-warmed complete M-199 medium containing 10% (v/v) 
tryptose phosphate broth (Invitrogen), 2.7% (v/v) NaHCO3 (Sigma-Aldrich), 5% 
(v/v) FBS (Gibco), 1% (v/v) pen-strep, 0.5% (v/v) gentamycin and 0.001% (v/v) 
fungizone (amphotericin B, 250 μg/ml) (Thermo Scientific). Complete CEF media 
were prepared using a range of FBS concentrations (0.5% to 10%), which were used 
for maintenance and vigorous proliferation of cells, respectively. CEFs were seeded 
in T175 flasks at a concentration of 1.7×10
7 cells per flask and then incubated at 
38.5oC with 5% CO2. Once confluent, cells were harvested by trypsinisation. Cell 
monolayers were rinsed with 10 ml PBS followed by addition of 6.5 ml trypsin/PBS 
(1:7.5) per flask and then incubated at 37oC for 6-8 min. Trypsin digestion was 
stopped by adding 10 ml M-199 medium containing 10% FBS. Harvested cells were 
pelleted by centrifuging at 500 g for 5 min. Pelleted cells were counted using a 
haemocytometer (section 2.2.2), resuspended in freezing medium and stored at -80oC 
(section 2.2.11). 
2.2.11 Preparation of cells for long-term storage 
For CEFs and COS-7 cells, confluent cell monolayers were harvested with 
trypsin/PBS (section 2.2.10) and counted as described previously (section 2.2.2). The 




freezing medium (95% v/v FBS, 5% v/v DMSO). COS-7 cells were resuspended at a 
concentration of 5×106 cells per ml. CEFs were resuspended at a concentration of 
2×107 cells per ml. For macrophages and DCs, following Histopaque 1077 
centrifugation, cells from the intermediate layer were collected, washed twice with 
PBS and centrifuged at 500 g for 5 min. Pelleted cells were resuspended in freezing 
media containing 1 volume FBS (Gibco) and 1 volume of 80% RPMI-1640, 20% 
DMSO. Cells were aliquoted into cryovials, a total of 5×107 cells were resuspended 
per vial. Cryovials were then wrapped with cotton wool, kept in a polystyrene box 
containing RT isopropanol and frozen at -80oC for 24-48 h. Samples were transferred 
into boxes previously kept at -80oC or in liquid nitrogen for long-term storage. 
2.2.12 Resurrection of cells from frozen stocks  
Recommended media were pre-warmed to 37oC. Cryovials were removed from 
liquid nitrogen and kept on ice until ready to thaw. Cells were thawed rapidly in a 
37oC water bath and transferred immediately to a Universal containing 10 ml of the 
appropriate culture medium. Cells were pelleted by centrifuging at 500 g for 5 min, 
resuspended in 10 ml of fresh medium and transferred to culture flasks or plates, 
depending on the experiment. Resurrected cells were always counted prior to culture 
and usually 6-8×106 CEFs were seeded in an T75 flask (12-15 ml media), while the 
numbers were 10-12×106 CEFs per T175 flask in complete M-199 media (32-35 ml) 
(section 2.2.10). 
2.2.13 Transfection of BAC DNA into CEFs using lipofectamine 
LipofectamineTM 2000 (Invitrogen) mediated transfection of CEFs with MDV BAC 
DNA was carried out using the ‘reverse transfection’ method described by Morgan et 




stage, rather than once the CEF monolayer was formed. CEFs, previously stored at -
80oC, were cultured in T75 flasks at 6-8×10
6 cells/flask 3-4 days prior to transfection. 
On the day of transfection, 1 μg of BAC DNA (section 2.1.5) was made up to 100 μl 
in volume with Opti-MEM® reduced serum medium (Gibco, UK) for each well of a 
6-well plate and 5 μl of lipofectamine were mixed with 95 μl of Opti-MEM medium 
in a separate tube. The DNA and lipofectamine samples were then mixed and 
incubated for 45-60 min at RT. During this incubation, CEFs were removed from the 
T75 flask using trypsin/EDTA and resuspended in 10 ml of Opti-MEM after pelleting 
cells by centrifugation. A cell count was carried out as described previously (section 
2.2.2). For each well, the DNA:lipofectamine solution was diluted in 600 μl Opti-
MEM and the total 800 μl of BAC DNA:lipofectamine was mixed with 1×106 CEF 
cells. The DNA:lipofectamine:CEF complex was then made up to 3 ml with Opti-
MEM and added to one well of a 6-well plate. Seeded plates were incubated at 
38.5oC with 5% CO2. Culture media were changed from reduced-serum Opti-MEM 
to pre-warmed 8% CEF media after 7 h. Depending on the confluency of cells, media 
were changed to pre-warmed CEF media containing 0.5-5% FBS the following day. 
2.2.14 Co-culturing macrophages with MDV-infected CEFs in Sterilin 
single-square plates 
On day 4 of macrophage culture in Sterilin single-square plates, cells were infected 
with virus infected CEFs (section 2.2.15) at the MOI of 0.1.  
The optimum level of infection was determined by this formula: 




Here, MOI represents multiplicity of infection which is determined by the number of 
viruses or plaques (pfu) used to infect a single cell. For example, if 1 plaque per cell 
is added, the MOI is 1. 
For 1×107 macrophages, 5 ml of cell-associated MDV were added to the culture plate 
with a total 15 ml of co-culture media (section 2.2.15) and incubated at 41oC with 
5% CO2. 
2.2.15 Co-culturing antigen-presenting cells (APCs) with infected 
CEFs in T75 flasks 
Due to the cell-associated nature of MDV, to infect APCs infected CEFs were used 
in co-culture with the previously cultured chicken bone marrow-derived APCs 
(macrophages and DCs) in T75
 flasks. Co-culture infection procedures were carried 
out using either virus-infected whole CEFs or with pre-sorted infected CEFs. On day 
4 of culture, APCs were infected with a range of infected CEFs (2-5×106 for sorted 
cells or 1×107 for whole CEFs). One flask of uninfected CEFs were also grown and 
added to one flask of macrophage or DC culture on the day of infection as control 
during cell sorting experiments. Co-culture medium was RPMI-1640 containing 2-
10% FBS (Gibco), 1% pen-strep and 1% L-glutamine. Medium for DCs was also 
supplemented with 5% CS. Depending on the experiments, co-cultured cells were 
incubated at 41oC with 5% CO2  for 1, 3 or 5 days post infection (dpi) and then 
harvested (section 2.4.3.2) for downstream experiments, such as flow cytometry or 
cell-sorting analyses. 
2.2.16 Isolation and culture of chicken splenocytes 
The spleen was removed aseptically in PBS, after killing the bird by cervical 




plunger. The single cell suspension was then transferred into a 20 ml Universal, 
avoiding any large clumps of tissue, and allowed to settle. In a 50 ml Falcon tube, 10 
ml Histopaque 1077 were added and the cell suspension was slowly pipetted into the 
tube to form a discrete layer above the Histopaque. The cells were then centrifuged at 
400 g, with brakes off, for 20 min at RT. After centrifugation, cells were taken off 
from the density gradient interface and washed by pelleting the cells twice with PBS. 
Cells were seeded in T75 flasks at 2.5×10
7 cells/flask after resuspending in complete 
RPMI-1640 medium containing 10% FBS, 5% CS, 1% pen-strep and 1% L-
glutamine, and incubated at 41oC with 5% CO2. Cells were then harvested by 
pipetting and resuspended in FACS buffer (PBS containing 1% BSA (bovine serum 
albumin) and 0.1% sodium azide). 
2.2.17 Co-culturing splenocytes with MDV-infected CEFs 
To determine if MDV infection could be transmitted from CEFs to B and T 
lymphocytes, splenocytes were co-cultured with MDV-infected CEFs. Lymphocytes 
were isolated from the spleen using methods described previously (section 2.2.15). 
Infected CEFs were also harvested and sorted on the same day (section 2.4.3.1). 
RPMI-1640 containing 10% FBS, 5% CS, 1% pen-strep and 1% L-glutamine was 
used for co-culturing and infection occurred in T75 flasks at a 1:5 ratio (2.5×10
7 
lymphocytes were infected with 5×106 MDV-infected CEFs). On 2 dpi, cells were 
harvested by pipetting and analysed by flow cytometry (section 2.4.2). 
2.2.18 Co-culturing B lymphocytes or splenocytes with MDV-infected 
macrophages 
MDV-infected macrophages were co-cultured either with splenocytes or pre-sorted B 




cells. B lymphocytes were sorted from the spleen using an AutoMACS Pro Separator 
(section 2.4.4) and mixed with MDV-infected macrophages. Macrophages, infected 
with GFP-MDV-CEFs, were sorted on 3 dpi as described in section 2.4.3.2 and 
mixed with B cells or with splenocytes at infection ratios of 1:5 to 1:20 (infected 
macrophages:B cells or splenocytes). Cells were placed in 6-well plates (for 
macrophages and B cells/splenocytes) or in T75 flasks (for macrophages and 
splenocytes) in RPMI-1640 containing 20% FBS, 5% CS, 1% pen-strep and 1% L-
glutamine, and incubated at 41oC with 5% CO2. The culture medium was 
supplemented with CSF-1 (1:25).  
To infect positively sorted B cells,  2×106 B lymphocytes were co-cultured with 
1×105 pre-sorted MDV-infected macrophages at an infection ratio of 1:20 (infected 
macrophages: positively sorted B cells). Cells were placed in 6-well plates, incubated 
at 41oC with 5% CO2 for 2.5 days. On the other hand, 2.5×10
6 negatively sorted B 
cells were co-cultured with 0.5×106 pre-sorted MDV-infected macrophages at an 
infection ratio of 1:5 (infected macrophages:negatively sorted B cells) in 6-well 
plates and incubated at 41oC with 5% CO2 for 1 day. 
While infecting splenocytes in 6-well plates, 2.5×106 splenocytes/well were infected 
with 0.5×106 pre-sorted infected macrophages, and in T75 flasks, 2.5×10
7 splenocytes 
were infected with 5×106 pre-sorted MDV-infected macrophages. In both cases, the 
infection ratio was 1:5 (infected macrophage:splenocyte). 
2.2.19 Re-infection of CEFs with infected macrophages 
In vivo MDV-macrophage infection was previously reported as a possible abortive 
infection (Barrow et al., 2003). Freshly cultured CEFs were co-cultured with MDV-




plates at 5-7×105 cells per well with 7-8% CEF media 2-3 days prior to addition of 
MDV-infected macrophages. In parallel, newly-isolated macrophages were infected 
with GFP-MDV-CEFs. On day 3 post-infection, infected macrophages were sorted 
and added to the freshly cultured CEFs with co-culture medium (3 ml/well) (section 
2.2.14) containing 0.5-1% FBS and CSF-1 (40 μl/ml). Cells were incubated at 41oC 
with 5% CO2. Transmission of virus infection was explored by observing 
fluorescence plaques formed in the CEF monolayers. 
2.3 Virus growth and propagation 
2.3.1 Virus 
The virus, CVI988 UL41 (Rep) GFP (R), used in this study was generated from a 
BAC construct of vaccine strain CVI988 (Rispens) of MDV serotype 1, in which the 
UL41 gene was replaced with GFP (green fluorescent protein). This was a kind gift 
from Dr. Bob Dalziel (The Roslin Institute). This mutant strain was constructed as 
part of a PhD project, the aim of which was to identify an MDV vector that could 
deliver influenza antigens to poultry, thus stimulating both humoral and cellular 
immune responses (Wasson, 2011). Previously, a MDV CVI988 BAC had been 
constructed to allow genes of interest to be inserted or deleted using mutagenesis 
(Petherbridge et al., 2003). The viral host shut-off (VHS) gene, UL41, was then 
identified as a non-essential gene to be replaced by the gene of interest. A UL41 
deletion mutant replicates as well as the parental strain in vitro (Gimeno and Silva, 
2008). Thus, the non-essential gene UL41 was replaced with the GFP gene, inserted 





2.3.2 Preparation of cell-associated MDV master stocks  
CEF cells, transfected with MDV BAC DNA (see section 2.2.13), formed plaques 
after 5-7 days, displaying the cytopathic effect of MDV infection. The entire cell 
monolayers of three wells of a 6-well plate were removed using 750 μl of 
trypsin/versene solution (1:9) per well. The infected cells were resuspended in 10 ml 
of 5% CEF medium after centrifugation at 500 g for 5 min. The supernatant was 
discarded and the pellet was resuspended in 10 ml pre-warmed 5% CEF media. 
Cryovials containing CEF cells, stored at -80oC, were removed and kept on ice until 
ready to thaw. The cells were thawed rapidly in a 37oC water bath, transferred to a 
Universal containing 10 ml of pre-warmed 5% CEF media and pelleted by 
centrifugation at 500 g for 5 min. Pelleted cells were resuspended in 10 ml of fresh 
5% CEF media, counted and 6-8×106 cells were transferred to each T75 flask. Ten ml 
of infected CEFs were transferred to the flask, which was then incubated at 38.5oC 
with 5% CO2.  
Flasks were observed daily until extensive cytopathic effect was seen, after 
approximately 4-5 days. The infected cell monolayers were removed using 
trypsin/PBS as described previously. The cells from each T75 flask were resuspended 
in 10 ml 5% CEF media and pelleted by centrifugation at 500 g for 5 min. Cryovials 
containing CEF cells were removed from the -80oC freezer (section 2.2.11) and kept 
on ice until ready to thaw. The cells were thawed rapidly in a 37oC water bath and 
transferred to a Universal containing 10 ml of pre-warmed 5% CEF media. Cells in 
Universals were pelleted by centrifugation at 500 g for 5 min. Pelleted cells were 
resuspended in 10 ml of fresh 5% CEF media, counted in a haemocytometer and 8-




Infected cells from each T75 flask, as well as 25 ml pre-warmed 5% CEF media, were 
transferred to each T175 flask. Flasks were incubated in a 38.5
oC incubator with 5% 
CO2. Once extensive cytopathic effects (CPE) were visible, the infected cell 
monolayers were removed using trypsin/PBS and pelleted by centrifugation at 500 g 
for 5 min. Pelleted cells in each T175 flask were resuspended in 2 ml freezing media 
and aliquoted into cryovials (200-400 μl/cryovial). All cryovials were stored at -
80oC. 
2.3.3 Infection of CEFs with MDV for plaque assays 
Previously stored CEFs (section 2.2.11) were cultured in 6-well plates at 5-7×105 
cells/well with 5-7% complete M-199 medium (section 2.2.10) and grown to 
confluence in 2-3 days. The cells were then infected with stock GFP-MDV (100 μl) 
in a serial dilution from 10-1 to 10-6.  
CEF cells, infected with MDV UL41 GFP R, developed focal CPE, also referred to 
as plaques, which consist of rounded, highly refractile cells, after 3-4 days. Cells 
were washed twice with PBS and fixed in ice-cold acetone: methanol for 2 min at 
RT. Fixatives were removed and 1 ml blocking buffer (CAS-Block, Invitrogen, UK) 
was added per well to block any non-specific binding. Plaques were then stained 
using diluted primary antibody HB3 (500 μl/well), specific for the MDV 
glycoprotein B (gB), and incubated at RT for 1 h. Cell monolayers were washed 
three times with 0.05% PBST (PBS and Tween-20) following incubation and the 
secondary antibody (rabbit anti-mouse IgG conjugated with horseradish peroxidase) 
was added (500 μl/well) and incubated again at RT for 1 h. Cell sheets were briefly 
washed three times with PBST and then combined with the specific developing 




until the colour developed. Red-colour plaques were visualised under an inverted 
microscope and counted on the day of staining. 
2.3.4 Growth and storage of MDV working stocks 
To prepare working stocks of MDV, CEFs were seeded in T175 flasks at a 
concentration of 1.1-1.2×107 cells/flask with 35 ml 8-10% complete CEF media in 
the 38.5oC incubator with 5% CO2. On day 2 of culture, when cells were 80-90% 
confluent, the cells in each flask were infected with 400 μl of stock virus (section 
2.3.2) with 0.5% 35 ml CEF media. Cells were incubated for 48 h and then harvested 
using trypsin/PBS as described previously (section 2.2.10). Harvested cells from 
each flask were pooled together, resuspended in 5% complete CEF media and 
reseeded in an equal number of T175 flasks containing 35 ml 5% CEF media. 
Reseeded cells were incubated for a further 48 h and then harvested with 
trypsin/PBS, resuspended in freezing media, aliquoted (250-500 μl/cryovial) and 
stored at -80oC as described previously (section 2.2.11). 
2.3.5 Improvement of virus titre 
MDV-infected CEFs were grown in large numbers and then pooled together to 
obtain a high virus titre. In two separate experiments, six and twelveT175 flasks of 
CEFs were grown and infected with MDV as described previously (section 2.3.4). 
Once plaques formed, cells were harvested using trypsin/PBS (section 2.2.10). Cells 
from six T175 flasks were pooled into one tube and resuspended in 2 ml freezing 
medium and stored at -80oC (section 2.2.11). Cells in the second experiment, with 
twelve T175 flasks of infected CEFs, were also treated as described above. Plaque 
assays for the virus stock from both the experiments were carried out according to 




2.3.6 Culture and growth of viruses from working stock for the 
infection of APCs 
Infected CEFs were grown and then sorted by FACS on the day they were to be used 
to infect macrophages and DCs. CEFs were cultured in T175 flasks for 6 days prior to 
the day of sorting at a concentration of 1.1-1.2×107 cells/flask with 35 ml 8-10% 
CEF media and then infected with 250 μl of working virus on day 2 of culture. 
Virus-infected CEFs were passaged to an equal number of flasks on day 4, after 
harvesting with trypsin/PBS as described in section 2.2.10. On day 6, cells were 
harvested and prepared for sorting (section 2.4.3.1). CEFs were also seeded at 6-
7×106 cells/flask and then infected with stock MDV (100 μl/flask) while culturing 
them in T75 flasks for specific experiments. 
2.3.7 Preparation of cell-free MDV stock 
Due to problems in the co-culture experiments with cell-associated MDV, an attempt 
was made to isolate a stock of cell-free MDV preparation as per methods used to 
prepare cell-free murid herpervirus 4. To do this, twenty T175 flasks of GFP-MDV-
infected CEFs were grown in complete M-199 medium as described in section 2.3.5. 
Once CPE were observed, medium from each flask was removed and the cells 
washed with 10 ml PBS. The cell monolayer was disrupted in PBS by pipetting up 
and down and collected in a 50 ml Falcon tube. The samples were centrifuged at 350 
g for 10 min at 4oC and the supernatants were discarded. Cell pellets from all tubes 
were pooled together and resuspended in 6 ml of suspension buffer (SPGA-EDTA 
buffer + 10% sorbitol) (Appendix 1). The cell pellet was then homogenised with a 
sterile dounce 25-30 times. The cell suspension was transferred to a sterile glass 




was poured into 1.5 ml Eppendorf tubes and centrifuged at 8000 g for 1 h at 4oC. 
Supernatants were collected in a Universal and kept on ice. The pellets were 
resuspended with suspension buffer, and homogenised again in the dounce with 
further centrifugation as described above. Supernatants were collected, pooled with 
the previous ones, aliquoted at100 μl into cryovials and stored at -80oC.  
2.3.8 Infection of macrophages with cell-free MDV 
Macrophages were grown in Sterilin compartmentalised (25-square) plates at 1×106 
cells/well as described in section 2.2.6. On day 4, culture medium was removed from 
each well. Cell-free virus was thawed and 200 μl virus was mixed with 1 ml co-
culture medium (section 2.2.14) added per well and incubated at 41oC with 5% CO2. 
2.4 Immunofluorescence techniques 
2.4.1 Antibodies 
Antibodies used in this study are shown in Table 2.1. 
2.4.2 Flow cytometry  
Depending on the experiment, cultured cells were harvested at different days of 
culture, stained with various antibodies to bind cell surface antigens and then 
analysed by flow cytometry to confirm their identity as immune cells. 
Cells were harvested with vigorous pipetting when cultured in 6-well plates or square 
plates and with 100 mM EDTA while cultured in T75 flasks (section 2.4.3.2). 
Harvested cells were pelleted by centrifugation at 500 g for 5 min and then 
resuspended in FACS buffer. Cells were counted and adjusted to 1-2×106 per 100 µl, 
plated at 100 µl/well in a U-bottomed 96-well plate and pelleted by centrifugation at 











chMHC II Mouse 
2G11/ 
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FITC 1:500 SouthernBiotech 
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mIgG Goat Polyclonal FITC 1:500 SouthernBiotech 




MDV gB Mouse Monoclonal ----- 1:100 
The Roslin 
Institute 
mIgG Rabbit Polyclonal HRP 1:100 Dako 
mIgG Goat Polyclonal Microbeads Neat Miltenyi Biotec 
Table 2.1. Antibodies used in this study. Ch: chicken; ov: ovine; bo: bovine; m: 
mouse. 
buffer and 50 µl per well of primary mAb added to the wells, mixed thoroughly on a 
plate shaker and incubated on ice for 20 min.The cells were pelleted as before and 
washed twice with 100 µl FACS buffer. Secondary Abs (conjugated with different 
fluorescent dyes) were added to wells (50 µl/well) and incubated on ice for 20 min. 




each well were then resupended in 100 µl FACS buffer, transferred to a FACS tube 
(12×75 mm polypropylene tube (BD Falcon, UK)) and topped up to 500 µl with 
FACS buffer. The cell viability dye, 7-AAD (7-aminoactinomycin D) (Life 
Technologies), was added occasionally at 5 µl per tube to allow exclusion of dead 
cells from the analysis. The cells were analysed by flow cytometry using a 
FACSCalibur instrument (BD Biosciences). Viable cells were gated based on 7-AAD 
staining and the resulting data were analysed with FlowJo software. 
2.4.3 Cell sorting by FACSAriaTM Ill cell sorter 
2.4.3.1 Harvesting CEFs and preparation for sorting 
CEFs were grown in T175 flasks and infected with GFP-MDV. On the day of APC 
infection, CEFs were harvested by trypsinisation. After removing medium from each 
flask, cell monolayers were washed once with 10-12 ml PBS. Then 6.5 ml of 
trypsin/PBS (1:7.5) was added to each flask and incubated at 37oC for 6-8 min. 
Following incubation, 10 ml M-199 medium containing 10% FBS were added to 
each flask to stop the digestion process. Harvested cells were pelleted by 
centrifugation at 500 g for 5 min. The cell pellets were resuspended in cell sorting 
buffer (PBS and 1% BSA) and staining procedures were carried out with primary 
(mouse anti-chicken CD45) and secondary antibodies (goat anti-mouse IgG1 
conjugated with Alexa Fluor 647), respectively, as described in section 2.4.2. Prior to 
the sort, antibody-stained cells were passed through a 70 μm cell strainer to prevent 
clogging of cells in the nozzle of the cell sorter and flow-through fluids were then 
collected in sterile FACS tubes. 500 μl of co-culture media (section 2.2.14) were 




cells was collected in each 15 ml Falcon tube and cell sorting analyses were done 
using FACSDiva v 6.1.3 software. 
2.4.3.2 Harvesting macrophages and DCs and preparation for sorting 
Both macrophages and DCs were harvested following the same procedures. After 
washing the cell monolayers once with 10 ml PBS, 5 ml of 100 mM EDTA (1 ml 0.5 
M EDTA and 4 ml PBS) were added to each T75 flask and incubated at 41
oC for 10-
12 min. Cells were collected in a 50 ml Falcon tube after incubation and remaining 
adherent cells were harvested using a cell scraper. Cells were then pelleted by 
centrifugation and stained with primary and secondary antibodies as previously 
(section 2.4.2) and prepared for sorting (section 2.4.3.1). 
2.4.4 B-cell sorting by AutoMACS 
Magnetically-labelled splenic B lymphocytes were sorted either positively or 
negatively with an AutoMACSPro Separator (Miltenyi Biotec). An aseptically 
collected spleen was mashed in PBS and passed through a 70 μm cell strainer. Red 
blood cells were separated using Histopaque 1077 by centrifugation at 400 g for 25-
30 min. Cells from the interface were collected carefully with Pasteur pastettes and 
washed twice with PBS. For positive B cell sorting, cells were stained with primary 
antibody, mouse anti-chicken Bu-1 (1:1000), while for negative sorting, cells were 
stained with anti-CD3 (1:1000) and incubated on ice for 20 min. Following 
incubation, the cells were washed once with AutoMACS Pro running buffer, stained 
with goat anti-mouse IgG microbeads, mixed well and incubated for 45 min on ice. 
Cell separation was then performed with an AutoMACS Pro Separator into collection 




2.5 Molecular techniques 
2.5.1 Extraction of RNA 
RNA extraction was carried out using RNeasy Mini Kits (Qiagen, UK). Buffer 
compositions are listed in Appendix 1. Target cell pellets were lysed with 350 μl 
buffer RLT, mixed with 1 volume of 70% ethanol and transferred to RNeasy mini 
columns. Columns were centrifuged for 30 s at 8000 g and the flow-through was 
discarded. 700 μl of wash buffer RW1 were added to the column, centrifuged at 8000 
g for 30 s, and the flow-through discarded. The column was then washed twice with 
500 μl buffer RPE, which includes centrifugation and discarding the flow-through as 
above. RNeasy spin columns were then placed in new 2 ml collection tubes and 
centrifuged at 10000 g for 1 min. RNA was eluted in fresh 1.5 ml low retention 
collection tubes (Sigma-Aldrich) by adding 30-70 μl RNase-free H2O to the column 
and centrifugation at 8000 g for 1 min. 
2.5.1.1 DNase treatment of RNA  
Ambion Turbo DNA-free Kits (Life Technologies) were used to remove 
contaminating genomic DNA from RNA derived from virus infection experiments.  
Details of the buffer compositions are given in Appendix 1. A 0.1 volume of 10× 
Turbo DNase buffer and 1 μl Turbo DNase were added to the previously extracted 
RNA (section 2.5.1) and mixed gently. The mixture was incubated at 37oC for 20-30 
min. DNase inactivation reagent (0.1 volume) was added after incubation, mixed 
well and incubated at RT for 5 min with occasional mixing. DNase-treated RNA was 




2.5.2 Quantification of nucleic acids 
DNA and RNA concentrations were determined with a NanoDrop Nd-1000 
spectrophotometer (ThermoFisher Scientific) at absorbances of OD260 and OD280. TE 
buffer for plasmids, nuclease-free H2O for BAC DNA and RNase-free H2O for RNA 
were used as negative controls.  
For RNA-Seq, RNA samples were also quantified precisely using the Qubit RNA 
Assay Kit with the Qubit 2.0 Fluorometer (Invitrogen). The kit contents are listed in 
Appendix 1. Qubit working solutions were made by diluting the Qubit RNA reagent 
1:200 in Qubit RNA buffer. Each standard tube (1 and 2) contained 190 μl of Qubit 
working solution and 10 μl of Qubit RNA standard. Each sample tube consisted of 
199 μl of Qubit working solution and 1 μl of RNA sample. The solutions in assay 
tubes were mixed by vortexing for 2-3 s, incubated at RT for 2 min and then read on 
the Fluorometer. The RNA concentrations were calculated using the following 
equation: concentration of sample = QF value × (200/x); where ‘QF value’ is the 
value given by the Qubit 2.0 Fluorometer and ‘x’ is the number of microliters of 
sample added to the assay tube. 
2.5.3 Reverse transcription of RNA 
Superscript III reverse transcriptase (Invitrogen, UK) was used for reverse 
transcription of RNA. As per the manufacturer’s instructions, extracted RNA (5-12 
ng) was mixed with 1 μl of oligoDT (50 μm), 1 μl of dNTP mix (10 mM) and made 
up to 13 μl with sterile, nuclease-free H2O. The mixture was heated to 65
oC for 5 min 
and then chilled rapidly on ice for 1 min. The contents were then collected by brief 
centrifugation and 4 μl 5× First strand buffer, 1 μl 0.1 M Dithiothreitol (DTT), 1 μl 




After a brief vortex and centrifugation, the samples were incubated at 50oC for 1 h, 
followed by 70oC for 15 min. The cDNA samples were stored at -20oC. 
2.5.4 Real-time quantitative RT-PCR analysis  
Total RNA from cells was extracted using RNeasy Mini kits (Qiagen). Cytokine 
mRNA expression levels were assessed using TaqMan real-time quantitative RT-
PCR (qRT-PCR) by a well-described method (Kaiser et al., 2000; Kaiser et al., 2003; 
Wu et al., 2010). Primers and probes used in this study for cytokines and 28S RNA-
specific amplification are given in Table 2.2. All probes were labelled with the 
fluorescent reporter dye 5-carboxyfluorescein (FAM) at the 5 end and the quencher 
N,N,N,N-tetramethyl-6-carboxyrhodamine (TAMRA) at the 3 end. QRT-PCR was 
performed using the TaqMan Fast Universal PCR master mix and one-step RT-PCR 
master mix reagents (Applied Biosystems, Cheshire, UK).  
   RNA 
   target                                 Probe/primer sequence (5'-3') 
 
28S Probe (FAM)-AGGACCGCTACGGACCTCCACCA-(TAMRA) 
F  GGCGAAGCCAGAGGAAACT 
R  GACGACCGATTTGCACGTC 
IL-6 Probe (FAM)-AGGAGAAATGCCTGACGAAGCTCTCCA-(TAMRA) 
F  GCTCGCCGGCTTCGA 
R  GGTAGGTCTGAAAGGCGAACAG 
IL-18 Probe (FAM)-CCGCGCCTTCAGCACGGATG-(TAMRA) 
F  AGGTGAAATCTGGCAGTGGAAT 
R  ACCTGGACGCTGAATGCAA 
Table 2.2. Primers and probes for TaqMan qRT-PCR. F: forward primer; R: reverse 
primer. 
Amplification and detection of specific products in a 10 μl reaction were performed 
using the 7500 Fast Real-Time PCR System with the following cycle conditions: one 




40 cycles of 60oC for 30 s. Quantification of mRNA was based on the increase in 
fluorescence detected by the 7500 Fast Sequence Detection System as a result of 
hydrolysis of the target-specific probes by the 5 exonuclease activity of the DNA 
polymerase during PCR amplification. The passive reference dye, 6-carboxy-c-
rhodamine, was used for normalisation of the reporter signal. Variations in sampling 
and RNA preparation for the Ct values for each cytokine or chemokine were 
normalized using the Ct value of the 28S rRNA product for the same sample (Ct 
indicates threshold cycle value - the cycle at which the change in the reporter dye 
passes a significance threshold). Standard plots of Ct against log10 [RNA] were 
obtained for all genes including 28S RNA. Normalized Ct values were calculated by 
the formula: Ct + (N't - C't) * S/S', where N't is the mean Ct for 28S RNA among all 
samples, C't is the mean Ct for 28S RNA in the sample, S and S' are the slopes of the 
regressions of the standard plots for the cytokine mRNA and the 28S RNA, 
respectively. Results are expressed as 40-Ct to get the actual Ct value by deducting 
each threshold cycle value from the total number of cycles (40).  
2.5.5 Polymerase Chain Reaction 
Polymerase Chain Reactions (PCRs) were performed on a Mastercycler Thermo 
cycler (Eppendorf, UK). Recombinant Taq DNA polymerase (Invitrogen) was used 
in all the PCR reactions. Primers used in this study are listed in Table 2.3. Primers 
were designed using Primer 3 software and supplied by Sigma.  
According to the manufacturer’s instructions, the reaction mixtures for pp38, gB and 
L-Meq contained 5 μl 10× PCR buffer minus Mg2+, 2 μl 50 mM MgCl2, 1 μl 10 mM 
dNTP mixture, 1.5 μl 10 μM forward primer, 1.5 μl 10 μM reverse primer, 0.8 μl Taq 




mixtures contained 5 μl 10× PCR buffer minus Mg2+, 1.5 μl 50 mM MgCl2, 1 μl 10 
mM dNTP mixture, 1 μl 10 μM forward primer, 1 μl 10 μM reverse primer, 0.6 μl 
Taq polymerase (5 Units/μl), 2 μl cDNA template and H2O to 50 μl. Cycling 
conditions were: denaturation at 95ºC for 3 min, then amplification with 30 cycles of 
94oC for 1 min, 59oC for 1 min, and 72oC for 30 s. The PCR was extended for 6 min 
at 72oC, and PCR products were stored at 25oC if used on the same day or at -20oC 
for later use. 























Table 2.3. Primers used for PCR. 
2.5.6 Agarose gel electrophoresis 
DNA analyses were carried out using agarose gel electrophoresis. PCR products up 
to 50 μl were mixed with 5-8 μl 6× DNA loading dye (Thermo Scientific) (see 
Appendix 1) and loaded into 2% (w/v) agarose gels with 5 μl SYBR® Safe DNA gel 
stain (Invitrogen) placed in a horizontal tank containing Tris-Acetate EDTA (TAE) 
buffer (see Appendix 1). Electrophoresis was performed at 400 mA and 140 V/cm2. 
The size of the DNA products was estimated by comparing with a GeneRuler DNA 
ladder mix (Thermo Scientific). Following the run, gels were visualised on a UV 




2.6 Imaging and Image processing 
2.6.1 Live cell confocal microscopy 
Infected and uninfected cells were sorted and then examined under a confocal 
microscope to reveal the detailed morphology of macrophages and DCs on day 3 
post-MDV infection. Prior to the sort, cells were stained with CD45 as per methods 
described in section 2.4.3.2. After sorting, cells were centrifuged at 1200 g for 5 min 
at 4oC and then resuspended in 1 ml co-culture media (section 2.2.14). Resuspended 
cells were placed in sterile chamber slides mounted on borosilicate cover glass 
(Nunc, ThermoFisher Scientific, USA) and incubated at 41oC for at least 2 h. Once 
settled, cells were examined under a Zeiss LSM710 confocal microscope and images 
were taken. Captured images were then analysed with Zen2011 image processing 
software. 
2.6.2 Time-lapse confocal video microscopy 
Video microscopy was carried out to explore the possible mode(s) of virus infection 
of macrophages on the day of MDV infection. Cells, after processing as described in 
section 2.2.6, were cultured in sterile chamber slides, at a concentration of 1×106 
cells/chamber, and infected on day 4 by addition of 1×105 sorted infected 
CEFs/chamber. Following infection, cells were placed under a Zeiss LSM710 
confocal microscope maintaining proper culture conditions with photos captured 
every 10 s. Pictures from an approximately 10 min long experiment were combined 
to create a movie. 
2.7 Statistical analysis 
All data were checked for normality and pairwise statistical comparisons between 




lines (61 and 72) were carried out with a General linear model with Tukey (95% 
confidence interval) and the mean difference of infected macrophages between the 
two inbred lines during cell sorting experiments was measured with 2-sample T-test 
(95% confidence interval) using Minitab 16 software (State College, USA). 
Statistical significance was determined as p<0.05. 
2.8 RNA-Sequencing (RNA-Seq) 
2.8.1 Cells and sample preparation 
BMDM and BMDC from inbred chicken lines 61 and 72 were infected with pre-
sorted MDV-infected CEFs as described previously (section 2.2.15). The infection 
ratio for macrophages was 1:5 (CEF:macrophage) for cell-sorting experiments on 1 
dpi and for DCs it was 1:2.5 (CEF:DC). Following infection, infected, uninfected 
and control APCs were sorted at 1 dpi (details in Chapter 5, section 5.6). RNAs were 
extracted from all groups of cells (section 2.5.1) and DNase treatments were carried 
out (section 2.5.1.1). 
RNA quantification was carried out using a Qubit RNA Assay Kit (section 2.5.2). A 
total of 24 RNA samples (infected and control APCs) from 1 dpi were sent for the 
RNA to be sequenced. 
2.8.2 Library preparation and sequencing 
RNA sequencing was carried out by Edinburgh Genomics facility (The Roslin 
Institute). Samples were prepared for mRNA sequencing using total RNA following 
the Illumina TruSeq RNA Sample Preparation v2 kit protocol. Resulting libraries 
were quality checked on an Agilent DNA 1000 bioanalyzer (Agilent Technologies, 
South Queensferry, UK) and then clustered onto a paired end flow cell using the 




sequencing was carried out on an Illumina HiSeq 2500 using an Illumina TruSeq 
Rapid SBS Kit (Illumina, Little Chesterford, UK). The Illumina HiSeq 2500 platform 
generated 16.7 -100.2 million RNA-Seq read-pairs per sample, with each read 125 
nucleotides in length, resulting in around 75 GB of data.  
Raw sequencing data were processed with the software CASAVA 1.8. The quality of 
the RNA-Seq reads was evaluated using the software FastQC. Adapter sequences 
were trimmed with using the software Cutadapt and data were provided as FASTQ 
files. 
2.9 Analysing data to reveal differential gene expression 
Trimmed reads were analysed with the help of an expert bioinformatician (Richard 
Kuo, The Roslin Institute) to explore the differentially expressed (DE) genes in 
MDV-infected and control APCs. The data analysis pipeline included the following 
steps. 
2.9.1 Mapping reads to the reference genome 
The short reads were aligned to the chicken genome sequence (Galgal4, Ensembl 
release 78). The procedures included analysis of data using Bowtie and TopHat. 
Bowtie (v1.0.0) is an ultrafast short-read aligner that employs a Burrows-Wheeler 
index and a full-text minute-space (FM) index. Reverse permutation of the characters 
in text, as in the Burrows-Wheeler algorithm, was applied in Bowtie to allow the 
large sequencing data to be searched efficiently while keeping the memory footprint 
small. The FM index is the exact-matching algorithm and Bowtie used two 
extensions to allow the sequencing errors or genetic variations to be matched. Bowtie 




TopHat (v2.0.13) is a script that aligns RNA-Seq reads to the chicken reference 
genome in order to identify exon-exon splice junctions. Bowtie cannot align reads 
that span introns. TopHat was created to address this issue of large gaps in 
alignments. It uses Bowtie as an alignment tool and breaks up reads into smaller 
pieces called segments. Many of these segments align contiguously which results in 
build-up of an index of splice junctions. The goal of mapping was to create an 
alignment file, also known as a Sequence/Alignment Map (SAM) file for each of the 
samples that contained, among other details, one line for each of the reads in the 
sample denoting the reference sequence to which it maps, the position in the 
reference sequence, and a Phred-scaled quality score of the mapping (Li et al., 2009). 
2.9.2 Counting reads using HTSeq-count 
Following alignment of the RNA-Seq reads, the data were translated into a 
quantitative measure of gene expression by counting the number of reads that map to 
each gene. Reads aligned to annotated coding regions of the chicken reference 
genome were summarised using HTSeq-count, a tool developed with HTSeq that 
pre-processes RNA-Seq data for differential expression analysis by counting the 
overlap of reads with genes (Anders et al., 2015). 
2.9.3 Analysis using edgeR 
Following summarisation of the total number of reads per gene, the differential gene 
expression was analysed using the software package edgeR (empirical analysis of 
digital gene expression in R). edgeR is designed for the analysis of replicated count-
based expression data (Robinson and Smyth, 2007; 2008). Differentially expressed 




2.10 Functional analysis of DE gene sets 
2.10.1 Analysis with DAVID 
DE significant (p<0.05) gene lists were submitted to DAVID (Database for 
Annotation, Visualization and Integrated Discovery) software package version 6.7 
(http://david.abcc. ncifcrf.gov/). The analysis classification stringency was set to high 
level and the resulting annotation clustering was then limited to an enrichment score 
of >1.00 and FDR for multiple testing was performed by the Benjamin and Hochberg 
method invoked within DAVID (Huang et al., 2009). 
2.10.2 Data analysis using Pathway Express 
To determine which biological pathways were involved with genes differentially 
expressed pre- and post-MDV infection, the Pathway Express software within the 
Onto-Tools suite (http://vortex.cs.wayne.edu/projects.htm) was used. Genes 
differentially expressed in the control and MDV-infected APCs (p<0.05) were 
analysed against a reference list of genes. Annotation was based upon the equivalent 
human genes. In this programme, the analysis was created upon the KEGG (Kyoto 
Encyclopedia of Genes and Genomes) pathways (Kanehisa and Goto, 2000) and it 
displayed the altered expression patterns of genes in biological pathways compared 
to a relevant control. The impact factor analysis included the classical statistics as 
well as other crucial factors such as the magnitude of each gene’s expression change, 
its type, position and interactions in the given pathways. Significance was 
determined using the gamma p-value, which is the p-value provided by the impact 
analysis. Gene networks involved in a particular experimental condition were 




2.10.3 Ingenuity pathway analysis (IPA) 
The IPA programme (Ingenuity Systems - http://www.ingenuity.com/) was used to 
reveal which canonical pathways were inherent in the control APCs and which were 
switched on following MDV infection in the host. The log p-value was calculated 
using the right-tailed Fisher Exact Test with a threshold level >1.3 (p<0.05). 
Canonical Pathways can be defined as idealised or generalised pathways that 
represent common properties of a particular signalling module or pathway. 
2.10.4 Analysis using the Expander programme 
Genes highly expressed in each of the APC groups in the resistant (61) and 
susceptible (72) lines were clustered by similar expression patterns and analysed for 
enriched gene ontology (GO) terms and transcription factor binding sites using the 
Expander (v4.1.1) software package (http://acgt.cs.tau.ac.il/expander/expander.html). 
The enrichment of particular GO terms or transcription factor (TF) binding sites 
within clusters was carried out by using the TANGO and PRIMA algorithms, 
respectively, included in the Expander package. 
2.10.5 Identification of MDV QTL candidate genes 
Genes associated with MD-resistance or susceptibility were identified from the 
chicken genome sequence (Galgal4, release 78) using the BioMart data mining tool 
within the Ensembl database (http://www.ensembl.org/biomart/index.html) based on 
areas of the genome known to be associated with QTL for resistance to MD (as 
defined in Table S1 on CD). This information was then analysed in conjunction with 



















Chapter 3:  
Developing a de novo in vitro MDV infection model 






MDV was primarily described as a lymphotrophic alphaherpesvirus for a long time. 
Though, apart from immune cells, MDV replicates well in vitro in non-lymphoid 
cells such as fibroblasts, kidney cells and embryonic skin cells (Churchill and Biggs, 
1967; Cook and Sears, 1970; Nazerian and Purchase, 1970; Dorange et al., 2000). As 
described in the well-established ‘Cornell model’ of MDV infection, the in vivo 
infection takes place by the cell-free virus wrapped in dander (Calnek, 2001) and 
phagocytic cells from the lungs carry the virus to the spleen and other lymphoid 
tissues following infection through respiratory tract. Virus was then presumed to pass 
to the lymphocytes where it caused lytic infection of B lymphocytes and lytic or 
latent infection in T cells. It was thought that T cells play a crucial role to spread the 
virus in various visceral organs and also in nerve tissues and that is how pathological 
lesions emerge after infection. The apparent predominant role of lymphocytes in this 
disease led scientists to carry out intensive studies on these cells over the years. As a 
result, B and T lymphocytes can be infected in vivo by MDV (Calnek et al., 1984b) 
and in vitro infections of these cells have also been described previously by Calnek 
et al. (1984a) and more recently by Kaspers (2014). However, the role of innate 
immune cells, especially APCs, cannot be ignored. APCs are important cells of the 
innate immune system and play a crucial role at early stages of microbial infection. 
The early differential viraemia (Burgess and Davison, 2002) and gene expression 
profiles (Smith et al., 2011) of MDV-infected MD-resistant and susceptible lines 
support the hypothesis that innate immunity plays a pivotal role in determining 
resistance to MD. However, very little is known about the early stages of MDV 




were the carriers of virus from the lungs to the lymphoid organs, it had not been 
possible to prove that MDV infects macrophages over the years until early 2000s, 
when Barrow et al. (2003) reported a new cell tropism of MDV by showing in vivo 
infection of macrophages for the first time. But their attempts, like those of others 
before (Haffer et al., 1979; von Bulow and Klasen, 1983), to infect macrophages in 
vitro were not successful, which led the authors to believe that macrophages require 
in vivo conditions for infection by MDV (Barrow et al., 2003). Therefore, the aim of 
this Chapter was to establish an in vitro model of MDV infection of APCs. Initial 
experiments focused on culture and characterisation of APCs from outbred J line 
birds. Following this, conditions for the infection of APCs with MDV were 
established and finally the MDV-infected APCs were characterised in detail. 
3.2 Generation of chicken BMDM and subsequent 
characterisation 
3.2.1 Morphological characterisation 
As described in section 2.2.6, bone marrow cells were isolated and processed from 
outbred J line chickens and cultured in Sterilin single-square plates (non-
compartmentalised). Cells were also incubated with zymosan particles to explore 
their phagocytic properties at day 7 of culture (section 2.2.8). 
Chicken bone marrow cells cultured without CSF-1 did not survive (Figure 3.1A). 
The cell population cultured with CSF-1 was heterogeneous with both loosely and 
strongly adherent cell types (Figure 3.1B). It has previously been reported that in 
vitro cultured macrophages show characteristic loosely and strongly adherent cells 
which are representative of immature and mature cells, respectively (Durban and 




phagocytosed zymosan particles (green beads; Figure 3.1C) which revealed that the 
















3.2.2 Characterisation by flow cytometry 
To induce maturation, cultured macrophages were stimulated with LPS (100 ng/ml) 
for 24 h (section 2.2.7), harvested by vigorous pipetting and then stained and 
examined by flow cytometry to confirm their identity as macrophages. 
Immunofluorescence staining was carried out following procedures described in 
section 2.4.2 using fluorescein isothiocyanate (FITC)-labelled antibodies against 
MHC II, chicken mannose receptor (MRC1L-B) and unconjugated antibodies against 
Figure 3.1. Morphological properties of BMDM cultured from outbred chickens. 
(A) Cells cultured without recombinant chicken CSF-1 (B) Cells grown with CSF-




CD11 and ovNKp46. Antibodies and the corresponding antigens are listed in Table 
2.1. The antibody, 2G11 (isotype IgG1) binds with chicken MHC class IIβ (B-L) 
molecules (Kaufman et al., 1990) expressed on the surface of APCs. KUL01 (isotype 
IgG1) is an antibody for the cells of mononuclear phagocytic system and was 
recently identified as binding to chicken mannose receptor, MRC1L-B (Staines et al., 
2014) and the antibody, 8F2 (isotype IgG1) (kindly provided by Bernd Kaspers, 
University of Munich) binds with CD11 expressed on chicken mononuclear 
phagocytes. Gr 13.1 (class IgG1) detects ovNKp46 (kindly provided by Dr. Timothy 
Connelly, The Roslin Institute) and was used as an isotype control antibody. From 
now on, the widely used terms for the antibodies and antigens such as MHC II, 
KUL01, CD11 and Gr 13.1 will be used and designated as ‘markers’ in this thesis. 
Macrophages were gated based on forward (FSC) and side scatter (SSC) and at least 
20,000 cells were counted for each sample. Analysing the data in SSC/FSC plots, the 
cultured cells were revealed to be a heterogenous population, as shown in Figure 
3.2A. Hence, around 70% of the total cells in both unstimulated and stimulated cells 
were gated as macrophages on the basis of cell granularity (SSC) and size (FSC). 
Unstimulated cells showed highest expression of CD11 (99.1%) along with higher 
expression of MHC II (74.7%) and KUL01 (66.3%) (Figure 3.2B). After LPS-
stimulation, no significant variation was observed in the level of surface expression 
of CD11 (99.4%). However, compared with unstimulated cells, KUL01 expression 
was increased nearly 15% in stimulated cells, whereas the expression of MHC II was 
significantly decreased (74.7% to 51.2%) following LPS stimulation (Figure 3.2B). 




























Figure 3.2. Phenotypic characterisation of BMDM derived from outbred chicken 
by flow cytometry. Cells were stimulated with LPS (100 ng/ml) on day 7 of culture 
for 24 h. (A) Unstimulated and LPS-stimulated cells were gated in SSC/FSC plot 
(B) The staining pattern of gated cells for the surface expression of CD11, KUL01, 
and MHC II. Red dashed line: unstained control; blue line: isotype control and red 
solid line: specific mAbs. FL1 shows the fluorescence of FITC. Left panel: 




3.3 Generation of chicken BMDC and subsequent 
characterisation  
3.3.1 Morphological characterisation 
Bone marrow cells from outbred J line chickens were aseptically processed as per 
methods in section 2.2.5 and cultured in 6-well plates. 
Chicken BMDC showed cellular aggregates on culture plates at day 6 (Figure 3.3B) 
which were evident from day 4. These cellular aggregates had the typical 
morphology of DCs (confirmed by Dr. Zhiguang Wu, personal communication). No 
cell aggregates were observed when chicken bone marrow cells were cultured under 










3.3.2 Characterisation by Flow cytometry 
BMDC from outbred chickens were cultured in 6-well plates, stimulated with LPS 
(200 ng/ml) on day 6 for 24 h to induce maturation (section 2.2.7) and then harvested 
by vigorous pipetting. Cells were characterised phenotypically by flow cytometry as 
per procedures in section 2.4.2. 
Figure 3.3. Morphological properties of BMDC cultured from outbred chickens. 
(A) Cells grown without cytokines (on day 6) did not show any cell aggregation. 





Cells were stained with FITC-labelled MHC II, KUL01 and non-labelled CD11 and 
CD40 (detected by antibody AV79, isotype IgG2a). Details of MHC II, KUL01 and 
CD11 are described in section 3.2.2. CD40 is a molecule from TNF-family expressed 
on the surface of APCs and also on thrombocytes (Kothlow et al., 2008). IL-A105 
binds with boCD8 (class IgG2a) (kindly provided by Dr. Timothy Connelly, The 
Roslin Institute) and was used as an isotype control antibody for CD40.  
Cell surface expression of CD11, MHC II and CD40 was reported previously in 
cultured DCs (Wu et al., 2010). In this experiment, along with these markers, KUL01 
was also tested in order to identify a common highly expressed marker for both 
macrophages and DCs. The results of single-colour flow cytometry of cultured DCs 
are shown in Figure 3.4.  
DCs were gated based on FSC/SSC pattern and 20,000 cells were counted for each 
sample. The cultured cells were a heterogenous population, as shown in the 
SSC/FSC plots (Figure 3.4A). The gated DC population included about 80% of the 
total cells in unstimulated and 65% in the LPS-stimulated cells (Figure 3.4A). 
Phenotypic analysis of unstimulated cells showed high surface expression of CD11 
(68.7%) and KUL01 (70.2%), moderate expression of MHC II (39.6%) and 
apparently no expression of CD40 (0.91%) (Figure 3.4B). Compared to unstimulated 
cells, the expression of CD11 and KUL01 was lower (40.3 and 49.6%, respectively) 
in LPS-stimulated cells, and MHC II expression was almost identical (34.8%), 
whereas the pattern of expression of CD40 (0.88%) in stimulated cells followed its 






























Figure 3.4. Phenotypic characterisation of BMDC derived from outbred chickens 
by flow cytometry. Cells were stimulated with LPS (200 ng/ml) on day 6 of culture 
for 24 h. (A) Unstimulated and LPS-stimulated cells were gated in SSC/FSC plot 
(B) The staining pattern of gated cells for the surface expression of CD11, 
KUL01, MHC II and CD40. Red dashed line: unstained control; blue line: isotype 
control and red solid line: specific mAbs. FL1 shows the fluorescence of FITC. 




As observed in macrophages, CD11 and KUL01 were also found to be highly 
expressed markers for DCs. However, KUL01 is well-characterised and 
commercially available, whereas the CD11 antibody is not fully-characterised and is 
considered as putative CD11c in chickens (Wu et al., 2010) and it is also 
commercially unavailable. Therefore, KUL01 was chosen as a suitable marker for 
both macrophages and DCs. 
3.4 Growth of virus stocks and infection of APCs 
3.4.1 Growth and titration of cell-associated MDV 
A GFP-encoded MDV strain was used in this study in order to identify infected cells 
(green) in culture as well as during flow cytometric analysis. MDV-infected CEFs 
were grown and plaque assays were carried out to titrate the virus in CEFs as 
described in section 2.3.3. Plaques were counted under an inverted microscope, but 
were also visible under bright field (Figure 3.5A) and by fluorescence microscopy 









The titre of the virus was calculated in plaque-forming units (pfu) per ml, which is a 
measure of the individual virus particles capable of forming plaques per unit volume. 
Figure 3.5. MDV plaques formed in CEFs visualised under (A) bright field and 




The pfu was determined by counting the dilution containing the least number of 
plaques, in other words, the lowest virus concentration at which the cells were 
infected. The least number of plaques appeared at the dilution of 10-3 and the 
calculated virus titre was 2×105 pfu/ml. This virus was constructed from an 
attenuated vaccine strain (CVI988) and intended for use as a vaccine vector for avian 
influenza virus antigens (Wasson, 2011) and the required titre for vaccination was 
1×103 pfu/mL (Landman and Verschuren, 2003). However, this titre was found not 
high enough to infect APCs as described below. 
3.4.2 Infection of macrophages with cell-associated MDV 
Macrophages were known to be infected by MDV in vivo (Barrow et al., 2003). 
Therefore, attempts were made to infect macrophages first in vitro. Macrophages 
were cultured in Sterilin square plates (in both single and 25-square plates) as per 
methods in section 2.2.6. 
The optimum level of infection was determined by this formula: 
Number of cells to be infected × MOI/ titre of virus.  
As for example, according to this formula, to infect 106 macrophages with a MOI of 
0.2 (2 pfu for 10 macrophages), 1 ml virus was required. This 1 ml virus usually 
represented MDV-infected CEFs from one T75 flask. The total number of CEFs from 
one T75 flask was around 10
7 and it was not possible to accommodate this number of 
cells with previously cultured 106 macrophages per well in 25-square plates. 
The Sterilin non-compartmentalised (single-square) plates were thought to be 
suitable for co-culturing these two types of cells as the plates are spacious. Also from 
this experiment, macrophages were cultured up to day 4 in these plates (section 




infection, cells cultured in these plates were tested for their differentiation to 
macrophages by flow cytometry. Hence, on day 4, macrophages were harvested by 
vigorous pipetting and then stained with CD45, KUL01 and MHC II as described in 
section 2.4.2. KUL01 was previously detected as a suitable marker (section 3.3.2). In 
this experiment, a new marker CD45 and one more (MHC II) from previous studies 
were used to test their surface expressions on macrophages at day 4. CD45 (detected 
by antibody AV53, isotype IgG1) was used as a marker for the common leukocyte 
antigen expressed in all haematopoietic cells. 
Flow cytometric analysis revealed that CD45 and KUL01 were the two 
homogeneous and highly expressed markers compared to cells stained with 
conjugate control, whereas the pattern of MHC II expression was not uniform in 












Figure 3.6. Flow cytometric characterisation of macrophages on day 4 cultured 
in Sterilin single-square plates. Surface staining of macrophages with CD45, 
KUL01, and MHC II compared to conjugate control (IgG1 conjugated with Alexa 




Following culture and characterisation of macrophages in Sterilin single-square 
plates on day 4, macrophages were co-cultured with cell-associated GFP-MDV in 
these plates as described in section 2.2.14. 
Cells were observed for several hours after incubation and it was found that CEFs 
were not able to adhere in these plates and remained floating. Cells were in the same 
condition when examined after 24 h of co-culture. Cells were then harvested by 
pipetting and analysed by flow cytometry after staining with KUL01, CD45 and Gr 
13.1 (isotype control) as per methods in section 2.4.2.  
The total number of cells was very low in each tube due to high level of cell death.  
In flow cytometric analysis, cells were gated first in the SSC/FSC plot (Figure 3.7A) 
and only 5000 cells per sample were counted. 
Analysing cells in the FL1-FL4+ channels following staining with KUL01 and CD45 
revealed that there were significant proportions of uninfected macrophages (37.2% 
and 40.3%, respectively) present in the co-cultured cells (Figure 3.7B). However, no 
infected cells, either CEFs (FL1+FL4-) or macrophages (FL1+FL4+), were detected in 
this experiment (Figure 3.7B). 
From this co-culture infection experiment, it was clear that CEFs cannot be grown 
and eventually co-cultured with macrophages in Sterilin square plates. Repeated 
trials also revealed that these plates do not support cell attachment and growth of 
CEFs. Hence, a suitable culture plate or flask will be required for co-culturing cells. 
It was also noted at this stage that as MDV requires live infected cells to transmit the 
infection in vitro, it would be important to check the frozen stock of MDV-infected 





























Figure 3.7. Flow cytometric characterisation of macrophages following co-
culture with MDV-infected CEFs in Sterilin single-square plates. (A) Cells were 
gated in SSC/FSC plot. (B) Gated cells from SSC/FSC plot were analysed in 
FL1/FL4 dot plots for the surface expression of KUL01 and CD45 in 
macrophages compared to isotype control (Gr 13.1). FL1 shows the fluorescence 
of intracellular GFP (green)-encoded MDV and FL4 shows the fluorescence of 
Alexa Fluor 647 (red) at the surface of the cells. Distribution of cells, FL1-FL4-: 
uninfected CEFs; FL1+FL4-: infected CEFs; FL1-FL4+: uninfected macrophages 




3.4.3 Number of live cells in frozen stock of MDV-infected CEFs 
MDV-infected CEFs, kept at -80oC for several weeks, were thawed and then stained 
directly with the cell viability dye, 7-aminoactinomycin D (7-AAD). This dye can 
penetrate cell membranes in dead cells and then binds DNA while it is not the case if 




















Figure 3.8. Percentage of viable cells in frozen MDV-infected CEFs. Cells were 
stored at -80oC for several weeks and then stained with the cell viability dye 7-
AAD. (A) Infected CEFs were gated in SSC/FSC plot. (B) SSC/FSC gated cells 
were analysed in FL3/FSC plot. FL3 shows the fluorescence of 7-AAD while FSC 
shows cell size. Highly stained cells (G3) are dead, moderately stained cells (G2) 
are dying and unstained cells (G1) are alive. (C) Live cells from G3, G1 and G2 
were plotted in FL1/FSC channel. FL1 shows the fluorescence of intracellular GFP 




Flow cytometric analyses revealed that the percentage of live cells was only 28.2% 
(G1) in frozen MDV-CEFs while the rest of the cells were either dead (G3:45.3%) or 
dying (G2:18.4%) as these cells were highly stained by 7-AAD (Figure 3.8B). When 
analysed further in the FL1 channel, only 0.58% cells were found to be GFP+ within 
these live CEFs (G1) and rest of the GFP+ CEFs (G3:1.4% and G2:0.37%) were 
present in dead and dying CEFs, respectively (Figure 3.8C). 
As a substantial number of GFP+ CEFs were dying in frozen stocks, the follow-up of 
this was to conduct an experiment with freshly cultured MDV-infected CEFs. 
3.4.4 Number of live cells in freshly cultured MDV-infected CEFs 
CEFs were cultured in T75 flask (section 2.2.12) and once confluent, cells were 
infected with working cell-associated MDV stock (section 2.3.4). Once plaques 
formed, CEFs were harvested (section 2.2.10) and stained directly with 7-AAD and 












Figure 3.9. Percentage of viable cells in freshly cultured MDV-infected CEFs. 
MDV-infected CEFs were cultured for 3 days and then stained with the cell 
viability dye 7-AAD. (A) Infected CEFs were gated in SSC/FSC plot. (B) SSC/FSC 
gated cells were analysed in FL3/FSC plot to gate live cells. FL3 shows the 
fluorescence of 7-AAD while FSC shows cell size. (C) Live cells were plotted in 





Flow cytometric analysis revealed that the percentage of live cells was very high 
94.2% (Figure 3.9B) compared to those in frozen stock (Figure 3.8B). Analysis of 
live cells in the FL1 channel also showed that more than 2% of the CEFs were GFP+ 
in the freshly cultured cells (Figure 3.9C) in comparison with frozen stock of MDV 
(0.58%) (Figure 3.8C). 
A significant proportion of CEFs were dying in frozen stocks and a higher 
percentage of GFP+ CEFs could be found in freshly cultured cells, but still the 
amount of GFP+ CEFs (2-3%) (Figure 3.9C) was not enough to conduct the co-
culture infection studies efficiently. 
Therefore, the next step was to explore techniques to increase the virus titre and at 
the same time to identify a suitable culture plate or flask to enable adherence of both 
CEFs and macrophages. 
3.4.5 Improvement of the virus titre 
MDV is strictly cell-associated in vitro and the virus titre so far was not high enough 
to perform the co-culture infection studies. Therefore, two experiments were carried 
out to improve the virus titre as described in section 2.3.5. In the first experiment, the 
virus was titred in infected CEFs harvested from six T175 flasks, whereas a total of 
twelve T175 flasks of CEFs were used in the second titration experiment. 
Plaque assays revealed that the titre was 5×105 pfu/ml in both the experiments which 
was not much higher compared to the previous titre (2×105 pfu/ml). Moreover, the 
previous virus titre was from the stock of one T75 flask of infected CEFs, but this titre 
contained stocks of infected CEFs from six and twelve T175 flasks which made co-
culturing of CEFs and macrophages more difficult. Dr. Lorraine-P Smith (The 




derived MDV was 2.5×103 to 4×105 pfu/ml which was also similar to the titre (104 to 
105 pfu/ml) routinely obtained by Prof. Benedikt Kaufer (Institute for Virology, 
Germany, personal communication). 
As the highest MDV titre (105 pfu/ml) was not high enough to conduct co-culture 
infection studies and repeated attempts failed to obtain a high titre, an attempt was 
made to prepare cell-free MDV from the cultured MDV-infected CEFs. 
3.4.6 Infection of macrophages with cell-free MDV  
MDV is a highly cell-associated virus and in vivo it only becomes cell-free in the 
feather follicle epithelium (FFE). Fully infectious, cell-free viruses can be processed 
and purified from FFE and thus used for in vivo infection studies; however, the titre 
is not high enough to work with in vitro (Prof. Venugopal Nair, The Pirbright 
Institute, personal communication). Hence, an attempt was made to isolate cell-free 
virus from the cultured MDV-infected CEFs. In order to do this, infected CEFs were 
harvested and processed as per methods used to prepare cell-free murid herpesvirus 4 
from infected cells (section 2.3.7). This method involves lysing of infected cells to 
release infectious virus particles. Cell-free GFP-MDV was prepared from twenty T175 
flasks of infected CEFs (section 2.3.7) and macrophages were then infected as 
described in section 2.3.8. Cells were observed daily and GFP expression was rarely 
seen even after 3-4 days of infection (Figures 3.10A.i and A.ii). This suggested a 
lack of virus replication and hence no infectivity of cell-free MDV in vitro. To 
confirm MDV was present in the supernatant, a PCR was performed and it indicated 
presence of MDV DNA (Figure 3.10B) in the suspension buffer (section 2.3.7) 





















As attempts made for improving the virus titre or to make cell-free MDV were not 
successful, it was then decided to continue work with freshly cultured cell-associated 
virus with some new concepts. Firstly, to prepare large amounts of viruses for each 
experiment and secondly, to count high numbers of cells during flow cytometric 
experiments to obtain a higher number of GFP+ cells for further analysis. In addition, 
a suitable culture plate or flask for co-culturing CEFs and macrophages had to be 
found. Efforts were made to culture macrophages in T75 flasks, as CEFs can be 
grown well in those flasks.  
Figure 3.10. Infection of macrophages with cell-free MDV preparation. (A.i and 
A.ii) Macrophage cultures on day 7, following infection with cell-free MDV on day 
4, showing very few expression of GFP. (B) PCR indicates presence of MDV DNA 
(L-Meq, 200 bp) in the cell-free virus preparation. L: GeneRuler DNA ladder mix, 
N: negative control (nuclease-free H2O). S: suspension buffer, SV: suspension 




3.4.7 Culture and characterisation of macrophages in T75 flasks  
To determine whether macrophages could be cultured in T75 flasks, chicken bone 
marrow cells were seeded in T75 flasks as described in section 2.2.9. While 
harvesting cells on day 4 by vigorous pipetting, cells were found to be strongly 
adherent to the culture flasks. So, macrophages were harvested using 5 ml of trypsin 
(2.5%)/PBS solution (1:7).  
In a separate experiment, cells grown in a T75 flask were harvested using 100 mM 
EDTA (section 2.4.3.2). In both cases, harvested cells were then analysed by flow 
cytometry to determine the surface expression of KUL01 in macrophages. 
To compare the KUL01 expression in both cases, macrophages were also cultured 
for 4 days in Sterilin square plates and harvested by pipetting only (section 2.2.6). 
Flow cytometric analysis indicated that macrophages harvested from T75 flasks using 
trypsin/PBS showed lower expression of KUL01 compared to those harvested by 
pipetting from square plate (Figure 3.11A), which could also be seen in the 
difference of their mean KUL01 expression (Figure 3.11A.i). However, this 
difference disappeared when macrophages from T75 flasks were harvested using 
EDTA as shown in the staining pattern (Figure 3.11B) and also in the mean KUL01 
expression (Figure 3.11B.i) compared to those in square plates. 
These two experiments showed that macrophages could be cultured and harvested 
successfully from T75 flasks. Therefore, the next step was to determine the 





























Figure 3.11. Comparison between macrophages cultured in Sterilin square plates 
and T75 flasks. (A) Surface expression of KUL01 in macrophages harvested from 
Sterilin square plates (by pipetting) as well as from T75 flasks (by trypsin) and (A.i) 
differences in geometric mean of KUL01 expression. (B) Surface expression of 
KUL01 in macrophages harvested from Sterilin square plates (by pipetting) as well 
as from T75 flasks (by EDTA) and (B.i) differences in geometric mean of KUL01 
expression. Blue line: isotype control in square plate, red line: isotype control in 
T75 flask, green line: KUL01 expression in square plate, black line: KUL01 





3.4.8 Phenotypic characterisation of macrophages cultured in T75 
flasks 
Macrophages were cultured in T75 flasks and harvested with EDTA as described 
previously (section 2.2.9). Following harvest, cells were stained with KUL01, CD45 




















Figure 3.12. Phenotypic characterisation of macrophages by flow cytometry 
cultured for 4 days in T75 flasks from outbred chickens. (A) Cells were gated in 
SSC/FSC plot. (B) SSC/FSC gated cells were plotted in FL3/FSC channel to gate 
live cells. FL3 shows the fluorescence of 7-AAD. (C) Live cells were tested for 
surface expression of KUL01 and CD45 compared with unstained cells and with 
cells stained with isotype control antibody (Gr13.1). FL4 shows the fluorescence of 




Cells were first analysed in SSC/FSC plot and more than 70% cells were gated as 
macrophages for further analysis (Figure 3.12A). Live cells were gated in FL3/FSC 
channel based on 7-AAD staining (Figure 3.12B). Phenotypic analyses of live cells 
showed that the surface expression of both KUL01 and CD45 was homogenous and 
very high (97.8% and 99.7%, respectively) in macrophages cultured in T75 flasks 
(Figure 3.12C).  
In this experiment, macrophages were successfully cultured and characterised in T75 
flasks. Therefore, the next step was to infect macrophages with cell-associated MDV 
in T75 flasks. 
3.4.9 Co-culture infection of macrophages with GFP-MDV CEFs 
BMDM from outbred chickens were cultured in T75
 flasks for 4 days (section 2.2.9). 
Meanwhile, MDV-infected CEFs were grown in two T75
 flasks following procedures 
in section 2.3.4. The CEF culture and infection procedures were planned such that 
fully formed and confluent plaques were visible on the day of macrophage infection 
(day 4 of macrophage culture). 
On day 4 of macrophage culture, infected CEFs from one T75
 flask were added to one 
T75
 flask of macrophage culture as per methods in section 2.2.15. One T75
 flask of 
uninfected CEFs was also grown and added to one separate T75
 flask of cultured 
macrophages as control. 
Cells were observed daily and it was found that a very thick cell monolayer was 
formed in both control and infected flasks at 2 dpi. These thick cell sheets 
spontaneously detached from the flasks at around 60 h post-infection. Therefore, 





























Figure 3.13. Co-culture infection of macrophages with MDV-infected CEFs. (A) 
Cells were gated in SSC/FSC plot on the basis of cell granularity (SSC) and size 
(FSC). (B) SSC/FSC gated cells were plotted in FL3/FSC channel to gate live cells. 
FL3 shows the fluorescence of 7-AAD. (C) Gated cells from FL3/FSC plot were 
analysed in FL1/FL4 dot plots for the surface expression of KUL01 and CD45 in 
macrophages compared to isotype control (Gr 13.1) in both control and infected 
cells. FL1 shows the fluorescence of intracellular GFP (green)-encoded MDV and 
FL4 shows the fluorescence of Alexa Fluor 647 (red) at the surface of the cells. 
Distribution of cells, FL1-FL4-: uninfected CEFs; FL1+FL4-: infected CEFs; FL1-




Cells were stained with KUL01, CD45 and Gr 13.1 following procedures in section 
2.4.2 and then analysed by flow cytometry. 
Phenotypic analysis revealed that co-cultured CEFs and macrophages had uniform 
cell granularity and size as shown in SSC/FSC plot (Figure 3.13A) and around 80% 
cells were gated to analyse in the FL3/FSC channels. Of these, more than 95% cells 
were found alive as they remained unstained with 7-AAD (Figure 3.13B). 
Flow cytometric analyses of live cells in both control and infected groups for the 
surface expression of KUL01 and CD45 are shown in Figure 3.13C. It was shown 
that CEFs and macrophages could be distinguished as separate cell populations in 
KUL01 and CD45 staining (Figure 3.13C). These figures also indicating infected 
CEFs (FL1+FL4-) and more importantly, for the first time infected cells were stained 
with KUL01 and CD45 (FL1+FL4+), which were most likely MDV-infected 
macrophages.  
Though these infected cell percentages were not high (1.39% and 1.63% for KUL01 
and CD45, respectively) (Figure 3.13C), a count of 2×106 cells per tube revealed that 
around 20,000 infected cells could be sorted from each of the antibody-stained FACS 
tubes, which in total would be almost 105 cells/T75 flask. A clear demarcation 
between CEFs and macrophages was observed after staining with CD45 in both 
control and infected group (Figure 3.13C) and therefore, CD45 marker was selected 
for the downstream cell sorting experiments. 
The results of this experiment were the first evidence that macrophages can be 
infected by MDV in an in vitro co-culture study. However, this method was found 




2.5 days and there was always a concern that cell monolayers could come off from 
the plastic at any time. 
One more concern that arose at this stage was that as macrophages appear in chicken 
embryo at the very early stage (3-4 days) of embryonic development (Cuadros et al., 
1993) and CEFs in this study were collected from 9-11 days old embryos, it was not 
clear whether or not these infected macrophages (Figure 3.13C) were derived from 
MDV-infected CEF cultures. 
To test this, freshly cultured CEFs and MDV-infected CEFs were tested for the 
presence of macrophages with KUL01 staining in the next experiment. 
3.4.10 Testing CEFs and MDV-infected CEFs for the presence of 
macrophages 
CEFs and MDV-infected CEFs were grown in T75 flasks as per the methods in 
section 2.3.5. Cells were harvested, stained with KUL01 and Gr 13.1 and then 
analysed by flow cytometry (section 2.4.2). 
Uninfected CEFs (Figure 3.14A) contained a significant amount of KUL01+ 
macrophages (12%). A similar proportion of cells (8%) was also observed in MDV-
infected CEFs and there were a few infected macrophages (0.07%) as well (Figure 
3.14B). 
It was discovered from this experiment that macrophages are present in uninfected 
and infected CEF cultures and so, the infected macrophages in previous experiment 
(section 3.4.9) could be derived from MDV-infected CEF cultures. As a 
consequence, an attempt was made to sort only GFP+ CEFs by FACS after staining 
MDV-infected CEFs with CD45 and then to infect macrophages with these pre-




























Figure 3.14. Flow cytometric analyses showing presence of macrophages in CEFs 
and MDV-infected CEFs. KUL01+ cells in (A) CEFs and in (B) MDV-infected 
CEFs while comparing with cells stained with isotype control (Gr 13.1). FL4 
shows the fluorescence of Alexa Fluor 647 conjugated with KUL01. FSC 




3.4.11 Sorting GFP+ CEFs and subsequent infection of macrophages 
Macrophages were grown in T75 flasks for 4 days as described previously (section 
2.2.9).  
MDV-infected CEFs were cultured in 5 T175 flasks according to procedures in section 
2.3.4. On the day of macrophage infection, infected CEFs from all the flasks were 
harvested and prepared for sorting as described in section 2.4.3.1. Prior to the sort, 
MDV-infected CEFs were stained with CD45 to distinguish macrophage populations 
from CEFs as shown in Figure 3.15 (Q2 and Q4). A total of 4.5×106 GFP+ CEFs 
(Q1) were sorted from 5 T175 flasks of MDV-infected CEFs (Figure 3.15). 
Sorted GFP+ CEFs were then added to one T75 flask of cultured macrophages (1×10
7 
cells) at an infection ratio of around 1:2 (CEF:macrophage) as per methods in section 
2.2.15 and incubated for 3 days. Cells were then harvested using EDTA (section 












Figure 3.15. Sorting GFP+ CEFs prior to co-culture with macrophages. On the day 
of macrophage infection, MDV-infected CEF cultures were stained with CD45 and 
then GFP+ CEFs (Q1) were sorted by FACS. Distribution of cells, FL1-FL4-: 
uninfected CEFs (Q3); FL1+FL4-: infected CEFs (Q1); FL1-FL4+: uninfected 



























Figure 3.16. Characterisation of macrophages by flow cytometry following 
infection with pre-sorted MDV-infected GFP+ CEFs. (A) Cells were gated in 
SSC/FSC plot on the basis of cell granularity (SSC) and size (FSC). (B) Gated cells 
from SSC/FSC plot were analysed in FL1/FL4 dot plots for the surface expression 
of KUL01 and CD45 in macrophages compared with isotype control (Gr 13.1). FL1 
shows the fluorescence of intracellular GFP (green)-encoded MDV and FL4 shows 
the fluorescence of Alexa Fluor 647 (red) at the surface of the cells. Distribution of 
cells in KUL01 and CD45 staining, FL1-FL4-: uninfected CEFs; FL1+FL4-: 





In a SSC/FSC plot, cells were gated based on cell granularity and size (60%) (Figure 
3.16A). Flow cytometric analyses for the surface expression of KUL01 and CD45 
revealed 6-9% double positive cells, indicating infected macrophages (Figure 3.16B). 
A significant proportion of uninfected CEFs (FL1-FL4- cells: 19-23%) were also 
evident in these figures (Figure 3.16B) which could be due to the presence of 
contaminating uninfected CEFs during  sorting of infected CEFs, as revealed in the 
purity check in a later experiment (Figure 3.17). These contaminant uninfected CEFs 
(12%) (Q3) had grown rapidly with co-culture media containing 10% FBS. So, lower 













This experiment indicated for the first time that macrophages could be infected in 
vitro with MDV, although as mentioned later (section 3.5.2), the presence of small 
numbers of contaminating infected CEFs still needs to be considered. It was 
Figure 3.17. Purity check of the sorted GFP+ CEFs. Distribution of cells, FL1-FL4: 
uninfected CEFs (Q3); FL1+FL4-: infected CEFs (Q1); FL1-FL4+: uninfected 
macrophages (Q4) and FL1+FL4+: infected macrophages (Q2). FL1 shows the 
fluorescence of intracellular GFP (green)-encoded MDV and FL4 shows the 




practically not feasible to generate large amounts of cell-associated viruses for the 
purpose of sorting around 5×106 GFP+ CEFs to use at an infection ratio of 1:2 
(CEF:macrophage) in each experiment. Therefore, it was decided to carry out 
experiments with a lower infection ratio and hence in the next experiment, 
macrophages were infected with pre-sorted MDV-CEFs at a ratio of 1:5. 
3.4.12 Infection of macrophages with pre-sorted GFP+ CEFs at a ratio 
of 1:5 
MDV-infected CEFs were sorted from 2 T175 flasks as described in section 3.4.11 
and 2×106 GFP+ CEFs were added to one T75 flask of macrophage culture with co-
culture media containing 5% FBS (section 2.2.15) at an infection ratio of 1:5 (Figure 
3.18A). Following infection, cells were incubated for 3 days (Figure 3.18B), 
harvested and then analysed by flow cytometry after staining with KUL01 and 
CD45. At least 106 cells were counted from each sample.  
In flow cytometric analysis, more than 80% cells were gated on the basis of cell 
granularity and size (Figure 3.19A). Of these, 96% cells were found to be alive after 









Figure 3.18. Infection of macrophage with pre-sorted GFP+ CEFs. The ratio of 




























Figure 3.19. Infection of macrophages with pre-sorted GFP+ CEFs at 1:5 ratios 
(CEF:macrophage). (A) Cells were gated in SSC/FSC plot. (B) SSC/FSC gated 
cells were analysed in FL3/FSC plot to identify live cells after staining with 7-AAD. 
(C) Live cells from FL3/FSC plot were analysed in FL1/FL4 dot plots to detect 
KUL01+ and CD45+ macrophages compared to unstained control and isotype 
control (Gr 13.1). FL1 shows the fluorescence of intracellular GFP (green)-
encoded MDV and FL4 shows the fluorescence of Alexa Fluor 647 (red) at the 
surface of the cells. Distribution of cells in KUL01 and CD45 staining, FL1-FL4-: 
uninfected CEFs; FL1+FL4-: infected CEFs; FL1-FL4+: uninfected macrophages 




Live cells were then analysed in FL1/FL4 dot plots to detect MDV-infected 
macrophages. The proportion of infected macrophages, as shown by KUL01 and 
CD45 staining (FL1+FL4+), was 1.79% and 2%, respectively and very few uninfected 
CEFs (FL1-FL4-) were observed (Figure 3.19C). A count of 106 cells per tube 
revealed that at least 105 infected macrophages could be sorted from one T75 flask in 
the downstream cell-sorting experiments. A repeat of this experiment resulted in 
similar figures. 
As macrophages from outbred chickens were successfully infected in this 
experiment, attempts were then made to culture and infect DCs with MDV-infected 
CEFs in T75 flasks. 
3.4.13 Culture and characterisation of BMDC in T75 flasks 
Following the successful development of a method for culturing and infecting 
macrophages in vitro with MDV-infected CEFs, the method was adapted for cultured 
DCs.  
The phenotypic properties of DCs cultured in T75 flasks were determined first by 
flow cytometry. DCs were grown in T75 flasks (section 2.2.9) and harvested as 
described previously (section 2.4.3.2) and then analysed by flow cytometry after 
staining with KUL01, CD45 and Gr 13.1(isotype control) (section 2.4.2).  
Around 70% cells were gated as DCs in SSC/FSC plot on the basis of cell granularity 
and size (Figure 3.20A). Analysis of these cells in the FL3/FSC plot after staining 
with 7-AAD revealed that 97.5% cells were alive (Figure 3.20B). Phenotypic 
analyses of live cells showed that CD45 was expressed on a higher (99.1%) 




DCs were successfully cultured in T75 flasks and characterised by flow cytometry in 
this experiment. Therefore, the next step was to infect DCs with MDV-infected CEFs 




















Figure 3.20. Phenotypic characterisation of DCs by flow cytometry cultured in T75 
flasks from outbred chickens. On day 4, cells were harvested using EDTA. (A) 
Cells were gated in SSC/FSC plot. (B) SSC/FSC gated cells were plotted in 
FL3/FSC channel to gate live cells. FL3 shows the fluorescence of 7-AAD. (C) 
Live cells were tested for surface expression of KUL01 and CD45 compared with 
unstained cells and also with cells stained with isotype control antibody (Gr 13.1). 




3.4.14 Infection of DCs with pre-sorted GFP+ CEFs at a ratio of 1:5 
BMDC were infected in T75 flasks with pre-sorted 2×10
6 GFP+ CEFs at a ratio of 1:5 
(CEF:DCs) as described previously (section 3.4.12). Following infection (Figure 
3.21A), cells were incubated for 3 days as described in section 2.2.14. It was 
observed that the number of GFP+ cells was highly reduced (Figure 3.21B) in DC 
culture on 3 dpi compared to those in macrophages (Figure 3.18B). Cells were 
harvested, stained with KUL01 and CD45 and then analysed by flow cytometry 










When analysed by flow cytometry, 63% cells were gated on the basis of cell 
granularity (SSC) and size (FSC) (Figure 3.22A). Of these, 98% cells were found 
alive after staining with 7-AAD (Figure 3.22B). 
Flow cytometric analyses of live cells in FL1/FL4 dot plots revealed that the 
proportions of infected DCs, based on KUL01 and CD45 staining (FL1+FL4+), was 
0.45% and 0.57%, respectively (Figure 3.22C).  
 
Figure 3.21. Infection of DCs with pre-sorted GFP+ CEFs. The ratio of infection 




























Figure 3.22. Infection of DCs with pre-sorted GFP+ CEFs at 1:5 ratios (CEF:DC). 
(A) Cells were gated in SSC/FSC plot. (B) SSC/FSC gated cells were analysed in 
FL3/FSC plot to gate live cells. (C) Live cells from FL3/FSC plot were analysed in 
FL1/FL4 dot plots for the surface expression of KUL01 and CD45 in DCs 
compared with unstained control and isotype control (Gr 13.1). FL1 shows the 
fluorescence of intracellular GFP (green)-encoded MDV and FL4 shows the 
fluorescence of Alexa Fluor 647 (red) at the surface of the cells. Distribution of 
cells in KUL01 and CD45 staining, FL1-FL4-: uninfected CEFs; FL1+FL4-: infected 




A count of 106 cells per tube revealed that it would be possible to sort at least 
2.5×104 infected DCs from one T75 flask in future cell-sorting experiments. A repeat 
experiment also showed similar results. 
As co-culture infection experiments with macrophages and DCs in outbred chickens 
and their characterisation by flow cytometry were successful, attempts were then 
made to further characterise infected and uninfected APCs using various techniques. 
3.5 Further characterisation of APCs following MDV infection  
3.5.1 Live cell confocal microscopy 
As described in section 2.6.1, infected and uninfected macrophages and DCs 














Figure 3.23. Cell sorting for live cell confocal microscopy. Sorting infected (In) 
and uninfected (Un) (A) macrophages and (B) DCs on 3 dpi. FL1 shows the 
fluorescence of intracellular GFP (green)-encoded MDV and FL4 shows the 
fluorescence of Alexa Fluor 647 (red) at the surface of the cells. Distribution of 
cells, FL1-FL4-: uninfected CEFs (Q3); FL1+FL4-: infected CEFs (Q1); FL1-
FL4+: uninfected macrophages or DCs (Q4) and FL1+FL4+: infected 




Infected and uninfected live macrophages and DCs were examined under a confocal 
microscope to determine the detailed morphology of cells. GFP was encoded by 
MDV, so green-coloured cells (GFP+) will indicate the presence of virus. The 
appearance of CD45+ cells will be red at the surface as it was labelled with Alexa 
Fluor 647. Cells were also examined to detect whether the expression of GFP was 
from the surface of the cells, as GFP+ MDV-infected CEFs could be adherent to 
APCs which can indicate virus infection of APCs in the cell sorter. 
Examination of infected macrophages revealed that there were intracellular vacuole-
like structures surrounding the nucleus (N) (Figures 3.24A.i and A.ii), which are 
most likely a feature of activated macrophages (Petricevich et al., 2008). GFP 
expression was in the cytoplasm and also in the nucleus, indicating MDV infection 
of these cells (Figures 3.24A.i and A.ii). Presence of GFP only in the cytoplasm 
could be an indication of phagocytosis of virus but not infection. Uninfected 
macrophages only showed the expression of CD45 (Figure 3.24B).  
The confocal pictures of both infected and uninfected DCs showed cells with 
dendrites, a feature which is characteristic of dendritic cells (Figure 3.25). Like 
macrophages, GFP was present in the nucleus (N) as well as in the cytoplasm of 
DCs, indicating MDV infection of DCs (Figures 3.25A.i and A.ii), whereas 
uninfected DC only showed the expression of CD45 (Figure 3.25B). 
Though CD45 expression was expected to be from the cell surface only, some 
intracellular expression was also observed in both infected and uninfected 
macrophages and DCs. These cells were stressed due to sorting that might have led 





























Figure 3.24. Visualisation of infected and uninfected macrophages using confocal 
microscopy. On day 3 post-MDV infection, cells were sorted and examined for (A.i 
and A.ii) infected macrophages and (B) uninfected macrophage. Green channel: 
cells examined for the expression of GFP-encoded MDV, red channel: cells 
examined for the expression of CD45 conjugated with Alexa Fluor 647 (red), 
merged channel: cells examined for combined expression of green and red. N: 
nucleus. Scale bar: 10 μm. Microscope: LSM710 Confocal AxioObserver with 























3.5.2 Characterisation of MDV-infected cells by RT-PCR 
RT-PCR was performed to define the transcription of virus genes in MDV-infected 
CEFs, macrophages and DCs following procedures described in sections 2.5.3 and 
2.5.5.  
 
Figure 3.25. Visualisation of infected and uninfected DCs using confocal 
microscopy. On day 3 post-MDV infection, cells were sorted and examined for (A.i 
and A.ii) infected DCs and (B) uninfected DC. Green channel: cells examined for 
the expression of GFP-encoded MDV, red channel: cells examined for the 
expression of CD45 conjugated with Alexa Fluor 647 (red), merged channel: cells 
examined for combined expression of green and red. N: nucleus. Scale bar: 10 μm. 




























Figure 3.26. RT-PCR showing transcription of virus genes in MDV-infected cells. 
Figures showing expression of herpesvirus specific (A) immediate early, ICP4 (200 
bp) (B) early, pp38 (198 bp) (C) late, gB (193 bp) genes and MDV specific (D) 
oncogene, L-Meq (200 bp). L = GeneRuler DNA Ladder Mix (Thermo Scientific), + 
= positive control: MDV-infected CEFs, - = negative control: nuclease-free H2O, M 
= infected macrophage (cDNA), MN = infected macrophage no-RT control (DNase 





Herpesvirus specific immediate early (ICP4), early (pp38) and late (gB) genes as 
well as the MDV-specific oncogene (L-Meq) were expressed (Figures 3.26A, B, C 
and D, respectively), in MDV-infected macrophages and DCs.  
Transcription of all virus genes in MDV-infected macrophages and DCs was 
compared with those in virus infected CEFs, which were used as a positive control. 
DNase treated RNA from both infected macrophages and DCs was used in PCRs as 
no-RT controls and no bands in these lanes (MN and DN) confirmed the 
transcription of all the virus genes in MDV-infected macrophages and DCs (Figures 
3.26A, B, C and D). However, these infected macrophages and DCs were not 100% 
pure but contained nearly 2% contaminant infected CEFs as revealed later when the 
cell purity was checked (section 3.5.4; Figure 3.30). 
3.5.3 Time-lapse confocal video microscopy 
To determine the possible mechanism(s) of MDV infection of macrophages, time-
lapse confocal video microscopy was carried out on the day of MDV infection as 
described in section 2.6.2. Images from an approximately 10 min long experiment 
were compressed to create a movie. Movies are provided herewith on a CD and two 
still pictures from movies A and B are shown in Figures 3.27 and 3.28, respectively. 
MDV is strictly cell-associated in vitro. The transmission of MDV between cells 
should therefore occur in a cell to cell mode. However, as discussed in Chapter 1 
(section 1.9), it is not exactly known yet how the virus transmits between cells. 
Moreover, as a phagocyte, macrophages might also engulf the MDV-infected CEFs 
and subsequently get infected. 
Analysis of movie A shows cells containing vacuoles which are characteristic of 




phagosomes with lysosomes (Petricevich et al., 2008). GFP particles can also be seen 
moving around within these vacuoles (as shown by arrows in Figure 3.27), indicating 
presence of virus. Presence of virus within these phagolysosomes might be an 
indication of phagocytosis of MDV-infected cells by macrophages which later could 
potentially turn into infection of cells. 
Possible cell-to-cell mode of transmission of MDV could be more clearly explained 
in the second video. Movie B illustrates a large infected macrophage-like cell (green 
nucleus indicating virus infection) showing intercellular connections with two other 
small-sized or apoptotic cells and also green cellular processes emerging from the 















Figure 3.27. A still picture from movie A. Figure showing possible mode of 
infection of macrophages by phagocytosis. Arrows indicate presence of GFP within 
the phagolysosome-like structures of cell. N: nucleus. Scale bar: 10 μm. 



















3.5.4 Re-infection of CEFs with MDV-infected macrophages 
To determine whether the in vitro MDV-APC infection is productive or abortive, 
CEFs were ‘re-infected’ with MDV-infected macrophages. The term ‘re-infection’ is 
used as virus infection was initially transmitted to macrophages from CEFs. 
Macrophages were used for infecting CEFs because it was possible to obtain more 
MDV-infected macrophages during cell sorting as the percentages of infected 
macrophages were higher than that of DCs (Figures 3.19C and 3.22C, respectively). 
 
 
Figure 3.28. A still picture from movie B. Figure showing possible cell to cell mode 
of transmission of MDV through cellular processes. Arrows indicate presence of 
green cellular projections from and between cells. N = nucleus. Scale bar: 10 μm. 























As described in section 2.2.19, CEFs were cultured in 6-well plates 2-3 days prior to 
the infection. MDV-infected macrophages were sorted on 3 dpi (Figure 3.29A) and 
added to the CEF culture (Figure 3.29B). 
After co-culturing of GFP+ macrophages with uninfected CEFs, plaque formation 
started from 2 dpi and fully formed plaques were observed at 5 dpi (Figure 3.29C). 
Figure 3.29. Re-infection of CEFs with MDV-infected macrophages. (A) MDV-
infected macrophages were sorted and (B) added to CEF culture, day 0 (on the day 
of infection). (C) Fully-formed plaques in CEF culture on 5 dpi. FL1 shows the 
fluorescence of intracellular GFP (green)-encoded MDV and FL4 shows the 
fluorescence of Alexa Fluor 647 (red) at the surface of the cells. Distribution of 
cells in sorting plot, FL1-FL4-: uninfected CEFs (Q3); FL1+FL4-: infected CEFs 





Formation of plaques in CEF cultures following infection with MDV-infected 
macrophages was an indication that MDV-macrophage infection is productive. 
However, in a repeat experiment the purity of the infected macrophages was checked 
by placing 1000 sorted cells in the same sorting plot and it was revealed that there 
were nearly 2% contaminant infected CEFs within the infected macrophages (Figure 
3.30). That means, within 105 infected macrophages there would be 2000 














In a separate experiment, freshly cultured CEFs were infected with pre-sorted MDV-
infected CEFs at low numbers to determine the least number of infected CEFs 
required for producing one plaque and it was observed that around 10 infected CEFs 
could form one plaque. 
Figure 3.30. Purity check of the infected macrophages. Contaminant cells were 
present from all sections with nearly 2% infected CEFs (Q1). FL1 shows the 
fluorescence of intracellular GFP (green)-encoded MDV and FL4 shows the 
fluorescence of Alexa Fluor 647 (red) at the surface of the cells. Distribution of 
cells in sorting plots, FL1-FL4-: uninfected CEFs (Q3); FL1+FL4-: infected CEFs 





























Figure 3.31. Triple-sorting of MDV-infected macrophages with corresponding 
purity check. (A) In the first sort, 1.28×106 cells were sorted and the purity check 
revealed presence of lots of contaminant cells (B) Sorted cells were re-sorted and 
there were 4 contaminant infected CEFs (Q1) per 1000 infected macrophages (C) 
After sorting macrophages for the third time, the purity check shows one infected 
CEF (Q1) per 1000 infected macrophages with a total of 87,789 cells remaining at 
the end. FL1 shows the fluorescence of intracellular GFP (green)-encoded MDV 
and FL4 shows the fluorescence of Alexa Fluor 647 (red) at the surface of the cells. 
Distribution of cells in sorting plots, FL1-FL4-: uninfected CEFs (Q3); FL1+FL4-: 
infected CEFs (Q1); FL1-FL4+: uninfected macrophages (Q4) and FL1+FL4+: 




Therefore, plaques observed in the previous experiment (Figure 3.29C) could 
perhaps be derived from contaminant infected CEFs. Therefore, it was then decided 
to re-sort infected macrophages prior to infect CEFs. 
3.5.4.1 Re-infection of CEFs with re-sorted MDV-infected macrophages 
MDV-infected macrophages were re-sorted to remove contaminant infected CEFs. 
As shown in Figure 3.31A, 1.28×106 infected macrophages were sorted first time and 
the purity check revealed that there were many contaminant infected CEFs (Q1). So, 
cells were sorted for a second time (Figure 3.31B) and 2×105 infected macrophages 
were sorted with 4 contaminant infected CEFs (Q1) per 1000 infected macrophages. 
These cells were sorted one more time (Figure 3.31C) and nearly 90,000 cells were 
sorted in the final sort. However, still one contaminant infected CEF (Q1) was 
noticed per 1000 infected macrophages when the purity was checked. 
These triple-sorted MDV-infected macrphages were then added to the CEF culture as 
per methods in section 2.2.18. 
Following infection, cells were observed daily under fluorescence microscope. 
Plaques were detected in CEF monolayers from day 3 onwards and a total of around 
50 plaques were counted on 5 dpi from a co-culture of CEFs with nearly 90,000 
infected macrophages. The majority of the plaques were fully-formed (Figures 
3.32A.i and A.ii). The infected macrophages contained contaminant infected CEFs 
and as mentioned previously (section 3.5.4), at least 10 infected CEFs were required 
to form one plaque. These 90,000 infected macrophages contained 90 contaminant 
infected CEFs and therefore, out of 50, at most 10 plaques could be derived from 90 
contaminant infected CEFs, while rest of the plaques were most likely formed from 




seemed to be a productive infection. Though out of these 50 plaques, a considerable 
number of plaques (10-12 plaques) were not fully formed as revealed simply by the 

















The goal of this Chapter was to develop an in vitro model of MDV infection of 
APCs. To date there has been no in vitro model for MDV infection of APCs. 
Repeated efforts, carried out over a course of time, have not been successful (Haffer 
et al., 1979; von Bulow and Klasen, 1983; Barrow et al., 2003). Therefore, the 
priority was to solve this enigma which would make it possible to study the role of 
Figure 3.32. Visualisation of plaques using fluorescence microscope formed in the 
CEF cultures on 5 dpi. CEFs were infected with triple-sorted MDV-infected 
macrophages. (A.i and A.ii) Fully-formed plaques. (B.i and B.ii) Appearance of 




APCs in resistance or susceptibility to MD in the inbred chicken lines. In this 
Chapter, attempts were made to establish and subsequently characterise an in vitro 
model of MDV infection of APCs in outbred J line chickens. For this, chicken bone 
marrow cells were first cultured and characterised and then infected with MDV. 
3.6.1 Culture and characterisation of APCs in outbred chickens 
Chicken bone marrow cells cultured with CSF-1 for 7 days displayed typical 
morphology of macrophages (Figure 3.1B) as shown in Garceau et al. (2010). 
Cultured macrophages were also phagocytic (Figure 3.1C) as revealed by the uptake 
of zymosan particles in a widely used in vitro phagocytosis assay (Reis e Sousa et al., 
1993). Macrophages grown in Sterilin single-square plates were verified 
phenotypically (CD11, KUL01, MHC II and CD45) by flow cytometry for the 
surface expression of various molecules to confirm their identity and also to select 
suitable antibodies for the downstream virus infection experiments. CD11 is a type 1 
transmembrane protein that is expressed on a wide variety of cells of myeloid lineage 
both in vivo and in vitro (Kansas et al., 1990; Hume, 2008; Wu et al., 2010; Hu et al., 
2012; Campisano et al., 2013). In the present study, chicken bone marrow-derived 
macrophages (both unstimulated and stimulated) showed very high surface 
expression of CD11 (Figure 3.2B). KUL01 is a widely used chicken macrophage and 
monocyte marker (Mast et al., 1998) which has recently been identified as a mannose 
receptor (Staines et al., 2014). High expression of KUL01 was observed in cells 
before LPS stimulation though it was increased after LPS-stimulation (Figure 3.2B). 
In contrast, the expression of MHC class II was high in unstimulated cells while it 
declined in LPS-stimulated macrophages (Figure 3.2B). MHC class II molecules are 




marrow cells cultured for 4 days in T75 flasks showed very high surface expression of 
KUL01 and CD45 (Figure 3.12C), indicating their differentiation to macrophages as 
early as day 4 of culture. CD45 is a pan-leukocyte marker, which was used in this 
study as it clearly distinguished macrophages from CEFs in flow cytometric analysis 
(Figure 3.13C).  
DCs were cultured from chicken bone marrow cells in 6-well plates with IL-4 and 
CSF-2 and then induced maturation with LPS. Cultured DCs can be matured by LPS 
in humans (Buelens et al., 1997) and this is also the case in chickens (Wu et al., 
2010). DCs showed typical cellular aggregates in culture (Figure 3.3B) as reported 
previously (Wu et al., 2010). 
Phenotypic characteristics of chicken bone marrow-derived DCs were determined by 
flow cytometry for the cell surface expression of CD11, MHC II, CD40 and KUL01. 
An elevated surface expression of CD11, MHC II and moderate expression of CD40 
in immature (unstimulated) DCs was reported previously (Wu et al., 2010). In this 
study, high surface expression of CD11 was observed in unstimulated DCs whereas, 
MHC II expressed moderately and apparently no expression of CD40 was noticed 
(Figure 3.4B). LPS inhalation induces maturation and hence caused up-regulation of 
MHC II in lung dendritic cells in mammals (Alexis et al., 2005) and also in chickens 
(de Geus et al., 2012). The surface expression of CD11, MHC II and CD40 was 
reported to be elevated in LPS-stimulated DCs (Wu et al., 2010). In contrast, in this 
study, CD11 and MHC II expressed moderately in LPS-stimulated cells with no 
expression of CD40 (Figure 3.4B). A moderate expression of MHC II (around 40%) 
and very low expression of CD40 (2-3%) was also observed in the splenic 




expresses at moderate levels in immune cells of vaccinated, outbred chickens and 
CD40 shows very low surface expression in all types of immune cells of these birds. 
However, in the absence of a positive control, the functional activity of the 
antibodies, especially for CD40, needs to be tested in future studies. 
A significant percentage of unstimulated and stimulated DCs showed high surface 
expression of KUL01 (Figure 3.4B), suggesting that KUL01 is also a surface marker 
for DCs. Expression of KUL01 was also reported in chicken epidermal dendritic 
cells (Igyártó et al., 2006). Characterising DCs cultured in T75 flasks for 4 days by 
flow cytometry indicated that they were fully differentiated as shown by high 
expression of KUL01 and CD45 (Figure 3.20C). In the present study, KUL01 was 
used as a common marker for both macrophages and DCs and there was no specific 
marker (such as DEC-205) to differentiate DCs from macrophages. Therefore, the 
difference between the two cell types was primarily based on the morphology 
(section 3.5.1) and hence there was a chance of potential overlap between the two 
cell types in the flow cytometry experiments. 
3.6.2 Attempts made to infect macrophages by MDV 
After culture and characterisation of APCs in outbred chickens, attempts were made 
to infect them with MDV. Macrophages were selected first for the in vitro infection 
because in vivo MDV-macrophage infection was reported previously (Barrow et al., 
2003). MDV remains firmly cell-associated in all cultured cells and unlike other 
herpesviruses, its infectivity cannot be recovered from supernatants or even from cell 
lysates (reviewed in Denesvre, 2013). However, an attempt was made to isolate and 
stock cell-free viruses from cultured cell-associated MDV, but infection of 




vitro MDV infections require co-culture of naïve cells with live infected cells. Thus, 
establishing a co-culture infection model was crucial but difficult to set up when it 
was revealed that both CEFs and macrophages are adherent to cell culture plates 
which made co-culturing of cells very problematic. The virus titre was also very low 
and thus, an average MDV titre of 105 pfu/ml was not sufficient to cause infection of 
macrophages. Repeated experiments to increase virus titre were not successful and 
caused an increase of CEF numbers which made co-culture infection experiments 
more difficult (section 3.4.5). Furthermore, Sterilin square plates, which are suitable 
for macrophage growth and differentiation, were found not to be supportive for cell 
attachment and growth of CEFs. As a result, macrophages were cultured in T75 flasks 
and then characterised phenotypically by flow cytometry (Figure 3.18). 
A significant number of MDV-infected CEFs died during storage and thawing of 
virus stocks (Figure 3.8), which led to the use of freshly cultured MDV-infected 
CEFs (Figure 3.9) in the co-culture infection experiments. This brought about an 
apparent success in MDV-macrophage infection (Figure 3.13), but it had not been 
possible to incubate co-cultured cells more than 2.5 days and those infected 
macrophages (section 3.4.9) could also be derived from MDV-infected CEF cultures 
as discussed below. 
CEFs used in this study were collected from 9-11 day old embryos (section 2.2.10). 
Embryonic macrophages appear in chickens as early as 2.5-4.5 days and their 
number increases gradually (Cuadros et al., 1993). They play a crucial role during 
embryonic development by phagocytosing apoptotic cells (Shepard and Zon, 2000). 
Macrophages also release soluble factors, such as nitric oxide (NO), which is 




production of iNOS in CEF cultures was observed by Xing and Schat (2000), which 
is also an indication of the presence of macrophage-like cells in CEF cultures. 
Likewise, the presence of KUL01+ cells was observed in this study in both 
uninfected and infected CEFs (Figure 3.14). As a widely recognised marker for 
macrophages, KUL01+ cells thus confirmed the presence of macrophages in CEFs. 
However, it was not possible to completely segregate macrophages from CEFs with 
KUL01 staining during sorting as shown in Figure 3.13 and hence CD45 was used to 
stain and then remove these contaminating macrophages by FACS. For this, MDV-
infected CEFs were stained with CD45 on the day of infection of APCs and only 
GFP+ CEFs were sorted (Figure 3.15) and thus successful MDV-infection of APCs 
was established. 
3.6.3 Infection of APCs with pre-sorted MDV-CEFs and subsequent 
characterisation 
For the first time, macrophages were successfully infected with MDV in vitro, as 
shown in flow cytometric analyses (Figure 3.19C), in contrast to the previous 
attempts (Haffer et al., 1979; von Bulow and Klasen, 1983; Barrow et al., 2003). 
Following the same procedures, DCs were infected and it was shown that DCs could 
also be infected by MDV in vitro (Figure 3.22C). MDV infection of DCs, either in 
vivo or in vitro, has not been reported previously. This is the first demonstration of 
MDV infection of DCs. The infection ratio was the same (1:5) in both co-culture 
studies with macrophages and DCs, but the number of MDV-infected DCs was 
approximately 4 times less compared to those of macrophages (Figures 3.22C and 
3.19C, respectively). However, one factor should be considered here. DCs were 




Despite the removal of the cytokine containing medium on the day of infection, 
differentiation of DCs with IL-4 might play a role in preventing MDV infection. The 
potential role of anti-inflammatory cytokines (such as, IL-10) during viral 
pathogenesis has been reported previously. For example, excessive or poorly timed 
IL-10 production in plasma may allow dengue virus (DENV) to escape from immune 
surveillance during its pathogenesis, whereas DENV induced IL-10 production might 
lead to immunosuppression and thus enhance viral replication (Tsai et al., 2013). On 
the other hand, GM-CSF (CSF-2) has been reported to cause inhibition of HIV-
1(Human immunodeficiency virus-1) replication in monocyte-derived macrophages 
(MDM) in vitro (Kedzierska et al., 2000). Therefore, as the role of IL-4 and CSF-2 
on MDV replication in DCs has not been studied yet, no conclusion can be drawn 
regarding the lower MDV infection of DCs compared to macrophages. 
The confocal microscopic view of live cells revealed the characteristic morphology 
of macrophages and DCs with or without MDV infection (Figures 3.24 and 3.25, 
respectively). Cells have empty vacuoles which most likely occurred due to 
activation by MDV (Figure 3.24). Macrophages might become activated when they 
contact a foreign particle or sense any specific stimulus (Janeway and Medzhitov, 
2002) which in turn causes formation of vacuoles in the cytoplasm (Petricevich et al., 
2008). These vacuoles play a role in taking up extracellular particles, and fusion of 
lysosomal compartments with vacuoles is a fundamental mechanism by which 
macrophages kill pathogens (Luzio et al., 2003). Lysosomal compartments are 
perhaps better adapted for digestion of internalised material and thus, the clearance 
of invading microorganisms, which is a major function for macrophages in innate 




revealed projections or dendrites from the surface of the cells which are 
characteristic of DCs (Figure 3.25). Dendrites enable DCs to interact with T cells 
(Banchereau and Steinman, 1998; Hugues et al., 2004). On 3 dpi, macrophages and 
DCs were infected with MDV as indicated by the emission of GFP from the nucleus 
of cells (Figures 3.24 and 3.25, respectively). Phagocytic cells would rapidly degrade 
any virus antigens present in phagosomes, and hence their antigenicity will be lost 
(reviewed by Aderem and Underhill, 1999). So, if MDV-infected CEFs are 
phagocytosed by macrophages, there will be no GFP expression in the nucleus or if it 
emits, it will only be from the cytoplasm unless MDV can evade lysosomal 
degradation. Herpesviruses can exploit endocytic pathways during entry to the cells 
(Clement et al., 2006). There are different forms of endocytosis, such as 
phagocytosis, macropinocytosis, caveolae mediated endocytosis, and clathrin-
mediated endocytosis (CME) and many viruses can hijack the CME machinery in 
order to be internalized into host cells (Doherty and McMahon, 2009). Phagocytosis 
is a clathrin-independent method of engulfing large extracellular particles and it most 
likely requires actin rearrangement and dynamin assembly and is regulated by 
signalling pathways that apparently involve action of RhoA GTPase and may also 
involve tyrosine kinases (Clement et al., 2006). HSV-1 (herpes simplex virus-1) 
infects cells by exploiting the endocytic pathway of cells with mimicking many 
features of phagocytosis, a feature which is common for other herpesviruses as well, 
such as CMV (cytomegalovirus) and HHV-8 (human herpesvirus-8) (Clement et al., 
2006; Tiwari and Shukla, 2012).  
MDV expresses herpesvirus specific immediate early (ICP4), early (pp38) and late 




confirmed the infection of macrophages by MDV (Barrow et al., 2003). In this study, 
the transcription of herpesvirus specific ICP4, pp38 and gB and MDV-specific L-
Meq was observed in MDV-infected macrophages and DCs (Figure 3.26), which is 
also a demonstration of virus infection. However, detection of viral antigens, 
including structural and non-structural proteins needs to be performed in future 
studies to confirm virus replication in APCs.  
Confocal video microscopy gives an indication of the possible modes of MDV 
transmission to macrophages on the day of infection. Movie A (also in Figure 3.27) 
illustrates GFP particles inside the intracellular vacuoles of macrophages, indicating 
internalisation of virus most likely by phagocytosis. Though it is not clear from this 
movie, as MDV is a cell-associated virus in vitro, phagocytosis of virus should 
therefore have occurred by phagocytosis of MDV-infected apoptotic cells by 
macrophages. Following internalisation, virus particles could either be destroyed 
within phagolysosomal compartments or cells can be infected by the viruses as 
herpesviruses have evolved mechanisms to escape lysosomal degradation by 
inhibiting autophagy. Autophagy is a cellular housekeeping process that delivers 
aged or unnecessary cytoplasmic organelles for lysosomal degradation, and thus 
facilitates pathogen degradation and pathogen fragment loading onto MHC 
molecules for antigen presentation to T cells (Mizushima et al., 2008). As for 
example, HSV-1 counteracts the induction of autophagy via ICP34.5 by antagonising 
autophagy-stimulating PKR (protein kinase RNA-activated) signalling (Orvedahl et 
al., 2007). Movie B (also in Figure 3.28) provides supportive evidence of cell-to-cell 
transmission of MDV to macrophages. MDV remains strictly cell-associated in vitro 




to-cell mode of virus transmission has only been described for enveloped viruses and 
it has been adopted by many animal virus families including herpesviruses as a 
potential way of evasion of humoral immunity (Sattentau, 2008). Alphaherpesviruses 
can transmit between cells by inducing syncytium formation and express a range of 
glycoproteins, gB, gD and gH-gL on the virus infected cell that have a role in cell-to-
cell fusion (Campadelli-Fiume et al., 2007; Reske et al., 2007). This video shows 
potential cellular connections with green cellular projections from and between cells, 
which are most likely actins (Caroline Denesvre, personal communication). During 
HSV-1 and PRV (pseudorabies virus) entry, rearrangement of the actin cytoskeleton 
associated with projection of plasma membrane took place, which was then followed 
by trafficking of virions in phagosome-like vesicles (La Boissiere et al., 2004; 
Favoreel et al., 2005; Clement et al., 2006). Schumacher et al. (2005) also reported 
that polymerisation of the actin cytoskeleton is required for the effective cell-to-cell 
spread of MDV in chicken embryo cells in vitro. To date, very little is known about 
MDV transmission to APCs in vitro, but as a herpesvirus this method could also be 
suggestive for MDV entry as it co-relates with the method described by Clement et 
al. (2006) in which the author mentioned that herpesviruses can induce actin or 
tubulin containing structures by which virions project towards adjacent cells (Figure 
1.6d). However, advanced imaging research is required to discover the exact mode of 
transmission of MDV to APCs. 
In order to determine the type of MDV-macrophage infection, attempts were made to 
re-infect CEFs with GFP+ macrophages in vitro. Barrow et al. (2003) reported that 
the in vivo MDV-macrophage infection is an abortive infection as infected 




were observed in CEF cultures in the first experiment (Figure 3.29), indicating the 
productive nature of MDV-macrophage infection. However, this conclusion came 
under suspicion due to presence of contaminant infected CEFs within the infected 
macrophages (Figure 3.30). MDV is strictly cell-associated in vitro and as shown 
previously, virus transmission could take place between cells fused together with 
intercellular bridges (Movie B). These ‘fused’ cells form doublets and by this way 
contaminant infected CEFs could perhaps be present in the sorted infected 
macrophage populations. For this reason, a separate gate was created in all the cell 
sorting experiments to keep these doublet cells out of the analysis, but surprisingly 
there were still contaminant cells in every sorting of infected cells (Figure 3.30). 
Infected macrophages were therefore sorted for three times to remove the 
contaminant infected CEFs though it was not possible to sort a fully pure population 
of infected macrophages (Figure 3.31C). However, infection of CEFs with around 
90,000 MDV-infected macrophages resulted in formation of approximately 50 
plaques in the CEF cultures (Figures 3.32A.i and A.ii), with considering the 
inclusion of at best 10 plaques which were, perhaps, formed from the contaminant 
infected CEFs. Among the plaques, not all were fully formed (Figures 3.32B.i and 
B.ii), but it needs to be considered that these infected macrophages were triple-sorted 
and hence severely stressed, which might have hindered the ability to produce fully-
formed plaques. However, further studies are required to clarify this. 
Following establishment of in vitro MDV-APC infection, B and T cells were co-
cultured with infected macrophages to determine if MDV infection could transfer 













Chapter 4:  








During in vivo infection, MDV is thought to be engulfed by phagocytes in the 
chicken lungs and carried to the lymphoid tissues where they initially infect B 
lymphocytes and subsequently infect activated T lymphocytes. Both B and T cells 
can be infected in vitro with MDV-infected CEFs (Kaspers, 2014) and an in vitro 
MDV-APC infection model has also been developed in the present study (Chapter 3). 
It has been proposed that in vivo the virus infection transmits from macrophages to B 
cells via the ellipsoid-associated reticular cells (EARCs) (Baigent and Davison, 
2004). In the spleen, EARCs, which border capillaries, are closely surrounded by B 
cells. These EARCs are phagocytic and MDV antigens could readily be identified in 
splenic EARCs (Jeurissen et al., 1989), a feature which suggests why B cells are the 
main targets for acute cytolytic infection of MDV (Baigent and Davison, 2004). 
However, it has not yet been reported in vitro that the virus infection could transfer 
from APCs to B and T cells. Barrow et al. (2003) first reported that MDV antigens 
can be detected in splenic macrophages in vivo, but at the same time this MDV-
macrophage infection was reported as a possible abortive infection because infected 
macrophages were not able to produce plaques in CEF cultures, suggesting that 
MDV infection cannot be transmitted from macrophages to other cells. However, in 
this thesis in vitro MDV-infected macrophages were able to form plaques in CEF 
cultures (Chapter 3), which suggests that MDV infection could possibly be 
transferred from macrophages to B or T cells. Therefore, the aim of this Chapter was 
to mimic this virus transmission process in vitro. Experiments were carried out using 




infected macrophages. Cells were then analysed by flow cytometry for the presence 
of MDV. 
4.2 Positive sorting and subsequent characterisation of B 
cells from spleen 
To determine whether MDV could be transferred from macrophages to B cells, B 
lymphocytes were co-cultured with in vitro infected macrophages. MDV-infected 
macrophages were chosen because co-culture studies showed that higher numbers of 

















Figure 4.1. Flow cytometric characterisation of pre- and post-sort B lymphocytes. 
(A) Cells were analysed in SSC/FSC gate (B) Surface staining of B cells with Bu-1 
compared to isotype control antibody (Gr 13.1) in FL4/FSC plots. FL4 shows the 




Prior to the infection, B cells were positively sorted from the spleen (section 2.4.4) 
and phenotypically characterised by flow cytometry as described in section 2.4.2 
after staining with Bu-1 and Gr 13.1(isotype control). Bu-1 (clone AV20, subclass 
IgG1) is expressed on B cells from bursa, spleen, thymus and peripheral blood 
lymphocytes (Rothwell et al., 1996). 
Cells from both pre- and post-sort tubes were analysed by flow cytometry to check 
the staining pattern of Bu-1. Flow cytometric analyses revealed that 88% cells were 
stained with Bu-1 after sorting, while prior to the sort, only 17.2% cells were Bu-1+ 
(Figure 4.1B). 
Following characterisation of positively sorted B cells, cells were infected with pre-
sorted MDV-infected macrophages. 
4.2.1 Infection of positively sorted B cells with MDV-infected 
macrophages 
Positively sorted B lymphocytes were co-cultured with MDV-infected macrophages 
as per methods in section 2.2.18 to determine if infected macrophages could infect B 
cells. As described in section 2.2.18, B cells were infected at an infection ratio of 1:5 
(infected macrophages:positively sorted B cells). After 2.5 days of infection, cells 
were stained with Bu-1 and Gr 13.1(isotype control) and characterised by flow 
cytometry (section 2.4.2). 
While running samples in the flow cytometer, cells were mistakenly acquired in the 
log phase of SSC instead of linear phase. However, around 95% of the SSC/FSC 
gated cells were found alive when analysed in FL3/FSC plot based on 7-AAD 




infected B cells (FL1+FL4+) following co-cultured with MDV-infected macrophages, 























Figure 4.2. Infection of positively sorted B lymphocytes with MDV-infected 
macrophages. Cells were infected at 1:20 ratios (infected macrophage:B cell). (A) 
SSC/FSC gated cells were analysed in FL3/FSC plot to gate live cells. FL3 shows 
the fluorescence of 7-AAD. (B) Live cells were analysed in FL1/FL4 dot plots to 
detect Bu-1+ cells compared to isotype control antibody (Gr 13.1). FL1 shows the 
fluorescence of intracellular GFP (green)-encoded MDV and FL4 shows the 
fluorescence of Alexa Fluor 647 (red) at the surface of the cells. Distribution of 
cells in Bu-1 staining, FL1-FL4-: uninfected splenocytes; FL1+FL4-: infected 




Co-culture of positively sorted B cells with MDV-infected macrophages did not 
result in infection of B cells (Figure 4.2B). Positive sorting of B cells may act as a 
stimulus which perhaps caused cell death as the cell numbers in each tube were very  
low. Therefore, the next step was to infect negatively sorted B cells with MDV-
infected macrophages. 
4.2.2 Infection of negatively sorted B cells with MDV-infected 
macrophages 
B lymphocytes were negatively sorted from spleens as positive sorting might cause 
increased cell death or alter the cell phenotype. Negatively sorted cells, containing B 
cells and other splenic non-T cells were collected as per methods in section 2.4.4 and 
co-cultured with pre-sorted MDV-infected macrophages at an infection ratio of 1:5 
(infected macrophages:negatively sorted B cells) (section 2.2.18). In this experiment, 
cells were incubated for 1 day after infection because incubation for a longer time 
could also be a cause of increased cell death. Cells were analysed by flow cytometry 
after staining with Bu-1 and Gr 13.1(isotype control) as described in section 2.4.2. 
Around 45% cells were gated in the SSC/FSC plot (Figure 4.3A) and of these, 65% 
cells were selected as live cells (Figure 4.3B). 
Flow cytometric analyses of live cells in the FL1/FL4 plot revealed that there were 
no infected B cells (FL1+FL4+), though 22% of live cells remained as uninfected B 
cells (Figure 4.3C). 
As repeated efforts to infect B cells with MDV-infected macrophages were not 





























Figure 4.3. Infection of negatively sorted B lymphocytes with MDV-infected 
macrophages. Cells were infected at 1:5 ratios (infected macrophage:B cells). (A) 
Cells were gated in SSC/FSC plot. (B) SSC/FSC gated cells were analysed in 
FL3/FSC plot to gate live cells. FL3 shows the fluorescence of 7-AAD. (C) Live cells 
were analysed in FL1/FL4 dot plots to detect Bu-1+ cells compared to isotype control 
antibody (Gr 13.1). FL1 shows the fluorescence of intracellular GFP (green)-
encoded MDV and FL4 shows the fluorescence of Alexa Fluor 647 (red) at the 
surface of the cells. Distribution of cells in Bu-1 staining, FL1-FL4-: uninfected 
splenocytes; FL1+FL4-: infected splenocytes; FL1-FL4+: uninfected B cells and 




Co-culture infection experiments were carried out to test if splenocytes could be 
infected with MDV-infected macrophages. Prior to the infection, splenocytes were 
characterised phenotypically by flow cytometry.Splenocytes were isolated and 
cultured in T75 flasks for 1 day as described in section 2.2.16. Single colour 
immunofluorescence staining was carried out with Bu-1, CD3 and Gr 13.1 (isotype 
control) using procedures in section 2.4.2. CD3 (antibody CT-3, class IgG1) was 


















Figure 4.4. Phenotypic characterisation of splenocytes on day 1 of culture by flow 
cytometry. (A) Cells were gated in SSC/FSC plot. (B) SSC/FSC gated cells were 
plotted in FL3/FSC plot to gate live cells. FL3 shows the fluorescence of 7-AAD. 
(C) Live cells were tested for surface expression of Bu-1 and CD3 compared with 
cells stained with isotype control antibody (Gr 13.1). FL4 shows the fluorescence of 




Approximately 40% cells were gated as live lymphocytes in the SSC/FSC plot 
(Figure 4.4A). Analysis of these cells in the FL3/FSC plot revealed that 80% cells 
were live (Figure 4.4B). Phenotypic analyses of live cells showed that 6% cells were 
Bu-1+, whereas more than 70% were CD3+ T cells (Figure 4.4C). 
It was suggested that in the in vivo MDV infection the virus is transmitted from 
macrophages to B cells in the spleen (Calnek, 2001). The ultimate target in this 
Chapter is to mimic this infection in vitro by co-culturing MDV-infected 
macrophages with splenocytes. Prior to this, an experiment was carried out to test if 
B and T cells can be infected with MDV-infected CEFs. Though in vitro infection of 
B and T cells has been described previously (Kaspers, 2014), this experiment was 
done to check whether it can be repeated under the existing experimental conditions. 
4.3.1 Infection of splenocytes with MDV-infected CEFs 
Splenocytes were co-cultured with MDV-infected CEFs to determine whether MDV 
infection could be transmitted from CEFs to B and if possible, T lymphocytes. 
Following isolation of splenocytes (section 2.2.16), cells were infected with pre-
sorted MDV-infected CEFs at a ratio of 1:5 (CEF:splenocyte) in T75 flask as per 
methods in section 2.2.17.  
Following infection, cells were incubated for 2 days as a substantial numbers of 
GFP+ cells were visible when examined under fluorescence microscope. At 2 dpi, 
cells were analysed by flow cytometry after staining with Bu-1, CD3 and Gr 13.1 
(isotype control) as described previously (section 2.4.2). 
Around 13% cells were gated as live lymphocytes in the SSC/FSC plot (Figure 
4.5A). Nearly 70% of the lymphocytes were found to be alive after staining with 7-




























Figure 4.5. Flow cytometric characterisation of splenocytes following infection 
with pre-sorted MDV-infected CEFs. Cells were infected at 1:5 ratios (infected 
CEF:splenocyte). (A) Cells were gated in SSC/FSC plot. (B) SSC/FSC gated cells 
were analysed in FL3/FSC plot to gate live cells. FL3 shows the fluorescence of 7-
AAD. (C) Live cells from FL3/FSC plot were analysed in FL1/FL4 to detect Bu-1+ 
and CD3+ splenocytes compared to isotype control (Gr 13.1). FL1 shows the 
fluorescence of GFP (green)-encoded MDV and FL4 shows the fluorescence of 
Alexa Fluor 647 (red) at the surface of the cells. Distribution of cells in Bu-1 and 
CD3 staining, FL1-FL4-: uninfected splenocytes; FL1+FL4-: infected splenocytes; 




Flow cytometric analyses of live cells in FL1/FL4 dot plots revealed that the 
proportion of infected B cells, as shown by Bu-1 staining, was 0.32%. On the other 
hand, the number of infected T cells (CD3+) was 1.31% (Figure 4.5C). 
It was clear from this experiment that MDV infection could be transmitted from 
infected CEFs to B and T cells in vitro in the present experimental conditions. Hence 
in the next experiment, an attempt was made to explore whether virus transmission 
could take place from MDV-infected macrophages to B or T cells. 
4.3.2 Infection of splenocytes with MDV-infected macrophages 
Following infection of B and T cells in vitro by MDV-infected CEFs, MDV-infected 
macrophages were co-cultured with splenocytes. 
Sorting large numbers of MDV-infected macrophages on 3 dpi was very challenging 
and in the first attempt (data not shown), 2.5×106 splenocytes were infected with 
0.5×106 infected macrophages in 6-well plates at 1:5 ratios (infected 
macrophage:splenocyte) as per methods in section 2.2.18. This experiment was not 
successful as GFP+ cells were not detected after 24 h of infection using flow 
cytometry. 
An attempt was then made to sort infected macrophages on 1 dpi. In this experiment, 
5×106 MDV-infected macrophages were sorted on 1 dpi and 2.5×107 splenocytes 
were infected at a ratio of 1:5 (infected macrophage:splenocyte) in T75 flask 
according to the procedures in section 2.2.18. Following infection, it was observed 
that the number of GFP+ cells was rapidly declining from the culture flask. Thus on 1 
dpi, cells were harvested by pipetting and subsequently analysed by flow cytometry 




























Figure 4.6. Flow cytometric characterisation of splenocytes following infection 
with pre-sorted MDV-infected macrophages on 1 dpi. Cells were infected at 1:5 
ratios (infected macrophage:splenocytes). (A) Cells were gated in SSC/FSC plot 
(B) SSC/FSC gated cells were analysed in FL3/FSC plot to gate live cells. FL3 
shows the fluorescence of 7-AAD. (C) Live cells were analysed in FL1/FL4 dot 
plots to detect Bu-1+ and CD3+ splenocytes compared to isotype control (Gr 13.1). 
FL1 shows the fluorescence of GFP (green)-encoded MDV and FL4 shows the 
fluorescence of Alexa Fluor 647 (red) at the surface of the cells. Distribution of 
cells in Bu-1 and CD3 staining, FL1-FL4-: uninfected splenocytes; FL1+FL4-: 





In the SSC/FSC plot, around 28% cells were gated as lymphocytes (Figure 4.6A) and 
nearly 90% of these cells were found to be alive after staining with 7-AAD (Figure 
4.6B). 
Analysis of live cells in FL1/FL4 dot plots revealed that there were apparently no 
infected B or T cells as shown by Bu-1 and CD3 staining (FL1+FL4+) (Figure 4.6C). 
Hence, attempts to infect splenocytes with MDV-infected macrophages were not 
successful.  
4.4 Discussion 
Splenic B and T cells or whole splenocytes were co-cultured with MDV-infected 
macrophages to determine whether the infection could transfer from macrophages to 
B or T cells. In the previous Chapter, MDV-infected macrophages produced plaques 
in CEF cultures, indicating that MDV-macrophage infection is a productive type of 
infection. During in vivo infection, MDV infection presumably transmits from 
macrophages to B cells possibly through EARCs in the lymphoid tissues. To mimic 
this process, several attempts were made to infect B and T cells with MDV-infected 
macrophages in vitro.  
Efforts were initially made by co-culturing sorted B lymphocytes with MDV-
infected macrophages. In the first experiment, B cells were positively sorted from 
spleen and subsequently co-cultured with MDV-infected macrophages, but there 
were no detectable infected B cells (Figure 4.2C). In the second experiment, B cells 
were negatively sorted as positive sorting might cause alteration of B cell-phenotype  
in culture. However, this co-culture infection experiment was also not successful as 




It was then tested whether B and T cells could be infected in vitro with MDV-
infected CEFs in the present experimental conditions. Although the number of 
infected cells were very low, it has been observed that both B and T cells could be 
infected in a single experiment where splenocytes were co-cultured with MDV-
infected CEFs (Figure 4.5C). In contrast, B and T cells were not infected after co-
culture with MDV-infected macrophages (Figure 4.6C). 
It was observed that, unlike MDV-infected CEFs, MDV-infected macrophages were 
very difficult to work with because they were found to die quickly after sorting as 
observed by the rapid disappearance of GFP+ cells in culture, a feature which most 
likely caused downstream experiments unsuccessful.  
Due to the strict cell-associated nature of MDV, it requires live cells to cause 
infection to other cells. In the experiments where CEFs were infected with sorted 
MDV-infected macrophages (Chapter 3), it was possible to incubate cells for a long 
time after infection due to high longevity of cultured CEFs. Infected macrophages 
also died in those experiments at 2-3 dpi but MDV infection was harboured in CEFs 
and gradually re-emerged by forming plaques from 3-5 dpi, a feature which was 
absent in B cell infections. Specific growth factors or activating ligands (such as 
CD40L) that promote growth and activation of B cells (Kothlow et al., 2008) were 
not used for B cell cultures in this study. This probably accounts for the observed 
rapid death of B cells and the failure to infect these cells with MDV.  
Although these experiments were not successful, it is still too early to draw the 
conclusion about the ability to infect of B and T cells in vitro with MDV-infected 
macrophages. Viral plaques were formed in CEF cultures co-cultured with infected 




macrophages to other cells. Further experiments are required to determine whether 
infection can be established in suitably activated B and T cells.  
Following establishment and characterisation of the in vitro MDV-APC infection 
model in outbred chickens, this model was then applied to APCs of inbred MD-















Chapter 5:  








MDV is primarily a lymphotrophic alphaherpesvirus though it also infects APCs in 
its life cycle. However, the cell or cells involved in resistance or susceptibility to MD 
are yet to be explored. Genetic resistance to MD is a complex trait, as genes from the 
MHC and also from outside of the MHC are involved. However, two chicken inbred 
lines, 61 and 72 which are highly resistant and susceptible to MD, respectively, are 
MHC-congenic (Cole, 1968), which shows that the resistance to MD is largely 
determined by genes outside of the MHC. Research has been carried out to determine 
the basis of resistance or susceptibility between the two lines, such as differences in 
the virus titre (10-fold higher in susceptible compared to resistant birds) in 
splenocytes (Lee et al., 1981) and differential cytokine expression in splenocytes (IL-
6 and IL-18 were expressed in susceptible but not in resistant birds) (Kaiser et al., 
2003) during the cytolytic phase of MDV infection. However, an in-depth study of 
the role of any specific immune cell population in resistance or susceptibility has not 
been carried out. Differential gene expression was observed in splenocytes of these 
two lines as early as 3 dpi (Smith et al., 2011) and by this time, MDV infection 
occurs in APCs, B and activated T cells. Therefore, any or all of these cells could be 
involved in determining resistance to MD. In this study, the hypothesis was tested 
that the resistance mechanism is expressed at the early phase of infection when MDV 
encounters APCs. To study the MDV infection of APCs in MD-resistant and 
susceptible birds, a de novo in vitro MDV-APC infection model has been developed 
(Chapter 3). In this Chapter, the model was applied to the APCs of these two inbred 
lines and the aims were to characterise infected and uninfected cells by flow 




qRT-PCR. APCs were first cultured and characterised phenotypically from the two 
lines and then infected with MDV-infected CEFs. 
5.2 Culture and characterisation of BMDM from the chicken 
inbred lines 61 and 72 
5.2.1 Morphological characterisation 
Chicken bone marrow cells from inbred lines 61 and 72 were cultured in T75 flasks for 
4 days following procedures described previously (section 2.2.9). In both cases, 
cultured macrophages showed a heterogeneous population containing loosely and 









5.2.2 Characterisation by flow cytometry 
Macrophages from two inbred lines were cultured in T75 flasks (section 2.2.9). On 
day 4, cells were analysed by flow cytometry after staining with KUL01, CD45 and 
Gr 13.1 (isotype control) as described in section 2.4.2. 
Around 48% and 72% cells were gated in SSC/FSC plots as macrophages for further 
analysis in lines 61 and 72, respectively (Figure 5.2A). Live cells were then gated in 
FL3/FSC plot based on 7-AAD staining (Figure 5.2B). 
Figure 5.1. Morphological properties on day 4 of BMDM cultured from inbred 




























Figure 5.2. Phenotypic characterisation of BMDM by flow cytometry from inbred 
chickens. (A) Cells from line 61 and 72 were gated in SSC/FSC plot. (B) SSC/FSC 
gated cells from both lines were plotted in FL3/FSC channel to gate live cells. FL3 
shows the fluorescence of 7-AAD. (C) Live cells from line 61 and 72 were tested for 
surface expression of KUL01 and CD45 and compared with unstained cells and 
cells stained with the isotype control antibody (Gr 13.1). FL4 shows the 




Phenotypic analyses of live cells revealed that the mean fluorescent intensity (MFI) 
of CD45 staining was higher than that of KUL01, though both were expressed on 
most macrophages (more than 95%) and there was no difference regarding KUL01 
and CD45 expression between two inbred lines (Figure 5.2C). 
Following culture and characterisation of macrophages in inbred lines, the next step 
was to repeat this experiment in DCs from lines 61 and 72 birds. 
5.3 Culture and characterisation of BMDC from the chicken 
inbred lines 61 and 72 









DCs were cultured from lines 61 and 72 following isolation and processing of bone 
marrow cells and seeded in T75 flasks for 4 days (section 2.2.9). Cellular aggregates 
were observed in the culture flasks at day 4 in both the inbred lines (Figures 5.3A 
and B). 
5.3.2 Characterisation by flow cytometry 
BMDC from inbred lines were grown in T75 flasks for 4 days as described in section 
2.2.9.  
Figure 5.3. Morphological properties of BMDC on day 4 cultured from inbred 




Immunofluorescence staining was carried out on day 4 with KUL01, CD45 and Gr 























Figure 5.4. Phenotypic characterisation of BMDC by flow cytometry from inbred 
chickens. (A) Cells from lines 61 and 72 were gated in SSC/FSC plots. (B) SSC/FSC 
gated cells from both lines were plotted in FL3/FSC plots to gate live cells. FL3 
shows the fluorescence of 7-AAD. (C) Live cells from lines 61 and 72 were tested for 
surface expression of KUL01 and CD45 and compared with unstained cells and 
cells stained with the isotype control antibody (Gr 13.1). FL4 shows the 




Around 60% and 70% cells were gated as DCs in SSC/FSC plots in lines 61 and 72 
birds, respectively (Figure 5.4A). Analysis of these cells in FL3/FSC plots with the 
staining of cell viability dye revealed that more than 80% of SSC/FSC gated cells 
were live in both the lines (Figure 5.4B). Phenotypic analyses of live cells revealed 
that the MFI of CD45 was higher than that of KUL01. CD45 was also expressed on a 
higher number (100%) of DCs compared to KUL01 (around 90%) in both the lines 
(Figure 5.4C). 
Following characterisation of macrophages and DCs in inbred lines, these cells were 
infected with pre-sorted MDV-infected CEFs in the next two experiments and 
subsequently characterised by flow cytometry. 
5.4 Infection and subsequent flow cytometric characterisation 
of BMDM from the inbred lines 
Chicken BMDM from lines 61 and 72 were grown in T75 flasks as described in 
section 2.2.9. Three T75 flasks of macrophages were cultured separately from each of 
the two inbred lines to carry out flow cytometric experiments on 1, 3 and 5 dpi. 
Meanwhile, MDV-infected CEFs were grown in two T175 flasks for each experiment 
as per methods in section 2.3.4. On day 4 of culture, macrophages were infected with 
pre-sorted GFP+ CEFs at an infection ratio of 1:5 (CEF:macrophage) as described in 
section 3.4.1. 
Following infection, cells were observed daily under the fluorescence microscope 
and it was noted that the number of GFP+ cells was gradually reduced as the time 





























Figure 5.5. Infection of macrophages with pre-sorted GFP+ CEFs in inbred lines. 
The ratio of infection was 1:5 (CEF:macrophage). Left panel: Line 61 macrophages 




Cells were harvested on 1, 3, and 5 dpi from both lines (Figure 5.5) for flow 
cytometric analyses after staining with KUL01, CD45 and Gr 13.1 (isotype control) 
as described in section 2.4.2. At least 106 viable cells were counted from each 
sample. 
On 1 dpi, around 88% of the SSC/FSC gated cells in line 61 and 75% of the 
SSC/FSC gated cells in line 72 were found alive after staining with 7-AAD (Figure 
5.6B). Flow cytometric analyses of live cells in FL1/FL4 dot plots, as shown in 
KUL01 and CD45 staining (FL1+FL4+), revealed that the proportion of infected 
macrophages was around 3 times higher in line 72 (36%), which is susceptible to 
MD, compared to those in line 61 (12%), which is resistant to MD (Figure 5.6C). 
These experiments were also repeated four times at the same infection ratio (1:5) 
with macrophages of two inbred lines for cell sorting purposes (section 5.6) on 1 dpi 
and the data were analysed using different software (FACSDiva instead of FlowJo). 
However, the percentages of infected macrophages in line 61 were 20.5%, 10%, 
13.5% and 7.8% (average 12.5%), whereas in line 72 macrophages the percentages 
were 30.5%, 27.7%, 45.8% and 13.7% (average 29.45%), still denoting a higher 
susceptibily of macrophages in line 72, though the mean difference between the two 
lines was not statistically significant (Figure 5.6D). 
More than 90% of the SSC/FSC gated cells were found alive on 3 dpi after staining 
with cell viability dye in both the lines (Figure 5.7B). The number of infected 
macrophages on 3 dpi, as observed in KUL01 and CD45 staining, was reduced in 
both line 61 (4%) and line 72 (10%) when compared to those on 1 dpi (Figure 5.6C), 



















































On 5 dpi, more than 90% of the SSC/FSC gated cells in both lines were identified as 
live cells in FL3/FSC plots (Figure 4.8B). Flow cytometric analyses of live cells 
following KUL01 and CD45 staining revealed that the number of infected 
macrophages was very few (around 0.6%) in the resistant line (61) compared to its 
susceptible counterpart (line 72, 5.5%) (Figure 5.8C). 
Figure 5.6. Characterisation of macrophages (Mac) by flow cytometry and during 
cell sorting following co-culture with MDV-infected CEFs in two inbred lines on 1 
dpi. Macrophages were infected with pre-sorted MDV-infected GFP+ CEFs at 1:5 
ratio (CEF:macrophage) (A) Cells were gated in SSC/FSC plots. (B) SSC/FSC 
gated cells were analysed in FL3/FSC plots to identify live cells. (C) Live cells were 
analysed in FL1/FL4 dot plots to detect KUL01+ and CD45+ macrophages 
compared to isotype control (Gr 13.1). (D) The percentages of infection of 
macrophages and the mean difference between the two inbred lines during cell 
sorting experiments. Statistical difference was measured with 2-sample T-test (95% 
confidence interval) using Minitab 16 software. FL1 shows the fluorescence of GFP 
(green)-encoded MDV and FL4 shows the fluorescence of Alexa Fluor 647 (red) at 
the surface of the cells. Distribution of cells in antibody stained plots, FL1-FL4-: 
uninfected CEFs; FL1+FL4-: infected CEFs; FL1-FL4+: uninfected macrophages 























































Figure 5.7. Flow cytometric characterisation of macrophages (Mac) following co-
culture with MDV-infected CEFs in two inbred lines on 3 dpi. Macrophages were 
infected with pre-sorted MDV-infected GFP+ CEFs at 1:5 ratio (CEF:macrophage) 
(A) Cells were gated in SSC/FSC plots. (B) SSC/FSC gated cells were analysed in 
FL3/FSC plots to identify live cells. (C) Live cells were analysed in FL1/FL4 dot 
plots to detect KUL01+ and CD45+ macrophages compared to isotype control (Gr 
13.1). FL1 shows the fluorescence of GFP (green)-encoded MDV and FL4 shows 
the fluorescence of Alexa Fluor 647 (red) at the surface of the cells. Distribution of 
cells in antibody stained plots, FL1-FL4-: uninfected CEFs; FL1+FL4-: infected 




























Figure 5.8. Flow cytometric characterisation of macrophages (Mac) following co-
culture with MDV-infected CEFs in two inbred lines on 5 dpi. Macrophages were 
infected with pre-sorted MDV-infected GFP+ CEFs at 1:5 ratio (CEF:macrophage) 
(A) Cells were gated in SSC/FSC plots. (B) SSC/FSC gated cells were analysed in 
FL3/FSC plots to identify live cells. (C) Live cells were analysed in FL1/FL4 dot 
plots to detect KUL01+ and CD45+ macrophages compared to isotype control (Gr 
13.1). FL1 shows the fluorescence of GFP (green)-encoded MDV and FL4 shows 
the fluorescence of Alexa Fluor 647 (red) at the surface of the cells. Distribution of 
cells in antibody stained plots, FL1-FL4-: uninfected CEFs; FL1+FL4-: infected 




5.5 Infection and subsequent flow cytometric characterisation 























Figure 5.9. Infection of BMDC with pre-sorted GFP+ CEFs in inbred lines. The 
ratio of infection was 1:5 (CEF:DC). Left panel: Line 61 DCs on 1, 3 and 5 dpi. 




Chicken BMDC were cultured in three separate T75 flasks from each of the two 
inbred lines as per methods in section 2.2.9 to carry out flow cytometric experiments 
on 1, 3 and 5 dpi. 
In parallel, MDV-infected CEFs were also grown in two T175 flasks for each 
experiment (section 2.3.4) and DCs were infected with pre-sorted GFP+ CEFs at a 
ratio of 1:5 (CEF:DC) (section 3.4.11). It was observed that the number of GFP+ 
cells was sharply reduced at the later days of infection (Figure 5.9). Flow cytometric 
analyses were carried out on 1, 3 and 5 dpi (Figure 5.9) after staining with KUL01, 
CD45 and Gr 13.1 (isotype control), according to procedures in section 2.4.2 and at 
least 106 viable cells were counted from each sample. 
On 1 dpi, around 85% of the SSC/FSC gated cells were found alive in FL3/FSC 
gating in both lines after staining with 7-AAD (Figure 5.10B). Live cells were placed 
in FL1/FL4 dot plots and the analyses of KUL01 and CD45 staining revealed that the 
proportion of infected DCs (FL1+FL4+) was almost identical in both the MD-
resistant (61) (6%) and MD-susceptible line (72) (around 5.5%) (Figure 5.10C). 
Over 90% of the SSC/FSC gated cells were identified as viable cells in FL3/FSC 
plots in both lines on 3 dpi (Figure 5.11B). Live cells were then analysed in FL1/FL4 
plots to detect the KUL01+ and CD45+ DCs. As for 1 dpi, no major difference was 
observed, in terms of the percentage of infected DCs, between two lines on 3 dpi, 
though the infected cell numbers were decreased (Figure 5.11C) compared to those 
on 1 dpi (Figure 5.10C). 
On 5 dpi, more than 90% of the SSC/FSC gated cells were found alive in FL3/FSC 
plots in both lines (Figure 5.12B). The KUL01 and CD45 staining revealed that the 























































Figure 5.10. Flow cytometric characterisation of DCs following co-culture with 
MDV-infected CEFs in two inbred lines on 1 dpi. DCs were infected with pre-sorted 
MDV-infected GFP+ CEFs at 1:5 ratio (CEF:DC) (A) Cells were gated in SSC/FSC 
plots. (B) SSC/FSC gated cells were analysed in FL3/FSC plots to gate live cells. 
(C) Live cells were analysed in FL1/FL4 dot plots to detect KUL01+ and CD45+ 
DCs compared to isotype control (Gr 13.1). FL1 shows the fluorescence of GFP 
(green)-encoded MDV and FL4 shows the fluorescence of Alexa Fluor 647 (red) at 
the surface of the cells. Distribution of cells in antibody stained plots, FL1-FL4-: 
uninfected CEFs; FL1+FL4-: infected CEFs; FL1-FL4+: uninfected DCs and 




























Figure 5.11. Flow cytometric characterisation of DCs following co-culture with 
MDV-infected CEFs in two inbred lines on 3 dpi. DCs were infected with pre-
sorted MDV-infected GFP+ CEFs at 1:5 ratio (CEF:DC) (A) Cells were gated in 
SSC/FSC plots. (B) SSC/FSC gated cells were analysed in FL3/FSC plots to gate 
live cells. (C) Live cells were analysed in FL1/FL4 dot plots to detect KUL01+ and 
CD45+ DCs compared to isotype control (Gr 13.1). FL1 shows the fluorescence of 
GFP (green)-encoded MDV and FL4 shows the fluorescence of Alexa Fluor 647 
(red) at the surface of the cells. Distribution of cells in antibody stained plots, FL1-
FL4-: uninfected CEFs; FL1+FL4-: infected CEFs; FL1-FL4+: uninfected DCs and 







































5.6 Sorting macrophages and DCs following MDV infection in 
inbred lines  
In order to explore the cellular basis of resistance to MD, GFP+ APCs were sorted 
following infection with MDV in vitro and RNA samples were sent for RNA-Seq. 
Macrophages and DCs from inbred lines 61 and 72 were cultured and infected with 
MDV as per methods in section 5.4 (for macrophages) and in section 5.5 (for DCs). 
Cell sorting was carried out on 1 and 3 dpi. The infection ratios varied because the 
number of infected cells was not consistent between macrophages and DCs during 
sorting. A higher number of cells (macrophages or DCs) were infected on 1 dpi than 
on 3 dpi and in general, the percentages of infected macrophages were higher than 
those of DCs (sections 5.4 and 5.5, respectively). Therefore, to obtain the optimum 
number of infected cells during sorting, higher infection ratios (1:2 or 1:2.5, 
CEF:APCs) were used for DCs and also for the sorting experiments on 3 dpi. In all 
other cases, an infection ratio of 1:5 was used. Prior to the sort, cells were harvested 
and prepared for sorting as described in section 2.4.3.1 (for CEFs) and in section 
2.4.3.2 (for APCs). As shown in Figure 5.13A, infected and uninfected macrophages 
Figure 5.12. Flow cytometric characterisation of DCs following co-culture with 
MDV-infected CEFs in two inbred lines on 5 dpi. DCs were infected with pre-
sorted MDV-infected GFP+ CEFs at 1:5 ratio (CEF:DC) (A) Cells were gated in 
SSC/FSC plots. (B) SSC/FSC gated cells were analysed in FL3/FSC plots to gate 
live cells. (C) Live cells were analysed in FL1/FL4 dot plots to detect KUL01+ and 
CD45+ DCs compared to isotype control (Gr 13.1). FL1 shows the fluorescence of 
GFP (green)-encoded MDV and FL4 shows the fluorescence of Alexa Fluor 647 
(red) at the surface of the cells. Distribution of cells in antibody stained plots, FL1-
FL4-: uninfected CEFs; FL1+FL4-: infected CEFs; FL1-FL4+: uninfected DCs and 




and DCs were sorted on 1 and 3 dpi. The ‘uninfected’ cells were sorted from the 
same flask as the infected cells were sorted and therefore, the uninfected cells were 
exposed to virus. Hence to obtain control APCs, sort-stressed uninfected CEFs were 
added to one separate T75 flask of macrophage or DC culture at 1:5 ratios on the day 
of infection of APCs in each experiment and ‘control’ macrophages or DCs that have 
been exposed to CEFs but not to MDV were then sorted on 1 and 3 dpi after staining 

















Figure 5.13. The overall model of cell sorting. On the day of infection, (A) GFP+ 
CEFs were sorted and added to macrophage (Mac) or DC culture and infected and 
uninfected macrophages or DCs were sorted subsequently on 1 and 3 dpi, (B) sort-
stressed uninfected CEFs were added to macrophage or DC culture followed by the 
sorting of control macrophages or DCs on the same days. FL1 shows the 
fluorescence of GFP (green)-encoded MDV and FL4 shows the fluorescence of 
Alexa Fluor 647 (red) at the surface of the cells. Distribution of cells in sorting 
plots, FL1-FL4-: uninfected CEFs (Q3); FL1+FL4-: infected CEFs (Q1); FL1-FL4+: 




After sorting, the purity of infected and uninfected APCs was checked (Figures 
5.14B and C, respectively) by placing 1000 sorted cells into the same sorting plot 
and it was shown that the uninfected APCs were a pure population, but infected 
APCs were not. Though a separate gate was created in each cell sorting experiment 
to keep the doublet cells out of the analysis, there were contaminating cells in the 
infected cell-group from each of the remaining three quarter (Q1, Q3 and Q4) 
(Figure 5.14B). 

















Figure 5.14. Checking purity of the sorted cells. On 1 and 3 dpi, (A) infected and 
uninfected APCs were sorted and (B) the purity of infected and (C) uninfected 
macrophages (Mac) or DCs was checked. FL1 shows the fluorescence of GFP 
(green)-encoded MDV and FL4 shows the fluorescence of Alexa Fluor 647 (red) at 
the surface of the cells. Distribution of cells in sorting plots, FL1-FL4-: uninfected 
CEFs (Q3); FL1+FL4-: infected CEFs (Q1); FL1-FL4+: uninfected APCs (Q4) and 




5.7 Characterisation of APCs from inbred lines after MDV 
infection by qRT-PCR 
BMDM and BMDC from the two inbred chicken lines 61 and 72 were infected with 
MDV and infected, uninfected and control APCs were sorted on 1 and 3 dpi (section 
5.6). Total RNA was extracted from all the groups (control, infected and uninfected) 
as described in section 2.5.1 and DNase treatment of RNAs was carried out (section 
2.5.1.1). The mRNA expression levels of two pro-inflammatory cytokines, IL-6 and 
IL-18 were then measured on 1 dpi in MDV-infected, uninfected and control 
macrophages and DCs from the two inbred lines using TaqMan qRT-PCR as 
described in section 2.5.4. The results are expressed as corrected 40-Ct and shown in 
Figures 5.15 and 5.16. 
No statistically significant difference (p>0.05) was observed in the mean IL-6 
mRNA expression of all macrophage and DC groups in the two inbred lines (Figures 
5.15A and B, respectively). IL-18 expression level was higher in all line 61 
macrophages compared to the expression in line 72. In infected macrophages, IL-18 
mRNA expression was significantly higher in line 61 compared to line 72 (p<0.05) 
(Figure 5.16A). There was no statistically significant difference (p>0.05) in IL-18 
mRNA expression of three DC groups between two inbred lines (Figure 5.16B). 
5.8 Discussion 
To explore the cellular basis of resistance to MD, APCs from two inbred lines 61 and 
72 were infected with MDV-infected CEFs using a previously developed infection 
model (Chapter 3) and subsequently characterised by flow cytometry and qRT-PCR. 
Despite sharing the same MHC genes, the chicken inbred line 61 is highly resistant 




























Figure 5.15. Quantification of IL-6 mRNA expression level in (A) macrophages and 
(B) DCs derived from inbred chicken lines on 1 dpi. Results are shown as corrected 
40-Ct for the expression of IL-6 in infected, uninfected and control macrophages 
(Mac) and DCs. The 40-Ct figures show means and standard deviations of three 
biological replicates from each line except for the line 72 uninfected macrophage 
group where values from two replicates were counted. Pairwise statistical 
comparisons between means in three groups of the two inbred chicken lines were 
carried out with a General linear model with Tukey (95% confidence interval) 

























The chicken inbred lines (61 and 72) show differences in viraemia level and gene 
expression profiles in splenocytes from the very early stages of MDV infection (Lee 
et al., 1981; Smith et al., 2011), suggesting that the inherent difference between two 
Figure 5.16. Quantification of IL-18 mRNA expression level in (A) macrophages 
and (B) DCs derived from inbred chickens on 1 dpi. Results are shown as corrected 
40-Ct for the expression of IL-18 in infected and uninfected macrophages (Mac) 
and DC compared to those in controls. The 40-Ct figures show means and standard 
deviations of three biological replicates from each line. Pairwise statistical 
comparisons between means in three groups of the two inbred chicken lines were 
carried out with a General linear model with Tukey (95% confidence interval) 




lines is due to differential responses of the innate immune system (Bumstead and 
Kaufman, 2004). The cells of the innate immune system, especially macrophages, 
play a crucial role during MDV infection. For example, peritoneal macrophages 
isolated from MDV-infected chickens inhibited the formation of MDV plaques in 
vitro (Kodama et al., 1979). Peritoneal macrophages also showed more phagocytic 
activity and plaque-inhibiting activity following MDV infection in susceptible than 
those of resistant chickens (Powell et al., 1983). In the present study, APCs from MD 
resistant (61) and susceptible (72) lines were infected with MDV in vitro for the first 
time.  
It was observed in the flow cytometric analyses that on 1 dpi, line 61 macrophages 
were approximately 3 times less infected than those of line 72 (Figure 5.6C). As 
mentioned before (section 5.4), these experiments were repeated four times at an 
infection ratio of 1:5 with macrophages of two inbred lines for cell sorting purposes 
and the data were analysed using a different software (FACSDiva instead of FlowJo) 
The mean diference of percentages of infection between two lines also denotes a 
higher susceptibily of macrophages in line 72 (Figure 5.6D). 
On 3 and 5 dpi, the numbers of infected macrophages gradually reduced in both the 
lines but line 72 macrophages were still infected higher in numbers (more than 2.5 
times) than line 61 macrophages (Figures 5.7C and 5.8C, respectively). 
The numbers of infected DCs were almost identical between two lines on 1, 3 and 5 
dpi (Figures 5.10C, 5.11C and 5.12C, respectively). The experiments on 1 dpi were 
also repeated four times using a higher infection ratio (1:2 or 1:2.5) in the cell sorting 
experiments to obtain optimum number of infected DCs (data were not shown). 




carried out at 1:5 infection ratio), but it was observed that a high infection ratio can 
produce increased number of infected DCs. 
The overall flow cytometric results revealed that, irrespective of lines and the days-
post infection, with a fixed infection ratio (1:5) a higher percentage of macrophages 
were infected than DCs. Moreover, a higher proportion of macrophages from 
susceptible line (72) were infected compared to the resistant line (61) but no apparent 
difference was observed in the number of infected DCs between two lines. This 
might be an indication that macrophages play a more important role to exert 
resistance or susceptibility to MD than DCs. Among the immune cells, macrophages 
are well-known to exert resistance to herpesvirus infections. For example, a 
macrophage-dependent and T-cell independent resistance to systemic HSV-1 
infection was demonstrated in mice where a selective reduction of macrophage 
function by silica treatment increased the susceptibility to HSV-1, but the reduction 
of thymic function by the aging process or by the combined effect of adult 
thymectomy and ATS (anti-mouse thymocyte serum) did not increase the 
susceptibility to HSV-1(Schlabach et al., 1979). 
Macrophages are thought to inhibit MDV replication as they release NO (nitric 
oxide) through the increased activity of iNOS. NO is presumed to be crucial for 
inhibiting MDV replication during the cytolylic and latent phases of infection in vivo 
as an increased level of NO was observed in splenocyte cultures of MDV-infected 
MD-resistant chickens (Xing and Chat, 2000).  
As an APC, DCs might be expected to infect at similar level to macrophages, but it 
was not the case. However, one factor should also be considered here. As in outbred 




contained the cytokines IL-4 and GM-CSF (CSF-2) as growth promoting factors. 
Though no studies have been performed yet regarding MDV infection, the inhibitory 
role of IL-4 and GM-CSF might be crucial in MDV replication and hence low 
infection to DCs (Kedzierska et al., 2000; Tsai et al., 2013). But if only the 
difference in inbred lines is considered, it can be said that no apparent variation was 
observed between MD-resistant and susceptible lines in the context of MDV-DC 
infection, suggesting that, like macrophages, DCs are infected by MDV but act only 
as a carrier of the virus to the lymphoid tissues and perhaps do not play a role in 
determining resistance to MD. 
However, the level of in vitro virus infection may vary within APCs. For example, 
Vatter and Brinton (2014) reported a higher number of SHFV (simian haemorragic 
fever virus) infected macrophages than those of DCs in macaque and baboons in 
vitro. Analysing the transcriptomic signatures of infected macrophages and DCs by 
RNA-Seq will be helpful to clarify this question. 
The mRNA expression levels of two pro-inflammatory cytokines, IL-6 and IL-18, in 
MDV infected APCs, were measured on 1 dpi in the three groups (infected, 
uninfected and control) of two inbred lines using Taqman qRT-PCR. Among the 
three groups, infected cells were sorted from the MDV-infected culture flask, while 
control cells were sorted from a separate flask which was not exposed to virus. A 
group of cells was also sorted as ‘uninfected’ APCs from the same MDV-infected 
flask (Figure 5.13) to study the pattern of cytokine expression in these virus exposed, 
but not infected, cells. 
The term ‘pro-inflammation’ is a widely used and has an association with stress 




with pathological lesions following MDV infection. For example, an elevated 
expression of IL-6 and IL-18 was measured in the brain tissues of chickens infected 
with a vvMDV strain that caused transient paralysis in chickens (Abdul-Careem et 
al., 2006). Pro-inflammatory cytokines may also play a role in determining resistance 
to MD. Recently, Haunshi and Cheng (2014) reported a differential expression of IL-
6 and IL-8 along with TLR3, between CEFs from resistant and susceptible lines, 
suggesting an important role for these cytokines in MD resistance. In a previous in 
vivo MDV infection study (Kaiser et al., 2003), the role of two pro-inflammatory 
cytokines, IL-6 and IL-18 was reported crucial regarding resistance or susceptibility 
to MD. Both cytokines were found to be expressed in the splenocytes of susceptible 
birds (lines 72  and P) and the authors suggested that it might lead to lymphoma 
formation in these birds, whereas in MD-resistant chickens (lines 61  and N) neither 
of the transcripts was expressed which was thought to be critical for promoting and 
maintaining latency in these chicken lines. 
In contrast to the previous study, IL-6 expression was observed here in both resistant 
(61) and susceptible (72) lines, though exact comparison cannot be made as previous 
expression was measured in splenocytes (Kaiser et al., 2003). In this study, no 
significant differences were observed in IL-6 expression levels within three groups in 
macrophages and DCs of both lines (Figures 5.15A and B, respectively).  
IL-18, which is also pro-inflammatory in nature (Okamura et al., 1995), induces 
production of IFN-γ in NK and T cells and a range of cells, including macrophages 
or monocytes and DCs produce this cytokine. As shown in Figure 5.16A, the IL-18 




(61) than in macrophages of the susceptible line (72), but no difference was observed 
in infected DCs between the two lines (Figure 5.16B). 
An elevated expression of pro-inflammatory cytokines during the cytolytic phase is 
most likely related to increased pathology in susceptible chickens (Kaiser et al., 
2003), which is also in agreement with a recent study where higher expression of IL-
18 was reported in caecal tonsils of MD-susceptible chickens (line 72) compared to 
MD-resistant chickens (line 63) at 6 and 14 dpi (Heidari et al., 2014), but the scenario 
is contradictory in this study where an elevated expression of IL-6 (Figure 5.15A) 
and IL-18 (Figure 5.16A) was measured in the infected macrophages of MD-resistant 
line (61), though a higher number of infected macrophages was found in the MD-
susceptible line (72) than the MD-resistant line (61) (Figure 5.6C). However, an 
increased expression of pro-inflammatory cytokines might lead to IFN-γ production 
in macrophages of MD-resistant (61) chickens which in turn may play an inhibitory 
role on MDV replication in these birds (Xing and Schat, 2000). Measuring other 
cytokine expression levels in APCs between the two inbred lines will be helpful to 
get a comprehensive idea regarding resistance to MD, which was not possible at this 
stage due to shortage of RNA. In future, an evaluation of viral transcripts in infected 
cells (from transcriptomic data generated in studies described in Chapter 6) could 
also be helpful both to confirm viral replication and to determine whether the pattern 
of transcription differs between cells from the two chicken lines. 
Following MDV infection of APCs in inbred chickens lines, RNA samples from 1 
dpi were sent for RNA-Seq to explore the differentially expressed  (DE) genes in 
control and MDV-infected APCs of two inbred lines. Funtional analyses of those DE 













Chapter 6:  
Functional analysis of differentially expressed genes  








Resistance to MD is multifaceted, as many features, including host genetics, virus 
and environmental factors, constitutively determine this mechanism. Again, within 
the host, various genes from inside and outside of the MHC are interrelated. The two 
MHC-homozygous inbred chicken lines (61 and 72) have differential resistance to 
infection with MDV, which suggests that resistance in these lines is mainly exerted 
by the genes outside of the MHC. Variation in gene expression is a major 
determinant of phenotypic variation and differences in MD genetic resistance are 
most likely due to variation in the transcriptional regulation of genes (Cheng et al., 
2013). Several potential non-MHC candidate genes for MD resistance or 
susceptibility have been identified so far in various cell types, such as TLR3 in CEFs 
(Haunshi and Cheng, 2014), GH and Ly6E in splenocytes (Liu et al., 2001; Liu et al., 
2003) and IRG1 in splenocytes (Smith et al., 2011), but it remains to be established 
specifically in which cell types this resistance signature is expressed. Immune cells, 
such as APCs, B and T cells are involved in MDV pathogenesis. In order to explore 
the resistance phenotype in innate immune cells, APCs from lines 61 and 72 were 
infected with MDV using a newly developed in vitro MDV-APC infection model 
(Chapter 5) and RNA samples were sent for transcriptomic analysis to determine 
differentially expressed (DE) genes in the two chicken lines pre- and post-MDV 
infection of APCs, by RNA-Seq. The aim of this Chapter was to carry out the 
functional analysis of these DE gene sets to explore the biological pathway(s) 





6.2 Differential gene expression in APCs pre- and post-MDV 
infection  
Analysis of RNA-Seq data was carried out with the help of a skilled bioinformatician 
(Richard Kuo, The Roslin Institute) to explore various categories of DE genes in 
infected and control APCs of the two inbred lines as described in section 2.9. As 
shown in Figure 6.1, the expression of genes was compared within the APCs of 
infected and control birds of lines 61 and 72. As mentioned before (section 5.6), 
infected and control APCs were obtained from separate flasks after co-culturing with 
infected and uninfected CEFs, respectively. In the top level of comparison, gene 
expression of infected vs control cells of each line was measured and compared. In 
the lower level comparisons, differential expression of genes was compared within 
infected and control cells of each of the two inbred lines. DE genes from lower level 










Various categories of differentially expressed genes were revealed by these analyses, 
such as up- or down-regulation in the control or infected group only, up- or down-
Figure 6.1. Levels of comparison to explore DE genes in infected and control 




regulation in both the control and infected groups, up-regulation in the control group 
but down-regulation in the infected group, and vice versa. In this Chapter, functional 
analysis of DE genes in the control (no expression of these genes in the infected 
group) and infected (no expression of these genes in the control group) groups was 
carried out using several software programmes. The comparative analysis was based 
on line 61, which means genes up-regulated in line 61 represent genes highly 
expressed in line 61 compared to line 72 and genes down-regulated in line 61 indicate 
genes highly expressed in line 72 compared to line 61.  
From the lists of DE genes, a subset of genes were selected in each category based on 
their fold changes (>2). The DE gene numbers that were used for functional analysis 
using various software packages are given in Table 6.1. The full lists of DE genes in 
macrophages and DCs are provided in Appendix 2 (Table S2.1 to Table S2.4 for 
macrophages and Table S2.5 to Table S2.8 for DCs). 
 
Category Up-regulated in line 61 
(compared to line 72) 
Down-regulated in line 61 
(compared to line 72) 
Terms used in this 
Chapter  
Highly expressed 
in line 61 
Highly expressed 
in line 72 
Macrophage control 173 263 
Macrophage infected 261 236 
DC control 183 234 
DC infected 401 122 




6.3 Analysis of DE genes using DAVID software package 
DE genes from each category were analysed using several software packages to 
reveal their involvement in various biological pathways. Analysis in DAVID was 
carried out to identify gene clusters with enriched biological terms in control and 
infected APCs as described in section 2.10.1. The enrichment score was calculated 
with a set of input genes highly associated with certain biological terms, which was 
statistically measured by a Fisher Exact test in the DAVID system. Usually a p-value 
equal to or smaller than 0.05 was considered to be strongly enriched in the annotation 
categories. The overall enrichment score for the group was based on the p-value of 
each term member. The higher the score, the more enriched it is; usually the 
threshold is >1. 
6.3.1 Analysing genes highly expressed in control and infected 
macrophages 
Genes highly expressed in line 61 control macrophages clustered in functions related 
to the regulation of apoptosis and cell death (Table 6.2), whereas highly expressed 
genes in line 72 control macrophages clustered mainly with growth and structural 
maintenance factors such as collagen, hydoxylysine and EGF (epidermal growth 
factor) (Table 6.3). 
Following MDV infection, the highly enriched gene clusters in line 61 macrophages 
were those engaged in immune responses such as cytokine and chemokine activity 
and JAK-STAT (Janus Kinase (JAK)-Signal transducers and activators of 
transcription (STAT)) signalling pathways (Table 6.4), but genes in line 72 
macrophages clustered in biological processes e.g. dephosphorylation and also with 




principal signalling mechanism for a wide array of cytokines and growth factors 
resulting in cell proliferation, differentiation, cell migration and apoptosis. A diverse 
array of ligands (e.g. cytokines, interferons, growth factors) and their receptors 
stimulate the JAK-STAT pathway (Vignais et al., 1996). An activation of JAK-
STAT signalling pathway was reported in splenocytes of broilers and layers 
following MDV-infection (Perumbakkam et al., 2013). Smith et al. (2011) also 








 Regulation of apoptosis 7 5 1.20E-02 
1/1.88 
Regulation of cell death 7 5 1.40E-02 









 Hydroxylysine 3 1.3 2.30E-03 
 Collagen triple helix repeat 4 1.7 9.70E-03 
1/2.08 VWA 3 1.3 2.90E-02 
 von Willebrand factor, type A 3 1.3 2.90E-02 
 Extracellular matrix 4 1.7 8.70E-02 
2/1.51 
Transmembrane receptor 
Protein serine/threonine kinase 
signalling pathway 
4 1.7 2.40E-02 
3/1.32 Mesoderm formation 3 1.3 2.80E-02 
4/1.29 Purine nucleotide binding 23 10 3.40E-02 




5/1.14 EGF-like domain 4 1.7 5.70E-02 
 EGF 4 1.7 6.10E-02 









 Chemokine activity 4 2 6.50E-04 
 SCY 3 1.5 2.60E-03 
          1/2.62 
Small chemokine, 
interleukin-8-like 
3 1.5 4.10E-03 




4 2 1.70E-02 
 Cytokine receptor 
activity 
4 2 6.10E-03 
2/1.76 JAK-STAT signalling 
pathway 
5 2.6 3.10E-02 












4 1.9 4.50E-02 
1/1.11 
Dephosphorylation 4 1.9 1.10E-01 
 
Propeptide: Removed 
in mature form 
3 1.4 8.00E-02 
2/1.09 Anchored to membrane 3 1.4 1.10E-01 
 Lipoprotein 4 1.9 1.40E-01 
3/1.07 Transmembrane region 8 3.8 2.80E-01 






6.3.2 Analysis of genes highly expressed in control and infected DCs 
The genes which showed high expression in line 61 control DCs clustered in 
biological processes such as activation, proliferation and differentiation of T cells 
(Table 6.6), but no high enrichment (>1) of gene clusters was observed in line 72 
control DCs.  
In line 61 infected DCs, DAVID analysis revealed various annotation clusters of 
genes in which top scored clusters were associated with growth and structural terms 
such as extracellular matrix and hydroxylysine and low scored gene clusters were 
involved in immune activities like innate immune response and chemotaxis (Table 
6.7). Genes highly expressed in line 72 infected DCs showed enrichment with the 
biological term signal peptide (Table 6.8) which is a short (5-30 amino acids long) 
peptide present at the N-terminus of the majority of newly synthesised secretory 










Alpha-beta T cell 
activation 











3 1.9 3.30E-01 













1/6.95 Extracellular matrix 19 6.1 3.00E-08 
2/5.67 
Collagen triple helix repeat 8 2.6 1.80E-06 
 Collagen 8 2.6 2.80E-06 
3/5.43 Carbohydrate binding 12 3.9 1.90E-06 
 Hydroxyline 4 1.3 1.50E-04 
4/3.09 von Willebrand factor, type A 5 1.6 4.50E-04 
 VWA 5 1.6 1.40E-03 
 Sarcolemma 4 1.3 5.00E-03 
 Fibrillar collagen, C-terminal 4 1.3 2.10E-04 
5/2.75 COLFI 4 1.3 5.60E-03 
 Collagen 4 1.3 1.80E-02 
6/2.36 domain:Ig-like C2-type 1,2,3 5 1.6 2.80E-03 
 IGc2 7 2.3 4.70E-03 
7/2.19 




5 1.6 1.10E-02 
9/1.57 Immunoglobulin-like 8 2.6 2.40E-02 
 IG 6 1.9 1.30E-01 
10/1.44 Fibronection, type III 6 1.9 2.40E-02 
 FN3 6 1.9 7.10E-02 
11/1.43 Endopeptidase activity 10 3.2 1.50E-02 
 Proteolysis 12 3.9 1.60E-01 
12/1.29 Chemotaxis 4 1.3   2.20E-02 
 Toll-Interleukin receptor 3 1 4.90E-02 
13/1.25 TIR 3 1 8.30E-02 
 Innate immune response 3 1 1.00E-01 













Signal peptide 8 8.2 4.70E-02 
 Glycoprotein 6 6.2 1.40E-01 
Table 6.8. DAVID analysis of genes highly expressed in line 72 infected DCs 
(p<0.05). 
6.4 Pathway Express analysis of DE genes 
Following DAVID analysis, which identified gene clusters with enriched biological 
terms, the DE gene sets were analysed using the Pathway Express software package 
(Draghici et al., 2007) in order to determine biological pathways associated with 
genes in control APCs and their potential alterations after MDV infection. As 
described in section 2.10.2, the analysis was based upon the KEGG pathways and 
significantly affected pathways (FDR-corrected gamma p value of <0.05) pre- and 
post-MDV infection of APCs in the two inbred lines are shown in Table 6.9 to Table 
6.16. The p-value was determined based on the impact analysis of each gene’s 
expression and interactions in a given pathway (section 2.10.2). Immune pathways 
previously known and relevant to this study are highlighted in red in both control and 
infected APCs. 
6.4.1 Analysis of genes highly expressed in control and infected 
macrophages 
No apparent difference was observed between control macrophages in the context of 
activated biological pathways in two lines. TGF-β signalling was the common 
immune pathway in lines 61 and 72 control macrophages (Tables 6.9 and 6.10, 
respectively). TGF-β signalling pathway is involved in many cellular processes 




important involvement of this pathway was reported in MDV-infected cells where 
MDV-1-miR-M3 blocked the protein level expression of Smad2 (a crucial element of 
the TGF-β signalling pathway), resulting in a cellular environment suitable for viral 
latency and oncogenesis (Xu et al., 2011). 
Following MDV infection, the JAK-STAT signalling pathway along with the 
cytokine-cytokine receptor interaction were significantly activated in line 61 
macrophages (Table 6.11), whereas in line 72 infected macrophages, natural killer 
cell mediated cytotoxicity pathway was the only immune pathway activated (Table 
6.12). As mentioned in section 6.3.1, the JAK-STAT pathway was reported to be 
activated in MDV-infected cells (Smith et al., 2011; Perumbakkam et al., 2013). An 
increased activity of cytokine-cytokine receptor interaction was also observed in 
splenocytes after MDV infection (Smith et al., 2011; Perumbakkam et al., 2013). NK 
cell cytotoxicity is a receptor mediated killing of virus-infected or tumour cells 
(Terunuma et al., 2008) and an activation of this pathway could be an indication of 
NK-cell involvement in response to MDV infection. The cytotoxic activity of NK 
cells was increased in MD-resistant chickens (61) compared to MD-susceptible 
chickens (72) following MDV infection (Garcia-Camacho et al., 2003) which is in 
contrast to present observation. 
6.4.2 Analysis of genes highly expressed in control and infected DCs 
Control DCs of the two inbred lines showed almost identical immune activities. 
TGF-β and JAK-STAT signalling were the two known immune pathways 





Following MDV infection, more immune pathways were activated in line 61 DCs 
compared to line 72. While a significant activation of JAK-STAT signalling pathway, 
cytokine-cytokine receptor interaction, antigen processing and presentation, and 
MAPK (mitogen activated protein kinase) signalling pathway was observed in line 61 
infected DCs (Table 6.15), genes highly expressed in line 72 infected DCs were only 
involved with cytokine-cytokine receptor interaction mechanisms (Table 6.16).  
Processing of antigen and its presentation on the surface in the context of MHC is a 
characteristic feature of APCs (Blum et al., 2013).  









1 Melanoma 7.342 1/71 0.005403562 
2 TGF-beta signalling pathway 6.702 2/87 0.009461541 
3 Pathways in cancer 5.679 2/330 0.022821967 
4 B cell receptor signalling pathway 5.172 2/65 0.035015059 
5 Regulation of actin cytoskeleton 5.152 5/217 0.035606653 
6 Type II diabetes mellitus 4.623 1/45 0.055236314 
Table 6.9. Pathway express analysis of genes highly expressed in line 61 control 
macrophages. Immune pathways are shown in red. 
 









1 ECM-receptor interaction 12.468 9/84 5.18E-05 
2 Focal adhesion 10.735 11/203 2.55E-04 
3 Neuroactive ligand-receptor 
interaction 
9.451 7/256 8.22E-04 
4 TGF-beta signalling pathway 4.952 4/87 0.042076 
5 Small cell lung cancer 4.626 5/86 0.0551 
Table 6.10. Pathway express analysis of genes highly expressed in line 72 control 




The role of MAPKs is very critical for cellular homeostasis, and loss of fine control 
of MAPK regulation due to mutation or changes in the expression of proteins 
regulating MAPK signalling, may contribute to cancer (Dhanasekaran and Johnson, 
2007). The MDV oncogene, Meq, was shown to transcriptionally regulate many 
genes in the MAPK and JAK-STAT signalling pathways, which are crucial for 
oncogenesis and/or include signalling mediators involved in apoptosis (Subramaniam 
et al., 2013). 
 









1 Phosphatidylinositol signalling 
system 
27.679 2/76 2.73E-11 
2 Cytokine-cytokine receptor 
interaction 
16.043 13/263 1.84E-06 
3 Adherens junction 9.76 1/78 6.21E-04 
4 JAK-STAT signalling pathway 9.506 7/155 7.82E-04 
5 Basal cell carcinoma 7.313 3/55 0.005543222 
6 Axon guidance 7.281 5/129 0.005701441 
Table 6.11. Pathway express analysis of genes highly expressed in line 61 infected 
macrophages. Immune pathways are shown in red. 
 









1 Phosphatidylinositol signalling 
system 
26.737 1/76 6.78E-11 
2 Adherens junction 14.571 3/78 7.31E-06 
3 Cell adhesion molecules (CAMs) 9.57 6/134 7.38E-04 
4 Gap junction 6.358 1/96 0.012750155 
5 Natural killer cell mediated 
cytotoxicity 
6.062 4/135 0.016452601 
6 Melanoma 6.029 1/71 0.016925134 
7 Focal adhesion 5.645 6/203 0.023491061 
8 Tight junction 5.363 4/135 0.029822264 
Table 6.12. Pathway express analysis of genes highly expressed in line 72 infected 
















1 Phosphatidylinositol signalling 
system 
24.953 1/76 3.78E-10 
2 TGF-beta signalling pathway 12.746 1/87 4.01E-05 
3 Basal cell carcinoma 8.158 1/55 0.002623169 
4 Adherens junction 6.915 1/78 0.007857865 
5 Leukocyte transendothelial 
migration 
6.321 4/119 0.013164216 
6 Axon guidance 5.502 4/129 0.026519097 
7 Adipocytokine signalling pathway 5.117 1/67 0.036665163 
Table 6.13. Pathway express analysis of genes highly expressed in line 61 control 
DCs. Immune pathways are shown in red. 
 
 









1 Phosphatidylinositol signalling 
system 
22.839 5/76 2.87E-09 
2 Small cell lung cancer 11.359 8/86 1.44E-04 
3 Adherens junction 9.055 1/78 0.001174 
4 Hematopoietic cell lineage 9.039 4/87 0.001192 
5 Melanoma 8.575 3/71 0.001807 
6 Cell adhesion molecules (CAMs) 8.424 2/134 0.002069 
7 Pathways in cancer 7.587 11/330 0.004354 
8 JAK-STAT signalling pathway 6.013 5/155 0.017159 
9 Focal adhesion 5.705 7/203 0.022323 
10 Renal cell carcinoma 5.516 4/69 0.026207 
Table 6.14. Pathway express analysis of genes highly expressed in line 72 control 


















1 Phosphatidylinositol signalling 
system 
25.802 2/76 1.67E-10 
2 ECM-receptor interaction 20.707 14/84 2.21E-08 
3 Cytokine-cytokine receptor 
interaction 
18.371 18/263 2.04E-07 
4 Focal adhesion 16.312 18/203 1.43E-06 
5 JAK-STAT signalling pathway 8.966 10/155 0.001272438 
6 Regulation of actin cytoskeleton 8.373 10/217 0.002165364 
7 Pathways in cancer 6.816 15/330 0.008567091 
8 Prostate cancer 6.453 5/90 0.011744346 
9 Calcium signalling pathway 6.415 9/182 0.01213702 
10 Complement and coagulation 
cascades 
5.872 5/69 0.019360027 
11 TGF-beta signalling pathway 5.846 6/87 0.019794811 
12 Melanoma 5.837 3/71 0.01994751 
13 Antigen processing and 
presentation 
5.605 3/89 0.024302573 
14 MAPK signalling pathway 5.588 9/272 0.024655626 
15 Adherens junction 5.554 3/78 0.025376685 
16 Pancreatic cancer 5.381 4/72 0.029373124 
17 Graft-versus-host disease 5.144 2/42 0.035845975 
18 Glioma 4.851 3/65 0.045758056 
Table 6.15. Pathway express analysis of genes highly expressed in line 61 infected 
DCs. Immune pathways are shown in red. 
 
 









1 Adherens junction 36.087 2/78 7.89E-15 
2 Tight junction 9.05 1/135 0.00118 
3 Cytokine-cytokine receptor 
interaction 
6.673 1/263 0.009703 
4 Basal cell carcinoma 5.967 2/55 0.017849 
5 Prostate cancer 4.784 3/90 0.048369 
Table 6.16. Pathway express analysis of genes highly expressed in line 72 infected 




6.5 Analysis of DE genes using IPA 
Complementary to the findings from Pathway Express, use of the IPA program 
(Ingenuity Systems) (section 2.10.3) revealed which canonical pathways were 
inherently expressed in control APCs and which were up-regulated following MDV 
infection of APCs. The p-value was calculated using the right-tailed Fisher Exact 
Test. By default, IPA applies a -log (p-value) cut-off of 1.3 (p<0.05), that means 
pathways with a p-value equal to or greater than 0.05 are not shown. 
6.5.1 Analysing genes highly expressed in control and infected 
macrophages  
A higher number of immune pathways were inherently expressed in line 72 control 
macrophages than in line 61. For instance, the cytotoxic T lymphocyte (CTL) 
mediated apoptosis of target cell was the only immune pathway in line 61 control 
macrophages (Figure 6.2A), but LPS/IL-1 mediated inhibition of RXR (retinoid X 
receptor) function, role of PKR (protein kinase RNA-activated) in interferon 
induction and antiviral response and SAPK /JNK signalling pathways were involved 
with genes highly expressed in line 72 control DCs (Figure 6.2B).  
LPS/IL-1 mediated inhibition of RXR function leads to decreased nuclear RXRα 
levels and reduced nuclear DNA binding and transcriptional activity (Zimmerman et 
al., 2006). An activation of this pathway was observed in the splenocytes of MDV-
infected chickens (Smith et al., 2011). 
PKR belongs to the family of pattern-recognition receptors (PRRs) which is in the 
centre of cellular response to different stress signals such as pathogens, lack of 
nutrients, cytokines, irradiation, mechanical stress or stress of endoplasmic 




sources. PKR pathway leads to stress response through activation of other stress 
pathways such as JNK, p38, NF-κB, PP2α (protein phosphatase 2α) and 
phosphorylated eIF-2α (eukaryotic translation initiation factor 2α) (Hotamisligil, 
2010). By catalysing the phosphorylation of eIF-2α, PKR leads to an inhibition of the 
initiation of protein synthesis (Meurs et al., 1990). In this study, an activation of PKR 
signalling in control macrophages may be due to the stress induced by culture 
conditions. 
Stress-activated protein kinases (SAPKs), also referred to as c-Jun N-terminal 
kinases (JNKs), play an important role in the regulation of key cellular processes, 
including survival and death (Bhoumik et al., 2007). 
More immune pathways were activated in macrophages from resistant birds (61) 
compared to susceptible birds (72) following MDV infection. The canonical immune 
pathways significantly induced by MDV infection in line 61 macrophages were JAK-
STAT signalling and eNOS signalling (Figure 6.3A), whereas in line 72 macrophages 
no immune pathway was activated following infection (Figure 6.3B).  
An involvement of JAK-STAT signalling pathway in MDV-infected cells was 
described previously. eNOS signalling is involved in synthesis of nitric oxide (NO) 
which is a short-lived free radical involved in varieties of physiological and 
pathological processes. NO is produced along with L-Citrulline by the oxidation of 
L-Arginine in the reaction catalysed by three different isoforms of NOS (nitric oxide 
synthase). Of them, neuronal (nNOS) and endothelial (eNOS) isoforms are Ca2+ 
dependent for their enzyme activity and inducible NOS (iNOS) is Ca2+-independent 
(García-Cardeña et al., 1996). eNOS plays a crucial role in the state of blood vessel 




vascular NO production are thought to contribute to the pathogenesis of certain 
vascular disorders such as atherosclerosis. Infection with MDV is sometimes 






















Figure 6.2. Ingenuity pathway analysis showing the most highly represented 
canonical pathways that genes highly expressed in (A) line 61 and (B) line 72 control 
macrophages are involved with. Arrows indicate the pathways related to immune 
mechanisms. The yellow line represents the ratio of the number of genes represented 
within each pathway to the total number of genes in the pathway. The threshold line 
showing pathways that have a p-value <0.05. 
A) Genes highly expressed in line 61 control macrophages 
   -log  
(p-value) 
B) Genes highly expressed in line 72 control macrophages 






























Figure 6.3. Ingenuity pathway analysis showing the most highly represented 
canonical pathways that genes highly expressed in (A) line 61 and (B) line 72 
infected macrophages are involved with. Arrows indicate the pathways related to 
immune mechanism. The yellow line represents the ratio of the number of genes 
represented within each pathway to the total number of genes in the pathway. The 
threshold line showing pathways that have a p-value <0.05. 
A) Genes highly expressed in line 61 infected macrophages 
  -log  
(p-value) 
  -log  
(p-value) 




6.5.2 Analysing genes highly expressed in control and infected DCs 
Before MDV infection, more immune pathways were involved with genes highly 
expressed in DCs of susceptible birds (72) (Figure 6.4B) than the resistant birds (61) 
(Figure 6.4A). In line 61 control DCs, the immune related canonical pathways were 
LPS/IL-1 mediated inhibition of RXR function, CTL mediated apoptosis of target 
cells and IL-15 signalling (Figure 6.4A). IL-15 plays an important role as an inducer 
of immune response by activating various signalling pathways including the JAK-
STAT, MAPK, and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B 
cells) pathways to control cell growth and differentiation, enhance phagocytosis and 
increase the inflammatory response (Jakobisiak et al., 2011; Perera et al., 2012). 
In line 72 control DCs, significantly expressed inherent immune pathways were 
CD40 signalling, p53 signalling, lymphotoxin β receptor (LT-βR) signalling, role of 
PKR in interferon induction and antiviral response  and IL-4 signalling (Figure 
6.4B). 
CD40-mediated signal transduction induces the transcription of a large number of 
genes implicated in host defence against pathogens. This is accomplished by the 
activation of multiple pathways including NF-κB, MAPK and STAT3 
(Chatzigeorgiou et al., 2009). CD40-CD40L ligation on the surface of dendritic cells 
regulates production of pro-inflammatory cytokines such as IL-8 and IL-12. Ligation 
of CD40 on monocytes is important in stimulating production of IL-1α, IL-1β, IL-6, 
and IL-8, as well as in the rescue of circulating monocytes from apoptosis (Sakata et 
al., 1995).  
The p53 pathway is composed of a network of genes and transcriptional regulators 




segregation and cell division (Vogelstein et al., 2000). In response to a stress signal, 
the p53 protein is activated in a specific manner by post-translational modifications, 
and this leads to either cell cycle arrest, a programme that induces cell senescence or 
cellular apoptosis (Jin and Levine, 2001). 
Signalling through the LT-βR pathway is a crucial element in the organisation of 
secondary lymphoid tissues. LT-βR activates multiple signalling pathways including 
transcriptional factor NF-κB, and cell death (Remouchamps et al., 2011).  
IL-4 binding to its receptor activates JAK/TYK2 followed by phosphorylation and 
dimerization of STAT6. The transcriptional regulator STAT6 is able to induce 
various genes that are involved immune function like IgE and MHC II (Bhattacharjee 
et al., 2013). 
Following MDV infection, line 61 DCs showed greater immune activity (Figure 
6.5A) than the DCs of line 72 (Figure 6.5B). The immune pathways significantly 
induced in line 61 DCs were STAT3 pathway, IL-6 signalling, DC maturation, PRR 
recognition of bacteria and viruses, JAK-STAT signalling, IL-15 production and NF-
κB signalling (Figure 6.5A).  
STAT3 mediates the expression of a variety of genes in response to cell stimuli, and 
thus plays a key role in many cellular processes such as cell growth and apoptosis 
(Yang et al., 2007). 
IL-6 is considered as a regulator of acute-phase responses and a lymphocyte 
stimulatory factor. The central role of IL-6 in inflammation makes it an important 
target for the management of infectious and inflammatory diseases. IL-6 and 
associated cytokines utilise JAK-STAT family members as major mediators of signal 




in the splenocytes of susceptible chickens but not in resistant lines following MDV 









































Figure 6.4. Ingenuity pathway analysis showing the most highly represented 
canonical pathways that genes highly expressed in (A) line 61 and (B) line 72 
control DCs are involved with. Arrows indicate the pathways related to immune 
mechanism. The yellow line represents the ratio of the number of genes represented 
within each pathway to the total number of genes in the pathway. The threshold line 
showing pathways that have a p-value <0.05. 
A) Genes highly expressed in line 61 control DCs 
   -log  
(p-value) 
    -log 
 (p-value) 


















































Figure 6.5. Ingenuity pathway analysis showing the most highly represented 
canonical pathways that genes highly expressed in (A) line 61 and (B) line 72 
infected DCs are involved with. Arrows indicate the pathways related to immune 
mechanism. The yellow line represents the ratio of the number of genes represented 
within each pathway to the total number of genes in the pathway. The threshold line 
showing pathways that have a p-value <0.05. 
A) Genes highly expressed in line 61 infected DCs 
B) Genes highly expressed in line 72 infected DCs 
   -log  
(p-value) 
A) Genes highly expressed in line 61 infected DCs 





Maturation of DCs leads to the up-regulation of MHC class I and II as well as co-
stimulatory molecules such as CD80, CD83 and CD86, leading to an enhanced 
antigen presentation function in DCs. Several factors trigger the maturation of DCs, 
including microbes, cytokines and other cells of the immune system. They also up-
regulate CCR7 (Wu et al., 2011), a chemotactic receptor that induces the dendritic 
cell to travel through the blood stream to the spleen or through the lymphatic system 
to lymphoid tissues. Mature DCs may also drive T cells to an antiviral Th1 immunity 
and an anti-MDV Th1 response was also suggested by Smith et al. (2011). 
Role of PRR in recognition of bacteria and viruses is an innate immune pathway 
which was also reported to be activated in MDV-infected splenocytes (Smith et al., 
2011). 
The NF-κB signalling is a key mediator in controlling both innate and adaptive 
immunity. After activation by a large number of inducers, NF-κB proteins regulate 
the transcription of a large number of genes, including antimicrobial peptides, 
cytokines, chemokines, stress-response proteins and anti-apoptotic proteins (Li and 
Verma, 2002). NF-κB was shown to involve in MDV-induced neoplastic 
transformation of lymphocytes in vivo (Kumar et al., 2012). 
In line 72 DCs, only MIF (macrophage migration inhibitory factor) regulation of 
innate immunity was activated after MDV infection (Figure 6.5B). MIF is primarily 
a regulator of innate immune responses to endotoxin and gram-negative bacteria 
(Meng and Lowell, 1997). It is an integral component of the host antimicrobial alarm 
system and stress response that promotes the pro-inflammatory functions of immune 




6.6 The JAK-STAT signalling pathway 
Analysing data using three software packages revealed that JAK-STAT was the 
common signalling pathway involved with genes highly expressed in line 61 infected 
macrophages and DCs. Therefore to get insight into the function of the molecules 
involved in this pathway, an illustrated diagram is provided in Figure 6.6 (for 
macrophages) and in Figure 6.7 (for DCs).  
The genes involved in line 61 infected macrophages include CSF3, IL-2Rα, IL-
13Rα2, IL-20Rα, IL-23R, STAT2 and STAT4 (Figure 6.6) and in line 61 infected 






















Figure 6.6. JAK-STAT signalling pathway shows involvement of genes (red) highly 









































Table 6.17. Various physiological and pathological functions accomplished by 
molecules involved in JAK-STAT signalling pathway. Adapted and modified from  
O'Sullivan et al. (2007) with permission from Elsevier. 
Figure 6.7. JAK-STAT signalling pathway shows involvement of genes (red) highly 




Interleukins, IFNs and haematopoietic growth factors activate JAK-STAT pathway 
(O’Shea et al., 2002) and SOCS1, SOCS3 and CISH (CIS) are negative regulators of 
JAK-STAT signalling pathway (Tamiya et al., 2011). The interactive functions 
between molecules involved in this pathway may play role in various physiological 
and pathological processes. As shown in Table 6.17, IFN-mediated activation of 
JAK-STAT pathway play crucial role in anti-viral immunity. 
6.7 Analyses using Expander programme 
The Expander programme was used to analyse the gene ontology (GO) functional 
annotations (section 2.10.4) to determine the functions of the genes highly expressed 
in control and MDV-infected APCs of lines 61 and 72, The transcriptional factor (TF) 
binding sites were also determined using the Expander software. Significance was 
determined as Bonferroni corrected p-values lower than 1.0E-4, which is the default 
value of the Expander programme. 
6.7.1 Analysis of genes in control and infected macrophages 
In line 61 control macrophages, genes were significantly involved in oxidoreductase 
activity (Figure 6.8), but no specific TF binding sites were identified.  
In line 72 control macrophages, significantly enriched gene functions were protein 
binding and anatomical structure formation (Figure 6.9A) and the genes had a higher 
proportion of IRF-7 (interferon regulatory factor -7) TF binding sites (Figure 6.9B). 
The frequency ratio (frequency in set divided by frequency in background) was 2 
(Figure 6.9B), which means presence of twice as many IRF-7 sites than would be 






























Figure 6.8. Expander programme showing the overrepresentation analysis of genes 
highly expressed in line 61 control macrophages. The GO biological process which 
is significantly enriched and the frequency of genes of the functional class within 
the examined set described as a percentage of the total.  
Figure 6.9. Expander programme showing the overrepresentation analyses of 
genes highly expressed in line 72 control macrophages. (A) The GO biological 
processes which are significantly enriched. The frequency of genes of a functional 
class within the examined set is described as a percentage of the total. (B) Genes 
showing significantly enriched IRF-7 TF binding sites. The frequency ratio 
(frequency of the set divided by the frequency of the background) is shown. 
   Line 61 control macrophages: 
   Enriched functional class 
       Line 72 control macrophages: 
(A) Enriched functional classes 
  Line 72 control macrophages: 
(B) Significantly enriched TF  































Figure 6.10. Expander programme showing the overrepresentation analyses of 
genes highly expressed in in line 61 infected macrophages. (A) The GO biological 
processes which are significantly enriched. The frequency of genes of a functional 
class within the examined set is described as a percentage of the total. (B) Genes 
showing significantly enriched ZNF42 TF binding sites. The frequency ratio 
(frequency of the set divided by the frequency of the background) is shown. 
  Line 61 infected macrophages: 
(B) Significantly enriched TF  
              binding sites 
       Line 61 infected macrophages: 




The functions of genes changed in infected macrophages compared with controls as 
could be predicted. Significantly enriched functional gene clusters in line 61 infected 
macrophages showed involvement in immune activities such as response to stimulus, 
immune response and cytokine activity (Figure 6.10A). A substantial number of 
these genes (list in Table S4.1 in Appendix 4) had ZNF42 (zinc finger protein 42) TF 
binding sites (frequency ratio 1.26) in their promoter regions (Figure 6.10B). ZNF42, 
also known as MZF1 (myloid zinc finger 1), is a putative tumour suppressor protein 
(Peterson et al., 2006; Mudduluru et al., 2010). No significantly enriched functional 
cluster of genes or TF binding sites was identified in line 72 infected macrophages.  
6.7.2 Analysis of genes in control and infected DCs 
Genes highly expressed in line 61 control DCs showed significantly enriched 
oxidoreductase activity (Figure 6.11) but no enriched TF binding sites was detected 

















Figure 6.11. Expander programme showing the overrepresentation analysis of 
genes highly expressed in line 61 control DCs. The GO biological process which is 
significantly enriched and the frequency of genes of the functional class within the 
examined set described as a percentage of the total.  
       Line 61 control DCs: 







































Figure 6.12. Expander programme showing the overrepresentation analyses of 
genes highly expressed in in line 61 infected DCs. (A) The GO biological processes 
which are significantly enriched. The frequency of genes of a functional class within 
the examined set is described as a percentage of the total. (B) Genes showing 
significantly enriched ZNF42 and NF-kB TF binding sites. The frequency ratio 
(frequency of the set divided by the frequency of the background) is shown. 
       Line 61 infected DCs: 
(A) Enriched functional classes 
       Line 61 infected DCs: 
(B) Significantly enriched  




Highly expressed genes in line 61 infected DCs showed many functionally enriched 
clusters related to physiological processes, such as polysaccharide binding, biological 
adhesion and defensive processes, such as immune response, response to stimulus 
(Figure 6.12A). A subset of these genes also showed enriched TF binding sites for 
ZNF42 (list in Table S4.2 in Appendix 4) and NF-κB in their promoter regions 
(Figure 6.12B). As mentioned before, ZNF42 acts as a putative tumour suppressor. 
The NF-κB family of transcription factors play crucial roles in inflammation, 
immunity, cell proliferation, differentiation, and survival (Oeckinghaus and Ghosh, 
2009). 
In line 72 infected DCs, no functional enrichment or TF binding sites was identified. 
6.8 Determining MDV QTL candidate genes 
The BioMart data mining tool within the Ensembl database was used (section 2.10.5) 
to identify genes involved in MD resistance or susceptibility based on previously 
identifined MDV QTLs (Vallejo et al., 1998; Yonash et al., 1999; McElroy et al., 
2005) (Table S1 on CD). Genes inherently different between control macrophages 
and DCs of lines 61 and 72 were also identified. A subset of genes from each group is 
given here (Table 6.18 to Table 6.21) which were selected based on high fold change 
and genes related to immune functions. In the case of infected APCs of lines 61 and 
72, two more selection criteria, namely previous reports and genes enriched with 
ZNF42 TF binding sites (lists in Tables S4.1 and S4.2 in Appendix 4), were also 
included. Full lists of MDV QTL candidate genes are provided in Appendix 3. 
Among the listed genes, previously reported putative candidate genes for MD-
resistance or susceptibility were CXCL13L2, FN1, LIPA, IL-15, IFITM5 (Smith et 




genes, CXCL13L2 and IFITM5 were also in the lists of genes identified in this study 




(A)  Line 61 control macrophages 
Gene QTL Chr. Fold Change Ensembl Gene ID 
BCL2  MD16-17 2 4 ENSGALG00000012885 
BLNK  MD22 6 2 ENSGALG00000006973 
CD247  MD1 1 3 ENSGALG00000015441 
ITGA1  MD25-30 Z 3 ENSGALG00000014891 
MLPH  MD10 7 5 ENSGALG00000003904 
PPP4R4  MD19-21 5 10 ENSGALG00000010950 
 
 
(B)  Line 72 control macrophages 
Gene QTL Chr. Fold Change Ensembl Gene ID 
ELOVL7  MD25-30 Z 8 ENSGALG00000014730 
FN1  MD10 7 2 ENSGALG00000003578 
IRG1  MD2 1 4 ENSGALG00000016919 
ISG12(2)  MD16-17 2 10 ENSGALG00000013575 
MAPK8IP1  MD19-21 5 7 ENSGALG00000008430 
RGSL1  MD23 8 8 ENSGALG00000003671 
SORCS3  MD22 6 97 ENSGALG00000008434 
TJP2  MD25-30 Z 10 ENSGALG00000015109 
Uncharacterised MD22 6 16 ENSGALG00000004653 
Uncharacterised  MD13 12 13 ENSGALG00000006325 
 
Table 6.18.  A subset of genes inherently expressed differently in (A) line 61 and (B) 











(A)  Line 61 infected macrophages 
Gene QTL Chr. Fold Change Ensembl Gene ID 
AMIGO3 MD13 12 2 ENSGALG00000028339 
BATF* MD19-21 5 3 ENSGALG00000010323 
BEST4 MD23 8 11 ENSGALG00000010126 
CXCL13L2*† MD8 4 3 ENSGALG00000010338 
GRIP2 MD13 12 24 ENSGALG00000006449 
IGSF3* MD1 1 2 ENSGALG00000015469 
IL-23R MD23 8 7 ENSGALG00000011212 
IRF-4 MD16-17 2 9 ENSGALG00000012830 
K60† MD7 4 3 ENSGALG00000011668 
LEPR MD23 8 3 ENSGALG00000011058 






(B)  Line 72 infected macrophages 
Gene QTL Chr. Fold Change Ensembl Gene ID 
CD274 MD25-30 Z 2 ENSGALG00000015032 
CHANK3 MD22 6 6 ENSGALG00000003135 
CLCN4 MD2 1 5 ENSGALG00000016607 
GALNTL4 MD19-21 5 10 ENSGALG00000005584 
IL-15† MD8 4 2 ENSGALG00000009870 
STS MD2 1 57 ENSGALG00000016622 
TCEANC MD2 1 6 ENSGALG00000016581 
TFPI MD10 7 11 ENSGALG00000002594 
TMEM61 MD23 8 5 ENSGALG00000010801 
Uncharacterised MD5 4 5 ENSGALG00000027201 
 
Table 6.19.  A subset of genes differentially expressed in (A) line 61 and (B) line 72 
infected macrophages. QTL = Quantitative Trait Loci, Chr. = Chromosome.* = gene 







(A)  Line 61 control DCs 
Gene QTL Chr. Fold Change Ensembl Gene ID 
BCL2 MD16-17 2 3 ENSGALG00000012885 
CD247 MD1 1 3 ENSGALG00000015441 
IL-15 MD8 4 3 ENSGALG00000009870 
IL-1R2 MD2 1 4 ENSGALG00000016782 
MYO16 MD2 1 32 ENSGALG00000016837 
PPARGC1A MD5 4 19 ENSGALG00000014398 
SRGAP3 MD13 12 7 ENSGALG00000008378 
TESC MD24 15 19 ENSGALG00000008206 
TLR7 MD2 1 3 ENSGALG00000016590 
TMEM116 MD24 15 6 ENSGALG00000004760 
TNN MD23 8 7 ENSGALG00000004538 






(B)  Line 72 control DCs 
Gene QTL Chr. Fold Change Ensembl Gene ID 
APOBEC4 MD23 8 9 ENSGALG00000020926 
AVD MD25-30 Z 7 ENSGALG00000023622 
BAFF MD2 1 2 ENSGALG00000016852 
CD2 MD1 1 90 ENSGALG00000015463 
FGF14 MD2 1 16 ENSGALG00000016866 
IRG1 MD2 1 9 ENSGALG00000016919 
ISG12(2) MD16-17 2 3 ENSGALG00000013575 
ITGA2 MD25-30 Z 5 ENSGALG00000014903 
MAPK8IP1 MD19-21 5 5 ENSGALG00000008430 
MX MD2 1 21 ENSGALG00000016142 
PTGS2 MD12 8 8 ENSGALG00000005069 
SH3PXD2A MD22 6 8 ENSGALG00000008293 
TRAF3 MD19-21 5 2 ENSGALG00000011389 
TRAIP MD13 12 3 ENSGALG00000002908 
Table 6.20.  A subset of genes inherently different in (A) line 61 and (B) line 72 









(A)  Line 61 infected DCs 
Gene QTL Chr. Fold Change Ensembl Gene ID 
BDKRB2* MD19-21 5 3 ENSGALG00000011080 
CD72* MD25-30 Z 4 ENSGALG00000002383 
CERCAM* MD14 17 4 ENSGALG00000004986 
CHB1 MD25-30 Z 7 ENSGALG00000005194 
COL25A1* MD8 4 4 ENSGALG00000010521 
COL3A1* MD10 7 4 ENSGALG00000002552 
COL6A3* MD10 7 4 ENSGALG00000003923 
COL7A1 MD13 12 8 ENSGALG00000005811 
CXCL12* MD22 6 2 ENSGALG00000028136 
F2RL2* MD25-30 Z 2 ENSGALG00000023379 
FN1† MD10 7 3 ENSGALG00000003578 
GZMA† MD25-30 Z 31 ENSGALG00000013548 
HTRA3* MD5 4 3 ENSGALG00000015575 
IFITM5*† MD19-21 5 2 ENSGALG00000004239 
IL-1RL1* MD2 1 4 ENSGALG00000016785 
IRF-3 MD19-21 5 2 ENSGALG00000014297 
ITGB5 MD9 7 2 ENSGALG00000011778 
LAMC2* MD23 8 2 ENSGALG00000004627 
LIF* MD24 15 2 ENSGALG00000008028 
LIPA† MD22 6 2 ENSGALG00000006378 
LMCD1* MD13 12 3 ENSGALG00000008349 
NFKBIZ* MD1 1 2 ENSGALG00000015346 
NR4A3* MD16-17 2 3 ENSGALG00000013568 
PAPPA2* MD23 8 11 ENSGALG00000004487 
PRRX2* MD14 17 4 ENSGALG00000028236 
RSFR* MD22 6 2 ENSGALG00000027165 
TBX3* MD24 15 3 ENSGALG00000008250 
TLR2B MD8 4 2 ENSGALG00000009239 
TMEM119* MD24 15 3 ENSGALG00000004893 
TMEM26* MD22 6 3 ENSGALG00000025862 
TSPAN15* MD22 6 3 ENSGALG00000004257 
WSCD2* MD24 15 3 ENSGALG00000004849 











(B)  Line 72 infected DCs 
Gene QTL Chr. Fold Change Ensembl gene ID 
GALNTL4 MD19-21 5 4 ENSGALG00000005584 
LGI2 MD5 4 6 ENSGALG00000028945 
NEGR1 MD23 8 5 ENSGALG00000011350 
SLC44A5 MD23 8 4 ENSGALG00000011379 
STS MD2 1 18 ENSGALG00000016622 
Uncharacterised MD19-21 5 8 ENSGALG00000025939 
Uncharacterised MD19-21 5 5 ENSGALG00000026584 
Table 6.21. A subset of genes differentially expressed in (A) line 61 and (B) line 72 
infected DCs. QTL = Quantitative Trait Loci, Chr. = Chromosome,* = gene with 
enriched ZNF42 TF binding sites, † = previously reported. 
6.9 Discussion 
Functional analyses of DE genes pre- and post-MDV infection of APCs from lines 61 
and 72 were carried out in this Chapter. The overall analyses in the three software 
packages revealed that, before infection immune activities were higher in APCs of 
the susceptible line (72) than those of resistant line (61), but this pattern reversed 
following MDV infection when APCs from line 61 exhibited a more strong immune 
response to MDV than the APCs of line 72, suggesting a potential role of APCs in 
determining resistance to MD in line 61 chickens. 
Expression of only a few TLRs was increased after MDV infection, specifically 
TLR2B in line 72 infected macrophages (Table S2.4 in Appendix 2) and TLR2B and 
TLR21 in line 61 infected DCs (Table S2.7 in Appendix 2). TLR21 is the avian 
equivalent of mammalian TLR9 and recognises pathogen CpG DNA (Brownlie et al., 
2009; Keestra et al., 2010), suggesting a potential role for this PRR in MDV 
infection. It is interesting that TLR2B, which recognises bacterial cell surface 




though it could be due to a positive feedback loop to drive innate anti-viral 
immunity. 
Host cells have developed multiple strategies to restrict viral infection. The 
expression of many of these restriction factors is subject to transcriptional regulation 
by IFN (Horner, 2014). Viral DNA or RNA is first recognised by cellular PRRs, 
which in turn recruit the PRR-mediated adaptor proteins and activate downstream 
signalling leading to production of IFNs (Kawai and Akira, 2006; Horner, 2014). 
IFNs bind to their receptor complex (IFNAR) present on the cell surface and trigger 
the JAK-STAT pathway to drive the synthesis of over 300 IFN-stimulated genes 
(ISGs), which can block virus replication at different phases of the replication cycle 
(Saito and Gale, 2008; Lemon, 2010; Horner, 2014). In this study, the expression of 
certain genes involved in controlling IFN response, such as BATF, BATF3, STAT 2 
and STAT4, was up-regulated in line 61 infected macrophages (Table S2.3 in 
Appendix 2), suggesting a role for these genes in IFN-mediated anti-MDV immunity 
in macrophages of MD-resistant chickens.  
The most highlighted immune pathway identified by three distinct software packages 
was the JAK-STAT signalling pathway. JAK-STAT is an important cellular pathway 
which has been linked to the genetic basis of MD resistance (MacEachern et al., 
2011; Perumbakkam et al., 2013). It is most likely to be involved in the innate 
immune response (Smith et al., 2011). Following MDV infection, a transcriptional 
up-regulation of the JAK-STAT and MAPK pathways was observed in the CEFs of 
the susceptible line but not in the resistant line, suggesting a role for these pathways 
in the expression of genes involved in cell survival and proliferation which might 




al., 2013). However, the JAK-STAT pathway may play a reverse role in MD-
resistant line as type I IFN mediated activation of JAK-STAT signalling pathway can 
induce apoptosis in virally infected cells resulting in limiting the spread of virus 
(Tanaka et al., 1998). A higher expression of STAT2 in MD-resistant birds was 
observed in splenic tissues at 4 dpi as compared to MD-susceptible birds, suggesting 
an activated host defence against MDV presumably by the IFN-mediated pathway in 
resistant birds (Sarson et al., 2008b).The signal transduction molecules, STAT2 and 
4 were up-regulated in this study only in line 61 infected macrophages (Figure 6.6). 
STAT1 and 2, together with IFN regulatory factor (IRF)-9, are involved in type I 
IFN signalling (Stark et al., 1998; Figure 6.13). Type I IFNs and the JAK-STAT 
pathway are exclusively related to anti-viral responses. For example, mice with 
deficiencies in the induction of type I IFNs and their receptors, or cytokine induced 
JAK-STAT signal transduction pathways are vulnerable to WNV (West Nile virus) 
and DENV (Dengue) infections (Samuel and Diamond, 2005; Shresta et al., 2005; 
Perry et al., 2009). A type I IFN-mediated activation of JAK-STAT signalling was 
found to be a key component of host defence mechanisms that consist of pathways 
regulating apoptosis against reovirus infection in the mouse brain (Goody et al., 
2007). In humans, expression of STAT1, STAT2, STAT3 and STAT5A has been 
observed during the latent phase of infection with EBV (Zhang et al., 2004). JAK-
STAT signalling pathways also regulate iNOS expression and NO production in 
macrophages (Sareila et al., 2006) and NO has an inhibitory effect on MDV 
replication (Xing and Schat, 2000; Djeraba et al., 2002a). 
STAT4 is involved in IL-12 mediated Th1 cell differentiation and proliferation 




STAT4 in line 61 infected macrophages suggests a role for macrophages in induction 
of an anti-MDV Th1 response, as described by Kaiser et al. (2003) and Smith et al. 
(2011). However, Th2 (Heidari et al., 2008a) or Treg (Buza and Burgess, 2007) 












Genes highly expressed in line 61 infected DCs were also involved in the JAK-STAT 
pathway. The genes include SOCS1 (suppressor of cytokine signalling 1), SOCS3 
and CISH (Cytokine-inducible SH2-containing protein, also known as CIS) (Figure 
6.7), which are potent suppressors of JAK-STAT signalling (Tamiya et al., 2011). 
Both SOCS1 and SOCS3 can directly inhibit JAK tyrosine kinase activity through 
their kinase inhibitory regions (KIR), a pseudosubstrate essential for the suppression 
of cytokine signals (Figure 6.14). SOCS3 also inhibits IL-12-induced STAT4 
activation by binding through its SH2 domain (Yamamoto et al., 2003), indicating a 
doubtful role for DCs in the Th1 mediated anti-viral immunity to MDV. 
Figure 6.13. Anti-viral and Th1 responses mediated by activated JAK-STAT 
pathway. Adapted and modified from Tamiya et al. (2011) with permission from 




















Genes highly expressed in line 61 control macrophages and line 72 control DCs were 
also involved in the JAK-STAT pathway, though in line 61 only one negative 
regulator gene (SOCS2) and in line 72 three cytokine receptors (IL-13Rα1, IL-13Rα2 
and IL-20Rα) were identified. However, following MDV infection this pathway was 
not activated in line 72 macrophages or DCs, suggesting a potential anti-viral role for 
the JAK-STAT signalling pathway only in line 61 (MD-resistant) chickens in 
response to MDV infection. 
A group of genes highly expressed in line 61 infected macrophages and DCs showed 
significantly enriched ZNF42 TF binding sites in their promoter regions (Tables S4.1 
and S4.2, respectively, in Appendix 4). ZNF42, commonly known as myeloid zinc 
Figure 6.14. Mechanism of suppression of JAK-STAT pathway by CIS, SOCS1, and 
SOCS3. All of these are induced by cytokine stimulation. CIS binds to the STAT5 
activating receptors, thereby suppressing further activation of STAT5, and induces 
degradation of the receptor. SOCS1 binds to JAKs, and SOCS3 binds to the 
receptor through the SH2 domain, but both inhibit JAK activity through the KIR. 





finger protein 1 (MZF1), is a zinc finger TF preferentially expressed in 
haematopoietic stem cells, myeloid progenitor cells, and in differentiated myeloid 
cells (Bavisotto et al., 1991; Morris et al., 1995). MZF1 is associated with 
haematopoiesis (Morris et al., 1995) and is also critical to the regulation of cell 
proliferation and apoptosis (Hromas et al., 1996; Robertson et al., 1998). Several 
reports suggest a contradictory role of MZF1 in tumourigenesis influencing cell 
migration and invasion. For example, a decreased expression of MZF-1 inhibited the 
expression of protein kinase C alpha (PKCα), which is an important family of 
signalling molecules that regulate cell proliferation, differentiation, transformation, 
and apoptosis, and thus reduced cell migration and invasion in human hepatocellular 
carcinoma (HCC) (Hsieh et al., 2006). In contrast, HCC cells transfected with 
antisense oligonucleotide of MZF-1 showed an inhibitory effect on tumour growth 
and prolonged time for tumour formation (Hsieh et al., 2007). Gaboli et al. (2001) 
reported that inactivation of MZF-1 in mice resulted in a striking increase in 
haematopoietic progenitors, with the eventual development of lethal myeloid 
neoplasias, suggesting a role of MZF-1 protein as tumour suppressor. Recently, Chen 
et al. (2014) reported that increased MZF-1 expression led to high ferroportin 
concentration, resulting in reduced iron-related cellular activities and decreased 
growth of human prostate tumour cells. From these perspectives, it can be said that 
MZF-1 has bi-functional transcriptional regulatory properties depending on the 
cellular environment.  
To date, the role of MZF1 TF binding sites in genes highly expressed during MDV 
infection has not been evaluated, though MZF1 was considered to have a repressive 




influenced the methylation status of CR1 (Chicken Repeat 1, the transposable 
elements located upstream of genes near the promoters) levels of IL-12α, which 
might have reduced the binding affinity of two transcriptional repressors, MZF1 and 
E47 (Yang et al., 2004; Yan et al., 2006), resulting in higher mRNA expression level 
of IL-12α in line 63 (MD-resistant) than line 72 (MD-susceptible) chickens. Smith et 
al. (2011) observed enriched HIC1 (hypermethylated in cancer 1, a tumour 
suppressor) TF binding sites in the genes down-regulated in MDV-infected 
splenocytes at 4 dpi, and hence suggested that MDV infection could block an anti-
tumour mechanism long before the MDV oncogene (Meq) is expressed. In the 
present study, a putative tumour suppressor TF binding sites (MZF1) was detected in 
genes highly expressed in APCs of the MD-resistant line (61) at 1 dpi, but not in the 
susceptible line (72). Takahashi et al. (2005) reported that transcriptional repression 
by MZF-1 required FHL3 (four and a half LIM domain protein 3) as a cofactor. On 
the other hand, FHL3 can also recruit a C-type binding protein (CtBP) as a co-
repressor by which they regulate gene expression (Turner et al., 2003). The 
interaction of CtBP with oncogene Meq plays a crucial role in MDV-induced 
lymphomas (Brown et al., 2006) and it was also speculated that by recruiting CtBP 
and its co-repressors, Meq might function in tumourigenesis and/or the establishment 
of latency in T cells (Brown et al., 2006). MDV induces T cell latency in resistant 
lines, whereas it induces latency and lymphoma formation in susceptible lines. 
Therefore, further studies will be required to explore the exact role of MZF1 in MD-
resistant chickens.  
The expression of several previously reported potential candidate genes for MD 




2003) and GZMA (Sarson et al., 2006) were highly expressed in line 72 and line 61 
infected DCs. An elevated expression of IRG1 was reported in splenocytes of MDV-
infected susceptible line (Smith et al., 2011). In this study, its expression was 
observed in control APCs of susceptible line, but not after infection.  
Two putative MD resistance genes (CXCL13L2 and IFITM5) had enriched ZNF42 
TF binding sites in their promoter regions (Tables 6.19A and 6.21A, respectively). 
The chicken CXCL13 chemokines are grouped as homeostatic chemokines like 
mammals though they may have inflammatory roles as well (Kaiser, 2012). Humans 
and mice have a single copy of CXCL13, but the chicken genome has three genes at 
the same locus (CXCL13L1, CXCL13L2 and CXCL13L3). Two of them, 
CXCL13L1 and CXCL13L2, interact with the receptor, CXCR5 (reviewed in Kaiser, 
2012). CXCR5 is involved in ligand mediated B-cell chemoattraction (Legler et al., 
1998; Chan et al., 2013) as well as providing essential signals for immunoglobulin 
production to B cells functioning together with CD4+ T cells (Breitfeld et al., 2000). 
During in vivo infection, MDV presumably passes from macrophages to B cells in 
the lymphoid tissues. An elevated expression of CXCL13L2 in MDV-infected 
macrophages in this study supports this hypothesis. Heidari et al. (2010) also 
reported a higher expression of CXCL13 at 5 dpi in splenocytes of chickens infected 
with a vv+ strain of MDV. 
The interferon-induced transmembrane protein 5 (IFITM5) was another putative MD 
resistance gene highly expressed in line 61 infected DCs. IFITM proteins are anti-
viral IFN-stimulated genes (ISGs) that disrupt distinct steps of the viral replication 
cycle (Brass et al., 2009). IFITM proteins effectively inhibit human RSV (respiratory 




subsequent replication steps (Zhang et al., 2015). Though IFITM5 was primarily 
recognised as a protein involved in bone mineralisation (Moffatt et al., 2008), later 
work identified it as a stimulator of the expression of interferon-induced genes 
(Hanagata and Li, 2011). Recently, IFITM5 was identified as a highly expressed 
gene in IBDV-susceptible chickens, suggesting an important role for this gene in 
resistance or susceptibility to virus infection (Smith et al., 2015). The chicken 
IFITM5 effectively restricted filovirus GP1,2 proteins-mediated entry, but had little or 
no effect on influenza A virus haemagglutinin-mediated entry (Huang et al., 2011). 
To date no report is available on the effect of IFITM5 during MDV infection, 
therefore further study is required to investigate the role of this gene in MD 
resistance. 
Although these functional analyses provide a broad picture of the transcriptional 
changes in infected cells and the differences between the chicken lines, no validation 
of DE genes has been carried out in this study due to the shortage of RNA. 
Therefore, further work is required to fully verify the findings. However, the data 
generated in this Chapter support the hypothesis that the resistance signature to MD 
is most likely determined at the APC level, as macrophages from line 61 showed 
greater activity of immune response genes compared to line 72. This is consistant 
with the findings reported in Chapter 5 and suggests differential activation of JAK-



















7.1 Overall perspective of this study 
The aim of this project was to explore the cellular basis of resistance to MD. Many 
studies have been carried out to explore the genes involved in resistance to MD, but 
it is not yet exactly known in which cell type resistance is expressed. In vivo, MDV 
infects several immune cells, including APCs, B and activated T cells. The 
hypothesis of this project was that the resistance is expressed at the very early stage 
of MDV infection, when the virus encounters APCs. In order to infect these cells in 
vitro with MDV, it was first necessary to develop an in vitro model of MDV 
infection of APCs because several previous attempts to establish an in vitro MDV-
macrophage infection model had not been successful (Haffer et al., 1979; von Bulow 
and Klasen, 1983; Barrow et al., 2003). Therefore, the major initial challenge was to 
develop a new in vitro MDV-APC infection model. Chicken bone marrow-derived 
macrophages and DCs were used for MDV-infection experiments and following 
establishment of an in vitro infection model, the model was applied to infect APCs of 
two inbred lines which provided an experimental means of investigating the cellular 
basis of resistance to MD in vitro rather than in vivo. 
7.2 Establishment of a de novo in vitro MDV infection model 
of APCs and subsequent characterisation  
The techniques involved in the development of a new MDV-APC infection model 
and the subsequent characterisation infected APCs were described in Chapter 3. The 
virus used was a recombinant CEF-associated construct of the vaccine strain 
(CVI988) of MDV, in which the host shut-off gene (UL41) was replaced with GFP. 
The encoded GFP was therefore helpful to determine the presence of the virus in 




As mentioned before, MDV is highly cell-associated and it never becomes cell-free 
in vitro (reviewed in Denesvre, 2013). Therefore, MDV-infected CEFs were co-
cultured with macrophages. The first problem encountered was that both CEFs and 
macrophages were adherent to culture plates and hence it was not possible to co-
culture an optimal amount of infected CEFs with macrophages. At the same time, the 
virus titre was found to be very low (section 3.4.5), and not sufficient to initiate 
infection of macrophages. Moreover, the culture plates (Sterilin square plates), which 
are suitable for macrophage growth and differentiation, did not support cell 
attachment and growth of CEFs (Figure 3.7). A substantial number of the infected 
CEFs were also dying during attempts to freeze MDV-infected CEFs (Figure 3.8), 
but MDV requires live cells to pass infection to other cells. Therefore, it was decided 
to use freshly infected MDV-infected CEFs in each experiment.  
All of the above-mentioned problems were almost completely overcome by co-
culturing fresh infected CEFs and macrophages in T75 flasks. A proportion of 
infected macrophages were detected by flow cytometric analysis of these cells after 
MDV infection (section 3.4.9). However, this success quickly came under suspicion 
as it was realised that those infected macrophages could also be derived from MDV-
infected CEF cultures as macrophages appear in chicken embryos as early as 2.5-4.5 
days (Cuadros et al., 1993). To overcome this, infected macrophages in CEF cultures 
were excluded by FACS after the culture cells were stained with an anti-CD45 mAb. 
Pre-sorted MDV-infected CEFs were then added to macrophage cultures and MDV-
infected macrophages were detected by flow cytometric analysis on 3 dpi (Figure 
3.19), which established a successful in vitro MDV-infection model of macrophages. 




though they had been uninfectable in previous studies (Haffer et al., 1979; von 
Bulow and Klasen, 1983; Barrow et al., 2003), probably due to the lack of a suitable 
co-culture method. Though, as described later, the infectivity of macrophages for 
other cell types such as B and T cells remains to be fully investigated, this provided 
model system could be helpful to study the effects of the virus on the responses of 
the APCs. 
Using this model, DCs from outbred chickens were also infected in vitro with MDV. 
The studies revealed that the cultured macrophages used in these studies were 
infected at higher numbers than cultured DCs (approximately 4 times higher) 
(Figures 3.19C and 3.22C, respectively). 
Infected APCs were then characterised using confocal microscopy and RT-PCR. 
Confocal microscopic views indicated the presence of infection in macrophages and 
DCs (Figures 3.24 and 3.25, respectively) by the presence of GFP in the nucleus. 
Although expression of herpesvirus specific genes was detected by RT-PCR (Figure 
3.26), the presence of 2% contaminant infected CEFs in these experiments means 
that these experiments need to be repeated. 
Confocal video microscopy was used to investigate the possible modes of MDV 
transmission to macrophages. Movies A and B illustrate possible phagocytosis-like 
and cell-to-cell mode of spread of MDV, respectively. In movie A (Figure 3.27), 
GFP can be seen interior to the vacuoles of a macrophage-like cell, suggesting entry 
of MDV into the macrophages through phagocytosis, though the exact mechanism 
could not be explained from this video. Therefore, advanced imaging techniques will 




A potential route of cell-to-cell transmission of MDV can be proposed based on 
images from movie B (Figure 3.28).This video shows actin-like intercellular 
projections; the green colour of those could be an indication of the transportation of 



















Actin is a highly dynamic protein with two basic forms, monomeric or globular actin 
(G-actin) and filamentous actin (F-actin), which are involved in a wide variety of 
Figure 7.1. Model of herpesvirus entry, maturation and egress. (A) Herpes virion 
“surfing” towards the plasma membrane along membrane protrusions for entry. 
(B) Capsid trafficking toward the nuclear periphery for budding via a myosin motor 
on F-actin. (C) US3-mediated depolymerisation of actin stress fibres. (D) US3-
mediated generation of membrane projection and cell to cell spread of herpesvirus. 
(E) Myosin IIA- and Rab6-dependent fission of nascent vesicles from the Golgi 
body. (F) Enveloped virion within a TGN (trans-Golgi network)-derived vesicle 
trafficking through cortical actin via myosin Va toward the plasma membrane for 




cellular processes, such as cell division, adherence, migration and transport of intra 
and extracellular materials (Roberts and Baines, 2011). Like all viruses, 
herpesviruses depend on host machinery to replicate and spread, and actin plays a 
crucial and diverse role in maintaining these functions.  
The importance of polymerisation of the actin cytoskeleton and the role of US3 
orthologue of MDV was reported previously for the effective cell-to-cell spread of 
MDV in chicken embryo cells in vitro (Schumacher et al., 2005). Figure 7.1 shows 
the role of actin in US3-mediated spread of herpesvirus. Therefore, it is more likely 
possible for MDV to spread between macrophages via actin-mediated cellular 
cytoskeletal protrusions. 
To determine if MDV-macrophage infection is productive or abortive in nature, 
CEFs were infected with MDV-infected macrophages (section 3.5.4) and triple-
sorted infected macrophages were to shown to form plaques were CEF culture 
(Figures 3.32A.i and A.ii), indicating the productive nature of MDV-macrophage 
infection which was in contrast to what was reported by Barrow et al. (2003).  
7.3 Infection of B and T cells 
In Chapter 4, attempts were made to infect B and T cells with MDV in vitro. MDV is 
believed to transmit from macrophages to B cells in the lymphoid tissues in vivo 
(Baigent and Davison, 2004). In order to mimic this process, several attempts were 
made to infect B and T cells with MDV-infected macrophages in vitro. However, 
none of these experiments was successful, probably because of the lack of growth 
factors in the B and T cell cultures to stimulate activation and retain cell viability. In 




stressed condition, which in turn causes early death of these cells in culture. Using a 
macrophage cell line could be a useful alternative to overcome this problem. 
7.4 Determining the cellular basis of resistance to MD in APCs 
of inbred chickens 
The newly developed in vitro MDV infection model was extended to infect APCs of 
MHC-identical inbred MD-resistant (line 61) and MD-susceptible (line 72) chickens 
(Chapter 5). Flow cytometric analyses showed that, at a fixed infection ratio (1:5), 
macrophages from line 72 were infected in greater numbers than those from line 61 
(section 5.4). DCs were infected at lower numbers than macrophages but there was 
no apparent difference between the two lines in the context of MDV-DC infections 
(Section 5.5). As mentioned before, DCs were also infected at lower numbers in 
outbred chickens. This lower infection of DCs in both outbred and inbred lines could 
be due to the different culture conditions used to generate the two cell types, in 
particular the addition to the DC cultures of IL-4 and CSF-2 (GM-CSF), which can 
have immunomodulatory activities (Kedzierska et al., 2000; Tsai et al., 2013).  
The lower infection of macrophages in resistant line 61 and higher infection in 
susceptible line 72 in this study suggests that macrophages play a critical role in 
exerting resistance to MD. Differential susceptibility or resistance in MHC-congenic 
chicken lines was also reported in the infection of macrophages with another 
alphaherpesvirus, ILTV (infectious laryngotracheitis virus) (Loudovaris et al., 
1991a). Moreover, the crucial involvement of macrophages in resistant chicken lines 
has been suggested in recovery from infection with ILTV. In an in vitro study, 
Loudovaris et al. (1991b) detected higher percentages of ILTV antigen-positive 




indicating that the macrophages from resistant chickens might be better able to 
process viral antigen and present it to the immune system, which in turn results in 
clearance of the infection.  
Macrophages are well-known to induce cellular resistance against MCMV (murine 
cytomegalovirus) (Selgrade and Osborn, 1974). Macrophages show intrinsic 
resistance to HSV infection by phagocytic and degradative functions, leading to 
presentation of viral antigens, as well as inhibition of virus replication (Sarmiento, 
1988). 
The mRNA expression levels of two pro-inflammatory cytokines (IL-6 and IL-18) 
were measured by Taqman qRT-PCR. Only IL-18 expression was significantly up-
regulated in line 61 infected macrophages compared to those from line 72 (Figure 
5.16A). Increased expression of pro-inflammatory cytokine in the resistant line was 
in contrast to previous reports where an elevated expression of pro-inflammatory 
cytokines was measured in susceptible chickens (Kaiser et al., 2003; Heidari et al., 
2014), though differences in experimental conditions between two studies need to be 
considered. 
Functional analyses of differentially expressed (DE) genes identified from RNA-Seq 
in MDV-infected and control APCs of the two inbred lines were carried out in 
Chapter 6. The JAK-STAT signalling appeared as a common pathway in the infected 
APCs of MD-resistant chickens (line 61). Activation of the JAK-STAT signalling 
pathway was previously reported in MDV-infected CEFs, but in MD-susceptible 
birds where it was considered to be most likely involved in the transformation of 
cells (Subramanium et al., 2013). Inappropriate and defective functioning of the 




cancer (Boudny and Kovarik, 2002). However, the JAK-STAT pathway, when 
activated by IFNs, can play a crucial role in anti-viral responses. Improta and Pine 
(1997) stated that susceptibility to virus infection could be determined by the cell's 
ability to respond to the autocrine effect of IFN by the STAT-mediated pathway of 
gene induction. The JAK-STAT pathway is involved in blocking replication of HSV-
1 in DCs and macrophages in mice (Mott et al., 2009). IFN-mediated recruitment of 
TNK1 (tyrosine kinase, non-receptor, 1) causes activation of the JAK-STAT 
signalling pathway, which in turn leads to inhibition of HCV (hepatitis C virus) 
replication in hepatocytes (Ooi et al., 2014). JAK-STAT activation not only has the 
potential to affect infection in the infected cells but also indirectly by altering the 
infected cell’s ability to generate an adaptive immune response. Down-regulation of 
key genes in the JAK-STAT signalling pathway in lung cells led to severe HPAIV 
(H5N1) infection at 24 h in chickens, but not in ducks, where expression of the same 
genes was either up-regulated or unchanged (Kuchipudi et al., 2014). 
Apoptosis of virus-infected cells can also be a strategy of host cells to limit virus 
transmission and thus confer resistance. In this study, higher apoptotic death of 
infected cultured line 61 macrophages was observed following MDV infection than 
line 72 (Figure 5.5). As mentioned before, type I IFN-mediated JAK-STAT 
signalling may induce apoptosis in virus-infected cells (Tanaka et al., 1998). Figure 
7.2 illustrates the mechanism of apoptosis of host cells following virus infection. 
Viral dsRNA plays an important role in JNK-2-and PKR-mediated cell death (Figure 
7.2A). It has been reported that DNA viruses, such as adenovirus, HSV and vaccinia 
virus, can produce dsRNA during their replication cycles within few hours of 




MDV replication, but an up-regulation of TLR3, which binds viral dsRNA (Guillot 























Figure 7.2. (A) Virus invades the cell and triggers the activation of proteins 
involved in the induction of interferon (IFN). In response to virus infection, IRF-3 
becomes phosphorylated and translocates to the nucleus to cooperate with 
transcription factors to induce IFN-beta. Viral dsRNA also activates JNK-2 and 
PKR, the latter assisting with IFN production perhaps through activation of the 
NF-kB pathway. Aside from inducing IFN, IRF-3, PKR and JNK-2 may also 
contribute towards regulating cell death or survival by inducing the activation of 
other genes. (B) Type I or II IFN binds to species specific cell surface receptors 
and through the JAK-STAT pathway induce the transcription of genes harbouring 
IFN-stimulated response elements (ISRE) or gamma-activation sequence (GAS) in 
their promoters regions, respectively. Genes known to be induced by IFN and to 
play a role in apoptosis include TRAIL, PKR, IRF-1 and PML. Adapted from 




The expression of TLR3 was also elevated in MDV-infected CEFs (Haunshi and 
Cheng, 2014), suggesting potential synthesis of dsRNA during MDV replication.  
DCs were infected at lower numbers than macrophages in both the lines but no 
differences were observed between the lines. Functional analyses revealed that 
similar biological pathways were activated in both the macrophages and DCs of the 
resistant line (61), while similar pathways were not involved with genes highly 
expressed in APCs of the susceptible line (72), suggesting that, like macrophages, 
DCs in line 61 are also involved in conferring resistance to MD. 
7.5 Future plans 
For establishing a new in vitro MDV-APC infection model, a recombinant virus 
construct of the MDV vaccine strain CVI988 was used in this study. Strains of vv or 
vv+ MDV produce higher levels of infection and infections are prevalent worldwide, 
but suitable recombinant strains of these viruses were not easily available for the 
studies. Therefore, these in vitro experiments need to be repeated using vv or vv+ 
strains of MDV in order to maximise infection in vitro and to reflect the 
pathogenicity of the viruses.  
Further experiments are required to confirm MDV replication in APCs and the 
productiveness of MDV-macrophage infection regarding infection of B and T cells. 
In order to fully validate the transcriptomic differences between APCs of two lines, 
RT-PCR also need to perform in future.  
The role of MZF1 (ZNF42) during MDV infection, especially its interactions with 
Meq, remains to be elucidated. It has been described as both a tumour-suppressing 
(Gaboli et al., 2001) and a tumour-promoting (Hseish et al., 2006) transcription 




line 61 (resistant) compared to genes highly expressed in line 72 (susceptible) infected 
APCs. Though MDV transforms lymphocytes in its life cycle, the expression of 
genes with enriched MZF1 TF binding sites in APCs might have an influence on 
tumourigenesis when the infection transmits from APCs to lymphocytes. However, 
the Meq oncoprotein of the MDV CVI988 strain is unable to induce lymphoma, as it 
has a 178 bp insertion which significantly diminishes its transactivation properties 
(Ajithdoss et al., 2009). Therefore, an oncogenic MDV strain should be used to 
clarify this. 
7.6 Conclusions 
An in vitro model of MDV-APC infection has been developed, for the first time, in 
this project. Carrying out MDV-infection studies in vivo is not always convenient for 
many labs around the world due to the lack of facilities as well as the risk of 
spreading MDV. This in vitro model will perhaps be helpful to perform intensive 
studies regarding MDV-APC interactions. This study also provides evidence that 
macrophages from resistant line 61 are involved in resistance to MD, most likely, at 
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1. General chemicals 
General chemicals were of analytical or molecular biology grade, supplied by Sigma-
Aldrich (Poole, UK) or Invitrogen (Paisley, UK). 
2. Solutions 
All solutions were made up in Milli-Q (reverse osmosis; ion-exchanged; activated 
charcoal filtration) water unless otherwise stated. All solutions for RNA-related work 
were made in RNase free H2O or 0.1% diethyl pyrocarbonate (DEPC)-treated H2O.  
2.1 Composition of solutions 
PBS                                                10 mM sodium phosphate, 140 mM sodium  
                                                        chloride (pH 7.4) 
PBST                                              PBS with 0.05% Tween-20 
SPGA-EDTA buffer                     0.218 M C12H22O11, 0.0038 M KH2PO4,  
                                                        0.0072 M K2HPO4, 0.0049 M C5H8NO4Na, 1% 
                                                        bovine serum albumin (BSA), 0.2% EDTA 
3. Nucleic Acid Electrophoresis 
Tris-Acetate EDTA (TAE)             40 mM Tris, 20 mM acetic acid, 1 mM EDTA 
                                                         (pH 8.0) 
DNA loading dye                           10 mM Tris-HCl (pH 7.6), 0.03% bromophenol 
                                                         blue, 0.03% xylene cyanol FF, 60% glycerol, 
                                                         60 mM EDTA 
4. Bacterial Media 
LB broth                                          10 g bacto tryptone, 5 g bacto yeast extract, 10 g 
NaCl, adjust to pH 7.0 with 5 M NaOH. Made up 




LB agar                            As above with 1.5% bacto-agar 
5. Buffer compositions of commercial kits 
5.1 AEC substrate Kit (BD Pharmingen) 
Acetate buffer                          Aqueous mix of 2.5 M sodium acetate, pH 5.0 
AEC chromogen                    3-amino-9-ethylcarbazole (AEC) in N, N-
dimethylformamide 
Hydrogen peroxide                         3% H2O2 in deionized water 
5.2 EndoFree Plasmid Maxi Kit (Qiagen) 
P1                                                     50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 100 
µg/ml RNase A 
P2                                                     200 mM NaOH, 1% SDS (w/v) 
P3                                                 3 M potassium acetate (pH 5.5) 
QBT                                              750 mM NaCl, 50 mM MOPS (pH 7.0), 15% 
isopropanol (v/v) and 0.15% Triton® X-100 (v/v) 
ER                                   Details not provided by manufacturer 
QC                       1 M NaCl, 50 mM MOPS (pH 7.0) and 15% 
isopropanol (v/v) 
QN                        1.6 M NaCl, 50 mM MOPS (pH 7.0) and 15% 
isopropanol (v/v) 
TE                               10 mM Tris-HCl (pH 8.0) and 1 mM EDTA 
5.3 NucleoBond® BAC100 Kit (Macherey-Nagel) 
S1                                                     50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 100 
µg/ml RNase A 




S3                                                 2.8 M KAc (pH 5.1) 
N2                                             100 mM Tris, 15% ethanol, 900 mM KCl, 0.15% 
Triton® X-100, adjusted to pH 6.3 with H3PO4 
N3                      100 mM Tris, 15% ethanol, 1.15 M KCl, adjusted 
to pH 6.3 with H3PO4 
N5                        100 mM Tris, 15% ethanol, 1 M KCl, adjusted to   
pH 8.5 with H3PO4 
5.4 RNeasy® mini Kit (Qiagen) 
RLT                   Aqueous mix containing guanidine thiocyanate 
RW1                        Aqueous mix containing guanidine thiocyanate 
RPE Details not provided by manufacturer 
5.5 Ambion® TURBO DNA-free™ Kit (Life Technologies)  
10× DNase buffer                           100 mM Tris-HCl pH 7.5, 25 mM MgCl2,  
                                                         5 mM CaCl2 
5.6 Qubit™ RNA Assay Kit (Invitrogen)  
Qubit RNA reagent  200× concentrate in DMSO 
(Component A) 
Qubit RNA Buffer  Details not provided by manufacturer 
(Component B) 
Qubit RNA Standard #1 0 ng/μl in TE buffer 
(Component C) 






















Table S2.1: DE genes in line 61 control macrophages. 
  Line  61 control macrophages  
Gene Ensembl Gene ID Fold Change 
AAED1 ENSGALG00000012624 3.871802 
ABCA2 ENSGALG00000001226 2.446491 
ADAM15 ENSGALG00000017301 2.51268 
ADAMTS10 ENSGALG00000001544 2.24844 
AGTPBP1 ENSGALG00000012595 2.729011 
ALDH7A1 ENSGALG00000008229 2.293892 
ALPK1 ENSGALG00000012074 2.16129 
ANGPTL4 ENSGALG00000000619 4.322561 
ANKRD6 ENSGALG00000015768 2.419207 
AP1AR ENSGALG00000028807 2.397185 
ARHGEF10L ENSGALG00000000449 2.036453 
ARL4A ENSGALG00000027757 3.808 
ARSB ENSGALG00000004438 3.099 
ASAP3 ENSGALG00000001710 2.794424 
ATP8B2 ENSGALG00000002326 2.390224 
AUH ENSGALG00000021843 2.054664 
BAAT ENSGALG00000005175 2.309857 
BAIAP2 ENSGALG00000006915 2.068186 
BAMBI ENSGALG00000025919 8.996994 
BARX2B ENSGALG00000001197 2.992784 
BCL2 ENSGALG00000012885 4.023935 
BCL2A1 ENSGALG00000006511 2.040889 
BDH1 ENSGALG00000006976 2.141704 
BIN1 ENSGALG00000011541 2.510232 
BLNK ENSGALG00000006973 2.048154 
BMP8B ENSGALG00000024064 5.44633 
BTF3 ENSGALG00000013512 2.184222 
C8G ENSGALG00000024004 2.491761 
C9orf91 ENSGALG00000007186 2.193739 
CATHL1 ENSGALG00000027973 3.34145 
CD247 ENSGALG00000015441 3.3085 
CDC14B ENSGALG00000012627 2.192045 
CDYL2 ENSGALG00000012978 3.248664 
CHIR-B3 ENSGALG00000027486 7.524471 
CHRNB2 ENSGALG00000002707 2.710536 
CHTL1A ENSGALG00000007174 5.467292 
CLIC5 ENSGALG00000016707 3.963166 
CNNM1 ENSGALG00000007489 2.500562 
COL4A3BP ENSGALG00000014952 2.310825 




  Line  61 control macrophages  
Gene Ensembl Gene ID Fold Change 
CTSA ENSGALG00000006876 2.339828 
CUZD1 ENSGALG00000023424 13.7112 
CYP46A1 ENSGALG00000011162 2.299543 
DNAH5 ENSGALG00000013268 4.442247 
DNAJA1 ENSGALG00000023066 2.066544 
EFHD2 ENSGALG00000013698 2.650462 
EPB41L4A ENSGALG00000000234 2.786597 
EXPH5 ENSGALG00000027243 5.54601 
FAM46D ENSGALG00000007157 4.165632 
FAM47E-STBD1 ENSGALG00000027872 2.97738 
FCGBP ENSGALG00000014150 2.886056 
FGF12 ENSGALG00000007219 3.973465 
FXYD6 ENSGALG00000025937 2.020587 
GAL1 ENSGALG00000022815 4.65347 
GAL6 ENSGALG00000016668 30.14668 
GBE1 ENSGALG00000015506 3.116434 
gga-mir-142 ENSGALG00000018344 3.640504 
gga-mir-1618 ENSGALG00000025287 3.078309 
gga-mir-1661 ENSGALG00000025240 4.667173 
gga-mir-3064 ENSGALG00000027517 2.413162 
gga-mir-3533 ENSGALG00000027736 3.212579 
GLRX ENSGALG00000027483 2.005971 
GP1BB ENSGALG00000021529 3.401331 
GPD1 ENSGALG00000012061 3.036604 
GPR142 ENSGALG00000022536 3.177413 
GPT2 ENSGALG00000004158 2.314629 
GRHPR ENSGALG00000005423 2.719062 
HAVCR1 ENSGALG00000017362 2.236034 
HERPUD1 ENSGALG00000001220 2.489729 
HES4 ENSGALG00000028015 2.403829 
HIC1 ENSGALG00000026718 4.088484 
HIP1 ENSGALG00000000930 2.77431 
HMGCS1 ENSGALG00000014862 2.200708 
HSD17B1 ENSGALG00000027429 3.769768 
IL17RC ENSGALG00000028970 2.306222 
IL1BETA ENSGALG00000000534 2.77692 
ILDR1 ENSGALG00000015136 3.226472 
INSIG1 ENSGALG00000017394 2.079145 
IRAK1BP1 ENSGALG00000015892 2.703687 
ITGA1 ENSGALG00000014891 2.689838 
ITM2B ENSGALG00000016996 2.134191 




  Line  61 control macrophages  
Gene Ensembl Gene ID Fold Change 
KCTD12 ENSGALG00000009628 3.336448 
KIAA0513 ENSGALG00000025938 3.447755 
KIAA1147 ENSGALG00000012874 2.554401 
KLF15 ENSGALG00000021702 26.23269 
KLF2 ENSGALG00000003939 2.002845 
KLHL13 ENSGALG00000009120 2.278936 
LEFTY2 ENSGALG00000009256 5.239073 
LGALS1 ENSGALG00000029043 2.02853 
LGR4 ENSGALG00000012191 2.072203 
LOC768803 ENSGALG00000003048 2.56365 
LRMP ENSGALG00000014011 2.227473 
LYSMD3 ENSGALG00000014651 2.129185 
MB21D2 ENSGALG00000007218 2.536567 
ME1 ENSGALG00000015849 2.107392 
MLPH ENSGALG00000003904 5.473601 
MPP3 ENSGALG00000002392 2.713062 
MYLK3 ENSGALG00000004334 2.672483 
N4BP2L1 ENSGALG00000017072 2.823663 
NADK2 ENSGALG00000003558 2.06234 
NAPEPLD ENSGALG00000008285 2.453588 
NCX1 ENSGALG00000008544 5.496456 
NEDD4L ENSGALG00000002917 3.065446 
NPL ENSGALG00000004614 2.353249 
NSA2 ENSGALG00000014942 2.150103 
ODF2L ENSGALG00000006804 3.565713 
OPRL1 ENSGALG00000027965 5.315932 
OSBPL1A ENSGALG00000015086 2.063202 
PIM3 ENSGALG00000023576 2.570633 
PINLYP ENSGALG00000026884 2.620325 
PLXDC1 ENSGALG00000023881 4.507664 
POUV ENSGALG00000026574 3.425265 
PPAP2A ENSGALG00000014711 2.401558 
PPP4R4 ENSGALG00000010950 9.976112 
PRRT3 ENSGALG00000006768 3.348119 
PSAT1 ENSGALG00000015180 2.259765 
RALGPS1 ENSGALG00000000906 4.149762 
RASGRP3 ENSGALG00000010435 2.545871 
RNF180 ENSGALG00000014743 4.469005 
RPL17 ENSGALG00000002696 2.413544 
RPS23 ENSGALG00000015617 2.449474 
RPS6 ENSGALG00000015082 2.425489 




  Line  61 control macrophages  
Gene Ensembl Gene ID Fold Change 
SCARB1 ENSGALG00000003018 2.625295 
SCN4A ENSGALG00000000252 5.826144 
SEC14L5 ENSGALG00000002111 4.381807 
SELO ENSGALG00000008694 2.082425 
SFXN1 ENSGALG00000003263 2.307113 
SLC1A4 ENSGALG00000008811 2.569569 
SLC24A4 ENSGALG00000010793 2.263344 
SLC7A5 ENSGALG00000027863 2.303132 
SLC7A5 ENSGALG00000005845 2.232606 
SMAD7A ENSGALG00000018639 2.54909 
SNCB ENSGALG00000021542 5.139743 
SNORD38 ENSGALG00000024758 2.570605 
SOCS2 ENSGALG00000011295 3.297936 
SSH2 ENSGALG00000021572 2.31678 
STARD4 ENSGALG00000000241 2.404333 
TBC1D8 ENSGALG00000016776 3.43013 
TCN2 ENSGALG00000009536 2.876404 
TGM3 ENSGALG00000004804 3.151073 
THRSPB ENSGALG00000028911 3.861224 
TIMD4 ENSGALG00000003876 2.570163 
TMC5 ENSGALG00000006911 2.737059 
TMEM130 ENSGALG00000003569 2.397255 
TMEM14A ENSGALG00000019894 2.087553 
TMEM186 ENSGALG00000027191 2.003926 
TRIB1 ENSGALG00000016311 2.340359 
TSNARE1 ENSGALG00000016161 4.445748 
TSPAN18 ENSGALG00000014072 2.484887 
TUSC1 ENSGALG00000017510 3.172573 
TXN ENSGALG00000015704 2.693107 
UACA ENSGALG00000008143 2.346389 
UBA5 ENSGALG00000011707 3.069636 
VPS37D ENSGALG00000026044 2.51481 
WBSCR17 ENSGALG00000001130 5.889157 
WDR63 ENSGALG00000008696 4.206663 
WSCD2 ENSGALG00000004849 2.437572 
ZNF608 ENSGALG00000005016 3.716776 
ZOV3 ENSGALG00000014877 2.082793 
ZSWIM3 ENSGALG00000006848 2.242438 
Uncharacterised ENSGALG00000028154 3.460428 
Uncharacterised ENSGALG00000028418 4.557042 
Uncharacterised ENSGALG00000025824 3.741026 




  Line  61 control macrophages  
Gene Ensembl Gene ID Fold Change 
Uncharacterised ENSGALG00000016998 3.48027 
Uncharacterised ENSGALG00000027621 2.27809 
Uncharacterised ENSGALG00000028162 3.934173 
Uncharacterised ENSGALG00000005873 2.829919 
Uncharacterised ENSGALG00000007197 2.02185 
Uncharacterised ENSGALG00000027596 2.782688 










































Table S2.2: DE genes in line 72 control macrophages. 
   Line 72 control macrophages  
Gene Ensembl Gene ID Fold Change 
ACAP3 ENSGALG00000001770 5.58647449 
ACSL5 ENSGALG00000008840 2.086845944 
ADAM8 ENSGALG00000003437 2.381783938 
ADIPOQ ENSGALG00000005554 4.208414513 
ALDH6 ENSGALG00000007129 6.530275887 
ANKRD13B ENSGALG00000026000 4.013797676 
ANKRD29 ENSGALG00000015034 3.618879408 
ANO10 ENSGALG00000026562 2.147324076 
APBB2 ENSGALG00000014262 3.432744823 
ARHGAP32 ENSGALG00000025860 2.991742016 
ATL2 ENSGALG00000000720 2.53961977 
ATP1B3 ENSGALG00000002764 2.182597707 
BAG3 ENSGALG00000009433 2.401920972 
BLIMP-1 ENSGALG00000015388 3.378797263 
BMPR1A ENSGALG00000002003 3.683473105 
C1R ENSGALG00000014659 3.696859913 
C1S ENSGALG00000014603 10.91546432 
C3H20ORF94 ENSGALG00000009016 2.71852822 
CAMK1G ENSGALG00000001319 3.534096756 
CCDC186 ENSGALG00000008956 2.047452625 
CCDC77 ENSGALG00000012987 3.604536489 
CCNF ENSGALG00000009201 2.407584033 
CDCP1 ENSGALG00000011882 3.076342015 
CDKN2C ENSGALG00000010537 2.882035474 
CENPN ENSGALG00000013494 2.963625569 
CENPO ENSGALG00000016609 2.345592219 
CEP19 ENSGALG00000006405 2.792350864 
CHIR-A2 ENSGALG00000027817 3.65601729 
CHIR-AB-502 ENSGALG00000028099 7.783366729 
CHIR-B4 ENSGALG00000027971 66.84382305 
CHIR-B4 ENSGALG00000023008 831.6999298 
CHIR-B4 ENSGALG00000028718 722.605047 
CHST2 ENSGALG00000026437 2.379693794 
CIITA ENSGALG00000007171 3.179096968 
CIP1 ENSGALG00000028318 3.177156626 
CLGN ENSGALG00000009826 5.971209945 
CLIC4 ENSGALG00000001262 3.559839642 
CLIP2 ENSGALG00000001291 3.397773023 
CMPK2 ENSGALG00000028982 7.647186156 




   Line 72 control macrophages  
Gene Ensembl Gene ID Fold Change 
CNKSR3 ENSGALG00000027159 2.297189867 
CNTNAP1 ENSGALG00000003123 2.742176351 
COL6A1 ENSGALG00000005974 4.662991137 
COL6A2 ENSGALG00000006126 4.942517341 
COL6A3 ENSGALG00000003923 3.520608147 
CROT ENSGALG00000008813 2.340632961 
CSF1 ENSGALG00000028217 2.338229305 
CSRP1 ENSGALG00000000318 2.010523748 
CTNND1 ENSGALG00000007330 2.119984147 
CTTNBP2NL ENSGALG00000026182 2.022261019 
CYP1A4 ENSGALG00000001325 16.94917599 
CYP4V2 ENSGALG00000020688 3.036950689 
DCHS1 ENSGALG00000004653 15.73701775 
DENND5B ENSGALG00000012944 9.683273816 
DMB2 ENSGALG00000000166 3.09005219 
DNAAF1 ENSGALG00000003258 3.668973778 
DOCK7 ENSGALG00000010967 2.246662507 
DUSP10 ENSGALG00000009450 2.511532947 
DUSP8 ENSGALG00000006647 2.594852686 
EAF2 ENSGALG00000011657 4.219791528 
EDA2R ENSGALG00000004599 2.853381726 
EDARADD ENSGALG00000014369 2.457884548 
EIF2AK2 ENSGALG00000010560 2.368768188 
ELOVL7 ENSGALG00000014730 7.53999656 
ENG ENSGALG00000005060 6.908284108 
ENPP3 ENSGALG00000002869 2.770176176 
EPHA2 ENSGALG00000023768 3.178721175 
EPHB6 ENSGALG00000014749 2.359809851 
EPN3 ENSGALG00000023279 3.21404597 
FAM107B ENSGALG00000028708 2.054521119 
FAM114A1 ENSGALG00000013583 2.114063863 
FLT1 ENSGALG00000017091 84.79895979 
FLVCR1 ENSGALG00000009807 3.30300422 
FMNL2 ENSGALG00000012525 2.828002165 
FMO6P ENSGALG00000003022 2.133413638 
FN1 ENSGALG00000003578 2.003467501 
FOXM1 ENSGALG00000013420 2.362225982 
FRMD4A ENSGALG00000006656 5.294633106 
GABRD ENSGALG00000001282 61.70928908 
GADD45 ENSGALG00000025977 3.359823293 
GALNT9 ENSGALG00000002242 3.876327129 




   Line 72 control macrophages  
Gene Ensembl Gene ID Fold Change 
GIMAP1 ENSGALG00000005650 3.015446908 
GINS2 ENSGALG00000028131 2.356422989 
GJC1 ENSGALG00000000997 3.694628293 
GLIPR2 ENSGALG00000028821 2.447182064 
GLUL ENSGALG00000003678 5.291541415 
GPAM ENSGALG00000008795 2.220146899 
GVINP1 ENSGALG00000016556 6.499811751 
H2AFX ENSGALG00000024338 2.703844102 
H2A-VII ENSGALG00000027425 3.310172694 
H2B-I ENSGALG00000027571 3.83479444 
HAIRY1 ENSGALG00000002055 2.90479543 
HAS2 ENSGALG00000016394 3.773983083 
HELZ2 ENSGALG00000006138 6.000176774 
HEPHL1 ENSGALG00000017214 6.82210564 
HRASLS ENSGALG00000007193 3.469678 
HSD17B11 ENSGALG00000010979 2.634108106 
HSP70 ENSGALG00000011715 3.785519814 
HTR1B ENSGALG00000015895 3.340330281 
HTR2A ENSGALG00000016992 7.027544443 
ID1 ENSGALG00000006210 2.965040419 
IFI27L2 ENSGALG00000021627 13.58998911 
IFIH1 ENSGALG00000011089 4.173334126 
IFITM5 ENSGALG00000026970 6.183513101 
IGFBP2 ENSGALG00000011469 4.001163605 
IL1RAPL2 ENSGALG00000008888 48.21464914 
IQCK ENSGALG00000028197 3.697301944 
IRF1 ENSGALG00000006785 2.250762731 
IRG1 ENSGALG00000016919 3.824919249 
ISG12(2) ENSGALG00000013575 9.711707091 
ITGAV ENSGALG00000002655 3.094613787 
JAG1 ENSGALG00000009020 3.431176189 
JAK3 ENSGALG00000028085 3.863499524 
JSC ENSGALG00000006346 4.022067529 
KCNB2 ENSGALG00000022800 3.096651404 
KIFC1 ENSGALG00000019837 2.147994548 
KLF5 ENSGALG00000016927 2.286725851 
KLHDC3 ENSGALG00000027645 4.57331162 
KLHL25 ENSGALG00000006826 2.497132459 
KNOP1 ENSGALG00000002042 2.098449943 
LACC1 ENSGALG00000016969 7.069673254 
LAMA5 ENSGALG00000005321 5.16725756 




   Line 72 control macrophages  
Gene Ensembl Gene ID Fold Change 
LARGE ENSGALG00000012559 2.849930187 
LGALS2 ENSGALG00000003213 14.79030328 
LIG1 ENSGALG00000013384 2.093158254 
LIMA1 ENSGALG00000006169 3.554803228 
LIPI ENSGALG00000015662 11.52030514 
LRP8 ENSGALG00000010692 2.916801781 
LRRC4 ENSGALG00000029160 3.426365904 
MAD2L1 ENSGALG00000011967 2.070416488 
MADPRT ENSGALG00000000871 6.593057662 
MANSC1 ENSGALG00000014147 2.784853202 
MAPK8IP1 ENSGALG00000008430 7.354179877 
MASTL ENSGALG00000007507 3.163956226 
MGAT3 ENSGALG00000012146 2.451175613 
MGST3 ENSGALG00000003445 2.047386299 
MICAL1 ENSGALG00000019751 2.165193348 
MITD1 ENSGALG00000016759 2.328916277 
MOV10 ENSGALG00000001558 2.426397915 
MPP6 ENSGALG00000010988 3.104073795 
MRC2 ENSGALG00000000461 3.57827136 
MTFR2 ENSGALG00000019967 2.445735922 
MTUS1 ENSGALG00000013615 2.890570873 
MXRA8 ENSGALG00000001561 3.372132646 
MYO1C ENSGALG00000002709 3.183981751 
MYO1E ENSGALG00000004150 2.382677315 
NACAD ENSGALG00000005603 5.961886788 
NAV2 ENSGALG00000003999 2.031552161 
NDRG1 ENSGALG00000016216 2.496850372 
NEFL ENSGALG00000000314 8.701689709 
NEU4 ENSGALG00000006361 15.11419911 
NIN ENSGALG00000012361 3.355535975 
NOG ENSGALG00000003114 28.42149679 
NT5C1A ENSGALG00000006608 2.732874671 
NTN4 ENSGALG00000006325 12.81925292 
OCSTAMP ENSGALG00000004340 15.72061908 
ODC1 ENSGALG00000016444 3.256505522 
ORC2 ENSGALG00000008234 2.018960361 
OSMR ENSGALG00000003747 3.142476653 
P2RX7 ENSGALG00000003863 2.880821337 
PALM ENSGALG00000001846 686.7271364 
PAPSS2 ENSGALG00000003689 2.044728899 
PARP14 ENSGALG00000012072 2.137566778 




   Line 72 control macrophages  
Gene Ensembl Gene ID Fold Change 
PATL2 ENSGALG00000002167 2.970342484 
PDE4DIP ENSGALG00000011777 2.410267485 
PDE7B ENSGALG00000013941 2.400745783 
PDIK1L ENSGALG00000026301 2.587494394 
PDLIM7 ENSGALG00000026159 2.133074247 
PFKL ENSGALG00000006543 2.223647424 
PIK3AP1 ENSGALG00000005547 2.165293124 
PISD ENSGALG00000006872 2.458319088 
PKD1 ENSGALG00000005714 2.144801021 
PKN3 ENSGALG00000004689 2.360729272 
PLACL2 ENSGALG00000011190 12.24393082 
PLCG1 ENSGALG00000016141 2.221594027 
PM20D2 ENSGALG00000015779 2.200681976 
PNPLA2 ENSGALG00000014569 2.07816151 
POGZ ENSGALG00000002505 3.547167451 
PPAR ENSGALG00000022985 13.20642383 
PRC1 ENSGALG00000012836 2.553010474 
PRSS12 ENSGALG00000005156 3.353308624 
PTCHD1 ENSGALG00000016358 4.388575404 
PTGS1 ENSGALG00000001314 6.625913477 
PTPRE ENSGALG00000009823 2.246271693 
PTTG1 ENSGALG00000001506 2.2818479 
RAB34 ENSGALG00000026315 2.688320643 
RACGAP1 ENSGALG00000006271 2.517730402 
RASAL3 ENSGALG00000029030 2.771665224 
RGSL1 ENSGALG00000003671 8.000150137 
RHOC ENSGALG00000001569 3.457512756 
RHPN2 ENSGALG00000004814 3.316621667 
RNF150 ENSGALG00000009865 3.576261702 
RNF208 ENSGALG00000008911 2.700589914 
RTTN ENSGALG00000013745 2.409371228 
RUFY4 ENSGALG00000025739 3.065413917 
SAMD9L ENSGALG00000009479 4.335827054 
SCN1A ENSGALG00000010943 4.674271764 
SCN4B ENSGALG00000007409 6.002679977 
SDC4 ENSGALG00000003932 2.318118136 
SEPT4 ENSGALG00000028193 2.504994692 
SERPINE2 ENSGALG00000005135 4.624228596 
SESN3 ENSGALG00000017204 2.767660386 
SH3RF3 ENSGALG00000016810 3.462534018 
SKA3 ENSGALG00000017128 2.040723394 




   Line 72 control macrophages  
Gene Ensembl Gene ID Fold Change 
SLC19A3 ENSGALG00000003025 5.761852294 
SLC2A6 ENSGALG00000002982 2.756368717 
SLC41A3 ENSGALG00000006235 3.498249719 
SLC7A3 ENSGALG00000005727 3.676171701 
SLCO2B1 ENSGALG00000017302 4.844445243 
SLCO4A1 ENSGALG00000005460 3.386073541 
SLMO1 ENSGALG00000013830 2.78299333 
SMC4 ENSGALG00000009553 2.028000423 
SMTN ENSGALG00000011865 2.590917506 
SORCS3 ENSGALG00000008434 96.7393813 
SPERT ENSGALG00000016981 2425.992891 
SPRY3 ENSGALG00000007448 33.30982895 
SPTBN1 ENSGALG00000023241 2.795195301 
SRGAP1 ENSGALG00000009825 3.656494705 
ST8SIA1 ENSGALG00000013211 6.409817536 
STOM ENSGALG00000001434 2.171156283 
SUSD4 ENSGALG00000009388 7.844970204 
SYNDIG1L ENSGALG00000010233 4.858235774 
SYNE2 ENSGALG00000011811 3.93085666 
TAAR1 ENSGALG00000013994 3.165421774 
TACC2 ENSGALG00000009516 5.594353216 
TAPBPL ENSGALG00000014428 2.044491878 
TBXA2R ENSGALG00000027241 2.820602652 
TFPI2 ENSGALG00000009512 9.673482581 
THBS2 ENSGALG00000011200 5.71317378 
TJP2 ENSGALG00000015109 9.667183245 
TK1 ENSGALG00000007191 3.121176943 
TLN2 ENSGALG00000003628 2.87988471 
TMCC2 ENSGALG00000000673 3.422988581 
TMEM201 ENSGALG00000002527 2.124849732 
TMTC2 ENSGALG00000010975 3.435268209 
TNFIP6 ENSGALG00000012481 3.771840757 
TNNI2 ENSGALG00000006591 2.984885486 
TOR1A ENSGALG00000023709 6.270273117 
TPCN2 ENSGALG00000007550 2.187598404 
TRAF2 ENSGALG00000009014 2.035230306 
TTC26 ENSGALG00000011847 2.891012355 
TUBE1 ENSGALG00000015017 2.948307758 
TWSG1 ENSGALG00000008400 2.66042892 
TXNRD1 ENSGALG00000012714 2.093036522 
UBXN2B ENSGALG00000015431 2.132393869 




   Line 72 control macrophages  
Gene Ensembl Gene ID Fold Change 
UNC13D ENSGALG00000002234 3.285827849 
USP12 ENSGALG00000017101 2.795555258 
USP18 ENSGALG00000013057 6.962800793 
VCAN ENSGALG00000015624 2.333172351 
VIPR1 ENSGALG00000005259 933.6545574 
WNT11B ENSGALG00000004401 7.761552371 
ZDHHC8 ENSGALG00000002124 2.381638152 
ZRANB3 ENSGALG00000012223 2.064620507 
Uncharacterised ENSGALG00000015276 4.902426345 
Uncharacterised ENSGALG00000020700 6.444272704 
Uncharacterised ENSGALG00000007846 63.80646277 
Uncharacterised ENSGALG00000027822 5.927773145 




































Table S2.3: DE genes in line 61 infected macrophages. 
        Line  61 infected macrophages 
Gene Ensembl Gene ID Fold Change 
ABI3 ENSGALG00000001287 2.885126032 
ABTB2 ENSGALG00000011609 2.686976225 
ADA ENSGALG00000004170 2.606289839 
ADAM9 ENSGALG00000013838 3.036049759 
AGBL2 ENSGALG00000024097 3.558190174 
ALDH3A2 ENSGALG00000003490 2.49653446 
AMIGO3 ENSGALG00000028339 2.128645538 
AMPD3 ENSGALG00000005662 2.149913351 
ANGPT1 ENSGALG00000027520 3.662895618 
ARSI ENSGALG00000005616 20.80847226 
ASB12 ENSGALG00000007594 3.077433713 
ATP7B ENSGALG00000017021 17.70034231 
B3GNT9 ENSGALG00000021345 2.080622354 
BATF ENSGALG00000010323 3.138413833 
BATF3 ENSGALG00000009816 5.596860906 
BCAR1 ENSGALG00000028291 2.032273139 
BDKRB1 ENSGALG00000020386 4.350207971 
BDKRB2 ENSGALG00000011080 2.411805771 
BEST4 ENSGALG00000010126 10.80578251 
BPIFC ENSGALG00000021025 4.623526845 
BRICD5 ENSGALG00000005883 3.659003303 
BUD13 ENSGALG00000025882 2.793408917 
C14orf159 ENSGALG00000010703 3.279067056 
C16orf93 ENSGALG00000021212 2.403234335 
C4 ENSGALG00000017040 5.183964756 
CA13 ENSGALG00000015820 2.339286065 
CAB39L ENSGALG00000017005 3.403533847 
CACNA1S ENSGALG00000000730 2.094571107 
CCBL1 ENSGALG00000009407 2.707198698 
CCDC65 ENSGALG00000028482 2.82125525 
CCDC88C ENSGALG00000027614 2.021492752 
CCKBR ENSGALG00000027913 2.429261322 
CCL1 ENSGALG00000002329 22.61966865 
CCL20 ENSGALG00000003003 5.057896837 
CCR7 ENSGALG00000027572 4.952319266 
CD1A1 ENSGALG00000012494 3.534067246 
CD3E ENSGALG00000007416 7.880156855 
CDKN1A ENSGALG00000026896 2.760567012 
CELA2A ENSGALG00000004568 2.953645327 




        Line  61 infected macrophages 
Gene Ensembl Gene ID Fold Change 
CHRDL2 ENSGALG00000017308 3.054368286 
CHRNA3 ENSGALG00000003014 3.823818256 
CNGA2 ENSGALG00000007282 2.168905448 
COCH ENSGALG00000009920 6.28307773 
COL13A1 ENSGALG00000004286 3.311831643 
COL7A1 ENSGALG00000005811 3.885690745 
CORO2A ENSGALG00000001933 7.969053854 
CPE ENSGALG00000027788 6.741504545 
CPNE2 ENSGALG00000001316 2.754450601 
CPNE7 ENSGALG00000000507 8.39176448 
CRMP1B ENSGALG00000015042 6.402110707 
CROCC ENSGALG00000027085 2.096910323 
CSF3 ENSGALG00000026420 2.498443545 
CSGALNACT1 ENSGALG00000010125 4.503659877 
CUBN ENSGALG00000008704 2.068661611 
CUTA ENSGALG00000001620 4.332086462 
CUX2 ENSGALG00000004598 2.381038252 
CX3CL1 ENSGALG00000026663 5.033155941 
CXCL13L2 ENSGALG00000010338 3.263677612 
CYP3A37 ENSGALG00000004449 4.396369146 
DGKH ENSGALG00000003841 4.318612829 
DIXDC1 ENSGALG00000007929 2.444657598 
DNAH9 ENSGALG00000001111 3.276394398 
DST ENSGALG00000016289 2.655743993 
DUSP16 ENSGALG00000028155 2.168386763 
DZANK1 ENSGALG00000008731 2.165755677 
EDA ENSGALG00000004481 3.079990348 
EPHA7 ENSGALG00000015593 13.04522977 
ERICH3 ENSGALG00000011356 3.155575101 
EVPL ENSGALG00000002108 2.937918007 
EX-FABP ENSGALG00000024011 2.222775163 
F2RL3 ENSGALG00000002570 2.203480451 
F5 ENSGALG00000015207 2.202326928 
FAM110D ENSGALG00000001453 2.532812836 
FAM134B ENSGALG00000026200 2.025929844 
FAM154A ENSGALG00000027314 3.104733195 
FAM181B ENSGALG00000022713 5.869737427 
FASN ENSGALG00000025905 2.050296977 
FBXO41 ENSGALG00000016087 3.816932967 
FHAD1 ENSGALG00000017714 6.576526394 
FLT4 ENSGALG00000005802 4.383895228 




        Line  61 infected macrophages 
Gene Ensembl Gene ID Fold Change 
FZD4 ENSGALG00000017242 2.820242672 
G0S2 ENSGALG00000023933 2.838379078 
GALR3 ENSGALG00000004127 2.005023215 
GAREML ENSGALG00000022838 2.807403996 
GEM ENSGALG00000015954 3.423282098 
GNGT2 ENSGALG00000026333 2.491001379 
GPAT2 ENSGALG00000014436 2.725948419 
GPR174 ENSGALG00000004111 4.078799485 
GPR39 ENSGALG00000012171 2.957593059 
GRIP2 ENSGALG00000006449 23.51643915 
GTSF1 ENSGALG00000001109 2.755232031 
HEMGN ENSGALG00000023061 2.974739553 
HEY1 ENSGALG00000027364 4.717339011 
HHLA2 ENSGALG00000022871 4.607573517 
HLF ENSGALG00000003059 2.281827868 
HPCA ENSGALG00000003573 3.458873918 
HPD ENSGALG00000004343 3.172186093 
HSPA12A ENSGALG00000028016 5.922633484 
HSPA12A ENSGALG00000009248 2.155061362 
IGDCC3 ENSGALG00000007371 2.222165724 
IGSF11 ENSGALG00000015084 2.915678966 
IGSF3 ENSGALG00000015469 2.070897728 
IL13RA2 ENSGALG00000020316 4.49295436 
IL20RA ENSGALG00000013869 6.865326748 
IL23R ENSGALG00000011212 7.11153038 
IL2RA ENSGALG00000006335 5.241353238 
INHBB ENSGALG00000028770 2.719880592 
IRF4 ENSGALG00000012830 8.546411329 
IRS2 ENSGALG00000016839 2.311884021 
ITGB1BP2 ENSGALG00000005493 10.45135463 
K123 ENSGALG00000006337 9.415051876 
K60 ENSGALG00000011668 2.73039348 
KBTBD3 ENSGALG00000028658 3.060382457 
KCNAB1 ENSGALG00000010269 23.40541545 
KCNH2 ENSGALG00000027043 8.140595457 
KCNJ5 ENSGALG00000001181 2.238738963 
KIAA1755 ENSGALG00000023590 2.610129237 
KIFC3 ENSGALG00000001020 2.51972451 
LAT2 ENSGALG00000029173 152.1779288 
LEPR ENSGALG00000011058 3.109279137 
LHCGR ENSGALG00000009095 3.036256301 




        Line  61 infected macrophages 
Gene Ensembl Gene ID Fold Change 
LIPG ENSGALG00000002712 2.68276657 
LOXL3 ENSGALG00000013254 3.078675016 
LRRC6 ENSGALG00000016244 2.901443706 
LSAMP ENSGALG00000015087 2.01906278 
LYZ ENSGALG00000009963 4.867377366 
LZTS1 ENSGALG00000016001 3.790344364 
MADCAM1 ENSGALG00000028341 10.93635636 
MAMDC4 ENSGALG00000008995 4.62253841 
MARCKSL1 ENSGALG00000021616 3.133070551 
MIEN1 ENSGALG00000026328 2.047020503 
MUC6 ENSGALG00000006740 3.675418211 
MVK ENSGALG00000013848 2.678900193 
MYL4 ENSGALG00000000585 2.649272788 
MYO10L ENSGALG00000011172 2.340519692 
NDNF ENSGALG00000011962 2.622867607 
NEB ENSGALG00000012495 2.23561941 
NINJ1 ENSGALG00000026891 2.3003172 
NME1 ENSGALG00000007305 2.264954051 
NR4A3 ENSGALG00000013568 2.356815885 
NRN1 ENSGALG00000029089 3.128368385 
ODZ3 ENSGALG00000010706 2.490415656 
OLFML2A ENSGALG00000001048 2.07162475 
P4HA3 ENSGALG00000017311 2.25047525 
PADI3 ENSGALG00000000479 2.474794321 
PAQR7 ENSGALG00000009680 2.941980974 
PCDH18 ENSGALG00000009732 2.517131234 
PDLIM4 ENSGALG00000027627 2.312743005 
PERM1 ENSGALG00000026875 3.797426826 
PHYKPL ENSGALG00000023920 2.009014426 
PKD2L2 ENSGALG00000006120 3.902041719 
PLCE1 ENSGALG00000028043 2.211014108 
PLEKHN1 ENSGALG00000002121 5.294426519 
PLOD2 ENSGALG00000006783 3.787488981 
PROM1 ENSGALG00000007645 2.586154805 
PRSS35 ENSGALG00000015847 2.425055502 
PSD ENSGALG00000005680 8.119824178 
PSMD4 ENSGALG00000028505 4.041903398 
PSMD4 ENSGALG00000026320 2.79399495 
PTCHD1 ENSGALG00000023347 2.328939565 
PTGES ENSGALG00000027357 2.879877179 
PTPN22 ENSGALG00000021656 2.053225759 




        Line  61 infected macrophages 
Gene Ensembl Gene ID Fold Change 
RAB11FIP3 ENSGALG00000002666 2.724481846 
RAPGEF3 ENSGALG00000006348 4.877311512 
RASSF7 ENSGALG00000006873 3.043780295 
RELT ENSGALG00000019033 6.34904231 
RNaseP_nuc ENSGALG00000025650 2.609890176 
RNF157 ENSGALG00000002008 4.067590714 
RRAD ENSGALG00000005140 2.067169798 
RUNX3 ENSGALG00000026821 3.523429118 
RUSC2 ENSGALG00000002371 2.086567435 
S100A11 ENSGALG00000009163 3.50947497 
SAMD4A ENSGALG00000012203 2.144478269 
SCARNA7 ENSGALG00000025666 2.924232187 
SDR42E1 ENSGALG00000005456 2.634376177 
SEMA3B ENSGALG00000013722 2.11385633 
SEMA3C ENSGALG00000008455 2.282269085 
SEMA3F ENSGALG00000013370 2.854706855 
SEMA4D ENSGALG00000003058 6.782338989 
SERINC2 ENSGALG00000021685 3.421281291 
SFRP5 ENSGALG00000006944 3.5324513 
SH2D1B ENSGALG00000028448 5.042172742 
SH3BP5 ENSGALG00000011550 2.031664472 
SHISA8 ENSGALG00000027568 5.573777113 
SLC12A3 ENSGALG00000002957 2.400261548 
SLC12A5 ENSGALG00000006930 3.367938384 
SLC15A1 ENSGALG00000016884 2.606432403 
SLC16A4 ENSGALG00000000417 4.992568735 
SLC26A11 ENSGALG00000007018 2.218857794 
SLC38A3 ENSGALG00000028871 3.467479421 
SLC46A2 ENSGALG00000027345 2.265559988 
SLC6A9 ENSGALG00000010098 2.956294151 
SLCO3A1 ENSGALG00000006871 2.824683683 
SLCO4C1 ENSGALG00000026768 2.060415124 
SMTNL1 ENSGALG00000028884 2.280941234 
SNORA27 ENSGALG00000017811 3.929658384 
SNORA73 ENSGALG00000021931 2.745869301 
SNORD35 ENSGALG00000021748 2.774445616 
snoU2_19 ENSGALG00000025390 4.508887978 
SPINT1 ENSGALG00000008469 2.106186417 
SPIRE2 ENSGALG00000000521 11.08055555 
ST3GAL1 ENSGALG00000016210 6.13833338 
STARD10 ENSGALG00000028681 4.103890435 




        Line  61 infected macrophages 
Gene Ensembl Gene ID Fold Change 
STAT4 ENSGALG00000025974 13.6460531 
STRIP2 ENSGALG00000026181 2.648076101 
SUGP2 ENSGALG00000003047 2.112050524 
SYPL1 ENSGALG00000029006 2.280573422 
SYT2 ENSGALG00000026033 9.877955567 
SYTL4 ENSGALG00000006786 3.19578674 
TBC1D24 ENSGALG00000001244 14.6929115 
TDRP ENSGALG00000016356 2.20411411 
TMED6 ENSGALG00000000654 4.596052535 
TMEM132E ENSGALG00000002312 31.75883189 
TMEM136 ENSGALG00000026316 2.325622149 
TMEM51 ENSGALG00000013643 2.03951447 
TNFRSF9 ENSGALG00000000543 2.177435955 
TNIP3 ENSGALG00000011961 2.633283918 
TNNC2 ENSGALG00000006835 2.731236752 
TNXB ENSGALG00000000182 2.322326451 
TRPM2 ENSGALG00000005631 2.632437195 
TSKU ENSGALG00000000761 4.713068235 
TTBK1 ENSGALG00000008627 2.055075262 
TUBA3E ENSGALG00000010439 2.915439388 
TUBB3 ENSGALG00000000059 3.657756722 
UCP ENSGALG00000017316 2.605759001 
UMODL1 ENSGALG00000016157 4.31446934 
USP43 ENSGALG00000017417 9.767652134 
VAV2 ENSGALG00000002699 2.858780351 
VWA5B2 ENSGALG00000000193 2.355836041 
WBSCR27 ENSGALG00000026762 2.15931029 
WNT4 ENSGALG00000004790 3.732024814 
WNT5B ENSGALG00000012998 4.395598467 
XG ENSGALG00000029002 5.292523637 
YF6 ENSGALG00000026292 10.44951891 
ZPLD1 ENSGALG00000015347 3.766216383 
ZSWIM5 ENSGALG00000010221 2.158446656 
Uncharacterised ENSGALG00000002614 16.34856499 
Uncharacterised ENSGALG00000022751 12.37891293 
Uncharacterised ENSGALG00000019325 5.475325603 
Uncharacterised ENSGALG00000027693 3.521908518 
Uncharacterised ENSGALG00000026622 3.098493533 
Uncharacterised ENSGALG00000023936 2.705520977 
Uncharacterised ENSGALG00000022080 2.53889931 
Uncharacterised ENSGALG00000020380 2.481085201 




        Line  61 infected macrophages 
Gene Ensembl Gene ID Fold Change 
Uncharacterised ENSGALG00000028163 2.240868082 
Uncharacterised ENSGALG00000029010 2.224913092 
Uncharacterised ENSGALG00000026256 32.37965098 
Uncharacterised ENSGALG00000027955 5.287637564 
Uncharacterised ENSGALG00000028959 4.696291309 
Uncharacterised ENSGALG00000014600 4.213936831 
Uncharacterised ENSGALG00000024335 3.848697297 
Uncharacterised ENSGALG00000027839 3.47512769 
Uncharacterised ENSGALG00000027203 2.508321151 
Uncharacterised ENSGALG00000027780 2.482143989 






















Table S2.4: DE genes in line 72 infected macrophages. 
 Line 72 infected macrophages  
Gene Ensembl Gene ID Fold Change 
ABCA1 ENSGALG00000015433 2.284856259 
ABCA1 ENSGALG00000015433 2.284856259 
ABCB1LB ENSGALG00000008912 4.388420445 
ACOX2 ENSGALG00000007132 2.116000533 
ACSS3 ENSGALG00000010940 132.3972858 
ADAM12 ENSGALG00000012740 5.114999423 
ADAMTS1 ENSGALG00000015792 2.613476819 
AFAP1 ENSGALG00000015556 2.770025457 
AKAP12 ENSGALG00000023073 2.636071774 
AKAP6 ENSGALG00000009995 2.677849771 
AKR1B1L ENSGALG00000013067 2.345489388 
ALPK2 ENSGALG00000002898 3.256460949 
AMDHD1 ENSGALG00000011414 2.645963727 
ANGPTL2 ENSGALG00000000927 2.123836445 
ARHGAP31 ENSGALG00000015077 2.243209264 
ARHGAP32 ENSGALG00000001192 2.667479125 
ARMC2 ENSGALG00000015289 2.37348205 
ARMC3 ENSGALG00000007864 3.76167533 
ARNT2 ENSGALG00000006445 2.652962068 
ART1 ENSGALG00000012603 2.155504116 
ATCAY ENSGALG00000001812 2.319862794 
BCAR3 ENSGALG00000005816 2.00352537 
BLK ENSGALG00000016661 2.505825862 
BTBD3 ENSGALG00000009028 2.137763807 
C10orf54 ENSGALG00000004673 2.382841561 
C11orf74 ENSGALG00000007941 2.984482827 
C12ORF32 ENSGALG00000013422 2.061702106 
C3AR1 ENSGALG00000013218 2.508183937 
C3D ENSGALG00000011509 2.317835814 
C7orf50 ENSGALG00000004055 2.011600709 
C8orf4 ENSGALG00000024083 2.399739867 
CAMKK1 ENSGALG00000001617 2.507321104 
CASS4 ENSGALG00000007744 4.463173808 
CC2D2A ENSGALG00000014514 2.070998064 
CD244 ENSGALG00000027074 3.065817773 
CD274 ENSGALG00000015032 2.239363806 
CDC42BPA ENSGALG00000009158 3.338876808 
CELSR1 ENSGALG00000013399 3.026995125 
CEP112 ENSGALG00000003975 2.009259245 




 Line 72 infected macrophages  
Gene Ensembl Gene ID Fold Change 
CFTII ENSGALG00000009046 2.314490848 
CHAC1 ENSGALG00000027874 2.641275999 
CHANK3 ENSGALG00000003135 6.388131299 
CHD1L ENSGALG00000015038 2.0472633 
CHIA ENSGALG00000023760 2.693292214 
CLCN4 ENSGALG00000016607 4.867920633 
CNBP ENSGALG00000027201 5.068905783 
COL22A1 ENSGALG00000016195 4.302647895 
COL5A2 ENSGALG00000002509 2.156004177 
COL5A2 ENSGALG00000002509 2.156004177 
COLEC12 ENSGALG00000014910 2.658889658 
CPED1 ENSGALG00000009002 2.382349132 
CR1L ENSGALG00000023950 2.336040526 
CREG2 ENSGALG00000026022 2.0099597 
CRIP1 ENSGALG00000002771 4.792668267 
CSF1R ENSGALG00000005725 2.282746004 
CSPG4 ENSGALG00000020561 2.146721293 
CXXC5 ENSGALG00000000884 2.803204177 
CYP3A4 ENSGALG00000004436 2.051461795 
CYTIP ENSGALG00000012545 2.838914077 
D2HGDH ENSGALG00000006347 2.103064713 
DHFR ENSGALG00000026757 2.544902446 
DHRS13 ENSGALG00000004009 2.701364664 
DHRS3 ENSGALG00000004256 2.466667635 
DISP3 ENSGALG00000004662 2.619254779 
DLC1 ENSGALG00000013715 3.340830997 
DMC1 ENSGALG00000012236 12.32489135 
DNASE1L3 ENSGALG00000005688 2.056467055 
DOCK10 ENSGALG00000005030 2.026680734 
DTNA ENSGALG00000015211 3.409978656 
DUSP4 ENSGALG00000011419 2.224808599 
EFNA5 ENSGALG00000000280 2.326144379 
ENTPD1 ENSGALG00000007078 2.200381235 
EPB41L5 ENSGALG00000011605 3.772613538 
EPHA3 ENSGALG00000015403 2.544264158 
EPHX1 ENSGALG00000010303 2.994728829 
ERMARD ENSGALG00000011186 2.023083863 
FABP3 ENSGALG00000000620 2.467862364 
FAM171B ENSGALG00000002646 2.463697055 
FAT1 ENSGALG00000013579 3.208763007 
FBXL8 ENSGALG00000003201 2.111170181 




 Line 72 infected macrophages  
Gene Ensembl Gene ID Fold Change 
FILIP1L ENSGALG00000015271 2.295710038 
FKBP10 ENSGALG00000025764 2.160043289 
FTD ENSGALG00000028696 2.867336572 
FYN ENSGALG00000026057 2.58279571 
GALNTL4 ENSGALG00000005584 9.88860378 
GCG ENSGALG00000011104 3.566890111 
gga-mir-22 ENSGALG00000024507 15.62169629 
GINS1 ENSGALG00000008538 2.250126695 
GLI3 ENSGALG00000012329 2.031254529 
GMPR ENSGALG00000012705 2.33264523 
GPC1 ENSGALG00000002342 2.403584709 
GPR126 ENSGALG00000013803 3.202171828 
GPR149 ENSGALG00000010337 2.590854867 
GPR161 ENSGALG00000015247 3.729185855 
GPR35 ENSGALG00000005546 2.620583269 
GPX7 ENSGALG00000010633 3.588262133 
GTPBP8 ENSGALG00000015190 2.109192498 
HHIPL1 ENSGALG00000011148 4.366191644 
HIC2 ENSGALG00000001403 7.27980541 
HLX ENSGALG00000027554 2.704010002 
HOMER2 ENSGALG00000006008 2.238729678 
HSPB1 ENSGALG00000001926 2.563295346 
IGF2 ENSGALG00000006555 2.582629281 
IL15 ENSGALG00000009870 2.371391429 
IL1RL2 ENSGALG00000016784 3.218722216 
IQSEC1 ENSGALG00000005042 2.237588038 
ITGB2 ENSGALG00000007511 2.12365685 
JAM2 ENSGALG00000015746 2.556718106 
JAM3 ENSGALG00000001472 5.665415182 
KCTD14 ENSGALG00000017266 2.600795894 
KIAA1161 ENSGALG00000005814 2.36111002 
KIF3C ENSGALG00000026973 2.923165642 
KMO ENSGALG00000007503 6.606353888 
KYNU ENSGALG00000012418 2.530235603 
LAMA3 ENSGALG00000015056 3.078121415 
LCAT ENSGALG00000028928 5.157175475 
LCT ENSGALG00000012260 2.376153339 
LGI2 ENSGALG00000028945 3.098630021 
LYRM2 ENSGALG00000015762 2.136756125 
MAP1A ENSGALG00000008425 2.23846226 
MAP1B ENSGALG00000014999 4.17102957 




 Line 72 infected macrophages  
Gene Ensembl Gene ID Fold Change 
MAP3K9 ENSGALG00000011008 2.290624759 
MARVELD3 ENSGALG00000000882 4.106969992 
MCM9 ENSGALG00000014883 2.163871722 
MCMDC2 ENSGALG00000015526 5.534868238 
MDM1 ENSGALG00000009905 2.209182435 
MEF2C ENSGALG00000014645 2.299681787 
MND1 ENSGALG00000009212 3.993046652 
MSC ENSGALG00000019470 7.393650131 
MTCL1 ENSGALG00000013357 2.378321146 
MYCT1 ENSGALG00000013603 2.01206745 
MYO10 ENSGALG00000012954 3.332734696 
NCEH1 ENSGALG00000009170 2.127177057 
NCKAP1 ENSGALG00000002750 2.325169544 
NDRG4 ENSGALG00000000874 2.154684211 
NEO1 ENSGALG00000001774 2.032750393 
NHSL1 ENSGALG00000026388 2.38616603 
NHSL2 ENSGALG00000028506 2.30848195 
NT5M ENSGALG00000004842 2.09394825 
NTHL1 ENSGALG00000005617 2.512575778 
NUDT15 ENSGALG00000016994 2.035045567 
NUP210 ENSGALG00000005078 2.297325526 
OSF-2 ENSGALG00000017046 3.536396883 
P2RY13 ENSGALG00000010374 2.008564369 
P2RY14 ENSGALG00000010380 2.612397981 
PAG1 ENSGALG00000015758 3.037136371 
PARD6B ENSGALG00000007994 2.66316772 
PARVG ENSGALG00000014203 2.035043599 
PATZ1 ENSGALG00000006934 3.365857826 
PDGFC ENSGALG00000009378 3.81349753 
PHGDH ENSGALG00000002988 8.230435015 
PIWIL1 ENSGALG00000002645 2.252610305 
PLCD4 ENSGALG00000003345 2.649349517 
PLS1 ENSGALG00000002647 3.461525082 
PON2 ENSGALG00000009689 3.071664185 
PPAPDC3 ENSGALG00000018700 2.557407678 
PPIC ENSGALG00000005346 2.790484715 
PRICKLE1 ENSGALG00000009556 2.292558682 
PRMT8 ENSGALG00000013272 7.781317916 
PSAP ENSGALG00000004747 2.430919175 
PTPN14 ENSGALG00000009784 2.939703975 
PTPRG ENSGALG00000007177 2.33074995 




 Line 72 infected macrophages  
Gene Ensembl Gene ID Fold Change 
PTX3 ENSGALG00000028284 3.135618705 
PXDN ENSGALG00000016377 2.863470942 
PYGO1 ENSGALG00000004369 4.94905209 
RAP1GAP2 ENSGALG00000005868 2.288083251 
RARRES1 ENSGALG00000009594 2.15718124 
RASSF8 ENSGALG00000014041 2.30040874 
RIMS2 ENSGALG00000016074 2.842228852 
SCML2 ENSGALG00000016537 2.518142196 
SCN9A ENSGALG00000027793 5.794355956 
SDR9C7 ENSGALG00000026353 2.179627607 
SERINC5 ENSGALG00000014798 2.38459441 
SFT2D2 ENSGALG00000019228 2.273467666 
SHC4 ENSGALG00000005011 2.065382859 
SHISA9 ENSGALG00000002946 3.218896798 
SHROOM3 ENSGALG00000011487 3.658144209 
SLAMF1 ENSGALG00000006229 3.273106166 
SLC11A1 ENSGALG00000011434 2.674946063 
SLC12A2 ENSGALG00000014690 2.023693598 
SLC13A3 ENSGALG00000004445 4.29513418 
SLC16A9 ENSGALG00000003172 2.443230015 
SLC1A6 ENSGALG00000000558 2.02395333 
SLC23A1 ENSGALG00000011717 7.764930946 
SLC2A11 ENSGALG00000006053 4.820204184 
SLC35G1 ENSGALG00000027678 2.048617585 
SLC39A10 ENSGALG00000007777 2.626997709 
SLC47A1 ENSGALG00000021541 3.14460684 
SORD ENSGALG00000002317 3.133279802 
SPECC1 ENSGALG00000004400 2.113303032 
SPNS3 ENSGALG00000001410 5.221785782 
SPON1 ENSGALG00000012027 2.983848873 
SQRDL ENSGALG00000005723 2.010400017 
SRPK1 ENSGALG00000006544 3.328704878 
STOX2 ENSGALG00000010646 2.899662063 
STS ENSGALG00000016622 56.78469533 
STXBP4 ENSGALG00000003033 3.609754781 
SYN2 ENSGALG00000004955 2.032059795 
SYNM ENSGALG00000007048 4.404670845 
SYT8 ENSGALG00000006602 2.130803389 
TBXAS1 ENSGALG00000012791 2.134254223 
TCEANC ENSGALG00000016581 6.440991004 
TFPI ENSGALG00000002594 10.86409282 




 Line 72 infected macrophages  
Gene Ensembl Gene ID Fold Change 
THSD1 ENSGALG00000017027 6.187235078 
THSD4 ENSGALG00000004087 2.455470372 
THY1 ENSGALG00000006751 3.211346775 
TLR2B ENSGALG00000009237 2.160125249 
TMEM237 ENSGALG00000008381 2.256304766 
TMEM242 ENSGALG00000013689 2.535126009 
TMEM61 ENSGALG00000010801 4.588152654 
TNFSF11 ENSGALG00000026163 2.924123432 
TPTE2 ENSGALG00000017031 3.188251964 
TRMT11 ENSGALG00000014831 2.191304036 
TTBK2 ENSGALG00000009176 2.113799632 
TUSC3 ENSGALG00000013674 4.658376226 
URAHP ENSGALG00000000549 2.058110576 
USP13 ENSGALG00000008909 4.620459903 
XYLT1 ENSGALG00000006757 2.45046257 
YES1 ENSGALG00000014860 2.268606361 
ZBTB40 ENSGALG00000004781 2.341049031 
17.5 ENSGALG00000005183 3.066113076 
Uncharacterised ENSGALG00000020995 2.166029554 
Uncharacterised ENSGALG00000028509 2.239553003 
Uncharacterised ENSGALG00000028794 2.386081092 
Uncharacterised ENSGALG00000028298 2.960858814 
Uncharacterised ENSGALG00000016099 3.56102635 
Uncharacterised ENSGALG00000027045 8.751754006 
Uncharacterised ENSGALG00000027466 13.70587224 
Uncharacterised ENSGALG00000026489 382.9792573 
Uncharacterised ENSGALG00000028649 3.201264545 












Table S2.5: DE genes in line 61 control DCs. 
 Line 61 control DCs  
Gene Ensembl Gene ID Fold Change 
ABAT ENSGALG00000007334 4.362351 
ABCB10 ENSGALG00000011096 2.241654 
ABCB11 ENSGALG00000010891 3.526945 
ACAD8 ENSGALG00000001557 2.460768 
ACYP2 ENSGALG00000027632 3.969239 
ADAMTS17 ENSGALG00000007069 3.535074 
ALDH2 ENSGALG00000004725 2.367326 
AMOTL2 ENSGALG00000006483 2.327923 
ATP6V1E1 ENSGALG00000013036 2.66668 
BCL2 ENSGALG00000012885 2.866962 
BCL2A1 ENSGALG00000006511 2.14631 
BIN1 ENSGALG00000011541 2.173061 
C14orf159 ENSGALG00000010703 2.532588 
C1orf123 ENSGALG00000026516 2.556338 
C1orf216 ENSGALG00000002353 3.280162 
C7orf50 ENSGALG00000004055 2.671745 
C9orf91 ENSGALG00000007186 2.823948 
CARTL ENSGALG00000028845 3.092511 
CCDC112 ENSGALG00000023042 2.766901 
CCDC73 ENSGALG00000012103 3.521495 
CCNJ ENSGALG00000006955 4.153005 
CD247 ENSGALG00000015441 3.252387 
CD3D ENSGALG00000007418 4.165199 
CECR1 ENSGALG00000013031 2.114495 
CLEC17A ENSGALG00000026510 2.358043 
CMTM7 ENSGALG00000011488 2.866281 
CO6 ENSGALG00000002118 2.666077 
COLEC12 ENSGALG00000014910 2.644773 
COMTD1 ENSGALG00000005000 2.440063 
CP ENSGALG00000010434 2.836561 
CXCR4 ENSGALG00000012357 5.728625 
CYBRD1 ENSGALG00000026652 2.659156 
CYP2U1 ENSGALG00000027908 2.795319 
CYP2W1 ENSGALG00000004050 8.088998 
CYP46A1 ENSGALG00000011162 2.725918 
DBNDD1 ENSGALG00000000528 2.95906 
DCXR ENSGALG00000002849 2.683553 
DERA ENSGALG00000013095 2.787303 
DIRC2 ENSGALG00000011679 2.347076 




 Line 61 control DCs  
Gene Ensembl Gene ID Fold Change 
DOCK2 ENSGALG00000002080 2.124767 
DZANK1 ENSGALG00000008731 3.019684 
EFCAB1 ENSGALG00000009473 5.759721 
EGLN1 ENSGALG00000011056 2.235434 
EHBP1 ENSGALG00000008906 2.407525 
EMP1 ENSGALG00000011803 2.192149 
EP4 ENSGALG00000014824 4.027639 
ESRRB ENSGALG00000010365 4.16001 
FAM134B ENSGALG00000026200 3.873328 
FAM169B ENSGALG00000007016 2.7465 
FAM180B ENSGALG00000028710 4.304358 
FANCA ENSGALG00000000516 2.91829 
FBP1 ENSGALG00000012613 2.959957 
FUCA1 ENSGALG00000004112 2.462781 
FUCA2 ENSGALG00000013773 2.240806 
FZD10 ENSGALG00000002652 6.463517 
GADD45B ENSGALG00000028143 3.638979 
GAL1 ENSGALG00000022815 24.16933 
GAL2 ENSGALG00000016669 23.04836 
GLDC ENSGALG00000015053 3.322959 
GLTP ENSGALG00000019017 2.141519 
GLUL ENSGALG00000008518 2.303609 
GOT1 ENSGALG00000007484 2.600721 
GP1BB ENSGALG00000021529 3.163247 
GPD1 ENSGALG00000012061 5.046171 
GPNMB ENSGALG00000010949 3.288551 
GPR157 ENSGALG00000002473 2.035751 
GPR34 ENSGALG00000016227 2.577156 
GPR35 ENSGALG00000005546 15.83732 
GSTA3 ENSGALG00000016322 2.907114 
GSTO1 ENSGALG00000008409 3.082421 
GUK1 ENSGALG00000005336 2.055942 
HAVCR1 ENSGALG00000017362 3.793223 
HDAC11 ENSGALG00000005092 3.008842 
HEXB ENSGALG00000014933 2.700026 
HEXDC ENSGALG00000001612 2.383707 
HOOK1 ENSGALG00000010889 2.709541 
HPS3 ENSGALG00000010437 2.183508 
HPSE ENSGALG00000011203 2.276489 
HYAL1 ENSGALG00000000785 2.306377 
IDH1 ENSGALG00000008818 2.031954 




 Line 61 control DCs  
Gene Ensembl Gene ID Fold Change 
IL15 ENSGALG00000009870 2.645298 
IL1R2 ENSGALG00000016782 4.361442 
INPP5B ENSGALG00000001606 2.598207 
KCTD4 ENSGALG00000016975 2.643302 
KCTD9 ENSGALG00000026855 3.665006 
KNTC1 ENSGALG00000004515 4.610545 
LAMTOR2 ENSGALG00000018760 2.150355 
LECT2 ENSGALG00000006323 13.54734 
LEFTY2 ENSGALG00000009256 11.89374 
LGALS1 ENSGALG00000029043 3.393004 
LINC00313 ENSGALG00000007526 4.315885 
LIPA ENSGALG00000023824 6.616439 
LPAR5 ENSGALG00000014455 22.42557 
LRRC32 ENSGALG00000004475 3.830536 
MMEL1 ENSGALG00000001115 15.682 
MMP13 ENSGALG00000017183 4.233303 
MPHOSPH6 ENSGALG00000005477 2.476144 
MPP2 ENSGALG00000002740 6.579817 
MRRF ENSGALG00000001333 2.272039 
MYL12A ENSGALG00000014852 2.23126 
MYO16 ENSGALG00000016837 32.48761 
NDUFS8 ENSGALG00000017675 2.346713 
NHEJ1 ENSGALG00000011335 2.914904 
NT5DC1 ENSGALG00000014964 3.870445 
NTN3 ENSGALG00000029072 3.385016 
OR8U1 ENSGALG00000003608 3.281856 
ORC4 ENSGALG00000012448 2.00074 
OSBPL1A ENSGALG00000015086 2.592263 
P4HA1 ENSGALG00000004325 2.075757 
P4HTM ENSGALG00000006937 2.016309 
PADI3 ENSGALG00000000479 8.502655 
PEX3 ENSGALG00000013777 2.203394 
PGK1 ENSGALG00000007936 2.12676 
PHYKPL ENSGALG00000023920 4.106094 
PIH1D3 ENSGALG00000004870 2.705887 
PIM1 ENSGALG00000000742 2.059678 
PLA2G7 ENSGALG00000016713 2.167974 
PLTP ENSGALG00000006894 4.357687 
PNPLA8 ENSGALG00000009505 2.124734 
PPAPDC1B ENSGALG00000003268 2.558207 
PPARGC1A ENSGALG00000014398 19.36173 




 Line 61 control DCs  
Gene Ensembl Gene ID Fold Change 
PRODH ENSGALG00000007728 3.184567 
PTDSS2 ENSGALG00000004300 2.320722 
PTPA ENSGALG00000015995 2.221795 
RAB33A ENSGALG00000024049 4.068741 
RABL2B ENSGALG00000009770 2.494518 
RAC2 ENSGALG00000012456 2.987144 
RFFL ENSGALG00000002225 2.234368 
RHBDF1 ENSGALG00000007434 2.942536 
RHBG ENSGALG00000013232 2.471026 
RHOU ENSGALG00000025738 2.774213 
RPAIN ENSGALG00000001666 2.249619 
RPLP1 ENSGALG00000016172 2.113429 
RYBP ENSGALG00000027845 2.380875 
S100A13 ENSGALG00000013478 4.643169 
S100A9 ENSGALG00000024272 37.15117 
SCD ENSGALG00000005739 3.951688 
SFXN3 ENSGALG00000023621 2.355273 
SLC15A1 ENSGALG00000016884 4.575215 
SLC16A3 ENSGALG00000002728 2.10965 
SLC24A4 ENSGALG00000010793 5.623099 
SLC29A3 ENSGALG00000004585 2.06271 
SLC48A1 ENSGALG00000018778 3.578205 
SLC7A5 ENSGALG00000005845 2.446225 
SNAPC5 ENSGALG00000007695 2.493589 
SNAPIN ENSGALG00000026796 2.010046 
SOX5 ENSGALG00000021318 6.91782 
SRGAP3 ENSGALG00000008378 6.547206 
SULT2B1 ENSGALG00000027106 10.04862 
SYTL2 ENSGALG00000014079 5.1697 
TCN2 ENSGALG00000009536 2.08469 
TESC ENSGALG00000008206 19.50306 
TEX264 ENSGALG00000003832 2.174396 
TLCD1 ENSGALG00000003973 2.505061 
TLR7 ENSGALG00000016590 3.167157 
TM2D1 ENSGALG00000020614 2.252325 
TMEM116 ENSGALG00000004760 5.885554 
TMEM14A ENSGALG00000019894 2.421552 
TMEM186 ENSGALG00000027191 3.385683 
TMEM233 ENSGALG00000020975 12.3687 
TMEM55A ENSGALG00000028264 2.287542 
TNN ENSGALG00000004538 7.080563 




 Line 61 control DCs  
Gene Ensembl Gene ID Fold Change 
TPST2 ENSGALG00000005626 2.386787 
TRABD ENSGALG00000008705 2.471546 
TRMT5 ENSGALG00000011904 2.13722 
TTR ENSGALG00000015143 2.936337 
TTYH2 ENSGALG00000026940 2.005066 
UACA ENSGALG00000008143 2.444433 
UQCRQ ENSGALG00000007096 5.021424 
VCAM1 ENSGALG00000005257 2.14985 
ZNF395 ENSGALG00000016619 4.119581 
ZNF518A ENSGALG00000006966 2.107058 
ZOV3 ENSGALG00000014877 4.488022 
Uncharacterised ENSGALG00000006003 2.766522 
Uncharacterised ENSGALG00000026436 5.692409 
Uncharacterised ENSGALG00000007320 8.938345 
Uncharacterised ENSGALG00000014551 2.049189 
Uncharacterised ENSGALG00000027621 2.039622 


















Table S2.6: DE genes in line 72 control DCs. 
 Line 72 control DCs  
Gene Ensembl Gene ID Fold Change 
AAK1 ENSGALG00000025953 3.214161 
AAK1 ENSGALG00000000019 2.82368 
ABCC4 ENSGALG00000016896 3.220963 
ACSL1 ENSGALG00000010628 2.28424 
ACSS2 ENSGALG00000003362 2.194795 
ADAM12 ENSGALG00000012740 5.166271 
ADAMTS2 ENSGALG00000006000 3.333654 
AKAP2 ENSGALG00000015656 2.441844 
AKR ENSGALG00000013072 4.11424 
ALOX5 ENSGALG00000005857 2.516818 
ANLN ENSGALG00000012104 2.385838 
ANTXR2 ENSGALG00000010892 3.055307 
ANTXRL ENSGALG00000005969 3.632429 
AOX1 ENSGALG00000008185 3.027527 
AP3B2 ENSGALG00000002136 4.835365 
APBB2 ENSGALG00000014262 2.193241 
APOBEC4 ENSGALG00000020926 8.661705 
APOLD1 ENSGALG00000011784 3.931298 
ARL16 ENSGALG00000019795 2.319814 
ARNT2 ENSGALG00000006445 2.609273 
ARVCF ENSGALG00000002040 4.201827 
ASB13 ENSGALG00000008401 2.915677 
ASS1 ENSGALG00000023689 2.397823 
ATF3 ENSGALG00000025887 3.401507 
AVD ENSGALG00000023622 6.607461 
B3GNT5 ENSGALG00000008758 2.8124 
BAFF ENSGALG00000016852 2.328021 
BARD1 ENSGALG00000003484 3.650705 
BATF3 ENSGALG00000009816 3.30796 
B-G ENSGALG00000002102 2.530319 
BRCA1 ENSGALG00000002781 2.532718 
BUB1 ENSGALG00000008233 3.237123 
C3H8ORF80 ENSGALG00000016572 2.079267 
CA6 ENSGALG00000002390 5.212401 
CALCRL ENSGALG00000002632 3.064022 
CAP2 ENSGALG00000012715 3.104264 
CAV2 ENSGALG00000009396 4.792467 
CCDC186 ENSGALG00000008956 2.091294 
CCDC30 ENSGALG00000004878 4.168901 




 Line 72 control DCs  
Gene Ensembl Gene ID Fold Change 
CD2 ENSGALG00000015463 89.84604 
CDC42BPA ENSGALG00000009158 3.172591 
CDR2 ENSGALG00000025743 4.465434 
CDR2L ENSGALG00000026295 5.141748 
CEP135 ENSGALG00000013776 4.665311 
CEP170 ENSGALG00000010733 2.026464 
CEP170B ENSGALG00000011639 3.89469 
CFAP74 ENSGALG00000001288 3.579261 
CHST3 ENSGALG00000024056 2.90404 
CIDEC ENSGALG00000026945 2.722033 
CLSPN ENSGALG00000002346 2.495311 
CMPK2 ENSGALG00000028982 3.017821 
CMYA5 ENSGALG00000026553 3.23926 
COL27A1 ENSGALG00000006958 2.854133 
COTL1 ENSGALG00000017644 2.0427 
CRTAM ENSGALG00000006527 3.450214 
CSF1 ENSGALG00000028217 2.380597 
CXorf21 ENSGALG00000016286 4.042675 
DCN ENSGALG00000011274 5.435235 
DCSTAMP ENSGALG00000016075 2.363014 
DDX6 ENSGALG00000021251 2.070979 
DGKD ENSGALG00000001730 3.111149 
DISP3 ENSGALG00000004662 3.519095 
DLG3 ENSGALG00000005817 2.798845 
DNER ENSGALG00000002958 3.265334 
DOC2B ENSGALG00000004917 3.311658 
DRAM1 ENSGALG00000012761 2.221845 
E2F1 ENSGALG00000003045 2.030165 
EHD4 ENSGALG00000008950 2.815592 
EIF2AK2 ENSGALG00000010560 2.268471 
EPAS1 ENSGALG00000010005 5.185308 
EPB41L3 ENSGALG00000014770 3.46429 
EPHA2 ENSGALG00000023768 3.654071 
EPSTI1 ENSGALG00000016964 2.072505 
EXOC3L1 ENSGALG00000011449 5.078498 
FAM129A ENSGALG00000004812 2.439999 
FAM160A1 ENSGALG00000010090 5.182576 
FAM92A1 ENSGALG00000015929 2.55281 
FARP1 ENSGALG00000016886 2.361419 
FGF14 ENSGALG00000016866 16.11005 
FILIP1L ENSGALG00000015271 3.512706 




 Line 72 control DCs  
Gene Ensembl Gene ID Fold Change 
FLRT2 ENSGALG00000010589 2.944568 
FLVCR1 ENSGALG00000009807 3.38302 
FMNL2 ENSGALG00000012525 4.15545 
FOXO6 ENSGALG00000026153 3.087849 
FRMD4B ENSGALG00000014627 2.132731 
FST ENSGALG00000014908 5.815029 
GFPT2 ENSGALG00000013760 2.753026 
GPR1 ENSGALG00000008589 3.312015 
GPR64 ENSGALG00000016511 4.514469 
GRIK1 ENSGALG00000015835 5.268596 
HELZ2 ENSGALG00000006138 6.656276 
HIVEP3 ENSGALG00000027365 2.707739 
HSPA12A ENSGALG00000009248 3.719682 
ICA1 ENSGALG00000010708 3.233572 
IFI27L2 ENSGALG00000021627 6.539193 
IFIH1 ENSGALG00000011089 2.788292 
IGSF1 ENSGALG00000026740 18.29941 
IL13RA1 ENSGALG00000006032 3.03893 
IL13RA2 ENSGALG00000020316 8.494457 
IL20RA ENSGALG00000013869 6.00459 
INOS ENSGALG00000005693 7.144601 
INPPL1 ENSGALG00000004336 2.271568 
IRF1 ENSGALG00000006785 2.676341 
IRG1 ENSGALG00000016919 8.667193 
ISG12(2) ENSGALG00000013575 3.110708 
ITGA2 ENSGALG00000014903 4.925297 
ITGB3 ENSGALG00000000379 2.496299 
ITPRIP ENSGALG00000025780 4.033324 
JAG1 ENSGALG00000009020 3.126474 
KCNB2 ENSGALG00000022800 3.878832 
KIF20B ENSGALG00000006470 2.986937 
KIF24 ENSGALG00000005806 3.043927 
KIF4A ENSGALG00000004195 2.223298 
KLHL25 ENSGALG00000006826 2.838743 
LACC1 ENSGALG00000016969 3.773694 
LAMB1 ENSGALG00000007905 2.788371 
LILRA6 ENSGALG00000027531 339.6525 
LILRB3 ENSGALG00000029032 5.122908 
LILRB4 ENSGALG00000027971 111.4473 
LIMS1 ENSGALG00000016807 2.002092 
LPIN2 ENSGALG00000014836 3.889093 




 Line 72 control DCs  
Gene Ensembl Gene ID Fold Change 
LYZ ENSGALG00000009963 10.99142 
MAF ENSGALG00000026258 3.330378 
MAPK8IP1 ENSGALG00000008430 5.178984 
MGLL ENSGALG00000005990 6.85518 
MLLT4 ENSGALG00000011329 5.717513 
MOB3C ENSGALG00000025946 2.326059 
MSC ENSGALG00000019470 2.906015 
MTUS1 ENSGALG00000013615 2.944023 
MX ENSGALG00000016142 21.12414 
MYCL ENSGALG00000024047 2.947625 
MYCT1 ENSGALG00000013603 2.080142 
MYO10L ENSGALG00000011172 4.623367 
MYOM1 ENSGALG00000014847 3.275138 
NCAPD3 ENSGALG00000001491 2.510597 
NCF2 ENSGALG00000004700 2.317791 
NECAB3 ENSGALG00000003065 2.637855 
NRIP3 ENSGALG00000005903 6.850114 
NRSN1 ENSGALG00000012670 5.269616 
OAS*A ENSGALG00000013723 3.14559 
OSCAR ENSGALG00000028805 2.444611 
PALM ENSGALG00000001846 3.559231 
PARVA ENSGALG00000005438 3.35183 
PAX-6 ENSGALG00000012123 3.174655 
PDE7B ENSGALG00000013941 2.028292 
PFKFB3 ENSGALG00000006324 2.681577 
PGM2 ENSGALG00000000486 2.554383 
PHLDB1 ENSGALG00000024033 2.130951 
PHTF2 ENSGALG00000008335 2.649401 
PID1 ENSGALG00000002963 2.492773 
PIK3C2A ENSGALG00000006121 2.035877 
PIK3CG ENSGALG00000008081 3.008285 
PLA2G4A ENSGALG00000005065 2.427602 
PLACL2 ENSGALG00000011190 9.303286 
PLAU ENSGALG00000005086 3.724025 
PLIN3 ENSGALG00000004157 3.023686 
PPP1R3C ENSGALG00000006670 7.221137 
PPP1R9A ENSGALG00000013233 2.500638 
PSTPIP1 ENSGALG00000002786 2.273055 
PSTPIP2 ENSGALG00000001745 4.165917 
PTGS2 ENSGALG00000005069 8.067149 
PTPN11 ENSGALG00000002005 2.219961 




 Line 72 control DCs  
Gene Ensembl Gene ID Fold Change 
RANBP9 ENSGALG00000012696 2.287852 
RBL1 ENSGALG00000001332 2.316836 
RBM24 ENSGALG00000012712 3.277087 
RGS2 ENSGALG00000002540 2.276782 
RGSL1 ENSGALG00000003671 2.914143 
RIF1 ENSGALG00000012484 2.238843 
RSPO3 ENSGALG00000014829 7.163923 
RTTN ENSGALG00000013745 3.187675 
SAMD9L ENSGALG00000009479 4.165428 
SCHIP1 ENSGALG00000009579 2.110766 
SCN4B ENSGALG00000007409 2.560368 
SDC1 ENSGALG00000016480 2.173996 
SEC24D ENSGALG00000011998 2.082223 
SEC61A1 ENSGALG00000005966 2.25264 
SERPINE2 ENSGALG00000005135 2.307838 
SH3KBP1 ENSGALG00000016420 2.170202 
SH3PXD2A ENSGALG00000008293 7.820266 
SLBP ENSGALG00000015712 4.656612 
SLC17A9 ENSGALG00000028225 6.816613 
SLC38A2 ENSGALG00000008497 2.410178 
SLC39A6 ENSGALG00000013209 2.531121 
SLC6A9 ENSGALG00000010098 2.401864 
SNORD24 ENSGALG00000017870 3.5626 
SNORD79 ENSGALG00000025527 7.089739 
SNX10 ENSGALG00000011046 2.239761 
SOGA1 ENSGALG00000003409 2.33502 
ST6GALNAC2 ENSGALG00000006900 2.117608 
STAG1 ENSGALG00000001277 2.215526 
STK35 ENSGALG00000026301 2.927718 
STXBP6 ENSGALG00000009847 2.396172 
SYNJ2 ENSGALG00000013727 2.704691 
TAAR1 ENSGALG00000013994 5.034264 
TAPBPL ENSGALG00000014428 2.00434 
TARM1 ENSGALG00000028728 11.00142 
TARM1 ENSGALG00000027348 5.221175 
TBR1 ENSGALG00000011122 5.407805 
TES ENSGALG00000009398 2.029989 
TGM2 ENSGALG00000006775 2.573378 
TLN2 ENSGALG00000003628 2.035472 
TMEM52 ENSGALG00000001304 2.446235 
TNIP3 ENSGALG00000011961 18.00498 




 Line 72 control DCs  
Gene Ensembl Gene ID Fold Change 
TOR1A ENSGALG00000023709 4.283338 
TRAF1 ENSGALG00000001583 2.976682 
TRAF2 ENSGALG00000009014 2.858458 
TRAF3 ENSGALG00000011389 2.377828 
TRAIP ENSGALG00000002908 2.743527 
TRANK1 ENSGALG00000012057 2.359156 
TRIB2 ENSGALG00000016457 2.607396 
TSPAN5 ENSGALG00000012227 3.266713 
TXNRD1 ENSGALG00000012714 2.277849 
UBE2O ENSGALG00000001971 2.242399 
UBE3C ENSGALG00000006461 2.424335 
UCH-L1 ENSGALG00000014261 20.02871 
UCK2 ENSGALG00000003510 2.596183 
USP54 ENSGALG00000005232 2.419621 
VNN1 ENSGALG00000013993 2.814097 
WBSCR16 ENSGALG00000001174 3.032102 
WFS1 ENSGALG00000015529 2.085233 
ZDHHC20 ENSGALG00000017126 2.256786 
ZFP92 ENSGALG00000015459 2.336782 
ZNF488 ENSGALG00000026560 6.084261 
Uncharacterised ENSGALG00000005720 5.771738 
Uncharacterised ENSGALG00000028525 7.944605 
Uncharacterised ENSGALG00000028022 4.764888 
Uncharacterised ENSGALG00000027396 4.988047 
Uncharacterised ENSGALG00000028509 3.569299 













Table S2.7: DE genes in line 61 infected DCs. 
 Line 61 infected DCs  
Gene Ensembl Gene ID Fold Change 
AADACL2 ENSGALG00000010364 2.06318 
AATK ENSGALG00000006901 3.775925 
ABCA1 ENSGALG00000015433 2.251189 
ABCA2 ENSGALG00000001226 2.9117 
ACTG2 ENSGALG00000006343 2.502703 
ADAM15 ENSGALG00000017301 3.084329 
ADAM28 ENSGALG00000000357 2.349058 
ADAM33 ENSGALG00000016038 2.735453 
ADAM8 ENSGALG00000003437 2.33543 
ADAMTS20 ENSGALG00000009572 32.08151 
ADAMTS4 ENSGALG00000026124 5.305531 
ADAMTSL3 ENSGALG00000006104 2.341151 
ADM ENSGALG00000005666 2.205009 
AEBP1 ENSGALG00000026047 2.527818 
AEBP1 ENSGALG00000028533 2.295753 
AHR ENSGALG00000004322 3.81857 
AMH ENSGALG00000024368 2.047903 
ANG ENSGALG00000003196 2.54811 
ANGPTL1 ENSGALG00000004290 4.622687 
ANGPTL4 ENSGALG00000000619 2.945939 
AQP1 ENSGALG00000005209 3.05925 
ARHGEF10L ENSGALG00000000449 2.941319 
ARHGEF17 ENSGALG00000017326 3.017314 
ARHGEF6 ENSGALG00000001894 6.102023 
ARR3 ENSGALG00000004251 4.180882 
ARRDC2 ENSGALG00000003527 2.970251 
ARSI ENSGALG00000005616 3.35109 
ASAP3 ENSGALG00000029131 5.625763 
ATHL1 ENSGALG00000004234 2.140033 
AZIN2 ENSGALG00000003614 2.018402 
BCAN ENSGALG00000013237 2.919479 
BDKRB1 ENSGALG00000020386 3.159899 
BDKRB2 ENSGALG00000011080 2.608207 
BEST1 ENSGALG00000007217 2.877149 
BEST4 ENSGALG00000010126 4.422654 
BMPER ENSGALG00000012184 3.609248 
BSN ENSGALG00000001849 2.275616 
BUD13 ENSGALG00000025882 3.126735 
C1orf109 ENSGALG00000021645 4.59533 




 Line 61 infected DCs  
Gene Ensembl Gene ID Fold Change 
CABYR ENSGALG00000015076 2.824065 
CACNA1E ENSGALG00000003833 2.850454 
CALD1 ENSGALG00000013071 3.419258 
CAMK1G ENSGALG00000001319 4.141536 
CAPN6 ENSGALG00000008006 4.211775 
CARD11 ENSGALG00000004398 2.185161 
CBFA2T3 ENSGALG00000006234 2.52105 
CCDC69 ENSGALG00000004354 2.22586 
CCL1 ENSGALG00000002329 3.196265 
CCLI10 ENSGALG00000014585 2.130617 
CD164 ENSGALG00000015238 2.089832 
CD180 ENSGALG00000023411 5.63282 
CD200 ENSGALG00000027419 3.064961 
CD40 ENSGALG00000007015 2.153177 
CD72 ENSGALG00000002383 4.246101 
CDC42EP1 ENSGALG00000026968 3.529627 
CDKN2A ENSGALG00000025805 3.749273 
CDKN2B ENSGALG00000026137 7.751854 
CERCAM ENSGALG00000004986 3.567019 
CFTII ENSGALG00000009046 2.64833 
CHB1 ENSGALG00000005194 6.850073 
CHRD ENSGALG00000026983 2.455968 
CISH ENSGALG00000002260 3.86852 
CKV1.1 ENSGALG00000000447 2.960743 
CLMP ENSGALG00000006507 3.007638 
CNTF ENSGALG00000026207 4.241655 
COL12A1 ENSGALG00000015908 2.921718 
COL16A1 ENSGALG00000026836 3.390311 
COL18A1 ENSGALG00000004338 2.759308 
COL1A1 ENSGALG00000023973 2.492793 
COL1A2 ENSGALG00000009641 2.831143 
COL25A1 ENSGALG00000010521 4.146638 
COL3A1 ENSGALG00000002552 3.567479 
COL5A1 ENSGALG00000002546 2.14859 
COL6A1 ENSGALG00000005974 4.940321 
COL6A2 ENSGALG00000006126 3.959898 
COL6A3 ENSGALG00000003923 4.147334 
COL7A1 ENSGALG00000005811 8.312927 
COL9A2 ENSGALG00000027526 2.081889 
CORO2A ENSGALG00000001933 3.243526 
CPNE4 ENSGALG00000011613 3.563191 




 Line 61 infected DCs  
Gene Ensembl Gene ID Fold Change 
CR1L ENSGALG00000023950 2.428168 
CREB3L1 ENSGALG00000008393 2.231926 
CROCC ENSGALG00000027085 2.291571 
CSF1R ENSGALG00000005725 2.044342 
CSF2RB ENSGALG00000012518 2.166307 
CSPG4 ENSGALG00000002678 4.947558 
CTGF ENSGALG00000002909 2.564298 
CTSB ENSGALG00000016666 2.282516 
CUBN ENSGALG00000008704 2.304798 
CUTA ENSGALG00000001620 2.450585 
CX3CL1 ENSGALG00000026663 2.607379 
CXCL12 ENSGALG00000028136 2.280116 
DAB2 ENSGALG00000003803 2.134187 
DAK ENSGALG00000028767 2.004198 
DAPK2 ENSGALG00000026070 2.391981 
DBN1 ENSGALG00000026644 3.89009 
DCHS1 ENSGALG00000017334 2.221799 
DDX25 ENSGALG00000000463 2.58488 
DDX60 ENSGALG00000009639 5.457969 
DNAH17 ENSGALG00000007106 2.583594 
DOCK2 ENSGALG00000025829 2.13143 
DSG4 ENSGALG00000017398 5.923493 
DYSF ENSGALG00000016105 2.009864 
ELFN1 ENSGALG00000004209 2.47501 
EMILIN2 ENSGALG00000014815 2.74481 
ENPP1 ENSGALG00000002896 3.87435 
ENPP3 ENSGALG00000002869 3.123562 
EPHA1 ENSGALG00000014687 2.817383 
ERBB2 ENSGALG00000018828 2.264386 
EX-FABP ENSGALG00000024011 10.82013 
F2RL2 ENSGALG00000023379 2.33234 
FAM178B ENSGALG00000028532 2.488818 
FAM181B ENSGALG00000022713 4.006557 
FAM188B ENSGALG00000023497 2.809656 
FAM19A3 ENSGALG00000026585 4.565765 
FAM78A ENSGALG00000003789 2.010868 
FBN1 ENSGALG00000004960 2.913064 
FBN3 ENSGALG00000000327 5.080241 
FCRL2 ENSGALG00000010507 3.45544 
FES ENSGALG00000008340 2.126706 
FGFRL1 ENSGALG00000015725 2.518049 




 Line 61 infected DCs  
Gene Ensembl Gene ID Fold Change 
FN1 ENSGALG00000003578 2.525055 
FOLH1 ENSGALG00000017234 4.521771 
FZD1 ENSGALG00000009064 2.014369 
FZD2 ENSGALG00000008433 2.264741 
G0S2 ENSGALG00000023933 4.514382 
GAP43 ENSGALG00000015089 5.683525 
GDPGP1 ENSGALG00000023246 2.108858 
GEM ENSGALG00000015954 3.865244 
GFI1 ENSGALG00000005940 3.02677 
gga-mir-3064 ENSGALG00000027517 2.589515 
GGT5 ENSGALG00000006501 2.316257 
GJA1 ENSGALG00000014873 2.54229 
GPR27 ENSGALG00000027091 3.27862 
GPR39 ENSGALG00000012171 3.385635 
GVINP1 ENSGALG00000016556 2.877879 
GZMA ENSGALG00000013548 30.53686 
HAS2 ENSGALG00000016394 3.18276 
HDC ENSGALG00000023436 2.250255 
HLX ENSGALG00000027554 2.638167 
HPGD ENSGALG00000010769 2.293296 
HSD11B1 ENSGALG00000028858 6.197842 
HSPB7 ENSGALG00000023772 2.386985 
HTRA3 ENSGALG00000015575 3.491413 
ID1 ENSGALG00000006210 2.128278 
IFITM5 ENSGALG00000004239 2.207587 
IGFBP4 ENSGALG00000028931 3.70241 
IGFBP5 ENSGALG00000011468 4.483867 
IL17RC ENSGALG00000028970 2.208836 
IL17RE ENSGALG00000029177 2.108406 
IL1B ENSGALG00000000534 3.459698 
IL1RL1 ENSGALG00000016785 3.974019 
IL22RA1 ENSGALG00000004221 3.230995 
IL6 ENSGALG00000010915 5.051559 
INSRR ENSGALG00000013253 4.867462 
IRF-3 ENSGALG00000014297 2.075582 
ISLR ENSGALG00000021525 5.915629 
ISLR2 ENSGALG00000029151 2.435596 
ITGA11 ENSGALG00000008007 2.287078 
ITGB5 ENSGALG00000011778 2.355724 
JAK3 ENSGALG00000028085 2.140763 
JSC ENSGALG00000006346 3.554703 




 Line 61 infected DCs  
Gene Ensembl Gene ID Fold Change 
KANK4 ENSGALG00000010953 2.649729 
KCNA4 ENSGALG00000012142 2.08187 
KCTD3 ENSGALG00000009678 2.056386 
KDELR3 ENSGALG00000012251 2.075624 
KIF26A ENSGALG00000011581 4.968181 
KIR3DL3 ENSGALG00000018535 2.184211 
KLF2 ENSGALG00000003939 2.839389 
KLHDC8A ENSGALG00000000684 3.046614 
KLRG2 ENSGALG00000029035 4.397498 
KREMEN1 ENSGALG00000005808 2.495434 
LAMB3 ENSGALG00000001343 3.594461 
LAMC2 ENSGALG00000004627 2.210837 
LAMP3 ENSGALG00000008759 3.381034 
LAMP5 ENSGALG00000008918 2.613694 
LDLRAD1 ENSGALG00000020647 2.827957 
LEPREL2 ENSGALG00000014490 4.568767 
LEPREL4 ENSGALG00000027462 3.685885 
LIF ENSGALG00000008028 2.096912 
LINGO1 ENSGALG00000002708 2.65109 
LIPA ENSGALG00000006378 2.063888 
LIPI ENSGALG00000015662 3.30116 
LMCD1 ENSGALG00000008349 2.79749 
LMO7 ENSGALG00000016920 2.540879 
LMOD1 ENSGALG00000028721 3.369962 
LOX ENSGALG00000028063 3.323812 
LOXL1 ENSGALG00000028247 2.036057 
LOXL3 ENSGALG00000013254 2.34276 
LPAR4 ENSGALG00000001701 2.38158 
LRRC32 ENSGALG00000000818 2.43629 
LRRC4 ENSGALG00000029160 3.144886 
LSAMP ENSGALG00000015087 2.241065 
LTBP1 ENSGALG00000010448 2.202396 
MADCAM1 ENSGALG00000028341 2.012223 
MADPRT ENSGALG00000000871 7.998343 
MALL ENSGALG00000023882 2.756876 
MALT1 ENSGALG00000027961 2.274118 
MAP3K12 ENSGALG00000026931 2.557896 
MAPKAPK3 ENSGALG00000002283 2.416673 
MCAM ENSGALG00000006764 3.410349 
MCF2L ENSGALG00000016834 2.376608 
MECOM ENSGALG00000009437 2.037626 




 Line 61 infected DCs  
Gene Ensembl Gene ID Fold Change 
MEI1 ENSGALG00000011919 2.181186 
MFAP2 ENSGALG00000027326 3.077756 
MORN5 ENSGALG00000001352 6.814699 
MPEG1 ENSGALG00000028536 2.255142 
MPL ENSGALG00000009965 3.034763 
MPZL2 ENSGALG00000007412 2.643982 
MR1 ENSGALG00000027693 3.300106 
MRC1 ENSGALG00000028304 3.373405 
MRC2 ENSGALG00000000461 3.279484 
MRGPRX4 ENSGALG00000022324 2.232936 
MRVI1 ENSGALG00000005632 2.545218 
MT4 ENSGALG00000028451 2.27103 
MT-ATP6 ENSGALG00000018368 2.146851 
MTCL1 ENSGALG00000013357 2.043254 
MTMR11 ENSGALG00000013350 3.456883 
MT-ND4 ENSGALG00000018364 2.123227 
MTSS1L ENSGALG00000002467 2.866614 
MXD1 ENSGALG00000013882 2.597616 
MYL9 ENSGALG00000028567 2.01545 
MYO1F ENSGALG00000001571 2.288433 
NANOS1 ENSGALG00000027980 2.418836 
NARF ENSGALG00000001603 2.066905 
NCX1 ENSGALG00000008544 3.456327 
NDNF ENSGALG00000011962 3.081744 
NDRG4 ENSGALG00000000874 2.023554 
NEURL ENSGALG00000008281 2.03377 
NEURL1B ENSGALG00000002846 2.163666 
NFKBIZ ENSGALG00000015346 2.105613 
NOX4 ENSGALG00000017235 3.734981 
NR4A3 ENSGALG00000013568 2.788466 
NRP2 ENSGALG00000008621 2.923782 
NT5E ENSGALG00000015833 7.013233 
NTM ENSGALG00000001437 5.317819 
NUMA1 ENSGALG00000001258 2.022952 
NXPH2 ENSGALG00000029083 4.168325 
ODZ2 ENSGALG00000001768 4.588546 
OLFML2B ENSGALG00000002667 2.325267 
OMG ENSGALG00000005594 2.295309 
OSBPL10 ENSGALG00000011474 2.001044 
P2RY12 ENSGALG00000010373 2.764976 
P2RY13 ENSGALG00000010374 3.30708 




 Line 61 infected DCs  
Gene Ensembl Gene ID Fold Change 
P4HA3 ENSGALG00000017311 2.60875 
PAPPA2 ENSGALG00000004487 10.89811 
PASD1 ENSGALG00000009063 2.622027 
PCBP4 ENSGALG00000026397 3.21335 
PCBP4 ENSGALG00000027695 2.669511 
PCSK6 ENSGALG00000007238 2.822889 
PCTP ENSGALG00000003099 2.287935 
PDGFRA ENSGALG00000013929 2.433223 
PDGFRB ENSGALG00000021313 3.494216 
PDLIM4 ENSGALG00000027627 2.734812 
PERP ENSGALG00000027207 2.18308 
PHF7 ENSGALG00000001908 4.209984 
PITPNM1 ENSGALG00000013185 2.518751 
PLCD3 ENSGALG00000025771 2.094803 
PLCD4 ENSGALG00000003345 2.332239 
PLVAP ENSGALG00000026147 3.188199 
PLXDC1 ENSGALG00000023881 3.949544 
PLXDC2 ENSGALG00000007956 2.349154 
PLXNA2 ENSGALG00000001264 3.800204 
PML ENSGALG00000001478 2.809481 
PPAP2C ENSGALG00000026834 2.120839 
PRELP ENSGALG00000003551 2.539896 
PROK2 ENSGALG00000007785 4.247384 
PRRX1 ENSGALG00000003324 2.272129 
PRRX2 ENSGALG00000028236 3.946995 
PRSS35 ENSGALG00000015847 2.598932 
PSMD4 ENSGALG00000028505 5.027432 
PTGS1 ENSGALG00000001314 2.514512 
PTX3 ENSGALG00000028284 6.444192 
PVALB1 ENSGALG00000012522 2.760439 
QPCT ENSGALG00000010617 2.227785 
RASGRP3 ENSGALG00000010435 2.079309 
RGPD1 ENSGALG00000013985 65.84136 
RGS13 ENSGALG00000026810 2.49157 
RNF144A ENSGALG00000028709 2.97246 
RNF213 ENSGALG00000006988 2.329437 
RPS6KA2 ENSGALG00000011473 2.430233 
RSFR ENSGALG00000027165 2.030674 
RTN4RL2 ENSGALG00000023441 2.121126 
RUFY4 ENSGALG00000025739 2.205498 
RUNX2 ENSGALG00000026484 2.070984 




 Line 61 infected DCs  
Gene Ensembl Gene ID Fold Change 
SATB1 ENSGALG00000011254 3.65688 
SCARA3 ENSGALG00000026651 2.733364 
SCARNA7 ENSGALG00000025666 2.531302 
SDK2 ENSGALG00000004464 3.533188 
SEMA3B ENSGALG00000013722 3.294215 
SEPT4 ENSGALG00000028193 2.270539 
SERPINF2 ENSGALG00000002987 2.605163 
SERPING1 ENSGALG00000007381 2.508244 
SERPINH1 ENSGALG00000011214 2.981399 
SFRP4 ENSGALG00000012073 2.498264 
SH3RF2 ENSGALG00000007415 8.383473 
SHANK2 ENSGALG00000026110 2.184718 
SHROOM4 ENSGALG00000027208 2.411571 
SIGLEC1 ENSGALG00000028510 27.87116 
SIGLEC15 ENSGALG00000021416 6.190811 
SIRPA ENSGALG00000006152 2.288473 
SLAMF1 ENSGALG00000024118 2.616391 
SLC10A4 ENSGALG00000014108 2.388347 
SLC18A2 ENSGALG00000009289 2.408956 
SLC38A4 ENSGALG00000009730 2.481271 
SLC39A10 ENSGALG00000007777 2.224507 
SLC43A2 ENSGALG00000002783 2.361197 
SLC4A11 ENSGALG00000016017 8.398968 
SLC9A5 ENSGALG00000007867 2.252328 
SNAI2 ENSGALG00000015241 3.224584 
SOCS1 ENSGALG00000007158 2.376085 
SOCS3 ENSGALG00000027786 2.330686 
SPON2 ENSGALG00000027109 3.090293 
SRPX2 ENSGALG00000006796 2.710535 
ST3GAL1 ENSGALG00000016210 2.010203 
ST8SIA6 ENSGALG00000008671 2.451565 
STAB1 ENSGALG00000001535 2.500814 
STON2 ENSGALG00000010579 2.288269 
SYDE1 ENSGALG00000026662 2.096622 
SYNE2 ENSGALG00000011811 2.2916 
SYNGR3 ENSGALG00000005589 2.088913 
SYNPO ENSGALG00000027330 2.77896 
SYT8 ENSGALG00000006602 2.75983 
SYTL4 ENSGALG00000006786 2.871941 
TAGLN ENSGALG00000011902 2.155361 
TAP1 ENSGALG00000026269 2.01572 




 Line 61 infected DCs  
Gene Ensembl Gene ID Fold Change 
TESK1 ENSGALG00000027658 3.132473 
TEX33 ENSGALG00000012490 8.467017 
TGFB2 ENSGALG00000009612 2.734592 
TGFBI ENSGALG00000006319 2.775837 
TIMP3 ENSGALG00000012568 3.387488 
TLE1 ENSGALG00000026521 4.602383 
TLE3 ENSGALG00000008120 3.047333 
TLL1 ENSGALG00000009567 2.94316 
TLL2 ENSGALG00000005519 3.483 
TLR21 ENSGALG00000000774 2.33597 
TLR2B ENSGALG00000009239 2.094941 
TMEM119 ENSGALG00000004893 2.58738 
TMEM132A ENSGALG00000003332 2.481927 
TMEM132D ENSGALG00000002671 2.147958 
TMEM173 ENSGALG00000000852 2.634185 
TMEM178A ENSGALG00000028327 3.429086 
TMEM178B ENSGALG00000028444 2.647493 
TMEM196 ENSGALG00000010865 2.130155 
TMEM26 ENSGALG00000025862 3.049727 
TMEM71 ENSGALG00000019426 2.024014 
TNC ENSGALG00000007113 2.134109 
TNFAIP2 ENSGALG00000011446 2.720546 
TNFIP6 ENSGALG00000012481 4.81799 
TNFRSF11B ENSGALG00000016114 4.642501 
TNFRSF6B ENSGALG00000006106 9.001829 
TNNC1 ENSGALG00000001459 2.728508 
TRAF3IP3 ENSGALG00000001373 2.363328 
TRIM62 ENSGALG00000028437 2.055228 
TRIM71 ENSGALG00000019622 2.408718 
TSPAN15 ENSGALG00000004257 2.657924 
TWIST1 ENSGALG00000026059 2.322944 
VANGL2 ENSGALG00000024120 2.198111 
VASN ENSGALG00000007807 2.454177 
VPS9D1 ENSGALG00000023468 2.220398 
VSIG4 ENSGALG00000020326 2.20509 
VTCN1 ENSGALG00000016211 2.208065 
VTN ENSGALG00000003589 2.963966 
VWA5B2 ENSGALG00000028294 2.862563 
WFDC1 ENSGALG00000005503 2.489335 
WSCD2 ENSGALG00000004849 3.267168 
XYLT1 ENSGALG00000006757 2.036287 




 Line 61 infected DCs  
Gene Ensembl Gene ID Fold Change 
ZNF330 ENSGALG00000009868 2.123302 
ZNF414 ENSGALG00000024378 2.570855 
ZNF521 ENSGALG00000015112 2.167128 
ZSCAN2 ENSGALG00000027097 4.008998 
Uncharacterised ENSGALG00000005873 3.083482 
Uncharacterised ENSGALG00000026220 488.8789 
Uncharacterised ENSGALG00000026256 13.5234 
Uncharacterised ENSGALG00000016484 9.557921 
Uncharacterised ENSGALG00000001629 4.01839 
Uncharacterised ENSGALG00000028016 3.903504 
Uncharacterised ENSGALG00000028922 3.718273 
Uncharacterised ENSGALG00000019325 3.46194 
Uncharacterised ENSGALG00000025973 2.91668 
Uncharacterised ENSGALG00000015276 2.786033 
Uncharacterised ENSGALG00000000819 2.606666 
Uncharacterised ENSGALG00000018781 2.571815 
Uncharacterised ENSGALG00000019932 2.559414 
Uncharacterised ENSGALG00000008629 2.4159 
Uncharacterised ENSGALG00000013973 2.387016 
Uncharacterised ENSGALG00000025728 2.245786 
Uncharacterised ENSGALG00000004854 2.220158 
Uncharacterised ENSGALG00000027352 2.217018 
Uncharacterised ENSGALG00000003670 2.184214 
Uncharacterised ENSGALG00000028182 2.136117 














Table S2.8: DE genes in line 72 infected DCs. 
 Line 72 infected DCs  
Gene Ensembl Gene ID Fold Change 
ADH1C ENSGALG00000012250 2.331773 
AKAP6 ENSGALG00000009995 2.302729 
ALKBH8 ENSGALG00000017170 2.049126 
APOA1 ENSGALG00000007114 13.44605 
AREG ENSGALG00000010866 2.423714 
ARL5B ENSGALG00000008557 2.752462 
ATP5J ENSGALG00000015751 2.260805 
C6orf58 ENSGALG00000014823 2.020697 
CCNE2 ENSGALG00000015985 2.60047 
CCSAP ENSGALG00000011084 2.034743 
CCSER1 ENSGALG00000010392 2.777602 
CD320 ENSGALG00000021688 2.87104 
CDKN3 ENSGALG00000012220 2.051264 
CELF3 ENSGALG00000028478 2.644073 
CENPK ENSGALG00000014753 2.142904 
CENPL ENSGALG00000026825 2.156348 
CGNL1 ENSGALG00000004294 5.82571 
CHIA ENSGALG00000023760 3.767571 
CHTL1A ENSGALG00000007174 4.49272 
CLCN4 ENSGALG00000016607 3.046699 
COL14A1 ENSGALG00000016411 4.321688 
CST7 ENSGALG00000008660 2.1898 
CYB5A ENSGALG00000013708 2.326181 
DACH1 ENSGALG00000016933 2.355691 
DAK ENSGALG00000005961 2.159722 
DMC1 ENSGALG00000012236 6.410244 
DNAI2 ENSGALG00000004495 3.930177 
ECHDC1 ENSGALG00000014828 2.77296 
EFCAB3 ENSGALG00000000382 3.033619 
ELOVL6 ENSGALG00000012131 2.00699 
ELOVL7 ENSGALG00000014730 2.338781 
EPHA5 ENSGALG00000011680 3.299416 
FAM13C ENSGALG00000001825 3.666876 
FAM161A ENSGALG00000008810 2.176809 
FAM175A ENSGALG00000011210 2.555401 
FBXL2 ENSGALG00000011975 2.344007 
FILIP1 ENSGALG00000015903 2.182781 
GALNTL4 ENSGALG00000005584 3.512756 
GIMAP2 ENSGALG00000029112 2.382143 




 Line 72 infected DCs  
Gene Ensembl Gene ID Fold Change 
GMNN ENSGALG00000013626 3.130713 
GPR132 ENSGALG00000027407 2.480896 
GPR37 ENSGALG00000027861 6.240084 
HCN4 ENSGALG00000001764 5.468598 
IQCK ENSGALG00000028197 2.170153 
JAG2 ENSGALG00000011696 2.939021 
KIF21A ENSGALG00000007098 2.275882 
KLF15 ENSGALG00000006245 2.747173 
LEF1 ENSGALG00000010529 3.092974 
LGI2 ENSGALG00000028945 5.783854 
LILRA3 ENSGALG00000028229 2.729724 
LRP8 ENSGALG00000010692 2.304365 
LY6E ENSGALG00000025879 3.197661 
MAMDC2 ENSGALG00000015115 2.715423 
MAPK12 ENSGALG00000019384 2.116528 
MCM9 ENSGALG00000014883 2.111067 
MCMDC2 ENSGALG00000015526 5.953758 
MED30 ENSGALG00000026340 2.345239 
MR1 ENSGALG00000027045 41.44911 
MRPS33 ENSGALG00000028879 2.078087 
MVK ENSGALG00000027759 2.547073 
MYH13 ENSGALG00000000779 7.006279 
MYH1G ENSGALG00000028612 2.588246 
NEGR1 ENSGALG00000011350 4.732262 
NMRK2 ENSGALG00000025751 4.073974 
NOG ENSGALG00000003114 2.101714 
NRN1 ENSGALG00000028813 3.133779 
NSG1 ENSGALG00000015010 2.959432 
NUBPL ENSGALG00000009983 2.015691 
PDE6C ENSGALG00000006626 2.712235 
PHGDH ENSGALG00000002988 2.470862 
PLCL1 ENSGALG00000008113 2.076025 
PLS1 ENSGALG00000002647 4.211592 
PODXL ENSGALG00000006409 3.285219 
PROSER2 ENSGALG00000006700 2.342766 
PRSS23 ENSGALG00000017244 2.260082 
PYGO1 ENSGALG00000004369 15.06014 
RDH10 ENSGALG00000026505 2.103382 
RHPN1 ENSGALG00000016143 2.568768 
RPL14 ENSGALG00000011523 2.266084 
RPP30 ENSGALG00000006486 2.111477 




 Line 72 infected DCs  
Gene Ensembl Gene ID Fold Change 
S100A10 ENSGALG00000028774 2.318623 
SALL3 ENSGALG00000012657 2.366587 
SBSPON ENSGALG00000015634 9.63557 
SEC61G ENSGALG00000013107 2.245488 
SESN3 ENSGALG00000017204 2.210621 
SETD4 ENSGALG00000016024 3.503497 
SETD6 ENSGALG00000028890 2.850795 
SH3BGRL2 ENSGALG00000015877 8.648823 
SHISA9 ENSGALG00000002946 2.139714 
SIPA1L2 ENSGALG00000011025 2.328392 
SKIDA1 ENSGALG00000017395 2.307617 
SLC13A3 ENSGALG00000004445 2.212562 
SLC25A15 ENSGALG00000017032 2.576981 
SLC2A5 ENSGALG00000002466 2.073321 
SLC44A5 ENSGALG00000011379 3.950476 
SNORA68 ENSGALG00000025464 3.11009 
SPAG6 ENSGALG00000007892 2.176209 
SRD5A1 ENSGALG00000013063 2.902929 
SSX2IP ENSGALG00000008763 2.442534 
STS ENSGALG00000016622 18.18441 
STXBP4 ENSGALG00000003033 3.642529 
SULT4A1 ENSGALG00000014189 2.271469 
TCEANC ENSGALG00000016581 2.530349 
TMCC3 ENSGALG00000011320 2.37792 
TMEM169 ENSGALG00000011493 2.869265 
TNFSF11 ENSGALG00000026163 11.69926 
TPTE2 ENSGALG00000017031 2.152685 
TREM-A1 ENSGALG00000023781 4.559349 
TSPAN12 ENSGALG00000009029 2.123325 
TSPAN13 ENSGALG00000027240 2.375663 
TUBA3E ENSGALG00000010439 2.558806 
U3 ENSGALG00000025958 3.14576 
UBXN2B ENSGALG00000015431 2.036169 
UCHL5 ENSGALG00000002524 2.197277 
UTP23 ENSGALG00000016120 2.366037 
WNT9A ENSGALG00000005401 3.409731 
ZNF800 ENSGALG00000028694 2.927765 
Uncharacterised ENSGALG00000002923 2.240975 
Uncharacterised ENSGALG00000026584 5.005097 


















Table S3.1: Line 61 control macrophages. 
         Line 61  control macrophages 
Gene QTL Chr. Fold Change Ensembl Gene ID 
AAED1 MD25-30 Z 4 ENSGALG00000012624 
AGTPBP1 MD25-30 Z 3 ENSGALG00000012595 
ARSB MD25-30 Z 3 ENSGALG00000004438 
AUH MD25-30 Z 2 ENSGALG00000021843 
BCL2 MD16-17 2 4 ENSGALG00000012885 
BLNK MD22 6 2 ENSGALG00000006973 
CD247 MD1 1 3 ENSGALG00000015441 
CDC14B MD25-30 Z 2 ENSGALG00000012627 
CNNM1 MD22 6 2 ENSGALG00000007489 
COL4A3BP MD25-30 Z 2 ENSGALG00000014952 
CYP46A1 MD19-21 5 2 ENSGALG00000011162 
EPB41L4A MD25-30 Z 3 ENSGALG00000000234 
FAM47E-STBD1 MD7 4 3 ENSGALG00000027872 
gga-mir-1618 MD23 8 3 ENSGALG00000025287 
GLRX MD25-30 Z 2 ENSGALG00000027483 
HMGCS1 MD25-30 Z 2 ENSGALG00000014862 
ITGA1 MD25-30 Z 3 ENSGALG00000014891 
LGALS1 MD7 4 2 ENSGALG00000029043 
LGR4 MD19-21 5 2 ENSGALG00000012191 
LYSMD3 MD25-30 Z 2 ENSGALG00000014651 
MLPH MD10 7 5 ENSGALG00000003904 
NADK2 MD25-30 Z 2 ENSGALG00000003558 
NPL MD23 8 2 ENSGALG00000004614 
NSA2 MD25-30 Z 2 ENSGALG00000014942 
ODF2L MD23 8 4 ENSGALG00000006804 
PINLYP MD25-30 Z 3 ENSGALG00000026884 
PPAP2A MD25-30 Z 2 ENSGALG00000014711 
PPP4R4 MD19-21 5 10 ENSGALG00000010950 
PSAT1 MD25-30 Z 2 ENSGALG00000015180 
RNF180 MD25-30 Z 4 ENSGALG00000014743 
RPS23 MD25-30 Z 2 ENSGALG00000015617 
RPS6 MD25-30 Z 2 ENSGALG00000015082 
SAT1 MD2 1 2 ENSGALG00000016348 
SCARB1 MD24 15 3 ENSGALG00000003018 
SLC24A4 MD19-21 5 2 ENSGALG00000010793 
SNORD38 MD23 8 3 ENSGALG00000024758 
STARD4 MD25-30 Z 3 ENSGALG00000000241 
TBC1D8 MD2 1 3 ENSGALG00000016776 
TCN2 MD24 15 3 ENSGALG00000009536 




         Line 61  control macrophages 
Gene QTL Chr. Fold Change Ensembl Gene ID 
TXN MD25-30 Z 3 ENSGALG00000015704 
WDR63 MD23 8 4 ENSGALG00000008696 
WSCD2 MD24 15 2 ENSGALG00000004849 
ZOV3 MD25-30 Z 2 ENSGALG00000014877 
Uncharacterised MD16-17 2 4 ENSGALG00000013268 
Uncharacterised MD19-21 5 2 ENSGALG00000027352 
Uncharacterised MD9 7 3 ENSGALG00000012061 
Uncharacterised MD13 12 3 ENSGALG00000006768 
Uncharacterised MD24 15 3 ENSGALG00000005873 
Uncharacterised MD24 15 4 ENSGALG00000028162 
Uncharacterised MD25-30 Z 2 ENSGALG00000002326 





















Table S3.2: Line 72 control macrophages. 
       Line 72 control macrophages 
Gene QTL Chr. Fold Change Ensembl Gene ID 
ADAM8 MD22 6 2 ENSGALG00000003437 
CDKN2C MD23 8 3 ENSGALG00000010537 
CLGN MD8 4 6 ENSGALG00000009826 
COL6A3 MD10 7 4 ENSGALG00000003923 
CTNND1 MD19-21 5 2 ENSGALG00000007330 
DOCK7 MD23 8 2 ENSGALG00000010967 
DUSP8 MD19-21 5 3 ENSGALG00000006647 
ELOVL7 MD25-30 Z 8 ENSGALG00000014730 
ENG MD14 17 7 ENSGALG00000005060 
FN1 MD10 7 2 ENSGALG00000003578 
GADD45 MD23 8 3 ENSGALG00000025977 
GALNT9 MD24 15 4 ENSGALG00000002242 
GFOD1 MD16-17 2 4 ENSGALG00000012730 
GLIPR2 MD16-17 2 2 ENSGALG00000028821 
GLUL MD23 8 5 ENSGALG00000003678 
IRG1 MD2 1 4 ENSGALG00000016919 
ISG12(2) MD16-17 2 10 ENSGALG00000013575 
ITGAV MD10 7 3 ENSGALG00000002655 
KLF5 MD2 1 2 ENSGALG00000016927 
LRP8 MD23 8 3 ENSGALG00000010692 
MAPK8IP1 MD19-21 5 7 ENSGALG00000008430 
MGST3 MD23 8 2 ENSGALG00000003445 
MITD1 MD2 1 2 ENSGALG00000016759 
NAV2 MD19-21 5 2 ENSGALG00000003999 
OSMR MD25-30 Z 3 ENSGALG00000003747 
P2RX7 MD24 15 3 ENSGALG00000003863 
PAPSS2 MD22 6 2 ENSGALG00000003689 
PIK3AP1 MD22 6 2 ENSGALG00000005547 
PISD MD24 15 2 ENSGALG00000006872 
PKN3 MD14 17 2 ENSGALG00000004689 
PNPLA2 MD19-21 5 2 ENSGALG00000014569 
PTCHD1 MD2 1 4 ENSGALG00000016358 
RGSL1 MD23 8 8 ENSGALG00000003671 
RNF150 MD8 4 4 ENSGALG00000009865 
SH3RF3 MD2 1 3 ENSGALG00000016810 
SLC41A3 MD13 12 3 ENSGALG00000006235 
SMTN MD24 15 3 ENSGALG00000011865 
SORCS3 MD22 6 97 ENSGALG00000008434 
SYNDIG1L MD19-21 5 5 ENSGALG00000010233 




       Line 72 control macrophages 
Gene QTL Chr. Fold Change Ensembl Gene ID 
TNNI2 MD19-21 5 3 ENSGALG00000006591 
TPCN2 MD19-21 5 2 ENSGALG00000007550 
UCK2 MD23 8 4 ENSGALG00000003510 
VCAN MD25-30 Z 2 ENSGALG00000015624 
Uncharacterised MD19-21 5 6 ENSGALG00000026970 
Uncharacterised MD19-21 5 3 ENSGALG00000006608 
Uncharacterised MD22 6 16 ENSGALG00000004653 
Uncharacterised MD22 6 3 ENSGALG00000005156 
Uncharacterised MD9 7 2 ENSGALG00000012072 
Uncharacterised MD23 8 6 ENSGALG00000020700 
Uncharacterised MD11 8 3 ENSGALG00000020688 





















Table S3.3: Line 61 infected macrophages. 
Line 61 infected macrophages 
Gene QTL Chr. Fold change Ensembl Gene ID 
ABTB2 MD19-21 5 3 ENSGALG00000011609 
AMIGO3 MD13 12 2 ENSGALG00000028339 
AMPD3 MD19-21 5 2 ENSGALG00000005662 
BATF MD19-21 5 3 ENSGALG00000010323 
BDKRB1 MD19-21 5 4 ENSGALG00000020386 
BDKRB2 MD19-21 5 2 ENSGALG00000011080 
BEST4 MD23 8 11 ENSGALG00000010126 
C14orf159 MD19-21 5 3 ENSGALG00000010703 
COCH MD19-21 5 6 ENSGALG00000009920 
COL13A1 MD22 6 3 ENSGALG00000004286 
COL7A1 MD13 12 4 ENSGALG00000005811 
CPE MD8 4 7 ENSGALG00000027788 
CRMP1B MD5 4 6 ENSGALG00000015042 
CSGALNACT1 MD8 4 4 ENSGALG00000010125 
CUX2 MD24 15 2 ENSGALG00000004598 
CXCL13L2 MD8 4 3 ENSGALG00000010338 
ERICH3 MD23 8 3 ENSGALG00000011356 
FAM134B MD16-17 2 2 ENSGALG00000026200 
FAM154A MD25-30 Z 3 ENSGALG00000027314 
GRIP2 MD13 12 24 ENSGALG00000006449 
HHLA2 MD1 1 5 ENSGALG00000022871 
HPD MD24 15 3 ENSGALG00000004343 
IGSF3 MD1 1 2 ENSGALG00000015469 
IL23R MD23 8 7 ENSGALG00000011212 
IRF-4 MD16-17 2 9 ENSGALG00000012830 
IRS2 MD2 1 2 ENSGALG00000016839 
K60 MD7 4 3 ENSGALG00000011668 
LEPR MD23 8 3 ENSGALG00000011058 
NINJ1 MD13 12 2 ENSGALG00000026891 
NR4A3 MD16-17 2 2 ENSGALG00000013568 
PCDH18 MD8 4 3 ENSGALG00000009732 
PLCE1 MD22 6 2 ENSGALG00000028043 
PSD MD22 6 8 ENSGALG00000005680 
RASSF7 MD19-21 5 3 ENSGALG00000006873 
RNaseP_nuc MD23 8 3 ENSGALG00000025650 
RUSC2 MD25-30 Z 2 ENSGALG00000002371 
SEMA3B MD13 12 2 ENSGALG00000013722 
SEMA3F MD13 12 3 ENSGALG00000013370 
SH2D1B MD1 1 5 ENSGALG00000028448 




Line 61 infected macrophages 
Gene QTL Chr. Fold change Ensembl Gene ID 
SLC38A3 MD13 12 3 ENSGALG00000028871 
SLC46A2 MD25-30 Z 2 ENSGALG00000027345 
SLC6A9 MD23 8 3 ENSGALG00000010098 
SMTNL1 MD19-21 5 2 ENSGALG00000028884 
SPINT1 MD19-21 5 2 ENSGALG00000008469 
UMODL1 MD2 1 4 ENSGALG00000016157 
ZPLD1 MD1 1 4 ENSGALG00000015347 
ZSWIM5 MD23 8 2 ENSGALG00000010221 
Uncharacterised MD2 1 5 ENSGALG00000029002 
Uncharacterised MD2 1 12 ENSGALG00000022751 
Uncharacterised MD19-21 5 4 ENSGALG00000006740 
Uncharacterised MD19-21 5 4 ENSGALG00000027520 
Uncharacterised MD19-21 5 2 ENSGALG00000020380 
Uncharacterised MD19-21 5 3 ENSGALG00000013838 
Uncharacterised MD22 6 3 ENSGALG00000007645 
Uncharacterised MD13 12 4 ENSGALG00000006944 
Uncharacterised MD24 15 3 ENSGALG00000013848 


















Table S3.4: Line 72 infected macrophages. 
Line 72 infected macrophages 
Gene QTL Chr. Fold change Ensembl Gene ID 
ABCA1 MD25-30 Z 2 ENSGALG00000015433 
ACOX2 MD13 12 2 ENSGALG00000007132 
ADAMTS1 MD2 1 3 ENSGALG00000015792 
AFAP1 MD5 4 3 ENSGALG00000015556 
AKAP6 MD19-21 5 3 ENSGALG00000009995 
BCAR3 MD23 8 2 ENSGALG00000005816 
C10orf54 MD22 6 2 ENSGALG00000004673 
C11orf74 MD19-21 5 3 ENSGALG00000007941 
CC2D2A MD5 4 2 ENSGALG00000014514 
CD274 MD25-30 Z 2 ENSGALG00000015032 
CHAC1 MD19-21 5 3 ENSGALG00000027874 
CHANK3 MD22 6 6 ENSGALG00000003135 
CLCN4 MD2 1 5 ENSGALG00000016607 
COL5A2 MD10 7 2 ENSGALG00000002509 
CREG2 MD2 1 2 ENSGALG00000026022 
DHFR MD25-30 Z 3 ENSGALG00000026757 
DNASE1L3 MD13 12 2 ENSGALG00000005688 
DUSP4 MD7 4 2 ENSGALG00000011419 
EFNA5 MD25-30 Z 2 ENSGALG00000000280 
ENTPD1 MD22 6 2 ENSGALG00000007078 
EPHA3 MD1 1 3 ENSGALG00000015403 
FAM171B MD10 7 2 ENSGALG00000002646 
FAT1 MD6 4 3 ENSGALG00000013579 
FTD MD19-21 5 3 ENSGALG00000028696 
GALNTL4 MD19-21 5 10 ENSGALG00000005584 
GLI3 MD16-17 2 2 ENSGALG00000012329 
GMPR MD16-17 2 2 ENSGALG00000012705 
GPX7 MD23 8 4 ENSGALG00000010633 
HHIPL1 MD19-21 5 4 ENSGALG00000011148 
IGF2 MD19-21 5 3 ENSGALG00000006555 
IL15 MD8 4 2 ENSGALG00000009870 
IQSEC1 MD13 12 2 ENSGALG00000005042 
JAM2 MD2 1 3 ENSGALG00000015746 
LGI2 MD5 4 3 ENSGALG00000028945 
MAP1B MD25-30 Z 4 ENSGALG00000014999 
MEF2C MD25-30 Z 2 ENSGALG00000014645 
MND1 MD8 4 4 ENSGALG00000009212 
MYO10 MD16-17 2 3 ENSGALG00000012954 
NCKAP1 MD10 7 2 ENSGALG00000002750 




Line 72 infected macrophages 
Gene QTL Chr. Fold change Ensembl Gene ID 
PATZ1 MD24 15 3 ENSGALG00000006934 
PDGFC MD8 4 4 ENSGALG00000009378 
PIWIL1 MD24 15 2 ENSGALG00000002645 
PTPRG MD13 12 2 ENSGALG00000007177 
SCML2 MD2 1 3 ENSGALG00000016537 
SERINC5 MD25-30 Z 2 ENSGALG00000014798 
SHROOM3 MD7 4 4 ENSGALG00000011487 
SLC12A2 MD25-30 Z 2 ENSGALG00000014690 
SLC16A9 MD22 6 2 ENSGALG00000003172 
SLC35G1 MD22 6 2 ENSGALG00000027678 
SPON1 MD19-21 5 3 ENSGALG00000012027 
STS MD2 1 57 ENSGALG00000016622 
SYN2 MD13 12 2 ENSGALG00000004955 
SYT8 MD19-21 5 2 ENSGALG00000006602 
TCEANC MD2 1 6 ENSGALG00000016581 
TFPI MD10 7 11 ENSGALG00000002594 
THNSL2 MD5 4 2 ENSGALG00000015939 
TMEM61 MD23 8 5 ENSGALG00000010801 
TTBK2 MD19-21 5 2 ENSGALG00000009176 
Uncharacterised MD2 1 3 ENSGALG00000016784 
Uncharacterised MD8 4 2 ENSGALG00000009237 
Uncharacterised MD5 4 5 ENSGALG00000027201 
Uncharacterised MD22 6 2 ENSGALG00000004747 
Uncharacterised MD23 8 4 ENSGALG00000016099 
Uncharacterised MD13 12 3 ENSGALG00000006544 
Uncharacterised MD24 15 5 ENSGALG00000006053 
Uncharacterised MD25-30 Z 2 ENSGALG00000005814 
Uncharacterised MD25-30 Z 2 ENSGALG00000020561 











Table S3.5: Line 61 control DCs. 
  Line 61 control DCs 
Gene QTL Chr. Fold change Ensembl Gene ID 
BCL2 MD16-17 2 3 ENSGALG00000012885 
C14orf159 MD19-21 5 3 ENSGALG00000010703 
C1orf123 MD23 8 3 ENSGALG00000026516 
CCDC73 MD19-21 5 4 ENSGALG00000012103 
CCNJ MD22 6 4 ENSGALG00000006955 
CD247 MD1 1 3 ENSGALG00000015441 
COMTD1 MD22 6 2 ENSGALG00000005000 
CYP46A1 MD19-21 5 3 ENSGALG00000011162 
DNASE2 MD23 8 2 ENSGALG00000028790 
EP4 MD25-30 Z 4 ENSGALG00000014824 
ESRRB MD19-21 5 4 ENSGALG00000010365 
FAM134B MD16-17 2 4 ENSGALG00000026200 
FAM180B MD19-21 5 4 ENSGALG00000028710 
FBP1 MD25-30 Z 3 ENSGALG00000012613 
FZD10 MD24 15 6 ENSGALG00000002652 
GLDC MD25-30 Z 3 ENSGALG00000015053 
GOT1 MD22 6 3 ENSGALG00000007484 
GPR34 MD2 1 3 ENSGALG00000016227 
GSTO1 MD22 6 3 ENSGALG00000008409 
HDAC11 MD13 12 3 ENSGALG00000005092 
HEXB MD25-30 Z 3 ENSGALG00000014933 
HOOK1 MD23 8 3 ENSGALG00000010889 
IL15 MD8 4 3 ENSGALG00000009870 
IL1R2 MD2 1 4 ENSGALG00000016782 
KNTC1 MD24 15 4 ENSGALG00000004515 
LGALS1 MD7 4 3 ENSGALG00000029043 
MYO16 MD2 1 32 ENSGALG00000016837 
P4HA1 MD22 6 2 ENSGALG00000004325 
P4HTM MD13 12 2 ENSGALG00000006937 
PPARGC1A MD5 4 19 ENSGALG00000014398 
PTDSS2 MD19-21 5 2 ENSGALG00000004300 
RYBP MD13 12 2 ENSGALG00000027845 
SCD MD22 6 4 ENSGALG00000005739 
SFXN3 MD22 6 2 ENSGALG00000023621 
SLC15A1 MD2 1 5 ENSGALG00000016884 
SLC24A4 MD19-21 5 6 ENSGALG00000010793 
SLC29A3 MD22 6 2 ENSGALG00000004585 
SRGAP3 MD13 12 7 ENSGALG00000008378 
TCN2 MD24 15 2 ENSGALG00000009536 




  Line 61 control DCs 
Gene QTL Chr. Fold change Ensembl Gene ID 
TEX264 MD13 12 2 ENSGALG00000003832 
TLR7 MD2 1 3 ENSGALG00000016590 
TM2D1 MD23 8 2 ENSGALG00000020614 
TMEM116 MD24 15 6 ENSGALG00000004760 
TNN MD23 8 7 ENSGALG00000004538 
TPGS2 MD25-30 Z 2 ENSGALG00000026547 
TPST2 MD24 15 2 ENSGALG00000005626 
VCAM1 MD23 8 2 ENSGALG00000005257 
ZNF518A MD22 6 2 ENSGALG00000006966 
ZOV3 MD25-30 Z 4 ENSGALG00000014877 
Uncharacterised MD22 6 7 ENSGALG00000023824 
Uncharacterised MD9 7 5 ENSGALG00000012061 
Uncharacterised MD24 15 2 ENSGALG00000004725 
Uncharacterised MD24 15 12 ENSGALG00000020975 



















Table S3.6: Line 72 control DCs. 
Line 72 control DCs 
Gene QTL Chr. Fold change Ensembl Gene ID 
ABCC4 MD2 1 3 ENSGALG00000016896 
AKAP2 MD25-30 Z 2 ENSGALG00000015656 
ALOX5 MD22 6 3 ENSGALG00000005857 
APOBEC4 MD23 8 9 ENSGALG00000020926 
AVD MD25-30 Z 7 ENSGALG00000023622 
BAFF MD2 1 2 ENSGALG00000016852 
BARD1 MD10 7 4 ENSGALG00000003484 
CALCRL MD10 7 3 ENSGALG00000002632 
CAP2 MD16-17 2 3 ENSGALG00000012715 
CD2 MD1 1 90 ENSGALG00000015463 
CHST3 MD22 6 3 ENSGALG00000024056 
CMYA5 MD25-30 Z 3 ENSGALG00000026553 
CXorf21 MD2 1 4 ENSGALG00000016286 
EHD4 MD19-21 5 3 ENSGALG00000008950 
FAM129A MD12 8 2 ENSGALG00000004812 
FAM160A1 MD8 4 5 ENSGALG00000010090 
FARP1 MD2 1 2 ENSGALG00000016886 
FGF14 MD2 1 16 ENSGALG00000016866 
FLRT2 MD19-21 5 3 ENSGALG00000010589 
FRMD4B MD13 12 2 ENSGALG00000014627 
FST MD25-30 Z 6 ENSGALG00000014908 
GPR64 MD2 1 5 ENSGALG00000016511 
GRIK1 MD2 1 5 ENSGALG00000015835 
IRG1 MD2 1 9 ENSGALG00000016919 
ISG12(2) MD16-17 2 3 ENSGALG00000013575 
ITGA2 MD25-30 Z 5 ENSGALG00000014903 
ITPRIP MD22 6 4 ENSGALG00000025780 
KIF20B MD22 6 3 ENSGALG00000006470 
KIF24 MD25-30 Z 3 ENSGALG00000005806 
LIMS1 MD2 1 2 ENSGALG00000016807 
MAPK8IP1 MD19-21 5 5 ENSGALG00000008430 
MGLL MD13 12 7 ENSGALG00000005990 
MOB3C MD23 8 2 ENSGALG00000025946 
MX MD2 1 21 ENSGALG00000016142 
NCF2 MD23 8 2 ENSGALG00000004700 
NRIP3 MD19-21 5 7 ENSGALG00000005903 
NRSN1 MD16-17 2 5 ENSGALG00000012670 
OAS*A MD13 12 3 ENSGALG00000013723 
PARVA MD19-21 5 3 ENSGALG00000005438 




Line 72 control DCs 
Gene QTL Chr. Fold change Ensembl Gene ID 
PIK3C2A MD19-21 5 2 ENSGALG00000006121 
PLA2G4A MD23 8 2 ENSGALG00000005065 
PLAU MD22 6 4 ENSGALG00000005086 
PPP1R3C MD22 6 7 ENSGALG00000006670 
PTGS2 MD12 8 8 ENSGALG00000005069 
RAD54L MD11 8 3 ENSGALG00000010356 
RANBP9 MD16-17 2 2 ENSGALG00000012696 
RBM24 MD16-17 2 3 ENSGALG00000012712 
RGSL1 MD23 8 3 ENSGALG00000003671 
SEC61A1 MD13 12 2 ENSGALG00000005966 
SH3KBP1 MD2 1 2 ENSGALG00000016420 
SH3PXD2A MD22 6 8 ENSGALG00000008293 
SLBP MD5 4 5 ENSGALG00000015712 
SLC39A6 MD16-17 2 3 ENSGALG00000013209 
SLC6A9 MD23 8 2 ENSGALG00000010098 
SNORD24 MD23 8 4 ENSGALG00000017870 
SNORD79 MD23 8 7 ENSGALG00000025527 
STXBP6 MD19-21 5 2 ENSGALG00000009847 
TRAF3 MD19-21 5 2 ENSGALG00000011389 
TRAIP MD13 12 3 ENSGALG00000002908 
TSPAN5 MD6 4 3 ENSGALG00000012227 
UCK2 MD23 8 3 ENSGALG00000003510 
USP54 MD22 6 2 ENSGALG00000005232 
WFS1 MD5 4 2 ENSGALG00000015529 
ZFP92 MD1 1 2 ENSGALG00000015459 













Table S3.7: Line 61 infected DCs. 
Line 61 infected DCs 
Gene QTL Chr. Fold change Ensembl Gene ID 
ABCA1 MD25-30 Z 2 ENSGALG00000015433 
ACTG2 MD22 6 2 ENSGALG00000006343 
ADAM8 MD22 6 2 ENSGALG00000003437 
ADM MD19-21 5 2 ENSGALG00000005666 
ANG MD22 6 3 ENSGALG00000003196 
ANGPTL1 MD23 8 5 ENSGALG00000004290 
ATHL1 MD19-21 5 2 ENSGALG00000004234 
BDKRB1 MD19-21 5 3 ENSGALG00000020386 
BDKRB2 MD19-21 5 3 ENSGALG00000011080 
BEST1 MD19-21 5 3 ENSGALG00000007217 
BEST4 MD23 8 4 ENSGALG00000010126 
BSN MD13 12 2 ENSGALG00000001849 
CACNA1E MD23 8 3 ENSGALG00000003833 
CD180 MD25-30 Z 6 ENSGALG00000023411 
CD72 MD25-30 Z 4 ENSGALG00000002383 
CERCAM MD14 17 4 ENSGALG00000004986 
CHB1 MD25-30 Z 7 ENSGALG00000005194 
CNTF MD19-21 5 4 ENSGALG00000026207 
COL25A1 MD8 4 4 ENSGALG00000010521 
COL3A1 MD10 7 4 ENSGALG00000002552 
COL6A3 MD10 7 4 ENSGALG00000003923 
COL7A1 MD13 12 8 ENSGALG00000005811 
CREB3L1 MD19-21 5 2 ENSGALG00000008393 
CXCL12 MD22 6 2 ENSGALG00000028136 
DAB2 MD25-30 Z 2 ENSGALG00000003803 
F2RL2 MD25-30 Z 2 ENSGALG00000023379 
FGFRL1 MD5 4 3 ENSGALG00000015725 
FN1 MD10 7 3 ENSGALG00000003578 
GFI1 MD23 8 3 ENSGALG00000005940 
GGT5 MD24 15 2 ENSGALG00000006501 
GPR27 MD13 12 3 ENSGALG00000027091 
GZMA MD25-30 Z 31 ENSGALG00000013548 
HTRA3 MD5 4 3 ENSGALG00000015575 
IFITM5 MD19-21 5 2 ENSGALG00000004239 
IL1RL1 MD2 1 4 ENSGALG00000016785 
IRF-3 MD19-21 5 2 ENSGALG00000014297 
ITGB5 MD9 7 2 ENSGALG00000011778 
KANK4 MD23 8 3 ENSGALG00000010953 
KCNA4 MD19-21 5 2 ENSGALG00000012142 




Line 61 infected DCs 
Gene QTL Chr. Fold change Ensembl Gene ID 
KREMEN1 MD24 15 2 ENSGALG00000005808 
LAMC2 MD23 8 2 ENSGALG00000004627 
LDLRAD1 MD23 8 3 ENSGALG00000020647 
LIF MD24 15 2 ENSGALG00000008028 
LIPA MD22 6 2 ENSGALG00000006378 
LMCD1 MD13 12 3 ENSGALG00000008349 
LMO7 MD2 1 3 ENSGALG00000016920 
MCF2L MD2 1 2 ENSGALG00000016834 
MPEG1 MD19-21 5 2 ENSGALG00000028536 
MPL MD23 8 3 ENSGALG00000009965 
MRVI1 MD19-21 5 3 ENSGALG00000005632 
NEURL MD22 6 2 ENSGALG00000008281 
NFKBIZ MD1 1 2 ENSGALG00000015346 
NR4A3 MD16-17 2 3 ENSGALG00000013568 
PAPPA2 MD23 8 11 ENSGALG00000004487 
PROK2 MD13 12 4 ENSGALG00000007785 
PRRX1 MD23 8 2 ENSGALG00000003324 
PRRX2 MD14 17 4 ENSGALG00000028236 
RSFR MD22 6 2 ENSGALG00000027165 
RTN4RL2 MD19-21 5 2 ENSGALG00000023441 
SATB1 MD4 2 4 ENSGALG00000011254 
SEMA3B MD13 12 3 ENSGALG00000013722 
SERPING1 MD19-21 5 2 ENSGALG00000007381 
SPON2 MD5 4 3 ENSGALG00000027109 
STON2 MD19-21 5 2 ENSGALG00000010579 
SYT8 MD19-21 5 3 ENSGALG00000006602 
TBX3 MD24 15 3 ENSGALG00000008250 
TESK1 MD25-30 Z 3 ENSGALG00000027658 
TLL1 MD8 4 3 ENSGALG00000009567 
TLL2 MD22 6 3 ENSGALG00000005519 
TLR2-2 MD8 4 2 ENSGALG00000009239 
TMEM119 MD24 15 3 ENSGALG00000004893 
TMEM132D MD24 15 2 ENSGALG00000002671 
TMEM178A MD19-21 5 3 ENSGALG00000028327 
TMEM26 MD22 6 3 ENSGALG00000025862 
TSPAN15 MD22 6 3 ENSGALG00000004257 
WSCD2 MD24 15 3 ENSGALG00000004849 
ZNF330 MD8 4 2 ENSGALG00000009868 
Uncharacterised MD1 1 3 ENSGALG00000027419 
Uncharacterised MD2 1 2 ENSGALG00000016211 
Uncharacterised MD2 1 66 ENSGALG00000013985 




Line 61 infected DCs 
Gene QTL Chr. Fold change Ensembl Gene ID 
Uncharacterised MD7 4 2 ENSGALG00000025728 
Uncharacterised MD19-21 5 2 ENSGALG00000027352 
Uncharacterised MD13 12 3 ENSGALG00000027695 
Uncharacterised MD24 15 2 ENSGALG00000004854 
























Table S3.8: Line 72 infected DCs. 
Line 72 infected DCs 
Gene QTL Chr. Fold change Ensembl Gene ID 
AKAP6 MD19-21 5 2 ENSGALG00000009995 
ATP5J MD2 1 2 ENSGALG00000015751 
CCSER1 MD8 4 3 ENSGALG00000010392 
CENPK MD25-30 Z 2 ENSGALG00000014753 
CENPL MD23 8 2 ENSGALG00000026825 
CLCN4 MD2 1 3 ENSGALG00000016607 
DACH1 MD2 1 2 ENSGALG00000016933 
ELOVL6 MD6 4 2 ENSGALG00000012131 
ELOVL7 MD25-30 Z 2 ENSGALG00000014730 
EPHA5 MD7 4 3 ENSGALG00000011680 
GALNTL4 MD19-21 5 4 ENSGALG00000005584 
GLT1D1 MD24 15 2 ENSGALG00000002679 
KLF15 MD13 12 3 ENSGALG00000006245 
LGI2 MD5 4 6 ENSGALG00000028945 
LRP8 MD23 8 2 ENSGALG00000010692 
MAMDC2 MD25-30 Z 3 ENSGALG00000015115 
NEGR1 MD23 8 5 ENSGALG00000011350 
NRN1 MD16-17 2 3 ENSGALG00000028813 
NSG1 MD5 4 3 ENSGALG00000015010 
NUBPL MD19-21 5 2 ENSGALG00000009983 
PDE6C MD22 6 3 ENSGALG00000006626 
RPP30 MD22 6 2 ENSGALG00000006486 
SALL3 MD16-17 2 2 ENSGALG00000012657 
SEC61G MD16-17 2 2 ENSGALG00000013107 
SETD4 MD2 1 3 ENSGALG00000016024 
SLC44A5 MD23 8 4 ENSGALG00000011379 
SRD5A1 MD16-17 2 3 ENSGALG00000013063 
SSX2IP MD23 8 2 ENSGALG00000008763 
STS MD2 1 18 ENSGALG00000016622 
TCEANC MD2 1 3 ENSGALG00000016581 
Uncharacterised MD6 4 2 ENSGALG00000012250 
Uncharacterised MD19-21 5 8 ENSGALG00000025939 


















Table S4.1: Line 61 infected macrophages - enriched ZNF42 TF binding sites. 
Line 61 infected macrophages 
Gene Ensembl Gene ID 
ARSI  ENSGALG00000005616  
BATF ENSGALG00000010323  
C14orf159 ENSGALG00000010703  
CCR7  ENSGALG00000027572  
CHRDL2  ENSGALG00000017308  
CORO2A ENSGALG00000001933  
CRMP1B  ENSGALG00000015042  
CUTA ENSGALG00000001620  
CXCL13L2  ENSGALG00000010338  
DIXDC1  ENSGALG00000007929  
EVPL ENSGALG00000002108  
GPR174 ENSGALG00000004111  
GPR39 ENSGALG00000012171  
HLF  ENSGALG00000003059  
HSPA12A  ENSGALG00000009248  
IGDCC3  ENSGALG00000007371  
IGSF3  ENSGALG00000015469  
ITGB1BP2 ENSGALG00000005493  
K123 ENSGALG00000006337  
LIPG  ENSGALG00000002712  
LZTS1  ENSGALG00000001727  
P4HA3  ENSGALG00000017311  
RELT  ENSGALG00000019033  
RNF157  ENSGALG00000002008  
SAMD4A  ENSGALG00000012203  
SDR42E1  ENSGALG00000005456  
SFRP5  ENSGALG00000007515  
SH3BP5 ENSGALG00000011550  
SLC15A1  ENSGALG00000016884  
ST3GAL1  ENSGALG00000016210  
STAT4 ENSGALG00000025974  
STRIP2 ENSGALG00000026181  
SYPL1  ENSGALG00000029006  
TRPM2 ENSGALG00000005631  
TUBA3E ENSGALG00000010439  
WNT4 ENSGALG00000004790  
WNT5B ENSGALG00000012998  








Table S4.2: Line 61 infected DCs - enriched ZNF42 TF binding sites. 
Line 61 infected DCs 
Gene Ensembl Gene ID 
ACTG2  ENSGALG00000006343  
ADAM33  ENSGALG00000016038  
AHR  ENSGALG00000010836  
AMH  ENSGALG00000024368  
ANGPTL4 ENSGALG00000000619  
AQP1  ENSGALG00000005209  
ARHGEF6  ENSGALG00000006439  
ARR3  ENSGALG00000004251  
ARRDC2  ENSGALG00000003527  
ARSI  ENSGALG00000005616  
BDKRB2  ENSGALG00000011080  
CAMK1G  ENSGALG00000001319  
CARD11  ENSGALG00000004398  
CCDC69  ENSGALG00000004354  
CCL1  ENSGALG00000002329  
CD164  ENSGALG00000015238  
CD40  ENSGALG00000007015  
CD72  ENSGALG00000002383  
CERCAM  ENSGALG00000004986  
CISH  ENSGALG00000002260  
COL18A1  ENSGALG00000004338  
COL1A2  ENSGALG00000009641  
COL25A1  ENSGALG00000010521  
COL3A1  ENSGALG00000002552  
COL5A1  ENSGALG00000002546  
COL6A3  ENSGALG00000003923  
CORO2A ENSGALG00000001933  
CPNE4  ENSGALG00000011613  
CTSB ENSGALG00000016666  
CUBN  ENSGALG00000008704  
CUTA ENSGALG00000001620  
CX3CL1  ENSGALG00000026663  
CXCL12  ENSGALG00000028136  
DAK  ENSGALG00000005227  
DAK  ENSGALG00000005961  
DDX25  ENSGALG00000000463  
DNAH17  ENSGALG00000007106  
DOCK2  ENSGALG00000002080  
ELFN1  ENSGALG00000004209  
EMILIN2  ENSGALG00000014815  
F2RL2  ENSGALG00000023379  
FAM78A ENSGALG00000003789  
FBN2  ENSGALG00000014686  
FZD1  ENSGALG00000009064  
GAP43  ENSGALG00000015089  
GEM  ENSGALG00000015954  
GJA1  ENSGALG00000014873  




Line 61 infected DCs 
Gene Ensembl Gene ID 
HPGD ENSGALG00000010769  
HTRA3  ENSGALG00000015575  
ID1  ENSGALG00000006210  
IFITM5 ENSGALG00000004239  
IL1RL1  ENSGALG00000016785  
IL6  ENSGALG00000010915  
ITGA11 ENSGALG00000008007  
KCNA4  ENSGALG00000012142  
KDELR3  ENSGALG00000012251  
KLHDC8A ENSGALG00000000684  
LAMB3  ENSGALG00000001343  
LAMC2  ENSGALG00000004627  
LAMP3  ENSGALG00000008759  
LIF  ENSGALG00000008028  
LINGO1  ENSGALG00000002708  
LMCD1  ENSGALG00000008349  
LRRC32  ENSGALG00000000818  
MALL  ENSGALG00000023882  
MAPKAPK3  ENSGALG00000002283  
MCAM  ENSGALG00000006764  
MPL ENSGALG00000009965  
MRC2  ENSGALG00000000461  
MXD1  ENSGALG00000013882  
MYL9  ENSGALG00000028567  
NDRG4  ENSGALG00000000874  
NEURL  ENSGALG00000008281  
NFKBIZ  ENSGALG00000015346  
NR4A3  ENSGALG00000013568  
NT5E ENSGALG00000015833  
NTM ENSGALG00000001437  
NUMA1  ENSGALG00000001258  
OSBPL10  ENSGALG00000011474  
P4HA3  ENSGALG00000017311  
PAPPA2  ENSGALG00000004487  
PCSK6  ENSGALG00000007238  
PCTP ENSGALG00000003099  
PDGFRB  ENSGALG00000021313  
PERP ENSGALG00000027536  
PLXDC2  ENSGALG00000007956  
PRELP  ENSGALG00000003551  
PRRX2  ENSGALG00000028236  
RSFR  ENSGALG00000027165  
RTN4RL2  ENSGALG00000023441  
RUNX2  ENSGALG00000026484  
S100A11  ENSGALG00000009163  
SDK2  ENSGALG00000004464  
SERPINH1  ENSGALG00000011214  
SFRP4  ENSGALG00000012073  
SLC18A2  ENSGALG00000009289  




Line 61 infected DCs 
Gene Ensembl Gene ID 
SLC43A2  ENSGALG00000002783  
SLC4A11  ENSGALG00000016017  
SNAI2  ENSGALG00000015241  
SOCS1  ENSGALG00000007158  
ST3GAL1  ENSGALG00000016210  
STON2 ENSGALG00000010579  
SYTL4  ENSGALG00000006786  
TAGLN  ENSGALG00000011902  
TAP1 ENSGALG00000026269  
TBX3 ENSGALG00000008250  
TIMP3 ENSGALG00000012568  
TLE1 ENSGALG00000012575  
TMEM119 ENSGALG00000004893  
TMEM26 ENSGALG00000025862  
TNFAIP2 ENSGALG00000011446  
TNFRSF11B  ENSGALG00000016114  
TNNC1  ENSGALG00000001459  
TRIM71 ENSGALG00000019622  
TSPAN15 ENSGALG00000004257  
VANGL2  ENSGALG00000024120  
VTN ENSGALG00000003589  
WFDC1  ENSGALG00000005503  
WSCD2  ENSGALG00000004849  
XYLT1  ENSGALG00000006757  
YIPF6 ENSGALG00000004584  
ZNF414  ENSGALG00000024378  
ZNF521  ENSGALG00000015112  
 
 
 
 
 
 
 
 
 
 
 
